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Abstract 
Inherited retinal dystrophies (RDs) are a clinically heterogeneous group of eye 
diseases that result from mutations in more than 250 genes. Genetic diagnosis of these 
diseases has, until recently, been hampered by the lack of suitable technologies to perform 
high throughput screening. This thesis describes two different strategies for using next 
generation sequencing (NGS) in RD patients to find the pathogenic mutation(s) involved. 
In the first results chapter, a customised capture reagent (called Retinome) designed 
against the known retinal dystrophy genes (RetNet, June 2010) was used in NGS analysis 
of 20 RD families. The disease-causing mutations were identified in 12 of 20 cases (60%). 
These included previously reported mutations in ABCA4 (c.6088C>T, p.R2030*; 
c.5882G>A, p.G1961E), RDH12 (c.601T>C, p.C201R; c.506G>A, p.R169Q), PROM1 
(c.1117C>T, p.R373C), GUCY2D (c.2512C>T, p.R838C), RPGRIP1 (c.3565C>T, 
p.R1189*), BBS2 (c.1895G>C, p.R632P) and SPATA7 (c.253C>T, p.R85*) and new 
mutations in CRB1 (c.2832_2842+23del), USH2A (c.12874A>G, p.N4292D), RP2 
(c.884-1G>T) and ABCA4 (c.3328+1G>C). In eight cases the causative mutation could 
not be unambiguously identified. 
In the second results chapter, whole-exome NGS was performed on five RD 
families that had been pre-screened with the Retinome reagent. This identified mutations 
in three known RD genes, MFSD8 (c.1006G>C, p.E336Q; c.1394G>A, p.R465Q), 
C8orf37 (c.555G>A, p.W185*) and TTLL5 (c.1627G>A, p.E543K), and mutations in two 
potentially new RD genes, LARGE (c.2089G>T, p.V697L) and FDFT1 (c.930C>G, 
p.F310L). 
In the third results chapter, whole-exome NGS was performed, without pre-
screening of known genes, in a family with atypical adult-onset RD with early macular 
involvement. NGS identified a mutation in a novel RD gene, DRAM2 (c.140delG, 
p.G47Vfs*3). Further DRAM2 screening in DNA panels identified a compound 
heterozygote case (c.494G>A, p.W165*; c.131G>A, p.S44N). DRAM2 was localised to 
the photoreceptor inner segment and retinal pigment epithelium. 
The relative merits of each approach are discussed. Identifying the pathogenic 
mutation facilitates counselling, carrier testing and may lead to a clearer prognosis. It may 
also influence future prospects for these families as new treatments become available.  
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Chapter 1- Introduction 
‘The eyes are surely the most sensitive, amazing and delicate organs humans 
possess. They are like a window through which we see the world, and are responsible for 
most of the information that reaches the brain, which is why humans depend on their sight 
more than any of the other senses’  
 
1.1 Gross anatomy of the human eye 
In simple terms, the eye is made up of three layers; an outer fibrous wall, a middle 
vascular layer and an inner neuronal layer (Cassin and Solomon, 1990). The outermost 
layer contains collagen and elastin fibres, and consists of the cornea and sclera. The 
cornea refracts light, accounting for approximately 70% of the total dioptric power of the 
eye, while the sclera is the protective coat that gives the eye its white colour. The middle 
layer consists of the choroid posteriorly, which provides oxygen and nourishment to the 
innermost layer of the eye, the retina. Anteriorly, the choroid connects with the ciliary 
body and iris (Figure 1.1).  
 
 
Figure 1.1. Schematic illustration showing the lateral view of a human eye. The diagram 
shows the three main layers of the eye: the cornea and sclera; the iris, choroid and ciliary body; 
and the retina (Adapted with a free license from Alila Medical Media, www.alilamedicalmedia. 
com/). 
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Images are made up of light reflected from the objects; this light enters the eye 
through the cornea, creating an upside-down image on the retina. The retina acts like the 
film in a camera; images come through the eye's lens and are focused onto the retina 
which converts these images into electrical signals and sends them via the optic nerve to 
the brain, where the image is translated and perceived in an upright position (Smerdon, 
2000). 
 
1.2 Embryonic development of the human eye 
1.2.1 Overview  
The formation of human eyes takes place between the third and the tenth week of 
embryonic development. The eye is derived from three key components (Ali and Sowden, 
2011) (Figure 1.2). First, the neuroepithelium gives rise to the optic vesicle and optic cup 
that eventually go on to form the retina, retinal pigment epithelium (RPE), the iris and its 
smooth muscles, ciliary body, the optic nerve, and part of the eye’s vitreous humour. 
Second, the surface ectoderm gives rise to the lens, the corneal epithelium, conjunctiva 
and caruncle, the lacrimal apparatus (glands and drainage system) and eyelid skin. Third, 
the mesenchyme gives rise to the extraocular muscles and the orbital and ocular vascular 
endothelium. 
 
1.2.2 Development of the optic cup and lens vesicle 
The eye begins to form on or about day 22 of embryonic development, when a 
progressively deepening groove known as the optic sulcus appears in the neural folds on 
both sides of the developing forebrain. As the neural tube closes, these two sulci become 
out-pocketings and form optic vesicles that extend toward the surface ectoderm and 
attenuate to form optic stalks. Interaction between the ectoderm and the optic vesicle 
induces a thickening of the ectoderm in that area (Weaver and Hogan, 2001) (Figure 
1.2A). This in turn invaginates, forming the lens placode (Figure 1.2B) and then a fully 
enclosed lens vesicle. At the same time, the optic vesicle invaginates to form a bilayered 
optic cup (Figure 1.2C). A groove on the inferior surfaces of the developing optic vesicle 
and stalk, known as the optic, or choroidal, fissure, allows blood vessels access to both 
the optic cup and the lens vesicle. These blood vessels consist of the hyaloid artery and 
its accompanying vein. Eventually when this fissure fuses, it encloses these vessels inside 
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the optic stalk. As the pregnancy advances, and the lens matures, the distal end of the 
hyaloid artery disintegrates, whilst its proximal end forms the central retinal artery. 
 
 
 
 
Figure 1.2. Embryonic development of the human eye. The surface ectoderm thickens (A) and 
invaginates together with the underlying neuroepithelium of the optic vesicle to produce the lens 
placode (B). The inner layer of the bilayered optic cup (C) produces neural retina whilst the outer 
layer gives rise to the retinal pigmented epithelium (RPE). When maturation is reached the neural 
retina comprises three cellular layers: photoreceptors, interneurons and retinal ganglion cells (D). 
(Adapted with a free license from Brown Lab, https://basicscience.ucdmc.ucdavis.edu/Brown_ 
Lab/index.html, The University of California). 
 
1.2.3 Development of the retina  
The bilayer of the optic cup differentiates to produce the outer pigment layer that 
will eventually form the RPE, whilst the inner layer forms the neural retina of the mature 
eye (Eiraku et al., 2011). The development of the RPE can be observed shortly after the 
fourth week, with melanin granules appearing in the cells within this layer. Two weeks 
later, around day 47 of gestation, the cells adjoining the intraretinal space start to 
differentiate into the photoreceptors (rods and cones) (Graw, 2003). This is followed by 
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the development of the interneurons that form the next layer (horizontal, amacrine and 
bipolar cells). Finally, the innermost layer forms the axons of the ganglion cells that will 
make up the optic nerve. Also, the cells of the optic cup inner layer generate a range of 
glia. The macular region is thicker than the rest of the retina until the eighth month, when 
the macular depression begins to develop. Although cones and rods can be first 
distinguished at week 15 of gestation and all of these retinal layers appear fully developed 
and discernible by eight months, the macular development especially for fovea 
centralis (the point of maximum optical resolution) is not complete until few months after 
birth (Hendrickson and Yuodelis, 1984). 
 
1.2.4 Development of other eye layers 
During weeks six and seven, the mesenchyme that surrounds the external surface 
of the optic cup condenses into the inner vascular layer, the choroid and the outer fibrous 
layer, the sclera. Mesenchyme anterior to the developing lens splits into two layers that 
form the anterior chamber of the eye. The inner layer is continuous with the choroid. The 
outer layer produces the stroma, one of the three layers of the cornea. The other two layers 
in the cornea, epithelium, and endothelium, develop from surface ectoderm and neural 
crest cells respectively. Developing neural and pigmented retinas meet at the outer lips of 
the optic cup where they differentiate into the epithelium of the iris and the ciliary body 
(Figure 1.2D), while stroma of the iris and the ciliary body develop from neural crest cells 
migrating into the area (Graw, 2003). The amount of melanin distributed in the stroma of 
the iris will determine the eye’s colour (Sturm and Larsson, 2009). The sphincter and 
dilator pupillae muscles connected to the iris stroma develop from optic cup 
neuroectoderm, while the ciliary muscle is formed by invading mesenchyme. Vitreous 
humour is also formed initially from mesenchymal cells originating in the neural crest. 
More of this gel-like substance is later added from the neuroectoderm of the optic cup. 
The eyelids start forming in week six and are derived partially from neural crest cells and 
partially from surface ectoderm just anterior to the cornea. Beginning as two folds of skin 
adhering to each other over the cornea, they later separate in the 27th week of 
development.  
 
 
 
5 
 
1.3 Retina 
The retina is a light-sensitive layer at the back of the eye that covers about 65 
percent of the eye’s interior surface. The retina converts light energy into electrical signals 
that are carried to the brain by the optic nerve. The retina is a very delicate and 
complicated structure consisting of two main layers, the RPE and the neural retina. 
 
1.3.1 Retinal pigment epithelium (RPE) 
The RPE is a pigmented monolayer of cuboidal cells that are in close proximity to 
the photoreceptor outer segments. The basal surface of the RPE rests on a prominent 
basement membrane called the Bruch’s membrane, where drusen, which are tiny yellow 
or white deposits found in dry age-related macular degeneration (AMD), are located. 
Large confluent drusen are a risk factor for progression of AMD (Davis et al., 2005; 
Edwards et al., 2005; Klein et al., 2005; Zareparsi et al., 2005; Gold et al., 2006; Yates et 
al., 2007; Despriet et al., 2009; Fritsche et al., 2013). RPE cells serve numerous diverse 
functions in the maintenance of retinal homeostasis. They transport ions, water, metabolic 
end products and nutrients such as glucose and fatty acids between the photoreceptor 
layer and the choriocapillaris (Rizzolo et al., 2011). During the visual cycle (Section 
1.4.4), the RPE maintains the photoreceptor excitability by isomerization of all-trans-
retinal to 11-cis-retinal (Baehr et al., 2003; Thompson and Gal, 2003). Importantly, 
photoreceptor cells undergo a daily renewal process, in which 10% of the photoreceptor 
outer segment (POS) is shed and subsequently phagocytosed by adjacent RPE cells. This 
daily phagocytosis and digestion of POS discs protects photoreceptors from the toxic 
effects of accumulated photo-oxidative products over a human lifetime (Kevany and 
Palczewski, 2010). This renewal of POSs is critical for the maintenance of photoreceptor 
structural integrity and function (LaVail, 1976; Strauss, 2005). A failure of any one of 
these RPE functions causes degeneration of the retina, loss of visual function and 
blindness (Marlhens et al., 1997; Morimura et al., 1998; Gal et al., 2000; Thompson et 
al., 2001; Gibbs et al., 2003; Bonilha, 2008; Sparrow et al., 2010a). 
 
1.3.2 Neural retina 
The neural layer of the retina is responsible for trapping the incident light rays and 
converting their energy into action potentials, which are then transmitted to the brain as 
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nerve impulses. The neural layer of the retina contains five kinds of cells. Photoreceptor 
cells, rods and cones, are specialized for light absorption. Bipolar, amacrine 
and horizontal cells receive information from the photoreceptors, process it in a variety 
of ways and pass this on to ganglion cells which relay the information to the brain. These 
cells have a unique ‘inverted’ arrangement, in which their sensory ends are directed away 
from incident light as light has to pass through several inner retinal layers before reaching 
the photoreceptors (Figure 1.3A) 
 
 
Figure 1.3. The five main cell types in the retina. (A) The arrangement of retinal cells is shown 
in a cross section. The five cell types in the neural retina are arranged into three layers, the 
photoreceptor layer (rods and cones), intermediate layer (bipolar, horizontal and amacrine cells) 
and the internal layer of ganglion cells. (B) The structure of the photoreceptors (rods and cones) 
consists of three cellular regions: an outer segment, an inner segment and the region of synaptic 
terminals. (Adapted from Livesey and Cepko (2001) with the permission of Elsevier Copyright 
Clearance Centre, License number: 3926710001545). 
 
1.3.2.1 Photoreceptors 
Human retinal photoreceptors consist of two distinct cell types, rods and cones 
(Figure 1.3B). Rods are the predominant photoreceptors in the peripheral retina, they 
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operation under dim light conditions but quickly saturate in bright light, and are mainly 
responsible for night vision, sensing brightness, contrast and motion (Rodieck and 
Rushton, 1976). There are relatively few cones at the retinal periphery but they increase 
in density in the central retina. Cones are relatively insensitive to light requiring relatively 
high light levels to activate them, and are hence functional in daylight. The cones are 
responsible for colour discrimination and visual acuity (Sugita and Tasaki, 1988). 
 
Rods and cones differ in their shape, type of photopigment present, retinal 
distribution and pattern of synaptic connections (Rodieck, 1998; Swaroop et al., 2010). 
In terms of their shape, both cell types are elongated, highly polarized and have an inner 
and outer segment connected by a modified cilium. The inner segments (IS) contain 
numerous elongated mitochondria in addition to endoplasmic reticulum and the Golgi 
apparatus. The different architectures of their outer segments (OS) represent a major 
distinctive feature of these two cell types. Rods have a slim rod-shaped OS structure 
whilst cones are conical-shaped. The OS structures of rods are composed of 
individualized discs, unconnected to the ciliary plasma membrane, whilst cones have a 
shorter OS that is composed of a series of discs that are connected to the membrane of 
the cilium (Arikawa et al., 1992). In terms of type of photopigment, rods contain the visual 
pigment rhodopsin while cones contain one of the colour opsins. The distribution of rods 
to cones is not uniform across the surface of the retina (Figure 1.4). The total number of 
rods in the human retina (91 million) far exceeds the number of cones (roughly 4.5 
million). As a result, the density of rods is much greater than cones throughout most of 
the retina. However, in the fovea, a tiny pit (1.5 mm in diameter) located in the macular 
region is responsible for sharp central vision. This area has an increased cone density of 
almost 200-fold, with a sharp decline in the density of rods. In fact, the central 0.35 mm 
of the fovea, called the foveola, is totally rod-free where all of the photoreceptors are 
cones (Purves et al., 2001). 
 
The pattern of synaptic connections of rods and cones contributes to the different 
characteristics of scotopic (rod) and photopic (cone) vision. Each retinal ganglion cell 
receives input from only one cone bipolar cell, which in turn, is contacted by only a single 
cone. In contrast, each rod bipolar cell is contacted by a number of rods, and many rod 
bipolar cells contact a given amacrine cell. More convergence makes the rod system a 
better detector of light since many rods amplify a small signal to generate a large response 
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in the bipolar cell. However, such convergence also reduces the spatial resolution of the 
rod system. The one-to-one relationship of cones to bipolar and ganglion cells is just what 
is required to maximize visual acuity (Mustafi et al., 2009). 
 
 
 
Figure 1.4. Distribution of rods and cones in the human retina. The graph illustrates that rods 
are present at a higher density throughout most of the retina, with a sharp decline in the fovea. 
Conversely, cones are present at low density throughout the retina, with a sharp peak in the centre 
of the fovea. (Adapted from free source: Psyc 2, Biological Foundations, http://mikeclaffey. 
com/psyc2/) 
  
1.3.2.2 Bipolar cells  
Bipolar cells are a type of neuron located in the inner nuclear layer (INL), which 
receive information from photoreceptors and horizontal cells to pass on to the ganglion 
and amacrine cells through their axons. Bipolar cells receive synaptic input from either 
rods or cones, but not both, so the cells can be classified on the basis of their synaptic 
connections. Morphologically, there are ten distinct sub-types of cone bipolar cells in the 
mammalian retina, and only one type of rod bipolar cell. Based on how they react to 
glutamate released by rods or cones, bipolar cells can be further classified into two 
different groups, ON and OFF bipolar cells (Euler and Schubert, 2015). In the dark, the 
photoreceptor releases glutamate, which hyperpolarizes (inhibits) the ON bipolar cells 
and depolarizes (excites) the OFF bipolar cells. However when light hits a photoreceptor 
cell, the photoreceptor releases less glutamate, and ON bipolar cells respond by 
depolarizing while OFF bipolar cells respond by hyperpolarizing. 
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1.3.2.3 Amacrine and horizontal cells  
Amacrine cells are interneurons which are synaptically active in the inner plexiform 
layer (IPL) and serve to integrate, modulate and interpose a temporal domain to the visual 
message before presentation to the ganglion cell. Amacrine cells are responsible for 70% 
of the input to the retinal ganglion cells (Farsaii and Connaughton, 1995). There are three 
types of amacrine cells (mono- bi- or tri-stratified) which contact different types of bipolar 
and ganglion cells (Cuenca et al., 2002). Horizontal cells are also part of the indirect path 
of signals that originate from the photoreceptors and transmit to the ganglion cells. 
Horizontal cells are much less numerous than bipolar cells, which tend to dominate the 
middle layer of the retina. The horizontal cells smooth the photoreceptor output spatially, 
providing a negative feedback (lateral inhibition) in a process that sharpens our perception 
of contrast and colour (Park et al., 2003; Jackman et al., 2011). 
 
1.3.2.4 Ganglion cells  
Ganglion cells collect visual information in their dendrites from bipolar and 
amacrine cells and transmit this to the brain. Based on the dendritic morphologies, 
at least 13 distinct types of retinal ganglion cells have been identified. All of them vary 
significantly in terms of their size, interconnections and responses to visual stimulation 
(ON/OFF) (Wassle, 2004). Photosensitive ganglion cells are important for reflexive 
responses to bright daylight and play a major role in synchronizing circadian rhythms 
(Berson et al., 2002). 
 
1.3.2.5 Müller cells  
Müller cells are the principal glial cells extending throughout much of the retina. 
They form the architectural support structures. The apex of the Müller cell is in the 
photoreceptor layer, whereas the basal aspect is at the inner retinal surface. There are ten 
million Müller cells in the mammalian retina (Sarthy and Ripps, 2001), which are 
responsible for the homeostatic and metabolic support of retinal neurons. They express 
numerous voltage-gated channels and neurotransmitter receptors, which recognize a 
variety of neuronal signals and trigger cell depolarization and intracellular calcium 
transport. Recently Müller cells have been implicated in an alternative visual cycle (the 
cone visual cycle) (Section 1.4.4). 
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1.4 Visual phototransduction 
Phototransduction is the process by which light is converted into a neural signal in 
rod or cone photoreceptors. The light is first absorbed by visual pigments in the 
photoreceptor OS, followed by a series of biochemical changes that lead to plasma 
membrane hyperpolarisation, in which an electric impulse flows through the retina to the 
bipolar and horizontal cells, followed by the amacrine and ganglion cells. Between each 
transfer, organization and processing occurs to the signal, and once a ganglion cell is 
activated, its axon carries the message through the optic nerve to the brain (McBee et al., 
2001). A visual pigment (photopigment) consists of two covalently linked components. 
These are membrane protein moiety, called an opsin, and a chromophore. The opsins are 
G protein–coupled receptors (GPCRs), also known as seven-transmembrane (7TM) 
domain receptors, which form a long helix that loops across the membrane bilayer seven 
times. The chromophore within the looped protein is 11-cis-retinal (11-cis-
retinaldehyde), which is a derivative of vitamin A, the component that actually absorbs 
the light photon (Menon et al., 2001; Filipek et al., 2003; Koyanagi and Terakita, 2014). 
All mammals have the same chromophore, but the membrane protein of the 
photopigments varies in different photoreceptor cell types. In rods the opsin is rhodopsin, 
whilst each cone will have one of three classes of opsin, Long wave-length, Medium 
wave-length or Short wave-length (L, M or S), which divide cones into red sensitive L-
cones, green sensitive M-cones and blue sensitive S-cones (Okano et al., 1992). 
 
1.4.1 Activation of the phototransduction cascade 
Striking of a photon initiates photoisomerization of 11-cis-retinal into all-trans-
retinal (Figure 1.5A) followed by conformational changes in the opsin to make the active 
intermediate (Meta II). The time scale for the formation of the Meta II is approximately 
one millisecond (ms) (Menon et al., 2001). Meta II then activates transducin (a 
heterotrimeric G-protein composed of Gα, Gβ, and Gγ subunits), by prompting the 
guanosine diphosphate (GDP) - guanosine triphosphate (GTP) exchange on the Gα 
subunit, leading to the dissociation of the GTP-bound form of Gα (Gα.GTP) from Gβγ 
(Mase et al., 2012). Gα.GTP in turn stimulates cyclic guanosine monophosphate-
phosphodiesterase (cGMP-PDE) to lower the cytoplasmic level of cGMP. PDE is 
composed of two catalytic subunits (PDEαβ in rods or two copies of PDEαs in cones) and 
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two inhibitory subunits (two copies of PDEγs in rods and in cones) (Cote, 2004). 
Gα·GTP acts by binding to an inhibitory subunit and removing its inhibitory influence on 
a catalytic subunit. The resulting increase in PDE activity increases the hydrolysis of 
cGMP to 5'-GMP and closes the cyclic nucleotide-gated (CNG) channels. Closure of the 
cation channels leads to a photoreceptor membrane hyperpolarization and reduces the 
glutamate release from the synaptic terminal of the cell.  
 
1.4.2 The termination of phototransduction 
Returning to the dark state occurs by the phosphorylation of Meta II by a G-protein-
coupled receptor kinase (GRK) followed by the binding of a protein called arrestin to cap 
the activity of Meta II (Figure 1.5B). Simultaneously, Gα·GTP self-deactivates by its 
intrinsic GTPase activity, which hydrolyzes the bound GTP to GDP and consequently 
returns to its inactive Gα·GDP state to be ready for activation again after reassociating 
with Gβγ (Kleuss et al., 1994). The GTPase activity of Gα·GTP is enhanced by PDEγ, 
and a GTPase-activating protein (GAP) complex, which consists of regulator of G-
protein-signalling isoform 9 (RGS9) with its anchor protein regulator of G protein 
signalling 9-binding protein (R9AP) and Gβ, another G-protein β-subunit-like protein 
(Arshavsky, 2013). Transducin deactivation acts by restoration of the inhibitory activity 
of PDE by its PDEγ. The free cGMP concentration then returns to the dark (high) level 
because of ongoing activity of the cGMP-synthesizing enzyme, guanylate cyclase (GC). 
In the dark resting state, there is a steady balance between the synthesis and hydrolysis of 
cGMP, and a single light flash transiently tips the balance toward hydrolysis (Lamb and 
Pugh, 2006). Meta II eventually decays to an intrinsically inactive state. The pigment then 
dissociates into opsin and free all-trans-retinal, a process called bleaching. The opsin also 
loses its bound arrestin and is dephosphorylated by a protein phosphatase 2A.  
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Figure 1.5. Summary of the phototransduction cascade in rods and cones. (A) Activation of 
the phototransduction cascade that results in the closure of cGMP-gated channels on the plasma 
membrane (from dark to light state). (B) Recovery of the phototransduction cascade that results 
in the re-opening of cGMP-gated channels on the plasma membrane (from light to dark state). R= 
rhodopsin (inactive); R*= rhodopsin (active); T= transducin; PDE= phosphodiesterase (inactive); 
PDE*= phosphodiesterase (active); NCKX= Na/Ca, K exchanger. IPM= interphotoreceptor 
matrix; Rgs9= regulator of G protein signalling protein 9; R9AP= regulator of G protein signalling 
9-binding protein (RGS9 anchor protein); GC= guanylate-cyclase; Arr= arrestin; GCAP= 
guanylate-cyclase-activating protein. (Adapted with a free license from Fu (2010)).  
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1.4.3 Phototransduction components and negative-feedback pathways 
Rods are more sensitive to light, and have adapted to detect light at lower levels 
than cones, whereas cones operate in bright light. Phototransduction for rods and cones 
has quantitative differences in the process depending on the nature of each subtype of the 
photoreceptor. There are not only quantitative differences in terms of sensitivity to 
brightness of light conditions between rod and cone phototransduction processes but there 
are also differences in protein isoforms that involved in each process (Table 1.1). Calcium 
(Ca2+) has a critical role in the adaptation of rods or cones to light (Torre et al., 1986). 
Closure of the CNG channels stops the Ca2+ influx, but the Ca2+ efflux through the 
exchanger continues, resulting in a decrease in the free Ca2+ concentration in the OS. This 
Ca2+ decrease triggers multiple negative feedback pathways to regulate phototransduction 
by opposing the effect of light, thus producing active adaptation by the cell to light. The 
main negative-feedback pathway acts on GC to enhance its activity. The activity of GC 
is facilitated by guanylate-cyclase-activating proteins (GCAPs), which in turn are 
controlled by Ca2+ in that they act well when not binding Ca2+ and poorly when they bind 
Ca2+ (Dizhoor et al., 2010). Thus, in darkness, the GC activity is only moderate because 
the high intracellular free Ca2+ keeps the GCAPs in check, whereas in the light, the GC 
activity is enhanced to oppose light because the GCAPs are more active due to lower free 
Ca2+.  
 
Another pathway is thought to act on the pigment kinase that phosphorylates Meta 
II to quench the latter’s activity, via a Ca2+-binding protein called recoverin. It is thought 
that recoverin in Ca2+-bound form inhibits the pigment kinase (Gorczyca et al., 2003). 
Thus, in the light, when Ca2+ is relatively low and recoverin loses its bound Ca2+, 
the kinase quenches Meta II quickly to reduce amplification, again opposing light. A third 
pathway acts on the CNG channel via calmodulin, which in Ca2+-bound form reduces the 
affinity of the channel for cGMP (Hsu and Molday, 1993). Thus, in darkness, the Ca2+-
calmodulin binds to the CNG channel and lowers its probability of opening. In the light, 
calmodulin loses its bound Ca2+ and dissociates from the channel, as a result of which 
the CNG channel is more likely to reopen because of its now higher affinity for cGMP, 
thus opposing the effect of light. Calmodulin, GCAPs, and recoverin are all EF-hand-type 
Ca2+-binding proteins. Of the three Ca2+-mediated regulatory pathways, the one acting on 
GC is the most important for low and intermediate light levels, above which the one via 
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recoverin begins to kick in, becoming increasingly important with still higher light levels. 
The regulatory pathway on the channel is weak and of minimal importance. 
 
 
A. Rod component Gene symbol 
Protein 
Symbol 
Activity/function 
Rhodopsin RHO Rho 
Light reception; a guanine nucleotide exchange 
factor (GEF) 
Transducin 
GNAT1 Tα Activator of rod phosphodiesterase (PDE) 
GNB1 Tβ 
Binds phosducin 
GNGT1 Tγ 
Phosphodiesterase (PDE) 6 
PDE6A PDE6α Cyclic guanosine monophosphate (cGMP) 
hydrolysis PDE6B PDE6β 
PDEG PDE6γ PDE inhibitor 
Cation channel 
CNGA1 CNGA1 
cGMP-gated cation channel 
CNGB1 CNGB1 
Exchanger SLC24A1 NCKX1 Cation Exchanger 
Guanylate cyclase  2 GUCY2F GC2 Produces cGMP from guanosine triphosphate (GTP) 
Arrestin SAG Arr Binds to phosphorylated Rho 
GC-activating protein 2 GUCA1B GCAP2 Guanylate cyclases (GC) activator at low Ca2+ 
B. Cone component  
Blue pigment OPN1SW S-opsin 
Light reception; GEF Green pigment OPN1MW M-opsin 
Red pigment OPN1LW L-opsin 
Cone transducin 
GNAT2 cTα 
Activator of cone PDE GNB3 Gβ3 
GNGT2 cTγ 
Cone phosphodiesterase 
PDE6C PDE6α′ cGMP hydrolysis 
PDE6H PDE6γ′ Inhibitor 
Cation channel 
CNGA3 CNGA3 
cGMP-gated cation channel 
CNGB3 CNGB3 
Cone exchanger SLC24A2 NCKX2 Cation exchanger 
Cone arrestin ARR3 cArr Binds to phosphorylated cone pigments 
Cone pigment kinase GPRK7 GRK7 Phosphorylates cone pigments 
GC-activating protein 3 GUCA1C GCAP3 GC activator at low Ca2+ 
C. Shared component  
Guanylate cyclase 1 GUCY2D GC1 Produces cGMP 
GC-activating protein 1 GUCA1A GCAP1 Mediates Ca2+ sensitivity of GC1and GC2 
PDEδ PDE6D PrBP/δ 
Prenyl binding protein; chaperone in intracellular 
trafficking 
Phosducin PDC Pdc Binds to Tβγ 
Rhodopsin Kinase GRK1 GRK1 Phosphorylates Rho 
GTPase-activating protein 
regulator of G-protein 
signalling 
RGS9 RGS9-1 
Accelerates GTP hydrolysis of G protein, transducin 
(Gt) αGTP (GtαGTP) 
RGS9 anchoring protein R9AP R9AP RGS9 anchoring protein 
G-protein b subunit 5 GNB5 Gβ5L GTPase activity 
 
 
Table 1.1. Photoreceptor components involved in visual phototransduction. Column 1 = 
components for rods (A) or cones (B) or shared (C), column 2 = gene symbol, column 3 = protein 
symbol, column 4 = activity and/or function of the component. (Sources: RetNet, https://sph.uth. 
edu/retnet/home .htm, Purves et al. (2001), Karan et al. (2008) and Yau and Hardie (2009)).  
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1.4.4 The visual cycle 
The visual cycle describes the pathway that occurs in the RPE and photoreceptors 
to recycle all-trans-retinal back to 11-cis retinal (Figure1.6). Most of the all-trans-retinal 
dissociates from the opsin complex with phosphatidylethanolamine and is transported to 
the cytoplasmic disc surface by the retina specific ATP binding cassette subfamily A, 
member 4 (ABCA4), and released into the cytoplasm as all-trans-retinal (Liu et al., 2000; 
Sparrow et al., 2010b). All-trans-retinal in the cytoplasm is reduced to all-trans-retinol 
(Vitamin A) by all-trans-retinol dehydrogenase (RDH) in a reversible nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent reaction (Palczewski, 2010). All-
trans-retinol is bound to the interphotoreceptor retinoid-binding protein (IRBP), leaves 
the photoreceptors and diffuses into the RPE (Jin et al., 2009). In the RPE, all-trans-
retinol is bound to cellular retinol-binding protein (CRBP) (Bridges et al., 1984) and 
esterified in a reaction catalyzed by lecithin retinol acyl transferase (LRAT) (Saari and 
Bredberg, 1989; Saari et al., 1993). These all-trans-retinyl esters are then hydrolysed and 
isomerized to 11-cis-retinol by the isomerohydrolase retinal pigment epithelium 65 
(RPE65) enzyme (Cai et al., 2009). Cellular retinaldyhyde binding protein (CRALBP) 
delivers the 11-cis-retinol to 11-cis-retinol dehydrogenase (11-cis-RDH) for oxidization 
of 11-cis retinol to 11-cis-retinal using NAD as a cofactor (Haeseleer et al., 2002). Finally 
11-cis-retinal is then bound to IRBP and diffuses from the RPE to combine with the opsin 
proteins ready for another photoisomerization reaction. 
 
This visual cycle is known as the classical cycle and it was associated with rods and 
is thought to apply to cones also. However more recently it has become known that Muller 
cells also possess a self-contained chromophore-regenerating mechanism exclusive for 
the cones. Cones are specialized for functioning in daytime vision where constant light 
increases the demand for 11-cis-retinal. In the proposed cone visual cycle, all-trans retinol 
generated in photoreceptors is transported to Müller cells and isomerized to 11-cis-retinol 
by an unidentified isomerase (Wang and Kefalov, 2011). This theory of the cone-specific 
retina visual cycle reflects the fact that Müller cells have the ability to generate 11-cis-
retinol from all-trans-retinol (Das et al., 1992; Kanan et al., 2008). In addition, Müller 
microvilli have visual cycle components such as CRALBP and IRBP (Dyer and Cepko, 
2000; Betts-Obregon et al., 2014). However the proposed cone-specific visual cycle 
pathway has not been proven yet. 
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Figure 1.6. The visual cycle. The visual cycle between photoreceptors and retinal pigment 
epithelium including enzymatic reactions that recycle the retinoids. Activation of the 
chromophore within the looped opsin by light leads to the isomerization of 11-cis-retinal to all-
trans-retinal. All-trans retinal is released, transported to the cytoplasm by ATP-binding cassette, 
subfamily A, member 4 (ABCA4) and modified to all-trans-retinol by all-trans-retinol 
dehydrogenase (all-trans-RDH). After that, it is transported to the RPE where it is esterified to 
all-trans-retinyle ester by lecithin retinol acyltransferase (LRAT). All-trans-retinyl ester is then 
isomerized to 11-cis-retinol by RPE65 and bound to cellular retinaldyhyde binding protein 
(CRALBP) for oxidation by 11-cis-retinol dehydrogenase (11-cis-RDH) to 11-cis-retinal. After 
transport back to the photoreceptor, 11-cis-retinal binds to opsin, rendering it sensitive to light. 
Retinoids are transferred from and to the photoreceptors bound to interstitial retinol-binding 
protein (IRBP, also known as RBP3). 
 
1.4.5 Phototransduction, visual cycle and retinal disease. 
All the components involved in the phototransduction process (Table 1.1) together 
with all the binding proteins and enzymes involved in the visual cycle or retinoid 
metabolism, have an important role in human vision. Defects in genes encoding the 
proteins that are involved in nearly every step of these pathways are responsible for 
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human-inherited retinal dystrophies (IRDs). For example mutations in GUCA1A (Downes 
et al., 2001a), GUCY2D (Kitiratschky et al., 2008), GUCA1B (Sato et al., 2005), PDE6A 
(Dryja et al., 1999), PDE6B (Shen et al., 2014b), PDE6C (Thiadens et al., 2009a), PDE6G 
(Dvir et al., 2010), PDE6H (Piri et al., 2005), CNGB1 (Bareil et al., 2001), CNGB3 
(Nishiguchi et al., 2005), CNGA1  (Dryja et al., 1995), PRPH2 (Nakazawa et al., 1994), 
RDH12 (Janecke et al., 2004), LRAT (Ruiz et al., 2001), RPE65 (Bowne et al., 2011a), 
RHO (Rosenfeld et al., 1992), SAG (Nakazawa et al., 1998), IRBP/RBP3 (den Hollander 
et al., 2009) and ABCA4 (Martinez-Mir et al., 1998; Zhang et al., 2015a) are all assosiated 
with varies types of IRDs (Tables 1.2, 1.3, 1.5 and 1.6). 
 
1.5 Inherited retinal dystrophy 
Monogenic retinal dystrophies (RDs) represent the most frequent inherited form of 
human visual handicap, affecting approximately 1 in 2000 individuals worldwide (Berger 
et al., 2010). The genetic basis of RDs is extremely heterogeneous. To date, more than 
250 genes have been found to have pathogenic mutations giving rise to the different forms 
of retinal disease (https://sph.uth.edu/retnet/sum-dis.htm#A-genes) and still new 
mutations and novel genes have yet to be discovered (Audo et al., 2012a; Tiwari et al., 
2016). The retinal disorders vary in terms of the cell types affected, the age of onset of 
visual problems and the inheritance pattern. There is also a wide range of clinical 
manifestations for these disorders including mild dysfunctions such as night blindness, to 
severe, early onset (congenital) RDs. The main RDs which form the basis of this study 
are briefly reviewed here. 
 
1.6 Retinitis pigmentosa (RP) 
1.6.1 Overview 
Retinitis pigmentosa (RP, OMIM 268000) is the most frequent subtype of inherited 
RD with a prevalence of approximately 1 in 3,000 to 1 in 5,000 individuals and affecting 
approximately 1.5 million people worldwide (Ammann et al., 1965; Berson, 1993; Haim, 
2002; Shintani et al., 2009; Bowne et al., 2011b). RP is characterized by progressive 
degeneration of the photoreceptors with subsequent degeneration of the RPE, typically 
starting in the peripheral retina and advancing towards the macula and fovea (Hamel, 
2006; Hartong et al., 2006).  
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At the cellular level, the peripheral rod cells are affected first causing rod 
photoreceptor degeneration and RP. Later the effect on central cones often prompts 
secondary cone degeneration. The photoreceptors die by apoptosis and this is reflected 
by a reduced outer nuclear layer thickness within the retina (Hartong et al., 2006; Marigo, 
2007). The bipolar cells in the retina remain intact and healthy even after rod cell 
apoptosis at the early stages of disease (Baumgartner, 2000). However, these fully 
functional bipolar cells try to re-establish communication with nerves of the other 
photoreceptor subtype (cones) leading to inappropriate signals in the cone cells. These 
inappropriate signals, over time, lead to cone dystrophy (John et al., 2000). It has been 
observed that the inner retina is preserved during the course of RP in the rd mouse model, 
as bipolar and horizontal cells are functional even after  photoreceptor loss  (Strettoi and 
Pignatelli, 2000).  
 
1.6.2 Clinical manifestation of RP 
Visual problems in patients with RP often begin in their early childhood, followed 
by severe visual impairment by the ages of 40 to 50 years (Mitamura et al., 2012; Wang 
et al., 2016b). The first symptom is increasing difficulty with night vision (night blindness 
or nyctalopia), followed by a progressive decrease in the visual fields leading to tunnel 
vision. Patients with RP suffer from defective light to dark and dark to light adaptation. 
In general, the earlier the age of onset of defective dark adaptation, the more severe the 
course of RP (Fahim et al., 2013). Loss of central visual acuity over time correlates with 
the presence of macular lesions early in the course of the disease (Flynn et al., 2001). 
Despite the early cone involvement in some cases of RP, the central visual acuity in both 
eyes is usually preserved for years or even decades until the end stages of the disease 
course (El-Asrag et al., 2015; Sergouniotis et al., 2015). There is a general correlation 
between age-related visual acuity and mode of inheritance. X-linked RP (XLRP) 
represents the worst prognosis for vision (<20/200), especially for male patients older 
than fifty years old. Autosomal dominant RP (adRP) has the best prognosis for vision 
(≥20/30) while autosomal recessive RP (arRP) has intermediate prognosis for vision 
(Fishman, 1978). 
 
In the earliest stages of RP, the fundus appearance appears normal followed by a 
fine dust-like intraretinal pigmentation (Figure1.7), generalized retinal arteriolar 
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narrowing and loss of pigment from RPE (Mathijssen et al., 2016). Pigmentation in the 
retina is a sign that light-sensing rod cells are deteriorating, so it becomes very difficult 
for the patient to see in dim light. With progression of rod photoreceptor degeneration, 
there is increasing loss of RPE pigment with intraretinal clumping of melanin, appearing 
as coarse clumps in the classic bone spicule configuration that predominantly exists in 
the peripheral retina. Vascular attenuation and waxy pallor of the optic nerve also become 
more apparent in individuals with RP at this stage (Ma et al., 2015). Later manifestations 
of RP include cataracts, photophobia, and macular oedema (Jackson et al., 2001). 
Moreover, some cases reported a serous retinal detachment and retinal lipid deposition 
(Dave et al., 2016). Patients with RP have diminished or absent a-wave (indicate activity 
of photoreceptors) and b-wave (derived from ON bipolar cells) in their electroretinograms 
(ERGs) (Dolan et al., 2002; Hamel, 2006).  
 
 
 
Figure 1.7. Colour fundus photography of patients with typical RP symptoms. Photograph 
of the right and left eye fundi in a normal individual (A) and affected RP patient (B). The RP 
patient fundus has peripheral intraretinal pigment deposits in a bone-spicule configuration 
(arrows), diffuse mottling of the retinal pigmented epithelium, attenuated retinal arterioles, waxy 
optic discs and a degenerated macula. (Adapted from Gao et al. (2016), no permission is needed). 
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1.6.3 Genetics of RP 
RP can be sub-classified into juvenile RP and late onset RP according to age of 
onset, while congenital peripheral RD would be classified as Leber congenital amaurosis 
(LCA, Section 1.8). RP has also been classified according to the distribution of retinal 
involvement such as central, pericentral, sector, or peripheral. The most common 
classification is based on the modes of inheritance, dividing RP into X-linked RP (XLRP), 
autosomal recessive RP (arRP), autosomal dominant RP (adRP) and digenic RP. RP can 
also be subdivided into non-syndromic and syndromic types. Non-syndromic cases are 
those in which symptoms and signs are confined to the eye alone, without systemic 
abnormalities, and these are inherited as an autosomal dominant (20-25%), autosomal 
recessive (20-30%), X-linked recessive (10-15%) or sporadic/simplex trait (30-40%). 4% 
of cases are so early in onset that they are grouped as part of LCA. Rarer forms also exist 
such as X-linked dominant, mitochondrial and digenic RP (Kajiwara et al., 1994). RP can 
also exist as part of a syndrome that affects other organs and tissues in the body. Most 
syndromic cases are inherited via an autosomal recessive pattern (Daiger et al., 2007; 
Ferrari et al., 2011) and the most frequent forms include Usher syndrome (USH) (10%) 
(Section 1.6.3.5) and Bardet-Biedl syndrome (BBS) (5%) (Section 1.6.3.6). 
 
1.6.3.1 Autosomal recessive RP (arRP) 
An autosomal recessive pattern of inheritance means both copies of a gene in each 
cell have mutations, that these affect men and women equally and that both parents are 
carriers. As each parent has a 50% chance of passing on the mutation, together they have 
a 25% chance of having offspring who inherit two mutated copies and are therefore 
affected (Wang et al., 2005). Consanguinity increases the likelihood that a recessive trait 
will be manifested. Parents and offspring who carry one copy of a mutated gene 
(heterozygous), typically do not show any signs and symptoms of disease (Ravesh et al., 
2015). arRP is the most frequent inheritance type of RP, with the 57 arRP genes identified 
to date accounting for approximately 20% to 30% of all RP cases. arRP genes encode 
proteins with a wide variety of retinal functions including in phototransduction, 
photoreceptor maintenance and function, the visual cycle, ciliogenesis and cell signalling 
(Table 1.2). 
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Gene 
Estimated 
frequency 
Potential function OMIM Gene 
Estimated 
frequency 
Potential function OMIM 
USH2A 12-20% Cellular structure 613809 TULP1 ≤1% 
Tissue development & 
maintenance 
602280 
ABCA4 2-5%  Visual cycle 601718 ZNF513 ≤1% Transcription factor 613617 
PDE6A 2-5% Phototransduction 613801 ARL6 ≤1% Transmembrane protein 613575 
PDE6B 2-8% Phototransduction 613801 NR2E3 Rare Transcription factor 611131 
RPE65 2-5% Visual cycle 613794 MAK ≤1% Cellular structure 614181 
CNGA1 1-2% Phototransduction 613756 MERTK ≤1% Transmembrane protein 613862 
AGBL5 ≤1% 
posttranslational 
modification of tubulin 
615900 MVK unknown Visual cycle /unknown 175900 
ARL2BP Unknown 
Photoreceptor 
maintenance and function 
615407 NEK2 ≤1% Cell division 615565 
BBS1 ≤1% Ciliogenesis  209901 NEUROD1 ≤1%  606394 
BBS2  ≤1% Ciliogenesis  616562 NRL ≤1% 
Tissue development & 
maintenance 
613750 
BEST1 ≤1% Anion channel 613194 PDE6G ≤1% Phototransduction 613582 
C2orf71 ≤1% Unknown 613428 POMGNT1 ≤1% Glycosylation 613157 
C8orf37 ≤1% Unknown 614500 PRCD ≤1%  Unknown 610599 
CLRN1 ≤1% Photoreceptor structure 614180 PROM1 ≤1% Cellular structure 612095 
CNGB1 ≤1% Phototransduction 613767 RBP3 ≤1% Visual cycle 180290 
CYP4V2 ≤1% 
Fatty acid and steroid 
metabolism 
608614 RGR ≤1% Visual cycle 613769 
DHDDS ≤1% Photoreceptor structure 613861 RHO ≤1% Phototransduction 613731 
DHX38 unknown Splicing 605584 RLBP1 ≤1% Visual cycle 607475 
EMC1 ≤1% Unknown 616846 RP1 ≤1% 
Tissue development & 
maintenance 
603937 
FAM161A ≤1% 
Tissue development & 
maintenance 
613596 RP1L1 ≤1% 
Tissue development & 
maintenance 
608581 
GPR125 ≤1% Unknown 612303 SLC7A14 1-2% Unknown 615725 
HGSNAT ≤1% Unknown  616544 SPATA7 ≤1% Unknown 609868 
IDH3B ≤1% Citric acid cycle 612572 TTC8 ≤1% Transmembrane protein 613464 
IFT140 ≤1% Intraflagellar transport 614620 ZNF408  ≤1% Transcription factor  616469 
KIZ 
≤1% in 
north 
African 
(Sephardic 
Jews) 
Cell division 616394 EYS 
Common 
in china, 
10-30% in 
Spain 
Cell signaling 612424 
IMPG2 ≤1% Cellular structure 613581 CRB1 
6-7% 
(Spain) 
Tissue development & 
maintenance 
604210 
KIAA1549 ≤1% Unknown 613344 CERKL 
3-4% 
(Spain)  
Cell signaling 608381 
IFT172 ≤1% Intraflagellar transport 615780 SAG 
2-3% in 
Japan 
Phototransduction 613758 
LRAT ≤1% Visual cycle 613341   
 
Table 1.2. List of genes implicated in autosomal recessive RP (arRP). Gene name, estimated 
frequency (%) of arRP attributed to mutations in this gene and potential function are listed along 
with the corresponding OMIM number. (Sources: RetNet, https://sph.uth.edu/retnet/home .htm; 
OMIM, http: //www.ncbi.nlm.nih.gov/omim; Ruiz et al. (1998); Klevering et al. (2004); Abd El-
Aziz et al. (2007); Avila-Fernandez et al. (2010); Daiger et al. (2013); Fahim et al. (2013); Nash 
et al. (2015)) 
 
The most prevalent mutant genes in arRP cases are USH2A, the PDE6A and B 
genes, EYS, ABCA4 and RPE65. USH2A is the most commonly mutated gene in Usher 
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syndrome type 2 (USH2) (Liu et al., 1999; Adato et al., 2000; McGee et al., 2010) 
(Section 1.6.3.5), but pathogenic variants in this gene also cause 10%-15% of non-
syndromic arRP (Rivolta et al., 2000; Xu et al., 2011; Zhao et al., 2014). USH2A encodes 
a protein called usherin that represents an important component of basement membranes. 
In the human retina, usherin localizes to the connecting cilia of photoreceptors, where it 
is likely to be involved in cargo delivery from the IS to the OS of the photoreceptor cell 
(van Wijk et al., 2004; Reiners et al., 2006; Maerker et al., 2008). 
 
More than 36,000 RP cases worldwide are due to defects in components of 
the heterotetrameric PDE 6 complex, estimated to account for approximately 6-14% of 
all diagnosed arRP (Ferrari et al., 2011). PDE6A, PDE6B and PDE6G, mutations in any 
of which cause RP, encode proteins important in the photoreceptor visual transduction 
cascade (Tsang et al., 1998) (Section 1.4). The PDE6 gene has a similar structure to the 
PDE5 gene. PDE5 expression is inhibited by sildenafil (Behn and Potter, 2001) and also 
heterozygous carriers of PDE6 mutations are at risk of losing vision when excessively 
inhibiting PDE6 with a commonly used medication for erectile dysfunction such as 
sildenafil, tadalafil, or vardenafil (Stockman et al., 2007; Tsang et al., 2008). 
 
Mutations in EYS (eyes shut homolog) appear to be a prevalent cause of RP in 
different population-based studies. Pathogenic variants in EYS are fairly common in the 
Chinese population (Abd El-Aziz et al., 2007), and accounts for 10%-30% of Spanish 
patients with arRP (Barragán et al., 2010). EYS is the largest gene that is known to be 
expressed in the human eye and is likely to have a role in the modelling of retinal 
architecture (Zelhof et al., 2006).  
 
ABCA4 and RPE65 encode proteins that are involved in retinoid metabolism (the 
visual cycle) (Section 1.4.4) and mutations in each of the two genes have been reported 
to account for between 2-5% of arRP cases. Mutations in ABCA4 also cause Stargardt 
disease (STGD) and are responsible for 30 to 60% of cases with autosomal recessive 
cone-rod dystrophy (CRD) (Section 1.7.3) (Cideciyan et al., 2009), while the RPE65 gene 
mutations also account for more than 10% of LCA patients (Section 1.8) (Gu et al., 1997; 
den Hollander et al., 2008).  
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1.6.3.2 Autosomal dominant RP (adRP) 
Autosomal dominant RP (adRP) affects men and women with equal frequency and 
severity and there tends to be a known history of the condition in the family, since an 
affected parent has a 50% chance of passing the defective gene to the offspring. Most 
cases that have been identified show complete penetrance of the mutation. However, great 
variation in phenotypes for adRP disease, even within the same pedigree, has been 
reported (Holopigian et al., 1996). adRP is the second most frequently inherited type of 
RP, accounting for approximately 15% to 20% of all RP cases, and 29 adRP genes have 
been identified to date. Like arRP genes, adRP genes encode proteins with a wide variety 
of retinal functions, including phototransduction, photoreceptor OS structure, tissue 
development & maintenance, regulation of cell growth and splicing (Table 1.3).  
 
Gene 
Estimated 
frequency 
Potential function OMIM Gene 
Estimated 
frequency 
Potential function OMIM 
RHO 20-30% Phototransduction 613731 PRPF3 ≤1% Splicing 607301 
PRPH2 5-10% 
Photoreceptor OS 
structure 
606419 PRPF4 unknown Splicing 615922 
PRPF31 5-10% Splicing 608133 PRPF6 Rare Splicing 613983 
RP1 3-4% 
Tissue development & 
maintenance 
603937 RDH12 Unknown Phototransduction 612712 
IMPDH1 2-3% Regulates cell growth 180105 ROM1 Rare Cellular structure 180721 
PRPF8 2-3% Splicing 607300 RP63 One family Unknown 614494 
KLHL7 1-2% 
Ubiquitin proteasome 
protein degeneration 
612943 RP9 Rare Splicing 607331 
NR2E3 1-2% Transcription factor 611131 RPE65 Rare Visual cycle 613794 
AIPL1 ≤1% 
Transport, protein 
trafficking 
604392 SNRNP200 1-2% Splicing 610359 
ARL3 ≤1% 
Transport, protein 
trafficking 
604695 SPP2 ≤1% Unknown 602637 
BEST1 Rare Anion channel 613194 TOPORS ≤1% 
Ubiquitin protein 
ligase 
609923 
CA4 Rare Unknown 114760 GUCA1B 
Rare (4-5% 
in Japan) 
Phototransduction 613827 
CRX 1% Transcription factor 602225 SEMA4A 
Rare (3-4% 
in Pakistan) 
Tissue development 
& maintenance 
610282 
HK1 ≤1% Glucose metabolic 605285 FSCN2 
Rare (3% in 
Japan) 
Cellular structure 607921 
NRL ≤1% 
Tissue development & 
maintenance 
613750   
 
Table 1.3. List of genes implicated in autosomal dominant RP (adRP). Gene name, estimated 
frequency (%) of adRP attributed to mutation of this gene and potential function are depicted 
along with the corresponding OMIM number. (Sources: RetNet, https://sph.uth.edu/retnet/ 
home.htm, OMIM, http: //www.ncbi.nlm.nih.gov/omim; Sohocki et al. (2000), Bowne et al. 
(2008), Daiger et al. (2008), Davidson et al. (2009), Bowne et al. (2011a), Tanackovic et al. 
(2011), Daiger et al. (2013), Fahim et al. (2013), Cvackova et al. (2014) and Nash et al. (2015)).  
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The most prevalent causes of adRP are mutations in RHO, PRPH2, PRPF31 and 
RP1. RHO, the first gene found to be mutated in RP (Dryja et al., 1990; Dryja et al., 1991), 
encodes the rod photoreceptor-specific rhodopsin. Absorption of a photon by this 
transmembrane protein initiates the visual phototransduction cascade (Section 1.4). More 
than 100 RHO pathogenic mutations have been reported to cause approximately 20-30% 
of all adRP cases (Wang et al., 2005). While extensive mutational heterogeneity has been 
characterized in human RHO (Lewin et al., 2014), one common founder mutation 
(NM_000539.3:c.68C>A, p.Pro23His) among Americans of European origin causes 
12%-14% of adRP in this population (Sullivan et al., 2006a). 
 
Mutations in Peripherin2/RDS (PRPH2) and PRPF31 are also common causes of 
adRP, each accounting for between 5%-10% of cases. Peripherin2 is a photoreceptor 
specific transmembrane glycoprotein necessary for the proper formation of both rod 
and cone POS. Mutations in PRPH2 are associated with a wide range of phenotypes 
including adRP, autosomal dominant macular degeneration (adMD) and complex 
maculopathies (Cheng et al., 1997; Stuck et al., 2016). PRPF31 encodes a protein 
involved in pre-mRNA splicing and genomic rearrangements in this gene account for 5-
10% of adRP, this form of adRP shows partial penetrance in that it often skips generations 
(Sullivan et al., 2006b; Villanueva, 2014).  
 
Known pathogenic variants in RP1 (Retinitis Pigmentosa 1) account for 3%-4% of 
adRP, with two common founder mutations (NM_006269.1: c.2029C>T, p.R677*and 
c.2285_2289delTAAAT, p.L762Yfs*17) accounting for 2%-3% of all adRP cases. 
(Payne et al., 2000; Gamundi et al., 2006; Audo et al., 2012b; Fahim et al., 2013). RP1 is 
a photoreceptor microtubule-associated protein that plays an essential and synergistic role 
with RP1L1 in OS morphogenesis to maintain the photosensitivity of rod photoreceptors 
(Yamashita et al., 2009) .  
 
1.6.3.3 X-linked RP 
XLRP is the least frequently inherited type of RP, accounting for only 10% to 15% 
of cases. In XLRP, there is no male to male transmission of the abnormal gene and female 
carriers have a 50% chance of passing XLRP to their sons, while all female offspring will 
have a 50% chance of being a carrier. Males with XLRP are characterized by a severe 
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phenotype during the early stages of disease. A milder phenotype can sometimes occur 
in female carriers (Comander et al., 2015), probably due to non-random or skewed 
inactivation of one X chromosome (Friedrich et al., 1993; Carrel and Willard, 2005). Six 
loci have been mapped on X-chromosome that are responsible for XLRP (RP6, RP23, 
RP24, RP34, RP2 and RPGR), but only three mutated genes have been identified so far. 
These are the retinitis pigmentosa GTPase regulator (RPGR/RP3), the retinitis 
pigmentosa 2 (RP2) and the retinitis pigmentosa 23 (RP23) or oral facial digital syndrome 
1 (OFD1).  
 
Pathogenic mutations in RPGR (OMIM 312610) are the most common cause of 
XLRP accounting for 70 to 75% of all XLRP cases and 15-20% of nonsyndromic RP in 
North American families (Breuer et al., 2002; Shu et al., 2007; Churchill et al., 2013). 
RPGR has two major transcripts, RPGRex1-19 that contains 19 exons, encoding 815 
amino acids protein, and RPGR-ORF15 that has 15 exons, encoding 1152 amino acids 
protein. RPGR-ORF15 shares exons 1-14 with RPGRex1-19 plus the exon open reading 
frame 15 (ORF15) that encodes 567 amino acids with a highly repetitive glycine and 
glutamic acid-rich domain (Meindl et al., 1996; Vervoort et al., 2000). RPGR mutations 
are associated with XLRP, CRD and MD. Most mutations in this gene are detected in 
ORF15 region that represent a mutational hotspot, with a mutation rate of 30-60% of all 
XLRP cases (Vervoort et al., 2000; Pusch et al., 2002; Shu et al., 2008; Branham et al., 
2012). RPGR localizes to the POS in human and to photoreceptor connecting cilia in 
mouse (Mavlyutov et al., 2002; Hong et al., 2003). RPGR is involved in ciliogenesis 
(Gakovic et al., 2011; Patnaik et al., 2015) and has many interacting partner proteins such 
as RPGR interacting protein 1 (RPGRIP1), RPGRIP1-like protein (RPGRIP1L), delta 
subunit of phosphodiesterase (PDEδ), structural maintenance of chromosomes (SMC) 1 
and SMC3 (Linari et al., 1999; Hong et al., 2001; Khanna et al., 2005). The role of the 
RPGR in ciliogenesis was supported by genetic studies where bronchiectasis, respiratory 
tract infections and sensorineural hearing loss, were associated with XLRP caused by an 
RPGR mutations with variable penetrance (Iannaccone et al., 2003; Koenekoop et al., 
2003; Zito et al., 2003; Moore et al., 2006) . Interestingly, mutations causing syndromic 
XLRP, to date, are restricted to exons 1–14, suggesting mutations in ORF15 may not be 
a cause of extraocular phenotypes (Tee et al., 2016). 
 
Approximately 10-15% of XLRP patients have mutations in the RP2 gene (OMIM 
312600). The amino-terminal domain of RP2 has a cofactor C domain that share 
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homology with tubulin-specific chaperone protein, essential component in tubulin folding 
(Evans et al., 2006). RP2 has a potential role for in maintaining Golgi cohesion and 
targeting of proteins to plasma membrane (Evans et al., 2010). Mutations in this gene 
cause incorrect folding of the photoreceptor or neuron-specific tubulin isoforms followed 
by progressive retinal degeneration (Bartolini et al., 2002; Patil et al., 2011). OFD1/RP23 
(OMIM 311200) is a more recently identified causative gene for XLRP (Webb et al., 
2012). OFD1 plays a role in controlling photoreceptor cilium length and number, and 
protects the photoreceptor from oxidative stress and apoptosis (Wang et al., 2016a). 
Mutations in OFD1 also cause a group of ciliopathy related disorders. These include 
Joubert syndrome (OMIM 300804) (Wentzensen et al., 2016) which is characterised as a 
neurodevelopmental disorder, with brain abnormalities called the molar tooth sign, 
respiratory problems in infancy and RD, and oral facial digital type 1 syndrome (OMIM 
311200) (Ferrante et al., 2001; Thauvin-Robinet et al., 2006; Tsurusaki et al., 2013), 
which is an X-linked dominant condition with lethality in males in the first or second 
trimester pregnancy and is characterized by facial anomalies, abnormalities in oral 
tissues, digits, brain, and kidney. 
 
1.6.3.4 Digenic and mitochondrial RP 
Other rare modes of RP inheritance include digenic RP which was reported as 
heterozygous mutations in PRPH2 and ROM1 (Kajiwara et al., 1994; Goldberg and 
Molday, 1996; Dryja et al., 1997). Also mitochondrial inheritance was reported in RP 
(Mansergh et al., 1999) in which mitochondrial DNA defects were transmitted through 
maternal transmission. 
 
 1.6.3.5 Usher syndrome (USH) 
Usher syndrome (USH) (OMIM 276900-276902) is an autosomal recessive genetic 
disease characterized by hearing loss, RP and in some cases vestibular dysfunction 
(balance problems). The syndrome is the most frequent cause of deaf-blindness, 
accounting for more than 50% of individuals who are both deaf and blind. It has a 
prevalence in the range of 1-4 per 25,000 people, and Usher cases represent between 10-
15% of all autosomal recessive RP cases (Boughman et al., 1983; Hartong et al., 2006; 
Kimberling et al., 2010; Millan et al., 2011; Mathur and Yang, 2015). Usher syndrome is 
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genetically and clinically heterogeneous and can be divided into three clinical subtypes 
based on severity of hearing loss and age-of-onset of retinal dysfunction.  
 Usher syndrome type 1. Congenital, severe-to-profound deafness, lack of 
development of speech, vestibular areflexia and onset of slowly progressive RP 
within the first decade of life. 
 Usher syndrome type 2. Congenital moderate-to-severe hearing impairment, normal 
vestibular responses and onset of RP within the second decade of life. 
 Usher syndrome type 3. Variable hearing loss, vestibular dysfunction and RP are 
sporadic and slowly progressive. 
 
RP in USH patients causes night-blindness and loss of peripheral vision due to rod 
photoreceptor degeneration. As the degeneration of the retina progresses, cone 
photoreceptors also degenerate and cone density can decrease by nearly 38% before 
visual acuity becomes abnormal (Sun et al., 2016). Loss of central vision results in USH 
patients becoming legally blind, and there is no known cure (Nagel-Wolfrum et al., 2014). 
To date, sixteen loci have been associated with USH: nine are involved in USH1, three 
in USH2, two in USH3 and two are not specified (Table 1.4) (Keats and Corey, 1999; 
Ebermann et al., 2010; Puffenberger et al., 2012; Khateb et al., 2014; Mathur and Yang, 
2015). From these loci, thirteen genes have been identified. They include six USH1, three 
USH2, two USH3, one USH modifier (PDZD7) and one a typical USH gene (CEP250). 
  
USH type locus Gene Potential function Estimated frequency 
USH1 
USH1B/DFNB2/DFNA1 MYO7A Actin-based motor protein 53%-63% 
USH1C/DFNB18 USH1C PDZ scaffold protein 1%-15%  
USH1D/DFNB12 CDH23 Cell adhesion 7%-20% 
USH1E unknown Unknown unknown 
USH1F/DFNB23 PDCH15 Cell adhesion 7%-12%  
USH1G USH1G Scaffold protein 0%-4% 
USH1H unknown Unknown unknown 
USH1J CIB2 Ca2+ and integrin binding unknown 
USH1K unknown Unknown unknown 
USH2 
USH2A/RP USH2A Cell adhesion 57%-79% 
USH2C GPR98/ ADGRV1 G-protein coupled receptor 6.6%-19% 
USH2D/DFNB31 DNFB31/WHRN PDZ scaffold protein 0%-9.5% 
USH3 
USH3A CLRN1 Auxiliary subunit of ion channels unknown 
USH3B HARS Synthesis of histidyl-transfer RNA unknown 
unknown unknown PDZD7 PDZ scaffold protein unknown 
unknown unknown CEP250 Centrosomal activity unknown 
 
 
Table 1.4. Genetics of Usher syndrome (USH). USH loci, genes, potential function and 
proportion of each USH subtype attributed to pathogenic variants in this gene. (Sources: RetNet, 
https://sph.uth.edu/retnet/ home .htm, Lentz and Keats (1993a), Lentz and Keats (1993b), Daiger 
et al. (2013), Mathur and Yang, (2015).  
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1.6.3.6 Bardet-Biedl syndrome (BBS)  
Bardet-Biedl syndrome (BBS) (OMIM 209900) is an autosomal recessive 
multisystemic genetic disorder characterised by heterogeneous clinical manifestations. 
These include primary features of the disease (obesity, renal anomalies, polydactyly, 
retinal degeneration, learning difficulties and hypogenitalism) and secondary features 
(speech deficit, hearing loss, developmental delay, cardiovascular anomalies, dental 
defects, hypertension, olfactory deficit and diabetes mellitus) (M'Hamdi et al., 2014; 
Khan et al., 2016b; Suspitsin and Imyanitov, 2016). The severity of BBS varies greatly 
even among individuals within the same family and symptoms may not be present at birth 
but usually develop in the first decade of life. The retinal degeneration in BBS patients is 
typically rod-cone dystrophy (RCD), which is reported to affect 93-100% of BBS patients 
(Suspitsin and Imyanitov, 2016). Fundus photographs of BBS patients usually show mid-
peripheral bone spicule formation with early macular atrophy involvement (Adams et al., 
2007). Night blindness is usually evident by age 7-8 years and most patients are legally 
blind by the second or third decade (Heon et al., 2005; Azari et al., 2006). 
 
BBS is a rare autosomal recessive genetic disorder with estimated frequency 
1:100,000 in the European and North America populations (Forsythe and Beales, 2013). 
Unusual higher incidence has been reported in isolated populations, such as 1:3,700 in 
Faroe Islands (Hjortshoj et al., 2009), 1:18,000 in Newfoundland (Moore et al., 2005) and 
1:13,500 in some Bedouin communities at Middle East (Farag and Teebi, 1989; M'Hamdi 
et al., 2011). This is likely to reflect the presence of local founder mutations or a high 
level of cousin-marriage in these populations.  
 
Twenty BBS genes have been identified so far (Suspitsin and Imyanitov, 2016), and 
all of them are involved in primary cilia functioning. 23% of BBS morbidity has been 
attributed to BBS1 (Muller et al., 2010), 8% to BBS2 (Fattahi et al., 2014), 0.4% to 
BBS3/ARL6 (Fan et al., 2004), 2% to BBS4 (Mykytyn et al., 2001), 0.4% BBS5 (Li et al., 
2004), 6% to BBS6/MKKS (Slavotinek et al., 2000), 2% to BBS7 (Badano et al., 2003), 
1% to BBS8/TTC8 (Ansley et al., 2003), 6% to BBS9/ B1 (Nishimura et al., 2005), 20% 
to BBS10 /C12orf58 (Stoetzel et al., 2006), 0.1% to BBS11/TRIM32 (Chiang et al., 2006), 
5% to BBS12/C4orf24 (Stoetzel et al., 2007), 4.5% BBS13 /MKS1 (Leitch et al., 2008), 
1% to BBS14/CEP290 (Leitch et al., 2008), 1% to BBS15/ C2orf86 (Kim et al., 2010), 
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1% to BBS16 /SDCCAG8 (Billingsley et al., 2012) and unknown proportions to BBS17/ 
LZTFL1(Schaefer et al., 2014), BBS18/BBIP1 (Scheidecker et al., 2014), BBS19/IFT27 
(Aldahmesh et al., 2014), and BBS20/IFT172 (Schaefer et al., 2016). 
 
1.7 Macular and cone related disorders. 
1.7.1 Overview 
Inherited macular and cone related disorders are a rare group of inherited eye 
diseases of the cone, or cone and rod photoreceptors, or RPE, that are associated with 
various forms of stationary or progressive visual impairment. Cone related degeneration 
is a clinically heterogeneous disease category within which the cone photoreceptors are 
primarily affected. Macular dystrophy (MD) is a diagnosis based on the anatomical area 
of the retina affected. Patients show a localised abnormality of the neuro retina at the 
macula whereas the retinal periphery is spared. In contrast, cone dystrophy (COD) and 
cone-rod dystrophy (CRD) affect a particular category of photoreceptor throughout the 
retina.  All patients with these diseases suffer from difficulties in detecting colour vision, 
facial recognition and reading (Hamel, 2007). These diseases are commonly divided into 
sub groups of retinal dystrophy, including achromatopsia (ACHM), COD, CRD, MD and 
other cone related disorders. All modes of Mendelian inheritance, i.e. autosomal recessive 
(AR), autosomal dominant (AD) and X-linked (XL) forms exist, and the disease can 
present as non-syndromic and syndromic forms. An AR inheritance pattern represents the 
main mode of inheritance, accounting for more than two third of all cases. AD inheritance 
accounts for 20-25% of all cases while X-linked inheritance represents only 1-5 % 
(Roosing et al., 2014). 
 
1.7.2 Achromatopsia (ACHM) 
Achromatopsia is an inherited retinal disease characterized by severely impaired or 
complete colour blindness. Patients present with significantly reduced visual acuity 
(<20/200), nystagmus and severe photophobia (Zelinger et al., 2015; Kohl et al., 2016). 
Most affected individuals with ACHM show normal rod responses but complete absence 
of cone responses on full-field electroretinography (ffERG). Sometimes the phenotype is 
described as incomplete ACHM with milder symptoms since residual cone function can 
be demonstrated by residual cone responses on ffERG (Kohl et al., 2000; Thiadens et al., 
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2009b). ACHM was thought to be a congenital and stationary disorder, but a progressive 
form of the disease has been reported with a changing macular appearance over time 
ranging from no apparent abnormalities to atrophic lesions (Thiadens et al., 2010; Kohl 
et al., 2012).  
 
The estimated prevalence of ACHM is 1:40,000 individuals and it is exclusively 
inherited in an AR manner. To date, six genes have been shown to be associated with 
ACHM. Five genes encode proteins that are involved in cone phototransduction, 
including 2 subunits of the cone cyclic guanosine monophosphate–regulated cation 
channel (CNGA3 and CNGB3) (Kohl et al., 1998; Sundin et al., 2000; Chen et al., 2015; 
Liang et al., 2015), the alpha subunit of the cone-specific G-protein transducin (GNAT2) 
(Kohl et al., 2002; Ouechtati et al., 2011), and the active and inhibitory γ subunits of the 
cone-specific phosphodiesterase PDE6C and PDE6H, respectively (Thiadens et al., 
2009c; Kohl et al., 2012). The sixth ACHM gene is ATF6, which encodes a transcription 
factor that acts as a key regulator of the unfolded protein response and cellular 
endoplasmic reticulum homeostasis (Ansar et al., 2015; Kohl et al., 2015). Mutations in 
CNGB3 represent the most common cause of AR ACHM, accounting for more than 40% 
of all cases, mainly owing to a single frameshift mutation (c.1148delC), which is found 
in approximately 70% of all CNGB3 disease-causing alleles (Kohl et al., 2005). CNGA3 
is mutated in about 25% of ACHM cases. Mutations in GNAT2, PDE6C, PDE6H and 
ATF6 are rare (Grau et al., 2011). 
 
1.7.3 Cone and cone-rod dystrophies (COD and CRD) 
1.7.3.1 Overview 
COD and CRD have an estimated worldwide prevalence of 1:30.000 to 1:40.000, 
display all types of Mendelian inheritance and are characterized by predominantly retinal 
pigment deposits to the macular region (Michaelides et al., 2004; Roosing et al., 2013). 
Patients with COD have normal cone function at birth, but develop progressive loss of 
cones and central vision during the first or second decade of life. Photophobia may also 
be observed but because the cone function is initially normal in COD, nystagmus does 
not usually exist. Fundus appearance varies from normal to a bull's eye maculopathy and 
the optic nerve may have variable degrees of temporal pallor (Perrault et al., 1998). 
Reduced cone responses with preserved rod responses on ERG are an important clinical 
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hallmark for the diagnosis of COD (Michaelides et al., 2006). Both diseases are 
characterized by loss of cone photoreceptors and a progressive visual decline, but CRD 
can be distinguished from COD by subsequent or simultaneous loss of rod photoreceptors 
(Roosing et al., 2014). 
 
An RD would thus be called a CRD in a patient who experienced a progressive 
inherited retinal disorder characterized by a primary loss of cone photoreceptors followed 
by involvement of rod photoreceptors. This is distinguished from COD by loss of both 
cones and rods on ERG (Scholl and Kremers, 2003). Symptoms resemble those of COD 
but patients with CRD also may experience nyctalopia caused by rod dysfunction. Fundus 
appearance in patients with CRD shows retinal vascular attenuation and peripheral 
pigment deposits. The course of CRD is generally more severe than COD. Disease 
symptoms usually become apparent in childhood with a rapid decline of the visual 
function to legal blindness before the age of 50. COD and CRD are clinically overlapping 
diseases and often difficult to distinguish at the advanced stage, and indeed CRD might 
be difficult to differentiate from RP based on clinical signs alone, but complete blindness 
is a more frequent occurrence in CRD than RP (Thiadens et al., 2012; Yokochi et al., 
2012).  
 
Figure 1.8. Colour fundus photography of CRD patient. Fundus changes with macular 
dystrophies show pigment deposits in the central macular area (arrow) and attenuated retinal 
arteries. (Adapted from Huang et al. (2012) with the permission of Elsevier Copyright Clearance 
Centre, License number: 3940440860754). 
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1.7.3.2 Genetics of COD and CRD 
Unlike ACHM, in which mutations in only six genes can explain the majority of 
the cases, Mendelian mutations in 33 genes are known to cause COD/CRD. 21 of these 
genes account for autosomal recessive COD/CRD, while 10 genes are responsible for 
autosomal dominant disease. In addition, two genes have been found to be responsible 
for X-linked COD/CRD (Table 1.5). CRD/COD genes encode proteins that are involved 
in multiple functions, including phototransduction, the visual cycle, cilia function and 
protein trafficking. The four major genes involved in the pathogenesis of COD/CRD are 
ABCA4 in AR COD/CRD, GUCY2D and CRX in AD COD/CRD and RPGR in X-linked 
COD/CRD (Hamel, 2007). 
Gene Inheritance Potential function OMIM 
PDE6C Recessive Phototransduction 600827 
PDE6H Recessive Phototransduction 601190 
CNGB3 Recessive Phototransduction 605080 
ABCA4 Recessive Visual cycle 601691 
RDH5 Recessive Visual cycle 601617 
RAX2 Recessive Transcription 610362 
RPGRIP1 Recessive Interacts with RPGR 605446 
ADAM9 Recessive Cell/matrix interaction 602713 
TTLL5 Recessive Cilia function 612268 
CACNA2D4 Recessive Ion channel 608171 
KCNV2 Recessive Ion channel subunit 607604 
CDHR1 Recessive Cellular structure 609502 
C21orf2 Recessive Unknown 603191 
C8orf37 Recessive Unknown  614477 
CNNM4 Recessive Unknown 607805 
RAB28 Recessive Unknown 612994 
CERKL Recessive Cell signaling 608381 
ATF6 Recessive Transcription factors 605537 
CNGA3 Recessive Phototransduction 600053 
GNAT2 Recessive Phototransduction 139340 
POC1B Recessive Centriole duplication and/or maintenance 614784 
PROM1 Dominant Cellular structure 604365 
GUCA1A Dominant Phototransduction 600364 
GUCY2D Dominant Phototransduction 600179 
PRPH2 Dominant Phototransduction 179605 
CRX Dominant Transcription factor 602225 
AIPL1 Dominant Transport, protein trafficking 604392 
HRG4 Dominant Neurotransmitter release 604011 
RIMS1 Dominant Neurotransmitter release 606629 
PITPNM3 Dominant Transport 608921 
SEMA4A Dominant  Axon guidance 607292 
RPGR X-Linked  Intraflagellar transport 312610 
CACNA1F X-Linked Calcium channel 300110 
 
 
Table 1.5. List of genes implicated in cone or cone-rod dystrophy (COD/CRD). Gene name, 
mode of inheritance and potential function are depicted along with the corresponding OMIM 
number. (Sources: RetNet, https://sph.uth.edu/retnet/home.htm; OMIM, http://www.ncbi.nlm. 
nih.gov/ omim). 
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The ABCA4 gene encodes an ATP-binding cassette (ABC) superfamily 
transmembrane protein that is expressed exclusively in retinal photoreceptors and is 
involved in retinoid metabolism (Section 1.4.4). Mutations in ABCA4 cause STGD 
disease and are responsible for 30 to 60% of the cases with AR COD/CRD (Hamel, 2007; 
Cideciyan et al., 2009). 
 
GUCY2D (LCA1) encodes retinal guanylate cyclase 1 (RetGC-1), which is one of 
a group of proteins that are important in determining how rods and cones can return to 
the resting state after being stimulated by light (Figure 1.5B, Table 1.1) (Perrault et al., 
2000; Tucker et al., 2004). Defects in this gene leave the eye unable to respond to light, 
which ultimately leads to RD. Biallelic mutations in GUCY2D are the most common 
cause of arLCA, accounting 12-21% of all disease cases, while monoallelic mutations are 
a common cause of COD/CRD/MD. Mutations in GUCY2D account for more than a third 
of cases with dominant form of COD/CRD/MD. Pathogenic variants in GUCY2D have 
been associated with RD characterized by photophobia, high hyperopia and poor but 
stable vision with no visual improvement (Perrault et al., 1999; Hanein et al., 2004). For 
the GUCY2D-LCA phenotype, more than half of the mutations identified in patients are 
truncating mutations that cause complete loss of retGC-1 catalytic activity and lead to 
loss of the outer nuclear layer and abnormal inner retinal and synaptic organization (Rozet 
et al., 2001; Milam et al., 2003). For the GUCY2D-COD/CRD/MD phenotype, the 
majority of the pathogenic missense mutations map in the catalytic domain of the protein 
causing dramatic consequences on protein activity (Jiang et al., 2015; Lazar et al., 2015). 
 
The CRX gene encodes the cone-rod homeobox protein, a transcription factor 
expressed in rod and cone photoreceptors in the retina and pinealocytes in the brain (Chen 
et al., 1997; Furukawa et al., 1997). CRX plays an essential role in the development and 
maintenance of functional mammalian rod and cone photoreceptors (Furukawa et al., 
1999). It interacts with transcription co-regulators including the rod-specific transcription 
factors NRL, NR2E3 and general co-activator proteins GCN5, CBP and p300 to control 
photoreceptor gene expression and induce rhodopsin promoter activity (Mitton et al., 
2000; Peng et al., 2005; Roduit et al., 2009; Nichols et al., 2010). Photoreceptors in 
homozygous Crx knock-out mice (Crx−/−) fail to form POS (Sanyal and Jansen, 1981; 
Humphries et al., 1997; Furukawa et al., 1999), leading to progressive degeneration 
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(Blackshaw et al., 2001; Morrow et al., 2005; Hsiau et al., 2007). Mutations in 
human CRX have been associated with adLCA, adCRD, adRP and arLCA with different 
ages of onset and severity (Sohocki et al., 1998; Dharmaraj et al., 2000; Rivolta et al., 
2001; Nichols et al., 2010; Walia et al., 2010; Huang et al., 2012). Disease-causing 
human CRX mutations can be divided into two groups. One group is mostly monoallelic 
frameshift mutations or amino acid substitutions within the DNA binding homeodomain. 
This group of mutations shows a dominant-negative effect on the wild-type allele activity 
(Mitton et al., 2000; Peng et al., 2005; Roduit et al., 2009; Nichols et al., 2010), and leads 
to a severe dominant retinal phenotype adCRD/adLCA (Sohocki et al., 1998; Paunescu 
et al., 2007; Wang et al., 2007; den Hollander et al., 2008; Huang et al., 2012). The other 
group of mutations also demonstrate a reduced ability of CRX to bind to the targeted 
protein (Nichols et al., 2010), but these mutations appear to represent hypomorphic alleles 
and are more likely to be associated with either autosomal recessive Leber congenital 
amaurosis (LCA) or less severe forms of dominant CRX-associated disease adRP 
(Swaroop et al., 1999). 
 
1.8 Leber congenital amaurosis (LCA) 
1.8.1 Overview 
Leber congenital amaurosis (LCA; OMIM 204000), first described by Theodor 
Leber in 1869 (Leber, 1869), represents the most severe and earliest form of IRDs, 
causing blindness in infants and children (Perrault et al., 1999). LCA is a rare disease 
with a population frequency between 1 in 30,000 to 1 in 81,000 (Koenekoop, 2004; Stone, 
2007), although the condition is more frequent in consanguineous populations or isolated 
communities (Sherwin et al., 2008). LCA represents almost 5% of all retinal dystrophies 
and 20% of children with visual impairment in special schools (Koenekoop et al., 2007). 
This dystrophy is highly heterogeneous, has complex genetic and clinical features and 
overlaps with the more severe forms of RP and COD/CRD (den Hollander et al., 2008). 
 
1.8.2 Clinical manifestation of LCA 
For the LCA infant, although blind at birth, the features usually first manifest at 
around the age of 6 weeks, when the parents notice the child’s eyes oscillating 
(nystagmus) (Zahn, 1978). LCA is characterized by severe and early visual impairment 
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and visual acuity among LCA patients ranges from 20/200 to perception of light only or 
no perception of light. Generally patients with LCA do not achieve visual acuity better 
than 20/400 (Cremers et al., 2002). Sluggish or near-absent pupillary responses reflecting 
severe retinal dysfunction and absence of electrical signals on ERG are also clinical 
hallmarks for LCA (Franceschetti and Dieterle, 1954; Chung and Traboulsi, 2009). 
The appearance of the fundus is extremely variable in patients. The retina may initially 
appear normal, but fundus abnormalities are frequently present later in life (Figure 1.9) 
including white dots at the level of the RPE, retinal vascular attenuation, bone-spicule 
pigment migration, macular coloboma or maculopathy. Refractive errors, photophobia 
and nyctalopia are also commonly detected (den Hollander et al., 2008; Chung and 
Traboulsi, 2009; Hull et al., 2014; Chacon-Camacho and Zenteno, 2015). 
 
Figure 1.9. Colour fundus photography of LCA patients with known genotypes. LCA 
associated with a CEP290 mutation has marked choroidal sclerosis, pale optic discs, barely visible 
retinal vessels and relative preservation of the posterior pole. CRX-associated LCA manifests as 
a prominent maculopathy with relatively normal appearing vessels and optic disc. The fundus in 
CRB1-associated LCA reveals a preserved para-arteriolar RPE (PPRPE) and nummular pigment 
changes. GUCY2D-associated LCA patients have a relatively normal retinal appearance including 
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retinal colour, retinal vessel calibre, and optic disc appearance. RPE65-associated LCA leads to 
RPE translucency but with relatively normal vessel calibre and a normal optic disc appearance. 
RDH12-associated LCA is characterised by nystagmus, nyctalopia and a prominent maculopathy. 
RPGRIP1-associated LCA patients have a retinal pigment epithelium degeneration with bone 
spicules and vessel dragging. (Adapted from den Hollander et al. (2008) with the permission of 
Elsevier Copyright Clearance Centre, License number: 3926710489180). 
 
1.8.3 Genetics of LCA 
LCA is genetically heterogeneous and can result from mutations in 24 genes (Table 
1.6). In most cases, LCA is inherited in an autosomal recessive manner and LCA genes 
encode proteins that play a variety of roles in the development and function of the retina 
such as normal development of photoreceptors, phototransduction, normal function of the 
cilia and protein trafficking.  
 
Locus Gene inheritance Potential function 
Estimated 
frequency 
OMIM 
LCA1 GUCY2D Recessive Phototransduction 12-21% 601777 
LCA2 RPE65 Recessive Visual cycle 3-16% 204100 
LCA3 SPATA7 Recessive Unknown 2-4% 609868 
LCA4 AIPL1 Recessive    Transport, protein trafficking 4-8% 604393 
LCA5 LCA5 Recessive Centrosome protein with ciliary function 1-7% 611408 
LCA6 RPGRIP1 Recessive Interacts with RPGR 4-6% 613826 
LCA7 CRX Dominant & Recessive    Transcription factor 2-3% 613829 
LCA 8 CRB1 Recessive    Tissue development and maintenance 9-13% 613835 
LCA9 NMNAT1 Recessive    Photoreceptor maintenance 5% 608700 
LCA 10 CEP290 Recessive Centrosomal & ciliary protein 20 -25% 611755 
LCA 11 IMPDH1 Dominant Regulates cell growth  Rare 613837 
LCA12 RD3 Recessive Splicing Rare 610612 
LCA13 RDH12 Recessive Phototransduction 4% 612712 
LCA 14 LRAT Recessive    Retinal metabolism ≤1% 613341 
LCA 15 TULP1 Recessive    Tissue development & maintenance 1-2% 613843 
LCA 16 KCNJ13 Recessive Potassium channel Unknown 614186 
LCA 17 GDF6 Recessive Growth factor Unknown 615360 
LCA18 
PRPH2/ 
/RDS  
Recessive Phototransduction Unknown 179605 
--- CABP4 Recessive Unknown Cell signalling 610427 
--- IQCB1 Recessive Interacts with RPGR & connecting cilia Unknown  09254 
--- IFT140 Recessive Intraflagellar transport  ≤1% 614620 
--- CLUAP1 Recessive Ciliogenesis Unknown 616787 
--- DTHD1  Recessive Unknown    Unknown 616979 
--- OTX2 Dominant    Transcription factor Rare 600037 
 
 
Table 1.6. List of genes implicated in Leber congenital amaurosis (LCA). Locus, gene name, 
mode of inheritance and potential function and estimated frequency are depicted along with the 
corresponding OMIM number ‘Sources: RetNet, https://sph.uth.edu/retnet/home.htm; OMIM, 
http: //www.ncbi.nlm .nih.gov/omim; Weleber et al. (2013); Nash et al. (2015). 
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Mutations in the CEP290, CRB1, GUCY2D and RPE65 genes are the most common 
causes of the disorder and only three genes CRX, IMPDH1 and OTX2 cause adLCA. 
Mutations in the other genes generally account for a smaller percentage of cases. 
 
CEP290 is the most frequently mutated gene in LCA and accounts for 20-25% of 
all cases (den Hollander et al., 2006; Perrault et al., 2007; Coppieters et al., 2010a). 
CEP290 encodes a centrosomal protein that is thought to play an important role in protein 
trafficking and ciliogenesis in many different cell types including retinal photoreceptor 
cells (Chang et al., 2006; Sayer et al., 2006; Craige et al., 2010). Interestingly, one intronic 
mutation (c.2991+1655A>G) accounts for up to 15% of all LCA cases in some European 
and North-American populations (den Hollander et al., 2006; Coppieters et al., 2010a). 
This deep-intronic CEP290 mutation creates a splice donor site that allows the insertion 
of a 128-bp cryptic exon to approximately 50% of the CEP290 transcripts, resulting in a 
premature termination of protein synthesis (den Hollander et al., 2006; Collin et al., 
2012). Mutations in the CEP290 gene have also been associated with a wide range of 
ciliopathies including Joubert syndrome (JBTS5, OMIM 610188), Senior–Loken 
syndrome (SLSN6, OMIM: 610189), Meckel syndrome (MKS4, OMIM 611134) and 
Bardet–Biedl syndrome (BBS14, 615991) (Baala et al., 2007; Brancati et al., 2007; Helou 
et al., 2007; Leitch et al., 2008; Coppieters et al., 2010b). The majority of the reported 
CEP290 mutations are truncating in all phenotypes with only a few missense mutations 
reported (Valente et al., 2006; Tory et al., 2007). Moreover there appears to be no 
genotype-phenotype correlation for CEP290 mutations leading to all these different 
diseases. The only genotype-phenotype correlation observed is with the common founder 
mutation (c.2991+1655A>G) which so far has only been seen in patients with isolated 
LCA (den Hollander et al., 2006; Perrault et al., 2007).  
 
RPE65 (retinal pigment epithelium 65) encodes a retinoid isomerohydrolase with 
an essential role in the visual cycle (Figure 1.6) (Moiseyev et al., 2005). RPE65 is 
essential for the conversion of activated all-trans-retinal to 11-cis–retinal, the universal 
chromophore of the visual pigments in both cone and rod photoreceptors (Section 1.4.4). 
More than 70 different point mutations in RPE65 are associated with severe early onset 
retinal dystrophies LCA (3-16%), RP (2-5%) and approximately 11% of early onset RCD 
(Gu et al., 1997; Marlhens et al., 1997; Thompson et al., 2000; den Hollander et al., 2008; 
Bowne et al., 2011a; Hull et al., 2016). All patients with RPE65 mutations had reduced 
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central vision at infancy or early childhood with nyctalopia as a prominent feature and 
varying degrees of nystagmus. The fundus appearance is usually normal in infancy but 
small subretinal white dots might appear later in childhood, possibly as a result of 
abnormal accumulation of retinyl esters (Lorenz et al., 2000; Galvin et al., 2005; Weleber 
et al., 2011). Thinning of the outer nuclear layer on optical coherence tomography (OCT) 
and low signal on fundus autofluorescence (FAF) are also common in patients with 
RPE65 mutations (Lorenz et al., 2004; Jacobson et al., 2008b). Electrophysiology 
demonstrates absent rod function but there may be residual cone function in childhood 
(Jacobson et al., 2009). This may reflect the alternative source of 11-cis-retinol that cones 
obtain from Müller cells (Kaylor et al., 2014). Mice lacking RPE65 (Rpe65−/−) cannot 
synthesize 11-cis-retinol and all-trans-retinyl esters over-accumulate in the RPE, whereas 
11-cis-retinyl esters are absent. As a result, photoreceptors in these mice lose sensitivity 
to light (Redmond et al., 1998; Cottet et al., 2006; Fan et al., 2008; Feathers et al., 2008). 
 
CRB1 is a human homologue of the Drosophila melanogaster gene coding for the 
protein crumbs (Crb). CRB1 is expressed in the retina and the brain, and is involved in 
photoreceptor morphogenesis (den Hollander et al., 1999). Mutations in the CRB1 gene 
are associated with variable RD phenotypes, ranging from congenital blindness in LCA 
to early-onset progressive visual impairment in early onset retinal dystrophy (EORD) and 
early onset RP (EORP) (Booij et al., 2005; Yzer et al., 2006; Vallespin et al., 2007a; Tosi 
et al., 2009; Henderson et al., 2011; Bujakowska et al., 2012). Among arLCA genes, 
CRB1 mutations represent one of the most frequent causes, accounting for between 9-
13% of all LCA cases (den Hollander et al., 2004; den Hollander et al., 2008; Benayoun 
et al., 2009). LCA and RP resulting from CRB1 mutations may be accompanied by 
specific fundus features. These include preservation of the para-arteriolar retinal pigment 
epithelium (PPRPE), which is a relative preservation of RPE adjacent to the retinal 
arterioles despite a panretinal RPE degeneration (Heckenlively, 1982), retinal 
telangiectasia/Coats-like vasculopathy, a condition in which abnormally permeable blood 
vessels lead to exudation and retinal detachment (Cahill et al., 2001; den Hollander et al., 
2001) and an increased retina thickness with altered laminar organization (Jacobson et 
al., 2003). 
 
IMPDH1 (inosine-5'-monophosphate dehydrogenase 1) is a housekeeping gene 
encoding a protein subunit that forms active homotetramers and catalyzes the rate-
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limiting step in de novo guanine synthesis. IMPDH1 performs this by converting inosine 
monophosphate (IMP) to xanthosine monophosphate (XMP) with the reduction of NAD 
(Senda and Natsumeda, 1994; Hedstrom, 1999). IMPDH1 levels are higher in the retina 
than in any other tissue and the protein is localized to the photoreceptor IS at synaptic 
terminals (Bowne et al., 2006). Mutations in IMPDH1 cause adRP or adLCA due to 
photoreceptor degeneration as reduced enzyme activity leads to reduced guanine 
nucleotide concentrations in the retina (Bowne et al., 2002; Coussa et al., 2015).  
 
OTX2 (orthodenticle homeobox 2) encodes a transcription factor that is critical for 
the development of the forebrain and eye. It is expressed in the neuroepithelium of most 
of the forebrain and midbrain, including the eye domain (Simeone et al., 1993). The 
protein plays a critical role in retinal photoreceptor development and maintenance, and is 
required for the development of the RPE (Martinez-Morales et al., 2003; Rath et al., 
2007). Mutations in OTX2 have been reported to cause adLCA and adMD (Vincent et al., 
2014). In mice, homozygous mutants (Otx2−/−) are embryonically lethal. Heterozygous 
mice show a wide phenotypic variability, including craniofacial malformation, known as 
otocephaly (Matsuo et al., 1995; Hide et al., 2002). 
 
1.9 Autozygosity mapping and genetic markers 
A consanguineous marriage is a union between two individuals who are related by 
a common ancestor. It can be a deeply rooted social trend that is widely practiced in some 
countries for economic benefit and for cultural reasons (Jaber et al., 1998; Na’amnih et 
al., 2014). Individuals from consanguineous marriages are at increased risk of developing 
a recessive condition (Hamamy, 2012; Shawky et al., 2013; Salway et al., 2016). This 
phenomena was first observed in children from a first cousin marriage who had 
alkaptonuria and albinisim (Garrod, 1902). Garrod’s observations were named 
homozygosity-by-descent by William Bateson in 1902. Using modern genetics analyses, 
affected patients in such families have been shown to have an increased frequency of 
uninterrupted homozygous segments in their genome. Such chromosomal segments come 
about as both segments have been passed down through separate branches of the family 
but are derived from a common ancestor and come together in the children, meaning these 
autozygous segments are identical by descent (IBD) from a common ancestor (Figure 
1.10). As the mutation and immediate surrounding DNA passes through successive 
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generations without recombination, IBD regions around a disease-causing allele can be 
used to map the mutation that causes recessive disease in a family (Lander and Botstein, 
1987). This was first demonstrated in Leeds, by Prof. Bob Mueller who used autozygosity 
mapping to identify disease-causing genes in local consanguineous Pakistani families 
(Mueller and Bishop, 1993).  
 
Figure 1.10. Principle of autozygosity mapping. First-cousin consanguineous pedigree showing 
the inheritance of a disease allele (red) through the generations. Affected children (IV.1 and IV.2) 
have inherited disease alleles and the surrounding haplotype from a common ancestor (I.2). 
Mapping of the disease locus can be achieved by locating the homozygous region shared by all 
affected individuals in the family. 
 
Before the human genome sequence became available, linkage maps were 
fundamental tools for many genetic studies. These had been created over the years using 
various types of polymorphic markers, since their conception by Sturtevant (Sturtevant, 
1913). Genetic linkage maps determine the linear position of genes or markers on a 
chromosome and can be used to search for IBD loci. As knowledge of the human genome 
sequence became available (Lander et al., 2001), a wide range of molecular markers have 
been used in studies. Before the completion of the human genome project, genetic maps 
were made using Random Amplified Polymorphic DNA (RAPDs), Restriction Fragment 
Length Polymorphisms (RFLPs), Amplified Fragment Length Polymorphisms (AFLPs) 
and microsatellites, also known as short tandem repeats (STRs). With access to the first 
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human genome sequence, more detailed maps were based on single nucleotide 
polymorphisms (SNPs). 
 
The three criteria considered essential for the development of linkage maps were 
ensuring a spread of markers across the genome, for the markers to be highly polymorphic 
and having a low genotyping error rate. STRs and SNPs are the markers most commonly 
used for the identification of loci for autosomal recessive diseases in consanguineous 
families (Acland et al., 1998; Bellingham et al., 1998; Aligianis et al., 2002; Ball et al., 
2010; Saqib et al., 2015). Microsatellites, which are di-, tri-, or tetra nucleotide tandem 
repeats, are variable in populations of DNA and within the alleles of an individual. They 
were until recently the genetic markers of choice as they are highly polymorphic and 
interspersed throughout the entire genome (Tian et al., 2008; Pemberton et al., 2009). 
However, despite being informative, STR genotyping is relatively complicated, time 
consuming, expensive, and can involve problematic PCRs which may lead to human 
errors in sizing the alleles. Furthermore, microsatellites account for about 3% of the 
genome and cannot be used for high resolution mapping (Ellegren, 2004). Advances in 
high-throughput DNA sequencing and bioinformatics, have led to the emergence of SNPs 
as genetic markers (Sachidanandam et al., 2001; Heaton et al., 2002). Despite the biallelic 
nature of SNPs that provide relatively less informativity, SNPs have a genetic stability, 
higher density, simpler nomenclature and can be suitably automated for data analysis and 
interpretation (Slate et al., 2009; Ball et al., 2010; Fernández et al., 2013). Moreover, 
modern SNP genotyping is almost fully automated and error rates tend to be much lower. 
Platforms such as the Affymetrix SNP Array 6.0 are now used, which includes more than 
906,600 SNPs to allow high-resolution genotyping. 
 
1.10 Sequence of the DNA sequencing 
Over the course of six decades, large amounts of time and resources have been 
invested in developing and improving the technologies that underpin genetic research. 
DNA sequencing is one method that has seen a vast improvement over the years. When 
considering the history of this technique, researchers have gone from being able to 
sequence only a short oligonucleotide of a single gene to the whole genome sequencing 
(WGS) that is available now. DNA sequencing can be summarised in two generations 
from the genesis of this field to the starting time of this study. 
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1.10.1 First-generation DNA sequencing 
Over two decades elapsed from the discovery of the double helix structure of DNA 
(Watson and Crick, 1953) to the introduction of several influential DNA sequencing 
protocols. Initial efforts at sequencing were met with limited success since the methods 
employed could only determine the nucleotide composition but were not powerful enough 
to determine the order of the nucleotides (Holley et al., 1961). However, the mid-1970s 
represent the real start of ‘first-generation’ DNA sequencing by widely adopted the plus 
and minus and the chemical cleavage techniques (Sanger and Coulson, 1975; Maxam and 
Gilbert, 1977). This method used radio-labelled DNA treated with chemicals designed to 
cleave fragments of the chain at specific bases, followed by migrating the labelled 
fragments through a polyacrylamide gel to determine the length and position of the 
nucleotides. 
 
Sanger's ‘chain-termination’ or dideoxy technique (Sanger et al., 1977) represented 
the most significant development amongst the first generation of DNA sequencing 
methods. This technique used polymerase-based copying of single-stranded DNA, but 
included a small proportion of radio-labelled chemical analogues of the nucleotides, 
chain-terminating dideoxynucleotides (ddNTPs), in each of four parallel reactions. The 
products were then run in adjacent lanes on a polyacrylamide gel to produce radioactive 
bands in the lanes, the positions of which corresponded to the sequence of nucleotides. 
Over time further improvements were made to this technique. Fluorescent dyes (Smith et 
al., 1986) were used instead of radioactive labelling to tag the different chain terminating 
analogues, allowing all four nucleotides to be resolved in a single lane. Capillary 
electrophoresis instead of a polyacrylamide gels, together with the use of laser induced 
fluorescence detection, allowed longer reads and avoided the need to cast new gels for 
each sequence. (Ruiz-Martinez et al., 1993; Hebenbrock et al., 1995). The polymerase 
chain reaction (PCR) replaced DNA cloning from libraries as the main method to generate 
the sequencing templates (Saiki et al., 1985; Saiki et al., 1988) and automated Sanger 
sequencing by capillary electrophoresis was established (Hunkapiller et al., 1991). This 
allowed 500-1000bp of DNA sample to be sequenced in 6–8 hours. This method is the 
gold-standard DNA sequencing technique that is still used in laboratories today to 
sequence short pieces of DNA. 
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1.10.2 Second-generation DNA sequencing 
The emergence of a new technique known as pyrosequencing (Roche GS FLX) 
paved the way for ‘next-generation sequencing’ (NGS) technologies for high-throughput 
sequencing. In this method, an enzymatic reaction occurs in which ATP sulfurylase 
converts pyrophosphate into ATP, which subsequently serves as the substrate for 
luciferase, meaning that the light produced is proportional to the amount of 
pyrophosphate (Nyrén and Lundin, 1985). The amount of incorporation is monitored by 
luminometric detection of the quantity of pyrophosphate released as each nucleotide is 
washed through the system in turn over the template DNA affixed to a solid phase. This 
signal is then used to infer DNA sequences (Hyman, 1988). The weakness with this 
technique though, is that errors can be caused by misjudging the length of homopolymer 
runs in this process, which may result in false single-base insertions or deletions (indels) 
in the DNA sequence readout (Ronaghi et al., 1998). 
 
The sequencing machines developed by different companies during the first decade 
of the new millennium dramatically increased the amount of DNA that could be 
sequenced, ranging from five hundred million bases of raw sequence (Roche) to billions 
of bases in a single run (Illumina, ABI SOLiD technology). These machines relied on 
performing massive numbers of parallel sequencing reactions on a micrometer scale on 
clonal beads (Roche and ABI SOLiD) or clonal bridges (Illumina). (Shendure and Ji, 
2008). Over the last decade, these three platforms are commercially leading second 
generation NGS platforms (Pareek et al., 2011).  
 
Here at Leeds the NGS facility (a partnership between the University of Leeds and 
the Leeds Teaching Hospitals NHS Trust) uses the Illumina NGS platform. For the 
Illumina Genome Analyser, sample preparation involves fragmentation of the DNA 
sample, enzymatically repairing the staggered ends, adding adenines (A) to the 3-ends of 
the DNA fragments and ligating adapters, followed by library amplification 
(Myllykangas et al., 2012). Solid-phase amplification is used to produce randomly 
distributed, clonally amplified clusters from fragments or mate-pair templates on a glass 
slide. The sequencing library is immobilised on the surface of a flow cell onto which a 
“lawn” of high-density forward and reverse primers has been covalently attached to the 
slide to create an ultra-dense primer field. The primer functionalised flow cell surface 
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serves as a support for amplification of the immobilised sequencing library by a process 
also known as “Bridge-PCR” (Figure 1.11A). The resulting bridged double-strand DNA 
is freed using a denaturing reagent. Repeated reagent flush cycles generate groups of 
thousands of DNA molecules, also known as “clusters,” on each flow cell lane. DNA 
clusters are then unbound from the complementary DNA strand (linearization), followed 
by blocking the free 3’-ends of the clusters and hybridising a sequencing primer. 
 
   
 
 
Figure 1.11. Illumina solid-phase amplification and four-colour cyclic reversible 
termination sequencing method. Illumina solid-phase amplification (A) is achieved through two 
basic steps, these being initial priming and extending of the single stranded single-molecule 
template, followed by bridge amplification of the immobilised template with immediately 
adjacent primers to form clusters. The four-colour cyclic reversible termination (B) uses 
Illumina’s 3′-O-azidomethyl reversible terminator chemistry on solid-phase-amplified template 
clusters. Following incorporation, a cleavage step removes the fluorescent dyes and regenerates 
the 3′-OH group using the reducing agent Tris (2-carboxyethyl) phosphine. (C) The four-colour 
images highlight the sequencing data from two clonally amplified templates. (Adapted from 
Metzker (2010) with the permission of Elsevier Copyright Clearance Centre, License number: 
3940451410070). 
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Cyclic reversible termination is the method employed by Illumina for sequencing-
by-synthesis. Firstly, a DNA polymerase bound to the primed template incorporates just 
one fluorescently modified nucleotide, which represents the complement of the template 
base. Following incorporation, the remaining unincorporated nucleotides are washed 
away (Figure 1.11B). Secondly the four colours of the four nucleotides are detected by 
total internal reflection fluorescence imaging using two lasers (Figure 1.11C). The 
synchronous extension of the sequencing strand by one nucleotide per cycle ensures that 
homopolymer stretches can be accurately sequenced. However, failure to incorporate a 
nucleotide during a sequencing cycle results in an off-phasing effect, and as the sequence 
extends, gradually more and more molecules lag behind in the extension so that the 
generalised signal derived from each cluster deteriorates over many cycles. Therefore, 
Illumina sequencing accuracy declines as the read length increases, which limits this 
technology to short sequence reads (Myllykangas et al., 2012). 
 
1.11 Aims 
There were two aims for this research project, both of which involved finding and 
characterising new mutations and genes involved in inherited retinal dystrophies using 
NGS technologies.  
The first approach described the Retinome project, which used targeted exome 
sequencing against all the known retinal dystrophy genes to attempt to identify the 
pathogenic mutation in twenty multiplex families with various different inherited retinal 
dystrophies. This approach identified mutations in known retinal dystrophy genes but also 
highlighted families in whom the pathogenic mutation could not be identified, suggesting 
that their Mendelian cause of retinal dystrophy may be in a gene that has not yet been 
implicated.  
The second approach used whole exome next generation sequencing from affected 
members in six families, each with a different inherited retinal disease, to identify the 
pathogenic mutation.  
 
 
 
 
 
46 
 
Chapter 2 - Materials and Methods 
 
2.1 Patient ascertainment  
Affected patients and their relatives were recruited in the ophthalmology clinics of 
the Eye Department, St. James’s University Hospital, Leeds, UK following their informed 
consent using a process that adhered to the tenets of the Declaration of Helsinki and was 
approved by the Leeds East Research Ethics committee (Project number 03/362). The 
patients underwent an eye examination by an experienced ophthalmologist to confirm 
their diagnosis of retinal dystrophy and the full clinical family history was taken. 
Peripheral blood or saliva was collected from the patient and where possible from 
additional family members for DNA extraction (Section 2.2).  
 
2.2 Genomic DNA extraction 
DNA was extracted from peripheral blood or saliva according to the following 
methods.  
 
2.2.1 Extraction of DNA from blood using phenol-chloroform extraction 
To extract DNA from a blood sample, 9ml of red cell lysis buffer [10mM/ml 
Potassium Bicarbonate (KHCO3), 155mM/ml Ammonium Chloride (NH4C1) and 
1mM/ml Ethylenediaminetetraacetic acid (EDTA)] was added to 3ml of whole blood and 
mixed by inversion for 10 minutes. The sample was centrifuged at 2,000 x g for 15 
minutes. After removing the supernatant, 500µl of cell lysis buffer [20ug/m1 RNAase A, 
0.25% [v/v] SDS, 10mM/ml Tris pH 8.0 and 100mM/ml EDTA] was added to the white 
cell pellet and incubated at 37°C for one hour. Proteinase K was then added at a final 
concentration of 100µg/ml and the sample was incubated at 55°C for one hour. An equal 
volume of phenol-chloroform (phenol: chloroform: isoamyl alcohol, 25: 24: 1) was added 
to the sample and mixed vigorously for 1 minute until an emulsion was produced. The 
aqueous and organic phases were then separated by centrifugation at 14,000 x g for 1 
minute. The upper aqueous phase was transferred to a new test tube and an equal volume 
of chloroform (chloroform: isoamyl alcohol, 24:1) was added. The nucleic acid in the 
upper aqueous phase was then precipitated from the solution by the addition of 0.1 volume 
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of 0.3M sodium chloride and 2.5 volumes of 100% ethanol. After mixing, the precipitated 
material was collected by centrifugation at 3,000 x g for 15 minutes. The ethanol 
supernatant was discarded and the nucleic acid pellet was washed with 70% ethanol. After 
centrifugation, the ethanol wash was removed and the pellet was air-dried for 5 minutes 
before re-dissolving in 30-50µl of 1 x Tris-EDTA (TE) buffer [10mM/ml Hydroxymethyl 
aminomethane hydrochloride (Tris-HCl) (pH 7.5) and 1mM/ml EDTA]. 
 
2.2.2 Extraction of DNA from blood using salt precipitation technique 
A salt precipitation technique was performed to extract DNA from fresh non-frozen 
blood samples. Briefly, 3ml of whole blood was aliquoted into a polypropylene tube and 
9ml of red cell lysis solution added. The samples were then mixed for 10 minutes at room 
temperature (RT) and then centrifuged at 2,000 x g for 10 minutes. The supernatant was 
removed and the remaining white cell pellet was re-suspended in 3ml white cell lysis 
solution by pipetting. To remove any contaminating protein, 1ml of protein precipitation 
solution (10M ammonium acetate) was added, and samples were vortexed for 20 seconds 
then centrifuged at 2,000 x g for 10 minutes. The supernatant was transferred into a fresh 
tube and the DNA was precipitated using 3m1 of isopropanol, followed by centrifugation 
for 10 minutes at 2,000 x g. The pellet was then washed twice in 70% ethanol and left to 
air dry. The precipitated DNA was dissolved in 1x TE buffer. 
 
2.2.3 Extraction of DNA from saliva 
Saliva samples were collected using Oragene® DNA sample collection kits (DNA 
Genotek Inc.) and the DNA extracted according to the manufacturer’s protocol. Briefly, 
30µl of PT-L2P reagent (provided with kits) was added to 750µl of saliva and incubated 
on ice for 10 minutes. The sample was then centrifuged at RT for 10 minutes at 3500 x g. 
600µl of the supernatant was transferred to a fresh tube and 720µl of 100% ethanol was 
added. The mix was inverted 10 times. The samples were then incubated for 10 minutes 
at RT and centrifuged for 10 minutes at 3500 x g. The pellet was washed in 500µl of 70% 
ethanol for 1 minute at RT. After drying, the pellet was re-dissolved in 50µl TE buffer 
then stored at -20°C. 
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2.3 Determining the concentration of purified nucleic acid 
The concentration of purified nucleic acids was measured using a Qubit® 
Fluorometer (Invitrogen) and the appropriate dsDNA/RNA assay kits according to the 
manufacturer’s instructions. Briefly, 1-10µl of sample were added to the Qubit 
dsDNA/RNA dilution reagent to make a final volume of 200µl and samples were 
vortexed and incubated for 2 minutes at RT. The Qubit® Fluorometer was calibrated 
using standards provided in each assay kit and the samples processed. A NanoDrop 
spectrophotometer (Thermo Scientific) was also used for measuring optical densities of 
DNA/RNA samples at 260/280 nm ratio (A260/280).  
 
2.4 The polymerase chain reaction (PCR)  
2.4.1 Primer design for standard PCR analysis 
Oligonucleotide primer pairs were designed to amplify products of 200-550 base 
pairs (bp) in size. The genomic DNA sequence for the region of interest (ROI) was 
obtained from Ensembl (http://www.ensembl.org) and UCSC Genome Browser 
(http://genome.ucsc.edu/) in the FASTA format with all exons in upper case and 
everything else in lower case. The primers were designed using the Primer3 program 
(http://bioinfo.ut.ee/primer3-0.4.0/) with length of 20 bp (range 18-27 bp), a primer 
melting temperature of 60°C (range 57-63°C) and GC% between 20% and 80%. Primer 
sequences were checked using the BLAT tool in the UCSC Genome Browser in order to 
check for unique primers for species-specific regions and to avoid known SNPs over the 
binding site. Primers used for RT-PCR were designed using the same methods described 
above, but in this case mRNA sequence was used as template and primers designed to 
span an exon-exon junction. 
 
For gene screening, the primers were designed to amplify the exonic region and at 
least 50 bp from the intron-exon boundary using the automated ExonPrimer tool 
(https://ihg.helmholtz-muenchen.de/cgi-bin/primer/ExonPrimerUCSC.pl?db=hg19&acc 
=uc009wfy.3) with the following settings: minimal distance between primer and exon 
(50-bp), primer region (70-bp), maximal target size (500-bp), overlap for large exon (50-
bp), annealing temperature (60°C), GC content (50%), primer size (17-[20]-27bp) and 
maximum length of mononucleotide repeat (4-bp). 
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2.4.2 Primer design for Gateway® cloning 
Cloning PCR primers were designed according to the guidelines provided by the 
Gateway® Technology protocol (Invitrogen) to amplify the full coding sequence of genes 
of interest, and to add gateway attB1 and attB2 restriction enzyme sequences to the 5’ 
and 3’ ends of a gene fragment. The Kozak sequence was also added to ensure protein 
expression. For 5’ primer, the attB1 sequence was added, followed by the Kozak 
sequence including ATG initiation codon, then 18-22 nucleotides at the start of the gene. 
For 3’ primer, the attB2 sequence was added, followed by 18-22 gene-specific 
nucleotides, while the stop codon was removed to allow an in-frame read with the attB2 
sequence (C-terminal fusion).  The GC content, GC clamp and melting temperature (TM) 
of gene-specific nucleotides for gateway attB primers was adjusted using an online 
oligonucleotide properties calculator (http://biotools.nubic. northwestern. edu/ Oligo 
Calc.html) (Kibbe, 2007). Finally for the 3` primer, the reverse complement of the 
sequence was used (http://www.bioinformatics.org/sms2/rev _comp.html).  
 
2.4.3 Standard PCR 
PCR was typically performed in 25µl volumes containing 20-50ng genomic DNA 
(gDNA) with the following reagents at the specified concentrations:1x PCR reaction 
buffer [20mM Ammonium sulphate ((NH4)2SO4), 20mM Tris-HCL (pH 8.4), 0.01% [v/v] 
Tween20 and 1.5 mM Magnesium chloride (MgCl2)], 10 picomoles of each of the 
F(forward) and R(reverse) primers, 200µM of each dATP, dGTP, dCTP and dTTP 
nucleotides and 1 unit Taq DNA polymerase (Invitrogen Ltd., Renfrew, UK). Thermal 
cycling was performed on this mixture with an initial denaturing step at 96ºC for 3 
minutes, followed by 35 cycles of 92ºC for 30 seconds (denaturing), 55-65ºC for 30 
seconds (annealing) and 72ºC for 30 seconds (extension). The final extension step was 
performed at 72ºC for 10 minutes. 
 
2.4.4 Hot-Shot master mix PCR 
20-50ng of gDNA was amplified in a 10 µl reaction volume, containing 50% [v/v] 
Hotshot Diamond PCR Master Mix (Clent Life Science, Stourbridge, UK), 5-10% [v/v] 
dimethyl sulphoxide (DMSO) and 10 picomoles of each primer. Touchdown PCR cycle 
was then performed on the mixture through the following ten steps: 
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2.4.5 Cloning PCR 
For cloning purposes, PCR reactions were performed with the designed cloning 
primers using platinum Pfx DNA polymerase (Invitrogen). The reactions were typically 
carried out on 60ng template DNA in a 50μl final volume that included 0.4μl of platinum 
Pfx DNA polymerase, 5μl of 10 x Pfx amplification buffer, 1.5μl of 10μM forward and 
reverse primer mix, 1.5μl of 10mM dNTPs, 1μl of 50mM magnesium sulphate (MgSO4) 
and 1μl of DNA template. Initial denaturation was performed at 94ºC for 5 minutes 
followed by 30 cycles of three steps: denaturation at 94ºC for 15 seconds, annealing at 
58ºC for 30 seconds and the extension step at 68ºC for 5 minutes. A final extension was 
performed at 68ºC for 10 minutes. 
 
2.5 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to analyse the presence and size of PCR 
products from the samples. Gels usually contained between 1.0% and 1.5% [w/v] of ultra-
pure agarose (Fisher Scientific). To prepare a gel, the desired amount of agarose was first 
dissolved in 0.5 x TBE buffer [44.5 mM Hydroxymethyl aminomethane (Tris), 44.5 mM 
Boric acid (H3BO3) and 1.25 mM EDTA (pH 8.0)], a process that was hastened by heating 
in a microwave oven. The solution was cooled to 55ºC, mixed with ethidium bromide 
(final concentration 0.5µg/ml), and then poured into a gel tray with gel combs inserted, 
to a depth of between 5 and 8 mm. When solidified, the gel was submerged under 0.5 x 
TBE buffer, in an electrophoresis tank. The combs were removed to create wells. Wells 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
95ºC for 10.00 mins (initial denaturing) 
95ºC for 0.30 mins (denaturing) 
67.5ºC for 0.30 mins (annealing) “Decrease by 0.5ºC every cycle” 
72ºC for 0.30 mins (extension) 
Go to step 2, repeat 13 times 
95ºC for 0.30 mins (denaturing) 
60 or 65ºC for 0.30 mins (annealing) 
72ºC for 0.30 mins (extension) 
Go to step 6, repeat 29 times 
72ºC for 7.00 mins (final extension) 
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within the gel were next filled with 2µl PCR product that had been mixed with 8µl of 1 x 
DNA loading dye [0.01% w/v Xylene cyanol, 0.01% w/v Bromophenol blue, 10% v/v 
Glycerol and 2x TBE buffer]. DNA molecular weight markers (Bioline) were also loaded 
alongside the samples. The gel was then run at 120 V for 30 minutes. Ethidium bromide 
stained DNA within the gel and was visualized using the ChemiDoc™ MP System (Bio-
Rad Life Science) under UV light (wavelength 320 nm). The image was analysed using 
Image Lab™ software (Bio-Rad Life Science). 
 
2.6 DNA extraction from agarose gels 
DNA bands of the correct size were excised from agarose gels using Qiagen’s 
QIAquick Gel Extraction kit protocol. Briefly, a DNA band was excised with a clean 
scalpel under long wave-length UV light using a Mineralight UVGL-58 lamp. Gel 
fragments were subsequently weighed and melted in QG buffer at 37°C for 15 minutes. 
The mixture containing DNA was centrifuged using a QIAquick column, following a 
wash with PE buffer, containing 70% ethanol. Finally, the DNA was re-dissolved in 1 x 
TE buffer. 
 
2.7 Genotyping 
2.7.1 Microsatellite marker genotyping 
Microsatellite markers were used for genotyping by standard PCR with the addition 
of a 5’-FAM (blue) fluorescent dye on the forward primers. The markers were selected 
and their genetic locations within given regions were identified using the UCSC Genome 
Browser (http://genome.ucsc.edu/) or NCBI Map Viewer (http://www.ncbi.nlm.nih.gov 
/map view/). PCR was performed according to the description in Section 2.4 using a 5’ 
fluorescently labelled forward primer. PCR products were visualised on a 1.5% agarose 
gel. 1µl diluted product was then added to a mixture of 0.5µl ROX-500 size standard 
(Applied Biosystems) and 8.5µl Hi-Di formamide (Applied Biosystems). Fragments were 
resolved and separated via electrophoresis on an ABI3130xl Genetic Analyzer (Applied 
Biosystems) using a 36cm array, POP7 polymer and the Fragment Analysis 36_pop7_1 
module (Applied Biosystems). Sizing of the microsatellite alleles was performed using 
Gene Mapper v.4 software (Applied Biosystems). 
 
52 
 
2.7.2 Affymetrix SNP chip genotyping  
Patient samples were SNP genotyped using the commercial service providers 
GeneService (London, UK) or AROS Applied Biotechnology (Denmark). Low-
resolution genotyping (250,000 SNPs) was undertaken by sending 500ng of gDNA at a 
concentration of 50ng/l to GeneService for genotyping using a 250K Affymetrix SNP 
chip. For high-resolution genotyping (1 million SNPs), 1µg gDNA was sent to AROS for 
hybridization to the Affymetrix 6.0 chip.  
 
The resulting Affymetrix SNP chip genotyping data were returned as CEL files, 
which were annotated by using Affymetrix Genotyping Console Software (http://www. 
affymetrix.com/estore/browse/level_seven_software_products_only.jsp?productId=131
535#1) into Microsoft Excel files containing SNP ID, chromosome, physical position and 
resulting allele call for each SNP assayed. Annotated genotype data was then analysed to 
identify potential autozygous regions using either AutoSNPa software (Carr et al., 2006), 
IBDfinder software (Carr et al., 2009) or SNP Viewer (http://snpviewer.sourceforge.net/) 
software using the default settings. Homozygous regions were exported to Microsoft 
Excel/Word for manual analysis. To visualise the SNP data at the genome level, or to 
combine the SNP chip genotyping data with SNP data generated from WES data (Section 
2.12), either AgileMultiIdeogram (http:// dna.leeds.ac.uk/ agile/AgileMultiIdeogram/) or 
AutoIdeogram (http://dna.leeds.ac.uk/AutoIdeogram/) software were used.  
 
2.8 Sanger sequencing 
2.8.1 PCR product preparation prior to sequencing  
Prior to performing the sequencing reaction, PCR products were either purified 
using Qiagen’s QIAQuick PCR Purification columns or treated with ExoSAP-IT 
(Affymetrix, Santa Clara, USA) consisting of Exonuclease I and Shrimp Alkaline 
Phosphatase for the removal of unincorporated dNTPs and primers. Each clean-up 
reaction of 7µl (2µl ExoSAP-IT and 5µl PCR product) lasted for 45 minutes (30 minutes 
at 37 ºC for treatment and 15 minutes at 80 ºC for inactivation). 
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2.8.2 Dye terminator sequencing on the AB13130xl Genetic Analyser 
Purified PCR products were sequenced using the BigDye® Terminator Cycle 
Sequencing Kit v3.1 (Applied Biosystems). Each sequencing reaction contained 1µl of 
purified PCR product, 0.5µl of BigDye® terminator v3.1 (Applied Biosystems), 1.5µl 5 x 
BigDye® terminator sequencing buffer (Applied Biosystems), 6µl distilled water and 1µl 
(1.6 picomoles) of the sequencing primer, giving a final reaction volume of 10µl. The 
sequencing reaction mixture was denatured initially for 1 minute at 96ºC, followed by 25 
cycles of 96ºC for 30 seconds, 50ºC for 5 seconds, and 60ºC for 4 minutes, with all 
temperatures ramped at 1ºC/second. DNA was then ethanol precipitated by adding 5µl of 
125mM EDTA and 60µl 100% ethanol to the sequencing product. Samples were mixed 
and underwent centrifugation for 30 minutes at 3,000 x g at 22ºC, followed by an inverted 
spin for 40 seconds at 200 x g. Next, 60µl of freshly prepared 70% ethanol was added, 
and samples were centrifuged for 15 minutes at 800 x g at 4ºC. Finally, an inverted spin 
was performed for 40 seconds at 200 x g and samples were left to air dry at RT for 15 
minutes. Pellets were re-dissolved in 10µl of Hi-Di formamide loading buffer (Applied 
Biosystems) and resolved at 60ºC using a 36cm array, POP-7 polymer and the default 
RapidSeq 36 POP7 module on an ABI3130xl Genetic Analyser (Applied Biosystems). 
The sequences produced were analysed using the Sequence Analysis v5.2 and SeqScape 
v2.5 software packages (Applied Biosystems). 
 
2.9 Whole genome amplification (WGA)  
WGA of gDNA was carried out using the GenomiPhi V2 kit (GE Healthcare, USA) 
according to the manufacturer’s guidelines, however half the recommended volumes 
were used. 0.5µl of the DNA sample was mixed with 4.5µl of the sample buffer followed 
by denaturation for 3 minutes at 95ºC. On ice, 4.5µl of reaction buffer and 0.5µl of the 
enzyme mix was added to each sample followed by incubation at 30ºC for two hours. The 
enzyme was then inactivated at 65ºC for 10 minutes. Amplified samples were diluted 1 
in 50 in distilled water and 2 µl from each sample was amplified in subsequent PCR 
reactions. 
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2.10 Whole exome sequencing (WES) 
2.10.1 Library preparation 
WES was carried out using commercial kits from Agilent Technologies: SureSelect 
XT Library Preparation kit ILM, SureSelect Target Enrichment and Herculase II Fusion 
DNA Polymerase, SureSelect XT Human All Exon V4 Capture or SureSelect XT Human 
All Exon V5 Capture Libraries. The standard Illumina protocol “SureSelect XT Target 
Enrichment System for Illumina Paired-End Sequencing Library” was followed 
(available from http://www.agilent.com/cs/library/usermanuals/ Public/G7530-
90000_SureSelect_IlluminaXTMultiplexed_1.8.pdf). Briefly, each DNA sample was 
quantified using the Qubit® dsDNA (Broad-Range) Assay (Invitrogen) (Section 2.3). 3μg 
of gDNA was diluted in 1 x TE buffer to a final volume of 250μl and added to a clearly 
labelled T6-30 glass tube (Covaris, USA). The DNA was then sheared in a water bath at 
20°C to fragment sizes of 150 to 200 bp using the Covaris system (Covaris S220 Sonicator 
and SonoLite software). This sheared DNA sample was then purified using Agencourt 
AMPure XP magnetic beads (Beckman Coulter Genomics, South Plainfield, USA) and 
analysed using a DNA 1000 BioanalyzerTM (Agilent Technologies) to assess the 
distribution of DNA fragment sizes between 150-200 bp.  
 
The creation of blunt-ended fragments and 5'-phosphorylation of the ends were the 
next steps. 48µl of the purified sample was mixed with 35.2µl of nuclease-free water, 
10µl of 10 x end repair buffer, 1.6µl of dNTP mix, 1µl of T4 DNA polymerase, 2.2µl of 
T4 Polynucleotide Kinase, and 2 µl Klenow DNA Polymerase. This mixture was 
incubated in a thermal cycler for 30 minutes at 20°C, then the DNA fragments were again 
purified using Agencourt AMPure XP magnetic beads. After the fragment ends were 
repaired, adenosine overhangs were added to their 3’ ends (3'-dA overhangs) by 
incubation of 30µl of the sample with 3 µl of Exo(-) Klenow, 5µl of 10 × Klenow 
polymerase buffer, 11µl of nuclease-free water and 1µl dATP for 30 minutes at 37°C.  
 
The sample was then purified a third time using the magnetic beads. Paired-end 
adaptors were ligated on by adding 1.5µl T4 DNA Ligase, 10µl of 5 x T4 DNA ligase 
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buffer, 10µl of diluted SureSelect adaptor oligo mix and 15.5µl of nuclease-free water to 
13μl of the DNA sample, followed by incubating for 15 minutes at RT. Next, the sample 
was purified using the magnetic beads again and the adapter-ligated library was amplified 
in a 50μl PCR containing, 15μl of DNA sample, 1.25µl of SureSelect ILM indexing pre-
capture PCR reverse primer, 1.25µl SureSelect primer, 10μl of 5 x Herculase II reaction 
buffer, 1 μl of Herculase II fusion DNA polymerase, 0.5μl of 100mM dNTP mix, and 
21μl of nuclease-free water. The PCR mix was loaded into a thermal cycler with the 
following program: 98°C for 2 minutes (denaturation) and 6 cycles of 98°C for 30 
seconds, 65°C for 30 seconds and 72°C for 1 minute, followed by a final extension step 
of 72°C for 10 minutes. The amplified library was purified using the magnetic beads and 
analysed using a DNA 1000 BioanalyzerTM assay. Only samples with an 
electropherogram reading showing a single peak around 250 to 275 bp were taken through 
to the hybridisation steps.  
 
Each amplified library was quantified using the PicoGreen® double stranded DNA 
(dsDNA) quantitation assay (Invitrogen) according to the manufacturer’s instructions. 
The library was then hybridized and the exome was captured individually prior to addition 
of the indexing tag. For each hybridization reaction, 40μl of the hybridization buffer and 
5.6μl of SureSelect block mix were prepared according to the manufacturer’s protocol. 
750ng of the library DNA with a maximum volume of 3.4μl was added to 5.6μl of 
prepared SureSelect block mix then incubated for 5 minutes at 95°C. In a PCR plate 
maintained at 65°C, the prepared library was mixed with 13μl of the prepared 
hybridization buffer and 7μl of SureSelect capture library of biotinylated RNA 
oligonucleotide probes (5μl of SureSelectXT Human All Exon V4/V5 and 2μl of 25% 
RNase block), followed by incubation for 24 hours at 65°C in a thermal cycler with a 
heated lid at 105°C. The captured library was fished out using streptavidin-coated 
magnetic beads (Dynabeads MyOne Streptavidin T1, Invitrogen) on a magnetic separator 
according to the protocol guidelines. Subsequently, index tags were added to the captured 
library by post-hybridization amplification. 14μl of each DNA sample and 1μl of the 
appropriate index PCR primer were mixed with 35μl of Herculase II master mix (10μl of 
5 x Herculase II reaction buffer, 1μl of Herculase II fusion DNA polymerase, 0.5μl of 
100mM dNTP mix, 22.5μl of nuclease-free water and 1μl of SureSelect ILM Indexing 
post capture forward PCR primer), followed by loading into a thermal cycler for 2 minutes 
at 98°C, then 12 cycles of 30 seconds at 98°C, 30 seconds at 57°C and 1 minute at 72°C. 
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Final extension was at 72°C for 10 minutes. The samples were then purified using 
Agencourt AMPure XP beads and analysed using the 2100 BioanalyzerTM high sensitivity 
DNA assay (Agilent Technologies) which was expected to achieve a normal distribution 
around a peak ranging from approximately 300 to 400 bp. Six samples were pooled 
together in a final volume of 50μl, with each sample having a final concentration of 10nM. 
Finally, the cluster amplification was performed at the NGS facility (University of Leeds), 
followed by NGS using paired-end 100 bp reads on an Illumina 2500 HiSeq sequencer 
(Illumina Inc. UK). 
 
2.10.2 Analysis of WES data. 
The computational analysis of the WES data was performed using Unix console 
commands (Appendix 1) and a wide range of online servers. The quality of the raw data 
coming from the Illumina high throughput sequencing was determined by using FASTQC 
tools run on the Galaxy platform (Blankenberg et al., 2010). Quality scores across all 
bases, GC content per sequence, sequence length distribution and duplication levels were 
evaluated before any further analysis. After sequence quality monitoring, the sequencing 
data was aligned against the reference genome (hg19/GRCh37) using either the Bowtie2 
program (Langmead and Salzberg, 2012) or NovoAlign software (http://www.novocraft 
.com/ products/novoalign/). NovoAlign was preferred in exome depth and fishing CNV 
analysis or filtering the sample against in-house samples that had been analysed using the 
same aligner. Otherwise the Bowtie2 aligner was more widely used. The aligned files 
were sorted, indexed and processed in SAM/BAM format using the SAMtools suite of 
programs (Li et al., 2009) (http://samtools. sourceforge.net/). PCR duplicates were 
removed by Picard tools (http://broadinstitute. github.io/ picard/). The mean depth of 
reads per base was observed and the variants were then realigned locally and recalibrated 
using the Genome Analysis Toolkit (GATK) (https://www. broadinstitute. org/gatk, 
version 3.3-0). Indel and single nucleotide variants were called in the variant call format 
(VCF) format using the Unified Genotyper function of GATK (DePristo et al., 2011). 
The Integrative Genomics Viewer (IGV) (https://www. broadinstitute.org/igv/) 
(Robinson et al., 2011) was used for visualization and interactive exploration of the 
aligned data files. The variant list of each individual was annotated using ANNOVAR 
software (http://annovar. openbioinformatics.org/en/latest/) and filtered using the 
following criteria: selecting only DNA variants in coding regions, splice donor and 
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acceptor sites (±2 bp), removing synonymous changes, selecting variants with a greater 
than depth of coverage of 10 reads, filtering out exome variants that have a minor allele 
frequency (MAF) of greater than 1% in either dbSNP 138 (http://www.ncbi. 
nlm.nih.gov/SNP/), the 1000 Genomes (Abecasis et al., 2012), the exome variant server 
(EVS) or the Exome Aggregation Consortium (ExAC) databases (Section 2.14.4). For 
VCF files of patients of Pakistani origin, an additional filtering step was used to filter out 
all variants with MAF greater than 5% in a cohort of 3222 exomes of British Pakistani 
adults (Narasimhan et al., 2016) (http://www.genesandhealth.org/research/scientific-
data-downloads), this step was used through a perl script (Appendix 1) developed by Dr 
David Parry, University of Leeds. The final variant lists were initially compared to the 
known retinal dystrophy genes in the RetNet database (URL: https://sph.uth. edu/retnet/). 
The pathogenicity of variants was also assessed using a number of software either 
integrated in the ANNOVAR or used separately (Section 2.14.2). 
 
2.11 Targeted capture NGS 
2.11.1 Target design and library construction 
In order to enrich for specific targets from patient gDNA, a liquid-phase reagent 
comprising ‘SureSelect Target Enrichment’ biotinylated cRNA baits was designed 
against regions of interest using the Agilent Technologies eArray platform 
(http://www.genomics.agilent.com) (Agilent Technologies UK Limited, Wokingham, 
UK). For the library preparation, gDNA from each patient was sheared using the Covaris 
S220 sonicator (Applied Biosystems). Illumina sequencing adapters, containing 6 bp 
sequence tags were ligated to the samples, with each DNA sample being ligated to a 
different tag. The tagged DNA libraries were then captured using the SureSelect custom 
baits. Hybridization reaction, post-hybridization amplification, indexing and purification 
and pooling were done as previously descried (Section 2.10.1). The cluster amplification 
was performed at the NGS facility (University of Leeds) followed by NGS using single-
end 80 bp reads on an Illumina GAIIx Sequencer (Illumina Inc. UK).  
 
2.11.2 Targeted sequencing analysis and variant detection 
Sequence data were generated in qseq format and barcode sorted by their unique 5′ 
tag using NovoSort (http://www.novocraft.com/). Output data were aligned to the 
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reference human genome sequence, hg19, using NovoAlign software (v2.08.01) (http:// 
www. novocraft.com/products/novoalign/). Following realignment around indels using 
the GATK (v2.0.34) (https://www.broadinstitute.org/gatk, version 2.0-34). Unified 
Genotyper (DePristo et al., 2011) was used for variant calling. The output VCF files were 
annotated using ANNOVAR software (http://annovar.openbioinformatics.org/en/latest/). 
Analysis of read depth was performed using BED Tools (v2.15.0) (http://bedtools. 
readthedocs.io/en/latest/) and the GATK Count Reads walker (https://software. 
broadinstitute.org/gatk/gatkdocs/org_broadinstitute_gatk_tools_walkers_qc_CountRead
s.php). VCF file filtration was carried out as mentioned above (Section 2.10.2). Unix 
console commands used for the targeted sequencing analysis can be found in Appendix 
1. 
 
2.12 Homozygosity mapping using WES data 
Detection of homozygous regions from NGS data was performed using 
AgileGenotyper (Carr et al., 2013). The genome annotation file and exome SNP database 
were downloaded from AgileGenotyper (http//dna.leeds.ac.uk/agile/AgileGenotyper/ 
download.php) and then loaded with the aligned sequence data file of the sample to the 
software. Exported genotype data in text format was analysed using AutoSNPa software 
(Carr et al., 2006), and the locations of homozygous regions were displayed by using 
either AutoIdeogram (http://dna.leeds.ac.uk/AutoIdeogram/) or AgileMultiIdeogram 
(http://dna.leeds.ac.uk/agile/AgileMultiIdeogram/) software. 
 
2.13 Detection of copy number variation (CNV) using WES 
data 
Fishing CNV was used to compare the distribution of the depth of coverage between 
the sample and a large batch of control samples that sequenced in different sequencing 
run according to method described by Shi and Majewski (2013). Briefly the fastq file of 
the sample was processed as described above (Section 2.10.2) without duplicates 
removing step by Picard. The sample indexed Bam file was then treated by GATK’s 
Depth Of Coverage command with a minimum 10 value as base quality. Reads per 
kilobase per million mapped reads (RPKM) files were generated for the sample and 
seventy eight pooled control samples. The analysis was then performed on R package 
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FishingCNV (http://sourceforge.net/projects/fishingcnv/). False discovery rate (FDR) 
adjusted P-value of 0.05 was used as the threshold of detection and smaller values 
indicative of more confident calls. 
 
ExomeDepth analysis was to compare the read depths between the sample and a 
small batch of control samples that sequenced in the same sequencing run with the same 
version of the SureSelect Human All Exon capture reagent according to method described 
by Plagnol et al. (2012).The fastq files of all samples were processed as described for 
fishing CNV method up to indexing of the Bam file then analysed using the R package 
ExomeDepth (https://cran.r-project.org/web/packages/ExomeDepth/index.html). The 
output csv file prioritised according the highest Bayes factor (the log10 of the likelihood 
ratio of data for the CNV call divided by that of the normal copy number call). The read 
ratios of 0, 1, 1.5 and 2 indicated a homozygous deletion, a heterozygous deletion, a 
heterozygous duplication and a homozygous duplication respectively. Unix and R 
commands used for detection of CNV using WES data can be found in Appendix 2. 
 
2.14 Bioinformatics and computational biology 
The fields of bioinformatics and computational biology were widely used to 
investigate questions about biological composition, structure and function of gene/protein 
involved in this study. These approaches allow large-scale analysis (such as WES and 
targeted NGS analysis, Sections 2.10.2 and 2.11.2), designing (such as primer design, 
Section 2.4.1), prediction (such as software for predicting mutation pathogenicity, Section 
2.14.2) and obtaining data from many disciplines. The list of bioinformatics tools used in 
this study are listed below. 
 
2.14.1 Genetic, phenotypic and functional data sources 
The basic information about the candidate genes including genomic sequence, 
intron-exon structure, location of polymorphisms and amino acid conservation was 
obtained using the UCSC Genome Browser (http://genome.ucsc.edu/), while information 
about disease phenotypes was collected using Online Mendelian Inheritance in Man 
database (OMIM - http://www.ncbi.nlm.nih. aov/omim). Literature searches of 
techniques, genes and proteins were carried out using PubMed (http://www.ncbi.nlm. 
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nih.gov/pubmed), Genecards (http://www.genecards.org/), the Ensembl Genome 
Browser (http://www.ensembl.org/index.html) and NCBI site (http://www.ncbi.nlm.nih. 
gov/gene/).  
 
2.14.2 Software for predicting mutation pathogenicity 
A large number of in-silico tools have been developed to predict the effect of an 
unclassified variant on the protein function. These software tools play a key role in 
prioritizing the causative mutation candidates. Some of these tools are discussed below. 
 
2.14.2.1 Polymorphism phenotyping v2 (PolyPhen-2) 
PolyPhen-2 is a freely available, web-based program used to predict the possible 
impact of a non-synonymous variant on the stability and function of the protein 
(http://genetics.bwh.harvard.edu/pph2 /index.shtml). This tool integrates the indexes of 
UCSC Genome Browser’s human genome annotations together with the Vertebrate 
Genome Annotation (VEGA) database. The software estimates the probability score 
based on a combination of structural properties, comparative evolutionary profiles, the 
differences between all functionally known damaging alleles with non-damaging and the 
differences present between human and vertebrate orthologues (Adzhubei et al., 2010). 
The differences between human disease-causing mutations in the UniProt knowledgebase 
(UniProtKB) (http://www.uniprot.org/help/uniprotkb) and common human non-
synonymous single nucleotide polymorphisms (nsSNPs) with MAF>1% and no disease-
associated annotation are also considered in the prediction. PolyPhen-2 scores between 0 
and 1.00 are interpreted to give qualitative predictions as follows: <0.15 = benign 
substitution prediction, 0.15-0.85 = possibly damaging, and 0.85-1.00 = probably 
damaging. 
 
2.14.2.2 Sorting intolerant from tolerant (SIFT) 
SIFT is a web-based program that classifies the amino acid substitutions as tolerated 
or deleterious (http://sift.jcvi.org/). The probability matrix is calculated according to the 
degree of conservation of amino acid residues in multiple sequence alignments collected 
from homologues with similar functions using PSI-BLAST (Position-Specific Iterative 
Basic Local Alignment Search Tool). The software has a default cut-off threshold of 0.05. 
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SNPs with SIFT scores higher than this threshold are regarded as tolerated (Ng and 
Henikoff, 2003). 
 
2.14.2.3 The BLOSUM62 matrix 
The BLOSUM62 substitution matrix can score all the possible exchanges of one 
amino acid with another (http://www.ncbi.nlm.nih.gov/Class/FieldGuide/BLOSUM62 
.txt). The matrix is derived from about 2,000 blocks of aligned sequence segments 
characterizing more than 500 groups of related proteins. The classification of protein 
patterns into families depends mainly on the regions thought to be important to protein 
function (motifs) in addition to how often the amino acid is substituted within the block 
of human related proteins. The “star-tree” score model ranges from -4 to +3 for non-
synonymous amino acid substitutions. A score of -4 means a big change in property when 
switching from one of the two amino acids in question to the other, which would be likely 
to alter protein function, so the amino acid substitution is highly unlikely to be benign. 
Conversely, a score of +3 means the substitution is between two amino acids with very 
similar properties, and is therefore likely to be benign. The Blosum62 substitution matrix 
should be used alongside other pathogenicity prediction tools because the data upon 
which it is based is restricted to a subset of conserved domains (Henikoff and Henikoff, 
1992). 
 
2.14.2.4 Align-GVGD program 
The Align-GVGD program (Align-Grantham Variation and Grantham Deviation) 
is a web server that can localize the missense substitutions in genes of interest into a 
spectrum ranging from enriched neutral to enriched deleterious (http://agvgd.iarc.fr/ 
index.php). The program works on the combination of protein multiple sequence 
alignments (in FASTA format) and the biophysical characteristics of amino acids. The 
biophysical variation at each alignment position is converted to a Grantham Variation 
score. The prediction classes form a spectrum (C0, C15, C25, C35, C45, C55 and 
C65) with C65 most likely to affect the protein function and C0 least likely (Tavtigian et 
al., 2006).  
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2.14.2.5 MAPP program 
Multivariate Analysis of Protein Polymorphism (MAPP) is one of the missense 
prediction tools that can be downloaded and run locally (http://mendel. 
stanford.edu/SidowLab/downloads/MAPP/index.html). This application can be used to 
predict if the effect of the mutation will have a good or bad effect on the physicochemical 
properties of the protein including polarity, volume and hydropathy (Stone and Sidow, 
2005). 
 
2.14.2.6 Mutation taster 
Mutation taster is a fast web-based program (http://www.mutationtaster.org) used 
to evaluate different types of DNA mutations: synonymous, non-synonymous, nonsense 
and frameshift. The software integrates various data sources such as HapMap, Ensembl, 
dbSNP and SwissProt/UniProt. For this study, the scripts were downloaded and integrated 
into ANNOVAR software to run locally on a Unix-based system. A prediction is given 
as either ‘disease-causing’ or ‘polymorphism’ along with a P value indicating the security 
of the prediction (with 1 being most secure) (Schwarz et al., 2014). 
 
2.14.2.7 CADD score  
Combined Annotation-Dependent Depletion (CADD) is a novel functional meta-
annotation tool (http://cadd.gs.washington.edu/) that can evaluate and score the 
deleteriousness of a large number of single nucleotide substitutions and indel variants 
(Kircher et al., 2014). CADD works as a framework that integrates data from 63 existing 
tools into one calculated metric score called the C-score of the variant. Unlike other 
annotation tools, CADD does not rely solely on the conservation information of the amino 
acid residues but also on the functional genomic data such as DNase I hypersensitivity 
and transcription factor binding; protein-level scores such as PolyPhen, SIFT and Align-
GVGD; expression levels in commonly studied cell lines and exon-intron boundaries 
determined by transcript data. The C-score is calculated according to a combination of all 
of these data. A scaled CADD score of 10 means that a variant is amongst the top 10% of 
deleterious variants in the human genome. A scaled CADD score of 20 means that the 
variant is in the top 1%. A scaled CADD score of 30 means that the variant is in the top 
0.1%. 
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2.14.3 Splice site prediction tools  
In-silico splice prediction tools were used for the interpretation of intronic and 
exonic mutations that can lead to splicing defects. Two web based programs were used, 
Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools /splice.html) 
and NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) (Hebsgaard et al., 1996; 
Reese et al., 1997). These tools work as neural network based programs to find possible 
5' and 3' splice sites. For each variant, two data sheets of reference and variant sequences 
including the surrounding genomic sequence of two or more exons were uploaded 
separately to the program. The output data of the possible splice acceptor and splice donor 
sites with the confidence scores were compared between the reference and variant 
sequences.  
 
2.14.4 db SNP, 1000 Genomes, the EVS Server and ExAC database 
The single nucleotide polymorphism database (dbSNP) is a public-domain archive 
for a broad collection of simple genetic polymorphisms for a variety of organisms, 
maintained at the National Center for Biotechnology Information (NCBI) (http://www. 
ncbi.nlm.nih.gov/ SNP/). The 1000 genomes project is a public catalogue of human 
variation and genotype data of over 1,000 unidentified individuals from around the world 
(US, UK, China and Germany) (http://www.1000genomes.org/). The Exome Variant 
Server (EVS) (http://evs.gs.washington.edu/EVS/) and Exome Aggregation 
Consortium (ExAC) (http://exac.broadinstitute.org/) are two different databases that 
collect frequencies of variants in populations from multiple studies. EVS based on WES 
data of 6503 well-phenotyped individuals from various ethnicities, while ExAC includes 
a larger cohort of 60,706 unrelated individuals sequenced as part of various disease-
specific and population genetic studies. The data of individuals affected by severe 
paediatric disease has been removed from ExAC shared datasets, so these have been 
frequently used as a control population for calculating allele frequencies and filtering out 
potential benign variants observed at a relatively common frequency in the databases 
(Song et al., 2016). 
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2.14.5 Protein bioinformatics tools 
Interactive protein analysis servers were used to perform basic bioinformatics 
analysis on any candidate protein. ExPASy translate tool is an online tool 
(http://web.expasy.org/translate/) that was used for translating a nucleotide sequence 
(DNA/RNA) to a protein sequence. ClustalW (http://www.ebi.ac.uk/Tools/msa 
/clustalw2/) and Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) are fast web-
based programs that were used for multiple sequence alignments of amino acids in a 
protein. NCBI reference sequences of interest and orthologous protein sequences in 
FASTA format were pasted into this software. The output of multiple sequence alignment 
was arranged from top to bottom according to the degree of similarity indicating the 
conservation of an amino acid of interest and of the surrounding amino acid residues. 
Finally, the Protter tool was used for visualization of proteoforms 
(http://wlab.ethz.ch/protter/start/) and predicting protein sequence features (Omasits et 
al., 2014). 
 
2.14.6 Linkage analysis 
Two-point linkage analysis was carried out using Superlink (http://bioinfo.cs.  
technion.ac.il/superlink-online/) (Silberstein et al., 2006). This method uses a Bayesian 
network model to compute the likelihood scores for complex pedigrees, such as 
consanguineous pedigrees with multiple inbreeding loops. The software requires a 
pedigree (ped) file, describing the details and genotyping results of the individuals to be 
analysed in each pedigree, and a data (dat) file, describing the type of analysis required 
and allele frequencies. The resulting data is given as the logarithm of the odds (LOD) 
score.  
 
2.15 RNA extraction 
Total RNA was extracted using the TRIzol RNA extraction kit (Invitrogen) 
according to the manufacturers’ instructions. Before starting, the equipment was sterilized 
by treatment with 3% hydrogen peroxide solution (H2O2) for 30 minutes prior to use. The 
deionized water was treated with 0.1% [v/v] diethyl pyrocarbonate (DEPC) (Sigma) for 
at least 16 hours and then autoclaved. For tissues, the sample was homogenized with a 
pellet pestle motor in the presence of the 1ml TRIzol/100mg tissue until the tissue was 
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completely dissolved in solution. For cells, 1ml TRIzol per 10cm2 of the culture dish was 
used to lyse the cells, followed by incubation at RT for 5 minutes. Homogenised tissue or 
lysed cells were then transferred to a microfuge tube and 200µl chloroform was added 
per 1ml of TRIzol reagent. Samples were then vortexed for 5 seconds followed by 
incubation for 3 minutes at RT, and then spun at 12,000 x g for 15 minutes at 4°C. The 
aqueous phase was then transferred to a fresh tube and the RNA was precipitated by 
adding 500µl isopropanol per 1ml of TRIzol. Samples were incubated at RT for 10 
minutes, then centrifuged at 12,000 x g for 10 minutes at 4°C. The RNA pellet was then 
washed with 1ml 75% ethanol per 1ml TRIzol used, and centrifuged at 7500 x g for 5 
minutes at 4°C. The air-dried RNA pellet was re-dissolved in DEPC-treated water. Total 
human RNA from adult and fetal tissues was purchased from ClonTech (Catalog No. 
636643, Mountain View, USA). 
 
2.16 Reverse transcriptase PCR (RT-PCR) for first strand 
cDNA synthesis 
Complementary DNA (cDNA) was synthesised from total RNA using Moloney 
Murine Leukemia Virus reverse transcriptase (MMLV RT) (Invitrogen). 1µl (100ng) of 
random primers (Invitrogen) was incubated with 0.5µg of total RNA and 10µl of DEPC-
treated water at 70°C for 10 minutes, followed by chilling on ice. 4µl 5 x MMLV RT 
buffer (Invitrogen), 2µl 10mM dNTPs (Invitrogen), 2µl 0.1M DTT (dithiothreitol) 
(Invitrogen) and 10U (0.25µl) of RNAsin (Promega, USA) were then added to each 
reaction which was incubated at 37°C for a further 2 minutes. 0.5µl (100U) MMLV RT 
was added to each sample followed by incubation at 37°C for 1 hour then denaturation of 
the enzyme at 95°C for 5 minutes. Finally, samples were stored in the freezer at -20°C 
until required for PCR amplification with specific primers. 
 
2.17 Histology and immuno-staining 
2.17.1 Harvesting mouse eyes and embryos 
The most humane way to euthanize male and pregnant female mice, as defined in 
schedule 1 of the Animal Scientific Procedures Act, 1986, was used to obtain mouse 
embryos and adults for histology and immune-staining. Embryos at E11.5 or later 
embryonic stages were dissected out from the uterus and yolk sac in cold 1 x phosphate-
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buffered saline (PBS) [one PBS tablet (Sigma-Aldrich)/200ml ddH2O]. Adult mouse eyes 
were carefully dissected using micro-scissors and 45 degree forceps under a dissecting 
microscope (Section 2.18).  
 
2.17.2 Preparation of frozen sections  
Whole embryos and eyes were transferred to fixative solution 0.4% [w/v] 
paraformaldehyde (PFA) in 1 x PBS for 4-24 hours, followed by cryoprotection 
incubation in 30% [w/v] sucrose in 1 x PBS for two hours. Using round cork discs, 
embryos and eyes were embedded in "Optimum Cutting Temperature (OCT)" (Raymond 
A Lamb Limited, UK) solution followed by snap freezing in isopentane 
supercooled over liquid nitrogen. The tissues were sectioned at 5µm thickness using a 
CM30505 cryostat (Leica). The specimen temperature of the cryostat was set to -21±3°C. 
Thin sections were placed onto SuperFrost plus slides (Menzel Glaser, Germany) and 
stored at -80°C until required. 
 
2.17.3 Preparation of paraffin sections  
Dissected embryos and mouse eyes were fixed by overnight immersion in 4% [w/v] 
PFA in 1 x PBS at 4°C. Following three washes in 1 x PBS solution, the tissues were 
processed using an automated system. The tissues were initially dehydrated by immersion 
in 70%, 90% and 100% ethanol; each three times for 30 minutes at RT followed by three 
immersions in xylene for 20 minutes each at RT. The tissues were then embedded in 
paraffin wax (58-60 ºC), two changes, 1.5 hour each. The blocks of paraffin embedded 
tissues were sliced at 4µm thickness using an RM2255 microtome (Leica). These tissue 
sections were placed onto SuperFrost plus slides (Menzel Glaser, Germany) and allowed 
to dry overnight at RT. The sections were later stored either at RT or for long-term storage 
at 2-8°C. 
 
2.17.4 Haematoxylin and eosin (H&E) staining  
Hematoxylin-eosin (H&E) staining was used for a proper evaluation of paraffin-
embedded or frozen tissue sections. For paraffin sections, air-dried slides were initially 
placed directly on a hot plate at 60°C for 15 minutes, followed by de-paraffinization 4 
times in fresh xylene for 3 minutes each. The slides were rehydrated by immersion in a 
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series of descending dilutions of ethanol (100%, 75% [v/v], 50% [v/v] and 25% [v/v]). 
Each was immersed twice for 3 minutes per immersion and then finally washed under 
running tap water for 2 minutes. The slides were stained with Mayer's haematoxylin stain 
[0.05g/ml Aluminum potassium sulphate, 0.001g/ml Hematoxylin, 0.0002g/ml Sodium 
iodate and 2%[v/v] Glacial acetic acid] for 2 minutes and washed under running tap water 
for 2 minutes. They were then immersed in Scott's tap water (pH = 8) containing 0.2% 
[v/v] sodium bicarbonate (NaHCO3) and 1% [v/v] MgSO4 for a few seconds, followed 
by immersion in tap water for a further minute, then stained in eosin for 2 minutes and 
washed in tap water for 2 minutes. The tissue sections were dehydrated in ascending 
grades of ethanol, each twice for 3 minutes and finally immersed three times in xylene, 3 
minutes per immersion. For frozen tissue sections, only steps from staining of Mayer’s 
haematoxylin to the staining of eosin were performed. The slide containing the specimen 
was protected under a coverslip using DPX mounting media (Solmedia ltd, 
Shrewsbury, UK) which was allowed to dry at RT before examining under light 
microscope (Section 2.18). 
 
2.17.5 lmmunohistochemistry (IHC)  
Immunohistochemical staining on slides containing paraffin-embedded tissues was 
carried out using the Novolink TM Max Polymer Detection system (Leica) according to 
the manufacturer’s guidelines. The specimens were initially de-waxed using xylene then 
rehydrated in decreasing concentrations of ethanol as described previously (section 
2.17.4). Antigen retrieval pre-treatment was performed in a pressure cooker by boiling 
slides in a solution containing 1mM EDTA in distilled water for 2 minutes at 121°C and 
maximum pressure at 15psi (103.4kPa). The slides were then allowed to cool down for 
an additional 2 minutes in tap water prior to continuing the staining procedure. In a 
humidity chamber, the endogenous peroxidase activity was blocked by incubating each 
slide for 5 minutes with 100 µl (2 drops) of 3% hydrogen peroxide (H2O2) provided with 
the kit. This was followed by three washes in 1 x Tris buffered saline (TBS) (pH 7.5) 
[50mM Tris, 0.8% [w/v] Sodium chloride (NaCl), 0.02% [w/v] Potassium chloride (KCl) 
and 6.0M Hydrochloric acid (HCl)] for 3 minutes each. 100 µl (2 drops) of protein blocker 
[0.4% [w/v] Casein, 0.2% [w/v] Bronidox and 1x PBS] was added to each slide for 5 
minutes to block the non-specific antigenic sites, followed by three washes in 1 x TBS 
for 3 minutes each. The slides were then incubated for 2 hours at 4°C in primary antibody 
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diluted to the recommended concentration in antibody diluent solution [250mg bovine 
serum albumin (BSA), 50 ml 1x TBS and 0.01% NaN3]. The antibodies that were used in 
these experiments are listed in Table 2.1. Following incubation, three washes in 1 x TBS-
Tween [1x TBS-T (pH 7.5) and 0.1% [v/v] of Tween20] were performed for 5 minutes 
each, before a 30 minute incubation was carried out with 100µl (2 drops) of "Post Primary 
Block" provided with the kit (10% [v/v] animal serum in TBS/0.9% ProClinTM 950) to 
facilitate the penetration of the subsequent polymer reagent. A further three washes in 1 
x TBS-Tween were performed for 5 minutes each. 
 
Next, sections were incubated for 30 minutes with 100µl (2 drops) of NovoLink 
Polymer (Anti-goat/rabbit IgG-poly-HRP, 8.0µg/m1) provided with the kit and specific 
to the species of animal the primary antibody was raised in. This was followed by three 
washes in 1 x TBS-Tween, for 5 minutes each. A high-sensitivity diaminobenzidine 
(DAB) substrate-chromagen system (Nonvocastra DAB chromogen and NovoLink DAB 
substrate) was prepared according to the manufacturer's instructions for the brown end-
product at the site of the targeted antigen. 100µl of prepared DAB was used per slide, 
followed by incubation for 5 minutes, then three washes in 1 x TBS each for 3 minutes. 
Counterstaining was performed in Mayer's haematoxylin for 2 minutes 30 seconds 
followed by dehydration in increasing concentrations of ethanol (25%, 50%, 75% and 
100%) for 3 minutes each followed by three rounds of 3 minute washes in xylene. DAB 
stained sections were mounted by a coverslip using DPX mounting media (Sigma) and 
left to air dry overnight before examining under the light microscope (Section 2.18). 
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Antibody name Raised in Recommended for 
Dilution used (1/x) 
Incubation times Source 
IF WB IHC 
DRAM2 (M-12) Goat Mouse and Rat 100 - 50 2 hours Santa Cruz Biotechnology 
DRAM2 Rabbit Human - 200 - 16 hours Novus Biologicals 
MFSD8 (S14) Goat Mouse, Rat and Human 100 - - 16 hours Santa Cruz Biotechnology 
LARGE (Y-14) Goat 
Mouse, Rat, Human and 
Chicken 
50 - - 16 hours Santa Cruz Biotechnology 
Rhodopsin Rabbit Mouse, Rat and Human 300 500 - 2-16 hours Sigma-Aldrich 
Alexa Fluor 568-conjugated Donkey Goat immunoglobulins 500 - - 1 hour Molecular Probes Incorporation 
Alexa Fluor 488-conjugated Chicken Rabbit immunoglobulins 500 - - 1 hour Sigma-Aldrich 
Rabbit Immunoglobulins 
(HRP) 
Rabbit Goat immunoglobulins - 2,000 - 1 hour Dako Cytomation 
Goat Immunoglobulins 
(HRP) 
Goat Rabbit immunoglobulins - - 2,000 1 hour Dako Cytomation 
 
Table 2.1. List of antibodies used in this study. Names of antibodies, species in which they were raised, species recommended for, used dilutions for 
immunofluorescence (IF), western blotting (WB) & immunohistochemistry (IHC), incubation times and the commercial source.
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2.17.6 Immunofluorescent (IF) staining on frozen tissue sections 
Before commencing the IF protocol, frozen tissue sections were thawed for 20 
minutes at RT, then washed twice in PBS for 5 minutes each. Slides were fixed either in 
ice-cold methanol for 5 minutes or 2% paraformaldehyde (PFA) at RT for 20 minutes. 
They were then incubated in a humidity chamber with blocking solution (1% w/v Marvel 
(non-fat milk) powder in PBS-T) [1xPBS and 0.1% [v/v] of Tween20] for one hour at 
RT. At the same time, primary and secondary antibodies were prepared in the same 
blocking solution according to the recommended dilutions and centrifuged at 10,000 x g 
for 5 minutes. Following blocking, slides were incubated with the primary antibody 
(100µl per slide) for 2 hours at 4°C, then washed three times in PBS-T for 5 minutes 
each. A solution of fluorophore conjugated secondary antibody was used to detect the 
primary antibody, whilst 4',6-diamidino-2-phenylindole (DAPI) at a final concentration 
of 1μg/ml was added for nuclear staining. After one hour of incubation in a dark chamber, 
the slides were washed three times in 1 x PBS-T for 5 minutes each, followed by 
mounting the slide with a coverslip and Mowiol® 488 mounting medium (Calbiochem®, 
Hertfordshire, UK). Slides were left to dry in a dark chamber at RT for at least 18 hours 
before examination under the confocal microscope (Section 2.18). 
 
2.17.7 Immunofluorescent (IF) staining on paraffin-embedded tissues 
This method of immunofluorescence labelling was carried out using primary 
antibodies that were recommended for work with formalin-fixed paraffin-embedded 
(FFPE) tissues. Slides containing sections of the paraffin-embedded tissue were placed 
on a hot plate at 60°C for 15 minutes, deparaffinized in fresh xylene and rehydrated by 
immersion in a series of descending grades of ethanol as previously described (Section 
2.17.4). Heat induced retrieval of antigen was performed as previously described (Section 
2.17.5). Slides were then incubated in a humidity chamber with blocking solution (1% 
w/v Marvel (non-fat milk) powder in PBS-T) for 60 minutes at RT. The incubation steps 
for primary and secondary antibodies were performed as described above (Section 
2.17.6), except that the incubation time for the primary antibodies was 16-18 hours. After 
mounting the coverslip as described above (Section 2.17.6) the slides were examined by 
confocal microscopy (Section 2.18). 
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2.17.8 The blocking peptide competition assay (BPCA) 
The Blocking Peptide Competition Assay (BPCA) was used to show the specificity 
of the primary antibody binding to the antigen. Primary antibodies were diluted to the 
recommended working concentration in the blocking solution. A master mix solution of 
1 to 20 molar ratio of antibody to peptide was incubated overnight on a rotator at 4°C. 
The prepared solutions were then used for staining as described previously.   
 
2.18 Microscopy 
2.18.1 Light microscopy 
Investigation and imaging of stained sections by immunohistochemistry (IHC) and 
H&E eosin were performed using a Nikon Eclipse TE-2000-E light microscope. 
 
2.18.2 Confocal microscopy 
IF stained tissue sections were visualized using a Nikon Eclipse Ti-E inverted 
microscopes. Slides were first viewed using wide-field epifluorescence with the DAPI 
blue filter (340-380nm excitation, 400nm emission), FITC green filter (460-500nm 
excitation, 505nm emission) and TRITC red filter (528-553nm excitation, 565nm 
emission). Image capturing and z-stacks were done using scanning confocal microscopy 
with 408nm BD (brilliant™ blue dye), 488nm Ar (argon) and 543nm helium-neon (G-
HeNe) lasers and 515/30 (blue), 540/50 (green) and 650LP (red) spectral detectors. 
Confocal images were processed using Nikon EZ-C1 3.50 software.  
 
2.18.3 Dissecting microscopy 
A Zeiss Stemi 2000-C stereo microscope supplied with a 10X/23 focusing eyepiece 
and auxiliary objectives was used for dissection of the mouse eye and isolation of the 
whole retina from the mouse eye (Section 2.19.1).  
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2.19 Isolation of mouse/cow retina and protein extraction 
2.19.1 Isolation of the mouse/cow retina 
Dissected adult mouse eyes were washed twice in PBS (Sigma-Aldrich) before 
proceeding to extract the retina. Under the dissecting microscope, a small hole in the 
posterior of the limbus was made by an 18 gauge needle. After puncturing the limbus, 
tissue at the circumference of the limbus was cut and the cornea, iris, lens and sclera were 
removed using autoclaved micro-scissors and forceps. Next, the vitreous humour was 
extracted and the retina was carefully separated from the eyecup using two autoclaved 
micro-forceps. Snap frozen cow eyes provided by Mr Mike Shires, University of Leeds. 
Eyes were left at RT to defrost, then washed twice in PBS. The cow retina was then 
extracted using a similar method to the one described above except that the dissecting 
microscope was not required. 
 
2.19.2 Preparation of the protein extract from the mouse/cow retina 
Total protein from either the mouse or the cow retina was prepared by adding 2 ml 
of protein lysis buffer [20mM HEPES, 150mM NaCl, 1mM EDTA, 1x Protease inhibitor 
cocktail and 10% [W/V] Dodecylmaltoside (DM)] to each extracted retina. The tissue 
solution was homogenised with a pellet pestle motor and then incubated on an overhead 
shaker for 30 minutes at 4°C. The solution was then centrifuged at 16,000 x g for 10 
minutes at 4°C to pellet cell debris. The resulting supernatant was transferred to a new 
eppendorf tube. The protein concentration was determined using Bradford assay (Section 
2.19.3) and samples were used for western blot analysis (Section 2.20) and pull-down 
assays (Sections 2.21). 
 
2.19.3 Measuring protein concentration 
The amount of extracted protein was quantified using the Bradford Assay (DC 
protein assay, Bio-rad). Before starting the assay, the following reagents were prepared 
using either the protein lysis buffer described before (Section 2.19.2) or radio 
immunoprecipitation assay (RIPA) buffer [50mM Tris-HCl pH 8, 150mM NaCl, 1% NP-
40, 0.5% Sodium deoxycholate, 0.1% SDS, 5mM EDTA and 1x Protease inhibitor 
cocktail]. Reagents of 10% protein lysis/RIPA buffer in ddH2O, 2μg/ml BSA solution in 
 
 
73 
 
10% protein lysis/RIPA buffer and seven different BSA standards as a dilution series 
ranging from 0.1 to 2μg/μl prepared in 10% protein lysis/RIPA buffer.  
 
Using a flat bottomed 96-well plate, 5μl of 10% protein lysis/RIPA was added once 
as a blank to correct the background absorbance, 5μl of each BSA standard was added in 
triplicate to the plate and 5μl of protein extract was also added to the plate in triplicate. 
20μl of Reagent S was added to 1ml of Reagent A, then 25μl of this Reagent, SA, was 
added to each well. Then 200μl of Reagent B was added to each well. The plate was 
incubated for 15 minutes on a shaker at RT, and then the absorbance at 690nm was read 
using a multiscan microplate reader (Titertek-Berthold®, Germany). Absorbance readings 
were analysed in Microsoft Excel by interpolation on a complete standard curve and 
consideration of the dilution factor to calculate volumes required for western blotting and 
pull-down assays.  
 
2.20 Western blotting 
Approximately 20µg of total protein was denatured by incubating at 95°C for 5 
minutes with 2 x Sodium Dodecyl Sulphate (SDS) western loading buffer [100mM Tris-
HCL (pH 6.8), 200mM β-mercaptoethanol, 20% [v/v] glycerol and 4% [w/v] SDS]. After 
denaturating, the samples were loaded onto a NuPAGE® gradient (4-12%) Bis-Tris 
PAGE gel (Invitrogen) alongside a SeeBlue Plus2 pre-stained protein marker 
(Invitrogen). The gel was run in an X-Cell SureLock electrophoresis tank filled with a 1 
x NuPAGE® MES-SDS running buffer (Invitrogen) at 120V for 90 minutes. An 
Invitrolon polyvinylidene difluoride (PVDF) membrane (Invitrogen) was activated by 
soaking in 100% methanol for 30 seconds followed by submerging in 1 x NuPAGE® 
transfer buffer (Invitrogen) containing 10% methanol for 5 minutes. In the X-Cell 
SureLock Blot module (Invitrogen), the SDS-PAGE gel and the activated PVDF 
membrane were sandwiched between blotting paper and a number of sponges soaked in 
1 x NuPAGE® transfer buffer (Invitrogen) containing 10% [v/v] methanol. The module 
was filled with l x transferring buffer whilst the surrounding tank was filled with cold 
distilled water, and the transfer was run at 30V for 60-90 minutes. Following transfer, the 
membrane was rinsed with PBS-T, then the membrane was incubated with western 
blocking solution (5% [w/v] Marvel dried non-fat milk powder in PBS-T) for between 1 
and 18 hours at 4°C with gentle agitation. The membrane was then incubated on a tube 
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roller with the primary antibody (diluted in blocking solution) for 2-18 hours at 4°C 
depending on the antibody used (Table 2.1). This was followed by three washes of PBS-
T of 5 minutes each. Next the membrane was incubated with the HRP conjugated-
secondary antibody (diluted in blocking solution) for 1 hour at RT with agitation. After 
three washes of 5 minutes each in PBS-T, the membrane was then placed on an acetate 
sheet and incubated with Femto Super Signal West reagent® (Thermo Scientific) 
according to the manufacturer’s guidelines to develop the immune-positive bands. 
Membranes were visualised on the ChemiDoc™ MP System with Image Lab™ software 
(Bio-Rad Life Science). If the membrane was to be re-used, it was first stripped in 0.2M 
sodium hydroxide prepared in distilled water for 5 minutes then the protocol was started 
again from the blocking step. 
 
2.21 Pull down assay  
The pulling down of protein complexes out of solution was attempted using Protein 
A plus agarose beads (Thermo Fisher Scientific). Approximately 1 mg of the protein was 
incubated on a rotating mixer with 2.5µg of the antibody and 600µl of 
immunoprecipitation (IP) washing buffer [150mM NaCl, 1% [v/v] NP40, 50 mM Tris-
HCl pH8.0, 10% [v/v] glycerol and 2mM EDTA] for 2 hours at 4°C. Meanwhile, 50µl of 
the beads were washed three times, with the first wash in 1 x TBS followed by 
centrifugation at 1,000 x g for 1 minute at 4°C, and the second and third washes were 
performed by adding 500µl of IP washing buffer followed by centrifugation at 1,000 x g 
for 1 minute each at 4°C. 25µl of the washed beads were added to the antibody-protein 
solution and then incubated overnight on the rotating mixer at 4°C. 60µl Neutralisation 
buffer (1M Tris, pH8) was added to the mixture before eluting three times in MicroSpin 
G-25 columns (GE Healthcare Life Sciences) using 200µl Elution buffer (200mM 
glycine, pH 2.5) for 20 minutes each at 4°C. The solution was then neutralized using the 
Neutralization buffer. Before the protein precipitation step, the sample was checked by 
silver staining (Section 2.22). Protein precipitation was achieved using a methanol 
(MeOH)/chloroform (CHCl3) mixture. 800µl MeOH was added to the sample which was 
then vortexed, followed by centrifugation at 9,000x g for 30 seconds, then 200µl CHCl3 
was added to the pellet and it was vortexed again, followed by centrifugation at 9,000x g 
for 30 second. The supernatant was carefully discarded, then 600µl of MeOH was added 
to the pellet, followed by vortexing and centrifugation at 16,000 x g for 2 minutes. Finally 
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the pellet was dried at RT for 5 minutes. The sample was then ready for analysis by mass 
spectrometry. 
 
2.22 Silver staining 
Prior to silver staining of proteins in polyacrylamide gels, the protein was 
denatured, loaded onto a NuPAGE® gel and run at 120V for 1.5 hours as described 
previously (Section 2.20). The gel was then fixed in a solution containing 50% [v/v] 
methanol and 5% [v/v] acetic acid for 20 minutes, washed in 50% methanol for 10 
minutes then washed in double-distilled water (ddH2O) for 10 minutes. For sensitizing, 
the gel was incubated with 0.02% [v/v] sodium thiosulphate for 1 minute, followed by 
rinsing twice in ddH2O for 1 minute per rinse. For the silver reaction, the gel was 
submerged in 0.1% [v/v] silver nitrate for 20 minutes, followed by two rinses in ddH2O 
for 1 minute each. For developing, the gel was incubated with 2% [v/v] sodium carbonate 
with 0.04% [v/v] formalin until the desired intensity of staining was produced. The 
developer solution was replaced with fresh solution when it turned yellow. The staining 
was terminated in 5% [v/v] acetic acid for 10 minutes. The gel was then washed twice in 
ddH2O, 5 minutes per wash, and imaged using an Olympus C-7070 digital camera which 
reflected light from a cold light source.  
 
2.23 Gateway® cloning technology 
The DNA fragment of interest was cloned into the plasmid vector pC-TAP GW332 
(Figure 2.1) provided by Prof. Colin Johnson, using the Gateway® cloning system 
(Invitrogen). Briefly, cloning PCR primers were designed to add gateway attB restriction 
enzyme sequences to the 5’ and 3’ ends of a gene fragment (Section 2.4.2). The PCR was 
carried out to amplify the full coding sequence of the gene of interest using Platinum Pfx 
DNA polymerase (Section 2.4.5). The PCR product was run on a 1.5% agarose gel and 
the DNA bands were excised from the agarose gel and purified using the Qiagen’s 
QIAquick Gel Extraction kit protocol (Section 2.6) according to the manufacturer’s 
recommendations. The entry clone was created by in-vitro recombination reaction using 
the enzyme BP Clonase® (Invitrogen). This entry clone was then used in an LR Clonase® 
reaction (Invitrogen) with the destination vector (pC-TAP GW332) to create the desired 
expression clone (Eg. pDRAM2-C-TAP). 
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Figure 2.1. Map of the C-TAP GW332 plasmid. 
 
 
2.24 Bacterial transformation and cell culture 
10-40ng of plasmid DNA was transfected into One Shot® ccdB Survival™ 
2T1R Chemically Competent Cells (Invitrogen) using heat shock. The DNA was added 
into a vial of defrosted One Shot® cells and mixed gently, followed by incubation on ice 
for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C without shaking, then 
placed on ice for 2 minutes. 250μl of pre-warmed Super Optimal Broth with Catabolite 
repression (SOC) medium (Invitrogen) was added to each vial followed by horizontal 
shaking at 37°C for 1 hour at 225 rpm. After incubation, 25μl from each transformation 
was then spread onto LB agar plates containing the appropriate antibiotic and incubated 
overnight at 37oC. A single colony was picked from the agar plate using a sterile 1µl loop 
and inoculated with 5ml of Luria-Bertani (LB) broth [Tryptone Yeast Extract Sodium 
Chloride (NaCl), 1.5% [w/v] agar and 50mg/ml Ampicillin] containing the appropriate 
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amount of desired antibiotic. The bacterial culture was then allowed to grow for 16 hours 
at 37oC with 225 rpm shaking. Only 1.5 ml of the culture was used for Miniprep plasmid 
DNA isolation, whilst the remaining culture was stored at 4oC for any further use.   
 
2.25 Plasmid DNA isolation and purification 
The Qiagen QIAprep® miniprep kit was used for small-scale plasmid DNA 
isolation and purification according to the manufacturer’s protocol. Cells from 1.5ml of 
bacterial culture were pelleted by centrifugation at 3220 x g then resuspended in neutral 
buffer containing RNAse A, followed by mixing with equal volume of alkaline lysis 
buffer. The lysis was then neutralized by addition of high salt neutralization buffer. 
Lysates containing DNA in a high salt solution were applied to a spin column and 
centrifuged at 3220 x g. The DNA was then washed by an ethanol buffer and eluted in 
50µl by buffer ddH2O.   
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Chapter 3. Screening for variants causing inherited 
retinal dystrophy using customized targeted capture 
and next-generation sequencing 
3.1 Introduction 
According to current knowledge, hereditary retinal dystrophies (RDs) are the most 
genetically heterogeneous group of diseases in humans. The genetic screening of patients 
with inherited retinal dystrophies is particularly challenging since all modes of 
inheritance are possible and conditions such as LCA, COD/CRD, RP and MD can be 
caused by mutations in any one of more than 250 genes (see RetNet, https://sph.uth.tmc. 
edu/retnet/). The genetic causes of many hereditary cases remain unknown (Wang et al., 
2005; Daiger et al., 2010; Perez-Carro et al., 2016; Weisschuh et al., 2016). The large 
number of genes implicated in RD means that mutation detection by Sanger sequencing 
of individual genes is highly labour intensive and inefficient.  
 
In the last six years, the introduction of next-generation sequencing (NGS) 
technologies has made it possible to simultaneously sequence multiple genes in one 
experiment. The work described in this chapter was initiated in the early days of applying 
NGS to find the pathogenic mutations in inherited eye diseases. A customised SureSelect 
solution-based targeted capture reagent was designed by a colleague, Dr David Parry 
(Section of Genetics, University of Leeds), which is hereafter referred to as the 
“Retinome” reagent. This reagent simultaneously captures all the exons and flanking 
splice site junctions of the 162 genes that had been shown to harbour mutations causing 
RD at the time of design, based on the RetNet database in July 2010. The full list of genes 
that were selected is shown in Appendix 3. Patient genomic DNA was sheared, tagged 
and pooled before hybridisation to the targeted reagent (Section 2.11). Probes could not 
be designed against 9 exons (Appendix 4) that have highly repetitive and purine rich 
sequences. The captured DNA from the pull-down experiment was analysed by next-
generation sequencing. 
 
This customised targeted reagent was first tested by Dr Parry on a cohort of four 
RD patients with known causative mutations in order to validate the capture reagent and 
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establish the pipeline for variant detection. The results confirmed that the pipeline used 
to identify pathogenic mutations was robust (Appendix 5). After validation of the capture 
reagent, libraries were prepared from genomic DNA of 20 patients selected from 20 
unrelated families diagnosed with various retinal degenerations for which no mutation 
had yet been identified. The families were recruited by Dr Martin McKibbin (Eye 
Department, St. James’s University Hospital), the library preparation was done by Dr 
Christopher Watson (Yorkshire Regional Genetics, St. James’s University Hospital) 
while the families analysed were chosen by Prof Chris Inglehearn, Dr Carmel Toomes 
and Dr Manir Ali (Section of Ophthalmology & Neuroscience, University of Leeds). 
These libraries were then pooled in pools of four samples, each with its own unique tag 
for later deconvolution, then this mix was hybridized to the Retinome capture reagent. 
The DNA captured was then subjected to NGS (Section 2.11.1). The 20 families included 
in this study, the diagnoses of the affected cases, possible inheritance patterns, ethnicity 
and summary information regarding numbers of affected cases and members available 
for sampling are recorded in Table 3.1.  
 
The output data from this experiment was analysed by the author as described in 
Section 2.11.2 and the list of candidate gene variants from each family was filtered on 
the basis of variant type (deletion, insertion, nonsense, missense, non-synonymous/ 
synonymous), population frequency, conservation, pathogenicity prediction and 
phenotype match. The major steps in the pipeline and the data filtration criteria used in 
the Retinome project are illustrated in Figure 3.1. Primers were designed against plausible 
candidate variants (Section 2.4.1), and these were PCR amplified (Sections 2.4.3 and 
2.4.4) and Sanger sequenced (Section 2.8) to confirm presence of the variants in the 
original samples and assess segregation in additional family members. The primer pairs 
used in this study are listed in Appendix 6. The results of these findings are presented in 
this chapter and contributed to publications Watson et al., 2014 and Shevach et al., 2015.  
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ID Ethnicity Diagnosis Inheritance pattern Number of affected cases 
Number of affected cases 
sampled 
Number of unaffected 
cases Sampled 
MA1a Asian LCA Recessive 4 2 0 
MA2a Asian CRD Recessive /Dominant 5 3 0 
MA3a Asian RP Recessive 3 2 0 
MA4a Asian RP Recessive 2 2 0 
MA5 European CRD/MD Dominant 2 2 0 
MA6a Asian RP Recessive 2 1 0 
MA7 European CRD Dominant 12 8 4 
MA8 European RP with Maculopathy Dominant /X-linked 10 9 5 
MA9 European CRD/MD Dominant 18 12 2 
MA10a Asian CRD Recessive 6 6 1 
MA11a European RP Recessive 2 2 0 
MA12a Asian CRD Recessive 9 6 9 
MA13a Asian RP Recessive 2 2 4 
MA14a Asian RP Recessive 2 2 0 
MA15a Asian CRD Recessive 4 4 7 
MA16a Asian LCA Recessive 2 2 0 
MA17a Asian RCD Recessive 2 2 0 
MA18 Asian CRD Recessive 3 3 4 
MA19a Asian RCD Recessive 8 3 3 
MA20a Asian RP Recessive 2 2 5 
 
Table 3.1. Summary of specific details of families that were studied in the Retinome project. The family ID, diagnosis, ethnicity, inheritance pattern, 
number of cases and numbers sampled are shown. a = consanguineous family, LCA = Leber congenital amaurosis, CRD = cone-rod dystrophy, RP = retinitis 
pigmentosa, MD = macular dystrophy and RCD = rod-cone dystrophy. (Adapted from Watson et al., 2014). 
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Figure 3.1. Schematic representation of the targeted NGS and variant detection data 
pipeline used in the Retinome project described in chapter 3. The flowchart illustrates the 
major steps of the pipeline, beginning with NGS library preparation (A) (Modified from 
http://www.genomics.agilent.com/article.jsp?pageId=3083) and ending with informatics for 
variant detection, filtering and selection (B). 
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3.2 Results 
3.2.1 Inherited retinal dystrophy families in whom the pathogenic 
mutation was found using the retinome reagent. 
3.2.1.1 Genetic analysis of family MA1 
For family MA1, the affected cases were diagnosed with LCA, while the family 
structure suggested recessive inheritance caused by an autozygous mutation (Figure 
3.2A). Based on the zygosity, the filtered variant list generated from the analysis of 
patient 2906 (Table 3.2) highlighted three homozygous variants in HMCN1, CRB1 and 
TRPM1 and three compound heterozygous mutations in USH2A, GPR98 and TOPORS. 
A novel homozygous deletion of 23 base pairs including part of exon 8 of CRB1 
(NM_201253.2:c.2832_2842+ 23del) (Figure 3.2B) was the only candidate variant that 
was consistent with the diagnosis (LCA) in the family. Sanger sequencing of this 
truncating CRB1 mutation in the other affected case from whom DNA was available 
(2907) provided further confirmation that the mutation is the pathogenic cause of disease. 
 
 
 
Figure 3.2. Molecular analysis of family MA1. (A) The pedigree of family MA1. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(2906) with the CRB1 mutation. (Adapted from Watson et al., 2014) 
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Chr Position Gene 
Coding 
Effect 
cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 186010250 HMCN1 missense NM_031935.2:c.6286A>G p.Ile2096Val 3 C0 Tolerated good Homo Immunoglobulin I-set  
1 197398744 CRB1 frameshift NM_201253.2:c.2832_2842+23del  p.? NA NA NA NA Homo  YES 
1 215820993 USH2A missense NM_206933.2:c.14662A>T p.Thr4888Ser 1 C0 Tolerated good Het Fibronectin, type III  
1 216405368 USH2A missense NM_206933.2:c.2920G>A p.Asp974Asn 1 C15 Deleterious bad Het EGF-like, laminin  
1 216496929 USH2A missense NM_206933.2:c.1437C>A p.Phe479Leu 0 C15 Deleterious bad Het Laminin, N-terminal  
3 63981343 ATXN7 missense NM_001177387.1:c.1845C>G p.Ser615Arg -1 C0 Tolerated good Het   
4 122766846 BBS7 missense NM_176824.2:c.1043A>G p.Glu348Gly -2 C65 Deleterious bad Het BBS7 protein  
5 89925326 GPR98 missense NM_032119.3:c.1809C>A p.Phe603Leu 0 C15 Deleterious bad Het   
5 90149261 GPR98 missense NM_032119.3:c.17365A>G p.Lys5789Glu 1 C0 Tolerated good Het   
7 33545217 BBS9 missense NM_198428.2:c.2258A>T p.Glu753Val -2 C0 Deleterious bad Het   
7 92140266 PEX1 missense NM_000466.2:c.1579A>G p.Thr527Ala 0 C0 Tolerated good Het   
8 38869207 ADAM9 missense NM_003816.2:c.226G>A p.Glu76Lys 1 C0 Tolerated good Het 
Peptidase M12B, 
propeptide 
 
9 32542056 TOPORS missense NM_005802.4:c.2467A>G p.Ser823Gly 0 C0 Tolerated good Het   
9 32542166 TOPORS missense NM_005802.4:c.2357G>A p.Arg786Gln 1 C0 Tolerated good Het   
10 50669416 ERCC6 missense NM_000124.2:c.3965G>T p.Gly1322Val -3 C65 Deleterious bad Het   
10 73573082 CDH23 missense NM_022124.5:c.9715T>C p.Ser3239Pro -1 C0 Deleterious bad Het   
15 31342673 TRPM1 missense NM_002420.4:c.1310G>T p.Gly437Val -3 C0 Deleterious bad Homo   
X 49076224 CACNA1F In-frame 
NM_005183.2:c.2439_2444dupTC
CTCC 
p.Glu824_Glu825d
up 
NA NA NA NA Het   
 
Table 3.2. List of candidate variants after alignment, variant calling and filtering for patient 2906 (female) for family MA1. The likely causative variant 
is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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The identification of this mutation was also consistent with linkage analysis data 
previously generated by Dr Ali for this family through Affymetrix 6.0 SNP homozygosity 
mapping on patients (2906 and 2907). This genotyping showed that there were four 
regions of homozygosity greater than 5 Mb shared between the two affected individuals; 
chr1:174,370,600-203,208,400 (28.8Mb), chr12:15,094,230-24,477,660 (9.4Mb, hg19), 
chr12:57,021,120-92,472,930 (35.5Mb, hg19) and chr15:69,828,190-89,825,460 
(20.0Mb, hg19). CRB1 (chr1:197,237,334-197,447,585; hg 19) is located in the second 
largest region. 
 
3.2.1.2 Genetic analysis of family MA2 
For family MA2, the pedigree structure, with both parents unaffected and in a 
consanguineous marriage, suggested a recessive mode of inheritance (Figure 3.3A). The 
clinical history and examination of the affected cases indicated CRD. Based on the 
zygosity, the variant list after next-generation sequencing analysis (Table 3.3) and Sanger 
sequencing of patient 2844 highlighted only one homozygous mutation in ABCA4 
(NM_000350.2:c.6088C>T, p.R2030*) (Figure 3.3B). Segregation analysis revealed this 
nonsense mutation in a heterozygous form in the affected offspring 2843 and 2845, 
suggesting that they both had another unidentified ABCA4 mutation on the other allele, 
which they had inherited from their mother. The c.6088C>T, p.R2030* mutation was 
previously reported in a family with affected cases that had early-onset non-syndromic 
RD (Singh et al., 2006). 
 
Figure 3.3. Molecular analysis of family MA2. (A) The pedigree of family MA2. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and affected family members (2844 
and 2845) with the ABCA4 mutation. (Adapted from Watson et al., 2014). 
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3.2.1.3 Genetic analysis of family MA3 
For family MA3, the family history suggested RP in the affected cases with a 
recessive mode of inheritance (Figure 3.4A). Targeted capture and next-generation 
sequence analysis on the index case 2908 identified only one homozygous variant (Table 
3.4). This variant was a novel homozygous missense mutation in USH2A (NM_206933.2: 
c.12874A>G, p.N4292D) (Figure 3.4B) which had a high pathogenicity profile with C15 
class by AGVGD, predicted to have a severe effect on the physicochemical of the protein 
by MAPP software and to be a deleterious mutation by SIFT. The amino acid residues 
are evolutionarily fully conserved from human to zebrafish (Figure 3.4C) and Sanger 
sequencing confirmed the mutation in both affected cases 2908 and 2909 from whom 
DNA was available. 
 
 
 
Figure 3.4. Molecular analysis of family MA3. (A) The pedigree of family MA3. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(2908) with the USH2A mutation are shown. (Adapted from Watson et al., 2014). (C) 
Evolutionary conservation of the part of the USH2A polypeptide that contains the missense 
mutation p.N4292D.
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Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 5925272 NPHP4 missense NM_015102.3:c.3706G>A p.Val1236Met 1 C0 Deleterious bad Het   
1 94471056 ABCA4 nonsense NM_000350.2:c.6088C>T p.Arg2030* NA NA NA NA Homo ABC transporter-like YES 
1 186120461 HMCN1 missense NM_031935.2:c.14738C>A p.Thr4913Asn 0 C0 Deleterious bad Het G2 nidogen/fibulin G2F  
1 215914751 USH2A missense NM_206933.2:c.11677C>A p.Pro3893Thr -1 C35 Deleterious bad Het Fibronectin, type III  
2 96950323 SNRNP200 missense NM_014014.4:c.4165G>A p.Val1389Ile 3 C0 Tolerated good Het DEAD/DEAH box type, N-terminal  
4 15554873 CC2D2A missense NM_001080522.2:c.2431G>A p.Glu811Lys 1 C0 Deleterious unknown Het   
6 65596607 EYS missense NM_001142800.1:c.2975G>T p.Cys992Phe -2 C0 Deleterious unknown Het Epidermal growth factor-like, type 3  
10 73405717 CDH23 missense NM_022124.5:c.1270G>A p.Val424Met 1 C0 Deleterious bad Het Cadherin  
12 76740134 BBS10 missense NM_024685.3:c.1631A>G p.Asn544Ser 1 C0 Tolerated good Het   
12 88480262 CEP290 missense NM_025114.3:c.4208G>C p.Arg1403Thr -1 C0 Tolerated good Het   
 
Table 3.3. List of candidate variants after alignment, variant calling and filtering for patient 2844 (male) for family MA2. The likely causative variant 
is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 68910315 RPE65 missense NM_000329.2:c.394G>A p.Ala132Thr 0 C0 Tolerated good Het Carotenoid oxygenase  
1 215848379 USH2A missense NM_206933.2:c.12874A>G p.Asn4292Asp 1 C15 Deleterious bad Homo Fibronectin, type III YES 
6 137193331 PEX7 splicing? NM_000288.3:c.748-5dupT p.?  NA NA NA NA Het   
9 120475185 TLR4 missense NM_138554.3:c.779T>C p.Leu260Pro -3 C25 Deleterious bad Het Toll-like receptor  
9 139333568 INPP5E missense NM_019892.3:c.304G>T p.Asp102Tyr -3 C0 Deleterious good Het   
10 73537449 CDH23 missense NM_022124.5:c.4858G>A p.Val1620Met 1 C15 Deleterious bad Het Cadherin  
11 66291004 BBS1 missense NM_024649.4:c.908T>C p.Val303Ala 0 C25 Deleterious good Het WD40 repeat-like domain  
16 56536660 BBS2 missense NM_031885.3:c.865A>G p.Ile289Val 3 C0 Tolerated good Het BBS2 protein  
X 13774746 OFD1 missense NM_003611.2:c.1271A>G p.Asn424Ser 1 C0 Deleterious good Het   
Table 3.4. List of candidate variants after alignment, variant calling and filtering for patient 2908 (female) for family MA3. The likely causative variant 
is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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3.2.1.4 Genetic analysis of family MA6 
For family MA6, the family history suggested recessive inheritance of RP caused 
by an autozygous mutation (Figure 3.5A). Targeted capture and next-generation 
sequencing of case 2771 (Table 3.5) highlighted two homozygous variants in PROM1 
and RDH12. PROM1 has a splice variant that is not predicted to cause defective splicing 
using software described in Section 2.14.3. However, both variant were test for 
segregation by confirmatory Sanger sequencing. This excluded the PROM1 variant and 
instead highlighted the missense mutation in exon five of RDH12 (NM_152443.2: 
c.601T>C, p.C201R) (Figure 3.5B). This homozygous mutation was previously reported 
by (Sun et al., 2007) in a family with LCA. Bioinformatics analysis of this mutation 
revealed a high pathogenicity profile with -3, C0, 0.03 and bad prediction scores in 
BLOSUM62, AGVGD, SIFT and MAPP respectively. 
 
 
 
Figure 3.5. Molecular analysis of family MA6. (A) The pedigree of family MA6. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(2271) with the RDH12 mutation. (Adapted from Watson et al., 2014). 
 
3.2.1.5 Genetic analysis of family MA7 
For family MA7, the pedigree structure suggested dominant inheritance with 
affected members being diagnosed with CRD (Figure 3.6A). Targeted capture and next-
generation sequencing analysis of patient 114 identified four candidate heterozygous 
mutations; three pathogenic missense variants in MERTK, PROM1, GRM6 and one 
possible splicing variant in EYS (Table 3.6). Based on the available literature, the 
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heterozygous missense mutation in PROM1 (NM_006017.2: c.1117C>T, p.R373C) 
(Figure 3.6B) was the only variant consistent with the phenotype and mode of inheritance. 
This substitution was previously identified in patients with disease symptoms of adCRD 
(Yang et al., 2008; Michaelides et al., 2010). It is predicted to be pathogenic with -3 score 
for BLOSUM62, C0 for AGVGD, 0.03 (deleterious) for SIFT and bad for MAPP. Sanger 
sequence validation of the mutation confirmed segregation with the disease in the 
members from whom DNA was available. 
 
 
Figure 3.6. Molecular analysis of family MA7. (A) The pedigree of family MA7. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(114) with the PROM1 mutation. (Adapted from Watson et al., 2014). 
 
3.2.1.6 Genetic analysis of family MA8 
For family MA8, all affected members had RP with macular involvement and the 
family structure suggested a dominant or X-linked mode of inheritance (Figure 3.7A). 
The final variant list produced from targeted capture and next-generation sequence 
analysis of patient 40 included 11 variants (Table 3.7). Three candidate variants in RP2, 
NR2E3 and RPGR were consistent with the phenotype and mode of the inheritance 
observed the family. Segregation analysis on genomic DNA from eight affected and three 
unaffected family members showed that only the novel splicing variant in RP2 
(NM_006915.2:c.884-1G>T) (Figure 3.7B) followed disease symptoms as expected for 
an X-linked dominant condition.  
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Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 186007997 HMCN1 missense NM_031935.2:c.5888G>T p.Gly1963Val -3 C0 Tolerated good Het   
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Homo  No 
5 82836537 VCAN missense NM_004385.4:c.7715C>T p.Ser2572Leu -2 C65 Deleterious bad Het Immunoglobulin I-set  
10 86008700 RGR missense NM_002921.3:c.271G>A p.Gly91Ser 0 C55 Deleterious good Het   
14 68193850 RDH12 missense NM_152443.2:c.601T>C p.Cys201Arg -3 C0 Deleterious bad Homo GPCR, rhodopsin-like, 7TM YES 
15 73029831 BBS4 missense NM_033028.3:c.1463C>A p.Thr488Lys -1 C0 Tolerated good Het Short-chain dehydrogenase/reductase SDR  
 
Table 3.5. List of candidate variants after alignment, variant calling and filtering for patient 2771 (male) for family MA6. The likely causative variant 
is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
 
Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
2 71134 ALMS1 missense NM_015120.4:c.5362A>G p.Asn1788Asp 1 C0 Tolerated unknown Het   
2 112722801 MERTK missense NM_006343.2:c.791C>G p.Ala264Gly 0 C55 Deleterious bad Het Immunoglobulin-like  
4 16014922 PROM1 missense NM_006017.2:c.1117C>T p.Arg373Cys -3 C0 Deleterious bad Het Prominin YES 
5 178413684 GRM6 missense NM_000843.3:c.1571C>T p.Pro524Leu -3 C65 Deleterious bad Het GPCR, family 3, nine cysteines domain  
6 66063346 EYS splicing? NM_001142800.1:c.1459+5C>T p.? NA NA NA NA Het   
16 53692694 RPGRIP1L missense NM_015272.2:c.1340T>C p.Leu447Ser -2 C0 Tolerated good Het   
 
Table 3.6. List of candidate variants after alignment, variant calling and filtering for patient 114 (male) for family MA7. The likely causative variant is 
orange shaded. Chr = chromosome, NA = not annotated and Het = heterozygous. (Adapted from Watson et al., 2014).  
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Figure 3.7. Molecular analysis of family MA8. (A) The pedigree of family MA8. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member (40) 
with the RP2 mutation. (Adapted from Watson et al., 2014). 
 
3.2.1.7 Genetic analysis of family MA9 
For MA9, diagnosis of the affected family members and family history revealed a 
macular dystrophy phenotype with a dominant mode of inheritance (Figure 3.8A). The 
variant list derived from analysis of genomic DNA from patient 530 included seven 
variants (Table 3.8), from which two heterozygous variants in HMCN1 and GUCY2D 
were highlighted as possible candidate variants consistent with the phenotype and mode 
of inheritance. Segregation analysis using additional family members from whom DNA 
was available excluded the HMCN1 variant as a cause of adMD in this family, but 
confirmed segregation of the previously reported GUCY2D mutation (c.2512C>T, 
p.R838C) (Figure 3.8B) (Van Ghelue et al., 2000; Wilkie et al., 2000) with the disease 
phenotype.  
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Figure 3.8. Molecular analysis of family MA9. (A) The pedigree of family MA9. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(530) with the GUCY2D mutation. (Adapted from Watson et al., 2014). 
 
3.2.1.8 Genetic analysis of family MA10 
Family MA10 is a large consanguineous family with six affected members 
diagnosed with autosomal recessive CRD (Figure 3.9A). After analyzing patient 1857, 
the filtered vcf file that was generated highlighted only one homozygous candidate 
variant (Table 3.9), a null variant in RPGRIP1 (NM_020366.3:c.3565C>T, p.R1189*). 
This mutation had previously been reported as a pathogenic cause of the disease (Abu-
Safieh et al., 2013) and segregation analysis on seven family members for whom DNA 
was available confirmed this mutation as the cause of disease symptoms in this family 
(Figure 3.9B). 
 
Figure 3.9. Molecular analysis of family MA10. (A) The pedigree of family MA10. Individuals 
from whom DNA was available are numbered and the proband is indicated by an arrow. (B) 
Sanger DNA sequencing chromatograms of a control subject and an affected family member 
(1857) with the RPGRIP1 mutation. (Adapted from Watson et al., 2014). 
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Chr Position Gene 
Coding 
Effect 
cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 103400669 COL11A1 missense NM_080629.2:c.3475G>A p.Gly1159Ser 0 C55 Deleterious good Het   
1 215844373 USH2A missense NM_206933.2:c.14074G>A p.Gly4692Arg -2 C65 Deleterious bad Het Fibronectin, type III  
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Het   
5 89969880 GPR98 missense NM_032119.3:c.4939A>G p.Ile1647Val 3 C0 Tolerated good Het 
Na-Ca exchanger/ integrin-
beta4 
 
10 13320305 PHYH in-frame 
NM_006214.3:c.1010_1012du
pGAT 
p.Asn337_Leu338ins
His 
NA NA NA NA Het   
11 119216627 MFRP missense NM_031433.2:c.283G>A p.Ala95Thr 0 C0 Tolerated good Het   
15 31294159 TRPM1 missense NM_002420.4:c.4678G>A p.Val1560Met 1 C0 Deleterious good Het   
15 6267 NR2E3 nonsense NM_014249.2:c.300C>A p.Cys100* NA NA NA NA Het 
Zinc finger, nuclear 
hormone receptor-type 
NO 
X 18674770 RS1 splicing? NM_000330.3:c.184+3G>T p.? NA NA NA NA Het  A 
X 38182144 RPGR missense NM_001034853.1:c.209G>A p.Gly70Glu -2 C0 Deleterious bad Het 
Regulator of chromosome 
condensation, RCC1 
A 
X 46736939 RP2 splicing NM_006915.2:c.884-1G>T p.? NA NA NA NA Hemi  YES 
 
Table 3.7. List of candidate variants after alignment, variant calling and filtering for patient 40 (male) for family MA8. The likely causative variant is 
orange shaded. Chr = chromosome, NA = not annotated. Hemi= hemizygous, Het = heterozygous and A = artefact. (Adapted from Watson et al., 2014). 
Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 186141213 HMCN1 missense NM_031935.2:c.15764T>C p.Ile5255Thr -1 C65 Deleterious bad Het EGF-like calcium-binding NO 
1 216172258 USH2A missense NM_206933.2:c.6628C>G p.Pro2210Ala -1 C25 Deleterious bad Het Fibronectin, type III  
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Homo   
16 53653005 RPGRIP1L missense NM_015272.2:c.3548C>G p.Ala1183Gly 0 C0 Deleterious bad Het   
16 53683031 RPGRIP1L splicing? NM_015272.2:c.2153-4G>C p.? NA NA NA NA Het   
17 7918018 GUCY2D missense NM_000180.3:c.2512C>T p.Arg838Cys -3 C65 Deleterious bad Het Haem NO binding associated YES 
20 10393439 MKKS missense NM_170784.1:c.724G>T p.Ala242Ser 1 C15 Deleterious good Het Chaperonin Cpn60/TCP-1  
Table 3.8. List of candidate variants after alignment, variant calling and filtering for patient 530 (female) for family MA9. The likely causative variant 
is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 215960153 USH2A missense NM_206933.2:c.10246T>G p.Cys3416Gly -3 C65 Deleterious bad Het Fibronectin, type III  
1 216062306 USH2A missense NM_206933.2:c.7685T>C p.Val2562Ala 0 C0 Tolerated good Het Fibronectin, type III  
2 96942928 SNRNP200 missense NM_014014.4:c.5983G>A p.Ala1995Thr 0 C0 Tolerated good Het Sec63 domain  
5 82835550 VCAN missense NM_004385.4:c.6728C>G p.Thr2243Arg -1 C0 Tolerated good Het   
9 139326278 INPP5E missense NM_019892.3:c.1547A>G p.Lys516Arg 2 C0 Tolerated good Het Endo-/Exo-nuclease phosphatase  
10 73337684 CDH23 missense NM_022124.5:c.767G>A p.Arg256His 0 C0 Deleterious bad Het Cadherin  
11 17531058 USH1C missense NM_153676.3:c.1858C>T p.Arg620Cys -3 C0 Deleterious unknown Het   
12 2022196 CACNA2D4 missense NM_172364.4:c.419C>G p.Ala140Gly 0 C0 Deleterious good Het   
14 21813304 RPGRIP1 nonsense NM_020366.3:c.3565C>T p.Arg1189* NA NA NA NA Homo - YES 
15 73028295 BBS4 missense NM_033028.3:c.1236A>T p.Glu412Asp 2 C0 Tolerated good Het   
16 53698905 RPGRIP1L missense NM_015272.2:c.1120C>T p.His374Tyr 2 C15 Deleterious good Het   
17 79503621 FSCN2 missense NM_001077182.2:c.1151C>A p.Ala384Glu -1 C0 Not scored unknown Het   
 
 
 
Table 3.9. List of candidate variants after alignment, variant calling and filtering for patient 1857 (female) for family MA10. The probable causative 
variant is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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3.2.1.9 Genetic analysis of family MA11 
For MA11, family history suggested recessive inheritance of RP with an 
autozygous mutation (Figure 3.10A). The variant list derived from analysing the index 
case 1267 included only one homozygous missense variant in BBS2 
(NM_031885.3:c.1895G>C, p.R632P) (Table 3.10), which was considered the most 
likely causative variant based on mode of inheritance of the family. Sanger sequencing 
confirmed the presence of the mutation in the second affected family member 2093 for 
whom DNA was available (Figure 3.10B). This mutation is likely to be pathogenic as it 
is predicted to have a deleterious effect on the protein by MAPP, it scores -3 on the 
BLOSUM62 matrix and C15 for AGVGD. Furthermore the amino acid residues are 
conserved through evolution from human to brown algae.  
 
Figure 3.10. Molecular analysis of family MA11. (A) The pedigree of family MA11. 
Individuals from whom DNA was available are numbered and the proband is indicated by an 
arrow. (B) Sanger DNA sequencing chromatograms of a control subject and an affected family 
member (1267) with the BBS2 mutation. (Adapted from Watson et al., 2014). (C) Evolutionary 
conservation of the part of the BBS2 polypeptide that contains the missense mutation p.R632P.  
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Chr Position Gene 
Coding 
Effect 
cDNA change 
Protein 
change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 6012898 NPHP4 splicing NM_015102.3:c.674-2A>G p.? NA NA NA NA Het   
1 94467548 ABCA4 missense NM_000350.2:c.6148G>C p.Val2050Leu 1 C25 Deleterious bad Het ABC transporter-like  
1 216011442 USH2A missense NM_206933.2:c.9262G>A p.Glu3088Lys 1 C55 Deleterious bad Het Fibronectin, type III  
4 16077349 PROM1 missense NM_006017.2:c.181A>G p.Ile61Val 3 C0 Tolerated good Het Prominin  
6 42153428 GUCA1B missense NM_002098.5:c.465G>T p.Glu155Asp 2 C0 Tolerated good Het EF-HAND 2  
6 80626456 ELOVL4 missense NM_022726.3:c.814G>C p.Glu272Gln 2 C0 Tolerated good Het GNS1/SUR4 membrane protein  
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
Potassium channel, voltage 
dependent, Kv, tetramerisation 
 
9 120476583 TLR4 missense NM_138554.3:c.2177G>T p.Gly726Val -3 C65 Deleterious bad Het 
Toll/interleukin-1 receptor 
homology domain 
 
11 76883864 MYO7A missense NM_000260.3:c.1868G>A p.Arg623His 0 C0 Deleterious good Het Myosin head, motor domain  
12 1908849 CACNA2D4 missense NM_172364.4:c.2987T>C p.Phe996Ser -2 C0 Tolerated unknown Het   
16 53686789 RPGRIP1L missense NM_015272.2:c.1810G>A p.Glu604Lys 1 C0 Deleterious bad Het 
Protein of unknown function 
DUF3250 
 
16 56530894 BBS2 missense NM_031885.3:c.1895G>C p.Arg632Pro -2 C15 Tolerated bad Homo BBS2 protein YES 
X 49082958 CACNA1F missense NM_005183.2:c.1409T>C p.Leu470Pro -3 C0 Deleterious bad Het  A 
 
 
Table 3.10. List of candidate variants after alignment, variant calling and filtering for patient 1267 (female) for family MA11. The likely causative 
variant is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous, Het = heterozygous and A = artefact. (Adapted from Watson et al., 
2014). 
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This result was consistent with the homozygosity mapping that was previously 
carried by Dr Ali on both affected individuals (1267 and 2093). That analysis revealed 
that BBS2 (chr16:56,518,259-56,554,008, hg19) localizes in the largest of three shared 
homozygous regions detected; one on chromosome 11 (45.6-55.4 Mb, for a total of 9.8 
Mb, hg19) and two on chromosome 16 (19.0-26.1 Mb, for a total of 7.1 Mb, hg19 and 
54.2-73.8 Mb, for a total of 19.6 Mb, hg19).  
 
These data represent for the first time the association between missense mutations 
in the BBS2 gene and partially penetrant RP. Family patients and their clinical notes were 
re-examined by Mr McKibbin in light of these findings. The index case (1267) first 
presented in an ophthalmic clinic with high myopia and poor visual acuity (VA) of 0.5 at 
five years of age. The VA deteriorated gradually to 0.25 at the age of 37 and 0.1 by the 
age of 45. Along with the abnormal retinal pigmentation, polydactyly in one hand 
(removed in childhood) and some learning difficulties were also reported. The second 
patient (2039) had only a mild ocular phenotype with bone spicule-like pigmentation but 
VA continued to gradually deteriorate over time, being 1.0, 0.3 and 0.01 by the age of 
39, 50 and 56 years respectively. 
 
3.2.1.10 Genetic analysis of family MA15 
For MA15, family structure suggested a consanguineous recessive mode of 
inheritance, with three affected members diagnosed with CRD (Figure 3.11A).The 
variant list generated from targeted sequencing of patient 3283 (Table 3.11) included 16 
variants. Based on the zygosity and phenotype observed in the family, the candidate 
variants of VCAN, GPR98, EYS, MYO7A were excluded, while the a nonsense mutation 
in SPATA7 (NM_018418.4:c.253C>T, p.R85*) (Figure 3.11B) was the most likely 
candidate. This homozygous truncating mutation segregated with the disease symptoms 
in the three affected family members and was heterozygous in eight unaffected family 
members for whom DNA was available. This homozygous mutation was previously 
reported in a family with LCA by (Mackay et al., 2011b). 
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Figure 3.11. Molecular analysis of family MA15. (A) The pedigree of the family MA15. 
Individuals from whom DNA was available are numbered and the proband is indicated by an 
arrow. (B) Sanger DNA sequencing chromatograms of a control subject, an affected (3283) and  
carrier (3280) family members with the SPATA7 mutation. (Adapted from Watson et al., 2014).  
 
3.2.1.11 Genetic analysis of family MA16 
The diagnosis in two members of family MA16 was LCA, and the presence of a 
consanguinity loop suggested a recessive mode of inheritance (Figure 3.12A). 18 variants 
were included in the final list produced after targeted sequencing, alignment, variant 
calling and filtering in the index case 3341 (Table 3.12). Based on the zygosity and 
phenotype, a homozygous missense mutation was identified in exon five of RDH12 
(NM_152443.2:c.506G>A, p.R169Q), as described previously by (Mackay et al., 2011a). 
This mutation was also present in the second affected member 3340 for whom DNA was 
available (Figure 3.12B). It is almost certainly pathogenic as it has been published before 
as a cause of arLCA, segregates with the disease in the family and is predicted to be 
deleterious (zero score) by SIFT, bad by MAPP, C35 by AGVGD and scores +1 for 
BLOSUM62. 
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Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 94473807 ABCA4 missense NM_000350.2:c.5882G>A p.Gly1961Glu -2 C65 Deleterious bad Het ABC transporter-like  
5 82817313 VCAN missense NM_004385.4:c.3188T>C p.Leu1063Pro -3 C0 Deleterious bad Homo   
5 89948189 GPR98 missense NM_032119.3:c.3443G>A p.Gly1148Asp -1 C65 Deleterious bad Homo   
6 64431505 EYS missense NM_001142800.1:c.8422G>A p.Ala2808Thr 0 C0 Deleterious unknown Het Laminin G, subdomain 2  
6 65300160 EYS missense NM_001142800.1:c.5600C>T p.Ser1867Phe -2 C0 Deleterious unknown Het   
8 55538820 RP1 missense NM_006269.1:c.2378G>T p.Arg793Ile -3 C15 Deleterious bad Het   
9 117266673 DFNB31 missense NM_015404.3:c.409G>C p.Glu137Gln 2 C0 Tolerated good Het   
9 139333403 INPP5E missense NM_019892.3:c.469G>T p.Gly157Trp -2 C0 Tolerated good Het   
11 66291279 BBS1 missense NM_024649.4:c.1036G>A p.Val346Ile 3 C25 Deleterious bad Het WD40 repeat-like-containing domain  
11 68115675 LRP5 missense NM_002335.2:c.452A>C p.Asp151Ala -2 C65 Deleterious bad Het LDLR class B repeat  
11 76891457 MYO7A missense NM_000260.3:c.2624C>G p.Ala875Gly 0 C0 Tolerated bad Het   
11 76891460 MYO7A missense NM_000260.3:c.2627A>G p.Glu876Gly -2 C0 Deleterious bad Het   
12 1906632 CACNA2D4 missense NM_172364.4:c.3065C>T p.Pro1022Leu -3 C0 Tolerated unknown Het   
14 88883069 SPATA7 nonsense NM_018418.4:c.253C>T p.Arg85* NA NA NA NA Homo - YES 
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
20 10622214 JAG1 missense NM_000214.2:c.2810G>A p.Arg937Gln 1 C0 Tolerated good Het   
 
 
Table 3.11. List of candidate variants after alignment, variant calling and filtering for patient 3283 (male) for family MA15. The probable causative 
variant is orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014).  
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Figure 3.12. Molecular analysis of family MA16. (A) The pedigree of family MA16. 
Individuals from whom DNA was available are numbered and the proband is indicated by an 
arrow. (B) Sanger DNA sequencing chromatograms of a control subject and an affected family 
member with the RDH12 mutation. (Adapted from Watson et al., 2014).  
 
3.2.1.12 Genetic analysis of family MA18 
Affected members of family MA18 were diagnosed with CRD and the family 
history suggested recessive inheritance, though there was no evidence of consanguinity 
(Figure 3.13A). Based on the zygosity, analysis of the variant list of patient 1484 (Table 
3.13) highlighted compound heterozygous variants in two genes, ABCA4 and RBP3. Even 
though RBP3 did not appear to fit the observed phenotype well, both variants were 
segregated in the three affected and four unaffected family members for whom DNA was 
available. Segregation analysis excluded RBP3 and confirmed the ABCA4 
(NM_000350.2) compound heterozygous mutations. The first was a novel splicing 
mutation that alters the splice donor site of exon 25 (c.3328+1G>C), while the second 
mutation was a previously reported missense change (c.5882 G>A, p.G1961E) (Figure 
3.13B) (Cella et al., 2009; Burke et al., 2012). The missense variant was predicted to be 
pathogenic [SIFT (damaging, zero score), BLOSUM62 (-2), MAPP (bad) and AGVGD 
(C65)].  
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Chr Position Gene 
Coding 
Effect 
cDNA change 
Protein 
change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 186072648 HMCN1 missense NM_031935.2:c.10618G>A p.Val3540Ile 3 C25 Deleterious bad Het Immunoglobulin I-set  
2 110187 ALMS1 missense NM_015120.4:c.8983G>A p.Val2995Ile 3 C0 Tolerated unknown Het   
2 169521 ALMS1 missense NM_015120.4:c.9917A>G p.Asn3306Ser 1 C0 Deleterious unknown Het   
3 121518211 IQCB1 missense NM_001023570.2:c.598C>A p.Leu200Ile 2 C0 Tolerated good Het   
3 132423114 NPHP3 missense NM_153240.4:c.1452A>G p.Ile484Met 1 C0 Deleterious good Het   
5 90149261 GPR98 missense NM_032119.3:c.17365A>G p.Lys5789Glu 1 C0 Tolerated good Het   
5 178418555 GRM6 missense NM_000843.3:c.727G>T p.Val243Phe -1 C0 Tolerated good Het 
Extracellular ligand-binding 
receptor 
 
6 64431505 EYS missense NM_001142800.1:c.8422G>A p.Ala2808Thr 0 C0 Deleterious unknown Het Laminin G, subdomain 2  
7 92157661 PEX1 missense NM_000466.2:c.89A>C p.His30Pro -2 C0 Tolerated bad Het 
Peroxisome biogenesis factor 1, 
alpha/beta 
 
8 38880817 ADAM9 missense NM_003816.2:c.887G>A p.Arg296Gln 1 C0 Tolerated good Het 
Peptidase M12B, 
ADAM/reprolysin 
 
10 95400223 PDE6C missense NM_006204.3:c.1646T>C p.Met549Thr -1 C45 Deleterious bad Het   
10 95405722 PDE6C missense NM_006204.3:c.1853C>T p.Thr618Met -1 C0 Tolerated good Het 
3'’5'’-cyclic nucleotide 
phosphodiesterase, catalytic 
domain 
 
11 76891457 MYO7A missense NM_000260.3:c.2624C>G p.Ala875Gly 0 C0 Tolerated bad Het   
14 68193755 RDH12 missense NM_152443.2:c.506G>A p.Arg169Gln 1 C35 Deleterious bad Homo 
Short-chain 
dehydrogenase/reductase SDR 
YES 
15 31325130 TRPM1 missense NM_002420.4:c.2648A>G p.Glu883Gly -2 C0 Deleterious bad Het Ion transport  
16 16295863 ABCC6 missense NM_001171.5:c.1171A>G p.Arg391Gly -2 C0 Deleterious bad Het transmembrane domain  
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
20 10389422 MKKS missense NM_170784.1:c.1015A>G p.Ile339Val 3 C0 Tolerated good Het Chaperonin Cpn60/TCP-1  
 
Table 3.12. List of candidate variants after alignment, variant calling and filtering for patient 3341 (male) for family MA16. The likely causative variant 
is orange shaded. Chr = chromosome, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014).    
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Figure 3.13. Molecular analysis of family MA18. (A) The pedigree of family MA18. 
Individuals from whom DNA was available are numbered and the proband is indicated by an 
arrow. (B) Sanger DNA sequencing chromatograms of a control subject and an affected family 
member (1484) with the ABCA4 mutation. (Adapted from Watson et al., 2014).  
 
3.2.2 Inherited retinal dystrophy families in whom variants of unknown 
significance were found 
3.2.2.1 Genetic analysis of family MA4 
For family MA4, the diagnosis of the affected patients was RP and the presence of 
consanguinity suggests a recessive inheritance pattern (Figure 3.14A). Targeted capture 
and next-generation sequence analysis of case 2833 (Table 3.14) identified a variant list 
with two homozygous missense variants in EYS (NM_001142800.1: c.7558A>G 
p.F2520L & c.334C>T, p.V112I) as possible candidates. Sanger sequencing validation 
in the other affected case 2910 confirmed the presence of both EYS variants in the 
homozygous state.  
 
However both variants gave low pathogenicity profile scores with unknown effects 
on protein function by MAPP and zero scores in BLOSUM62, SIFT and AGVGD. Public  
 
 
 102 
Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 6007259 NPHP4 missense NM_015102.3:c.1024C>T p.Arg342Cys -3 C0 Deleterious bad Het   
1 68904660 RPE65 missense NM_000329.2:c.963T>G p.Asn321Lys 0 C0 Deleterious good Het Carotenoid oxygenase  
1 94508316 ABCA4 splicing NM_000350.2:c.3328+1G>C p.? NA NA NA NA Het  YES 
1 94473807 ABCA4 missense NM_000350.2:c.5882G>A p.Gly1961Glu -2 C65 Deleterious bad Het ABC transporter-like YES 
2 96950323 SNRNP200 missense NM_014014.4:c.4165G>A p.Val1389Ile 3 C0 Tolerated good Het DEAD/DEAH box type, N-terminal  
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Het   
6 14945 C2 missense NM_000063.4:c.1103G>A p.Arg368Gln 1 C35 Deleterious bad Het von Willebrand factor, type A  
10 48389479 RBP3 missense NM_002900.2:c.1399C>T p.Pro467Ser -1 C0 Deleterious bad Het Interphotoreceptor retinol-binding No 
10 48389841 RBP3 missense NM_002900.2:c.1037G>A p.Arg346His 0 C0 Deleterious bad Het  No 
10 73551036 CDH23 missense NM_022124.5:c.6197G>A p.Arg2066Gln 1 C0 Tolerated good Het Cadherin  
12 76742114 BBS10 missense NM_024685.3:c.25G>T p.Gly9Trp -2 C0 Tolerated unknown Het   
12 88508951 CEP290 frameshift NM_025114.3:c.1833delA p.Leu612Phefs*5 NA NA NA NA Het   
14 89307227 TTC8 missense NM_144596.2:c.284A>G p.Lys95Arg 2 C0 Tolerated good Het   
15 31318408 TRPM1 missense NM_002420.4:c.3497A>T p.His1166Leu -3 C0 Tolerated good Het   
17 6329946 AIPL1 missense NM_014336.3:c.773G>A p.Arg258Gln 1 C0 Tolerated good Het Tetratricopeptide repeat-containing  
20 10393438 MKKS missense NM_170784.1:c.725C>T p.Ala242Val 0 C0 Tolerated good Het Chaperonin Cpn60/TCP-1  
X 31462606 DMD missense NM_004006.2:c.9076C>T p.Leu3026Phe 0 C0 Deleterious good Het Spectrin repeat  
X 153418535 OPN1LW missense NM_020061.4:c.532A>G p.Ile178Val 3 C0 Tolerated good Homo GPCR, rhodopsin-like, 7TM  
 
Table 3.13. List of candidate variants after alignment, variant calling and filtering for patient 1484 (female) for family MA18. The probable causative 
variants are orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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variant databases were checked to determine the frequencies of both alleles (Section 
2.14.4). The variant c.7558A>G was found at a frequency of 0.1% (5/5008) in dbSNP142 
(rs527486914), a frequency of 0.1% (5/5000) in 1000 Genomes and at a frequency of 
0.1623 % (35/21568) in the ExAC database including (34/7860, 0.4326%) in the south 
Asian population with only one reported homozygous state. The second variant 
c.334C>T was found at a frequency of 0.859% (43/5008) in dbSNP142 (rs112609906), 
a frequency of 0.86% (43/5000) in 1000 Genomes and at a frequency of 0.86 % 
(1048/121362) in the ExAC database including (534/16512, 3.32%) in the south Asian 
population with ten homozygous alleles. Moreover, a lack of amino acid conservation of 
the F2520 and V112 residues in vertebrates suggests that these variants may be benign. 
 
Sanger sequencing of the terminal exon of EYS, which was not covered by the 
capture reagent, failed to identify any other variants in the genomic DNA of the affected 
case However, it was noted that one of the EYS variants (c.7558A>G, p.F2520L) disrupts 
the second laminin G subdomain which is essential for normal protein function (Khan et 
al., 2010). Furthermore, previously generated Affymetrix 6.0 SNP chip analysis showed 
that there were two large regions of homozygosity shared between the two affected 
individuals (2833 and 2910): chr6: 47,001,610 - 88,893,510 in hg19, with a size of 41.9 
Mb and chr16: 31,656,080 - 48,554,250 in hg19, with a size of 16.9 Mb. EYS was in the 
largest region spanning chr6:64,429,876-65,531,616 in hg19, suggesting that one or both 
of these EYS variants may be the pathogenic cause of disease in these cases. These results 
were considered to be uncertain and remain to be proven. 
 
 
 
Figure 3.14. Pedigree of family MA4. Individuals from whom DNA was available are numbered 
and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
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Chr Position Gene Coding Effect cDNA change4 Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 5969225 NPHP4 missense NM_015102.3:c.1490C>G p.Pro497Arg -2 C0 Deleterious bad Het   
1 94544183 ABCA4 missense NM_000350.2:c.1319A>G p.Tyr440Cys -2 C15 Tolerated good Het Rim ABC transporter  
1 197297965 CRB1 missense NM_201253.2:c.484G>A p.Val162Met 1 C0 Tolerated good Het EGF  
1 215848645 USH2A missense NM_206933.2:c.12608A>G p.Gln4203Arg 1 C0 Tolerated good Het Fibronectin, type III  
4 123663048 BBS12 start loss NM_152618.2:c.1A>C p.? NA NA NA NA Het   
4 187118692 CYP4V2 missense NM_207352.3:c.610G>A p.Ala204Thr 0 C0 Deleterious bad Het Cytochrome P450  
6 64498971 EYS missense NM_001142800.1:c.7558A>G p.Phe2520Leu 0 C0 Tolerated unknown Homo Laminin G, subdomain 2 YES 
6 66204970 EYS missense NM_001142800.1:c.334C>T p.Val112Ile 3 C0 Tolerated good Homo  YES 
6 135726089 AHI1 frameshift NM_017651.4:c.2988delT p.Val997Serfs*20 NA NA NA NA Het   
8 87645092 CNGB3 missense NM_019098.4:c.1208G>A p.Arg403Gln 1 C0 Deleterious bad Het   
9 103059231 INVS missense NM_014425.2:c.2819G>A p.Arg940Gln 1 C0 Tolerated good Het IQ motif, EF-hand binding site  
10 73537449 CDH23 missense NM_022124.5:c.4858G>A p.Val1620Met 1 C15 Deleterious bad Het Cadherin  
11 76893481 MYO7A missense NM_000260.3:c.3121G>T p.Val1041Phe -1 C0 Deleterious good Het MyTH4 domain  
12 48371141 COL2A1 missense NM_001844.4:c.3235G>A p.Ala1079Thr 0 C0 Tolerated good Het   
15 12084 NR2E3 missense NM_014249.2:c.1186G>A p.Gly396Arg -2 C65 Deleterious unknown Het Retinoid X receptor  
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
17 72916365 USH1G missense NM_173477.2:c.566G>A p.Arg189Gln 1 C0 Tolerated good Het   
17 79502218 FSCN2 missense NM_001077182.2:c.967G>A p.Ala323Thr 0 C0 Tolerated good Het Fascin domain  
X 32509447 DMD missense NM_004006.2:c.2569C>T p.Pro857Ser -1 C0 Tolerated good Hemi Spectrin repeat  
 
 
Table 3.14. List of candidate variants after alignment, variant calling and filtering for patient 2833 (male) for family MA4. Teasted variants of uncertain 
significance are orange shaded. Chr = chromosome, NA = not annotated, Homo = homozygous, Het = heterozygous and Hemi = hemizygous. (Adapted from 
Watson et al., 2014).    
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3.2.2.2 Genetic analysis of family MA5 
For family MA5, the history suggests dominant inheritance of a CRD phenotype 
(Figure 3.15) but X-linked inheritance is also possible. The filtered variant list following 
analysis of patient 2278 included six variants (Table 3.15). Based on the phenotype and 
mode of inheritance, none were highlighted as possible causative variants for CRD in this 
family. However, all variants were tested for segregation and all were either shown to be 
sequencing artefacts or they did not segregate with the disease phenotype in the family. 
 
 
Figure 3.15. Pedigree of family MA5. Individuals from whom DNA was available are numbered 
and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
 
3.2.2.3 Genetic analysis of family MA12  
For family MA12, the family history suggested consanguineous recessive 
inheritance and affected individuals were diagnosed with CRD (Figure 3.16). According 
to the zygosity of variants generated from targeted sequencing of case 1024 (Table 3.16), 
one homozygous splice variant in PROM1 and two heterozygous missense variants in 
CDH23 were highlighted as possible candidate causative variants for the disease. Neither 
though are a perfect fit for the phenotype. Recessive mutations in PROM1 cause severe 
RP with macular involvement (Zhang et al., 2007) and recessive mutations in CDH23 
usually cause USH (Bork et al., 2001). The absence of segregation in other family 
members suggested that these variants were not the pathogenic cause of disease in this 
family.  
 
 
Figure 3.16. Pedigree of family MA12. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
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Chr Position Gene Coding Effect cDNA change Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 215844373 USH2A missense NM_206933.2:c.14074G>A p.Gly4692Arg -2 C65 Deleterious bad Het Fibronectin, type III No 
2 96942978 SNRNP200 missense NM_014014.4:c.5933G>C p.Gly1978Ala 0 C0 Tolerated good Het Sec63 domain No 
10 13336486 PHYH missense NM_006214.3:c.356C>T p.Thr119Met -1 C0 Deleterious bad Het Phytanoyl-CoA dioxygenase No 
16 16284103 ABCC6 missense NM_001171.5:c.1553G>A p.Arg518Gln 1 C0 Tolerated good Het transmembrane domain No 
16 53653005 RPGRIP1L missense NM_015272.2:c.3548C>G p.Ala1183Gly 0 C0 Deleterious bad Homo  No 
X 49076224 CACNA1F In-frame NM_005183.2:c.2442_2444dupTCC p.Glu825dup NA NA NA NA Het  A 
 
Table 3.15. List of candidate variants after alignment, variant calling and filtering for patient 2278 (female) for family MA5. Chr = chromosome, NA = 
not annotated. Homo = homozygous. Het = heterozygous and A = artefact. (Adapted from Watson et al., 2014).    
 
Chr Position Gene Coding Effect cDNA change12 Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Homo  NO 
6 5304 CFB missense NM_001710.5:c.26T>A p.Leu9His -3 C0 Deleterious bad Het Complement B/C2  
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
Potassium channel, voltage 
dependent, Kv, tetramerisation 
 
10 73553052 CDH23 missense NM_022124.5:c.6367G>A p.Gly2123Arg -2 C65 Deleterious bad Het Cadherin NO 
10 73563067 CDH23 missense NM_022124.5:c.7762G>C p.Glu2588Gln 2 C0 Tolerated good Het Cadherin NO 
12 76740134 BBS10 missense NM_024685.3:c.1631A>G p.Asn544Ser 1 C0 Tolerated good Het   
12 88454728 CEP290 missense NM_025114.3:c.6401T>C p.Ile2134Thr -1 C0 Deleterious bad Het   
16 56534761 BBS2 splicing? NM_031885.3:c.1397+5C>G p.? NA NA NA NA Het   
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
17 72916338 USH1G missense NM_173477.2:c.593A>C p.His198Pro -2 C0 Tolerated bad Het   
20 10625830 JAG1 missense NM_000214.2:c.2188A>G p.Met730Val 1 C0 Tolerated bad Het EGF, extracellular  
 
Table 3.16. List of candidate variants after alignment, variant calling and filtering for patient 1024 (male) for family MA12. Chr = chromosome, NA = 
not annotated, Homo = homozygous and Het = heterozygous. (Adapted from Watson et al., 2014).   
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3.2.2.4 Genetic analysis of family MA13 
For MA13, family history suggested recessive inheritance of RP (Figure 3.17). On 
the basis of zygosity and assumed recessive inheritance, the variant list generated from 
case 863 (Table 3.17) identified missense variants in GPR98 and MYO7A as the best 
candidates, though mutations in these genes usually cause recessive Usher syndrome 
(Jacobson et al., 2008a). Segregation analysis confirmed that these variants were not the 
cause of disease symptoms in this family.  
 
 
Figure 3.17. Pedigree of family MA13. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
 
3.2.2.5 Genetic analysis of family MA14 
For MA14, family history suggested RP with recessive inheritance due to an 
autozygous mutation in each case (Figure 3.18). The variant lists for patient 1518 (Table 
3.18) identified two heterozygous variants in BBS12 and one in FSCN2 as possible 
candidates though neither option appeared to fit the observed phenotype perfectly. 
Following analysis of the other affected sibling (1527) these variants were shown to be 
either sequencing artefacts or they did not segregate with the disease phenotype and so 
were unlikely to be the pathogenic cause of disease in this family. 
 
Figure 3.18. Pedigree of family MA14. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
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Chr Position Gene 
Coding 
Effect 
cDNA change 
Protein 
change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
4 100503136 MTTP missense NM_000253.2:c.136C>G p.Arg46Gly -2 C0 Tolerated good Het Lipid transport protein, N-terminal  
5 89924514 GPR98 missense NM_032119.3:c.1374T>A p.Phe458Leu 0 C15 Deleterious bad Het  No 
5 90149261 GPR98 missense NM_032119.3:c.17365A>G p.Lys5789Glu 1 C0 Tolerated good Het  A 
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
K channel, voltage dependent, K 
tetramerization 
 
9 117266942 DFNB31 missense NM_015404.3:c.140C>A p.Thr47Asn 0 C0 Tolerated good Het   
11 76891457 MYO7A missense NM_000260.3:c.2624C>G p.Ala875Gly 0 C0 Tolerated bad Het  No 
11 76910630 MYO7A missense NM_000260.3:c.4619C>T p.Ala1540Val 0 C0 Tolerated unknown Het FERM domain No 
 
Table 3.17. List of candidate variants after alignment, variant calling and filtering for patient 863 (female) for family MA13. Chr = chromosome, Het = 
heterozygous and A = artefact. (Adapted from Watson et al., 2014). 
 
Chr Position Gene 
Coding 
Effect 
cDNA change14 
Protein 
change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
4 15517532 CC2D2A missense NM_001080522.2:c.922T>C p.Phe308Leu 0 C0 Tolerated good Het   
4 123664710 BBS12 missense NM_152618.2:c.1663G>A p.Glu555Lys 1 C0 Tolerated good Het Chaperonin Cpn60/TCP-1 A 
4 123665061 BBS12 missense NM_152618.2:c.2014G>A p.Ala672Thr 0 C55 Deleterious bad Het  No 
5 178418549 GRM6 missense NM_000843.3:c.733A>G p.Ile245Val 3 C15 Tolerated bad Homo 
Extracellular ligand-binding 
receptor 
 
6 72892193 RIMS1 missense NM_014989.4:c.1019C>T p.Ala340Val 0 C0 Tolerated good Het   
6 137193331 PEX7 splicing? NM_000288.3:c.748-5dupT p.? NA NA NA NA Het   
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
K channel, voltage dependent, K 
tetramerization 
 
11 66283020 BBS1 missense NM_024649.4:c.442G>A p.Asp148Asn 1 C0 Tolerated good Het   
11 119216338 MFRP missense NM_031433.2:c.433G>A p.Gly145Arg -2 C25 Deleterious bad Het CUB  
16 53705492 RPGRIP1L missense NM_015272.2:c.1033C>A p.Gln345Lys 1 C0 Tolerated good Het   
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
17 79495853 FSCN2 missense NM_001077182.2:c.296G>T p.Arg99Leu -2 C0 Deleterious bad Het Fascin domain A 
Table 3.18. List of candidate variants after alignment, variant calling and filtering for patient 1518 (female) for family MA14. Chr = chromosome, NA 
= not annotated, Homo = homozygous, Het = heterozygous and A = artefact. (Adapted from Watson et al., 2014). 
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3.2.2.6 Genetic analysis of family MA17 
For family MA17, the family history suggested recessive inheritance of RCD 
caused by an autozygous mutation (Figure 3.19). Based on the zygosity, no obvious 
candidates could be identified from the final variant list of patient 3347 (Table 3.19).  
 
 
Figure 3.19. Pedigree of family MA17. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014).  
 
3.2.2.7 Genetic analysis of family MA19 
For family MA19, the family history suggested recessive inheritance of RCD with 
an autozygous mutation (Figure 3.20). The variant list of patient 1885 (Table 3.20) 
identified compound heterozygous variants in CC2D2A and PCDH15 as well as a variant 
in WFS1 with a high pathogenicity profile as possible candidates although none of the 
options appeared to fit the observed phenotype perfectly. Analysis of family members 
from whom DNA was available confirmed three of the putative variants were artefacts 
and the remaining ones in CC2D2A and WFS1 did not segregate with disease.  
 
 
Figure 3.20. Pedigree of family MA19. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
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Chr Position Gene 
Coding 
Effect 
cDNA change17 Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 5969225 NPHP4 missense NM_015102.3:c.1490C>G p.Pro497Arg -2 C0 Deleterious bad Het   
1 185976299 HMCN1 missense NM_031935.2:c.4515C>G p.Asp1505Glu 2 C0 Tolerated good Het Immunoglobulin I-set  
1 216348809 USH2A missense NM_206933.2:c.4412G>C p.Arg1471Thr -1 C0 Tolerated good Het   
1 243652316 SDCCAG8 missense NM_006642.3:c.1986G>T p.Arg662Ser -1 C0 Deleterious bad Het   
5 82816753 VCAN missense NM_004385.4:c.2628T>A p.His876Gln 0 C0 Deleterious bad Het   
5 90024663 GPR98 missense NM_032119.3:c.10339G>A p.Glu3447Lys 1 C0 Tolerated good Het EAR  
7 92147143 PEX1 missense NM_000466.2:c.686A>G p.Asn229Ser 1 C0 Tolerated unknown Het   
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
K channel, voltage 
dependent, K tetramerization 
 
9 120475128 TLR4 missense NM_138554.3:c.722A>G p.Asn241Ser 1 C0 Tolerated good Het Toll-like receptor  
10 102568919 PAX2 missense ENST00000370296.1:c.914C>T p.Ser305Leu -2 C0 Tolerated good Het 
Paired-box protein 2 C-
terminal 
 
11 86662343 FZD4 missense NM_012193.3:c.1455G>T p.Leu485Phe 0 C0 Deleterious bad Het Frizzled protein  
12 88472996 CEP290 missense NM_025114.3:c.5237G>A p.Arg1746Gln 1 C0 Tolerated good Het   
X 13765025 OFD1 missense NM_003611.2:c.781G>A p.Val261Ile 3 C0 Tolerated good Hemi   
 
Table 3.19. List of candidate variants after alignment, variant calling and filtering for patient 3347 (male) for family MA17. Chr = chromosome, Hemi 
= hemizygous and Het = heterozygous. (Adapted from Watson et al., 2014). 
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Chr Position Gene 
Coding 
Effect 
cDNA change19 Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
1 216270422 USH2A splicing? NM_206933.2:c.4758+3A>G p.? NA NA NA NA Het   
4 15982163 PROM1 splicing? NM_006017.2:c.2374-4dupG p.? NA NA NA NA Het   
4 6303810 WFS1 missense NM_006005.3:c.2288A>C p.His763Pro -2 C15 Deleterious bad Het  NO 
4 15513014 CC2D2A in-frame 
NM_001080522.2:c.685_687de
lGAA 
p.Glu229del NA NA NA NA Het  NO 
4 15539735 CC2D2A missense NM_001080522.2:c.1978G>C p.Val660Leu 1 C0 Tolerated good Het  A 
4 123665061 BBS12 missense NM_152618.2:c.2014G>A p.Ala672Thr 0 C55 Deleterious bad Het   
5 90149261 GPR98 missense NM_032119.3:c.17365A>G p.Lys5789Glu 1 C0 Tolerated good Het   
6 135787297 AHI1 missense NM_017651.4:c.404A>C p.Gln135Pro -1 C0 Tolerated unknown Het   
8 87645092 CNGB3 missense NM_019098.4:c.1208G>A p.Arg403Gln 1 C0 Deleterious bad Het   
9 120476570 TLR4 missense NM_138554.3:c.2164A>G p.Ile722Val 3 C25 Deleterious bad Het 
Toll/interleukin-1 receptor 
homology domain 
 
10 55582584 PCDH15 frameshift NM_001142763.1:c.4923delT p.Glu1642Argfs*5 NA NA NA NA Het  A 
10 55721600 PCDH15 missense NM_001142763.1:c.2936A>C p.Tyr979Ser -2 C0 Deleterious good Het Cadherin A 
12 76740134 BBS10 missense NM_024685.3:c.1631A>G p.Asn544Ser 1 C0 Tolerated good Het   
X 31854856 DMD missense NM_004006.2:c.7179A>C p.Lys2393Asn 0 C0 Deleterious bad Het Dystrophin/utrophin A 
 
Table 3.20. List of candidate variants after alignment, variant calling and filtering for patient 1885 (male) for family MA19. Chr = chromosome, NA = 
not annotated, Het = heterozygous and A= artefact. (Adapted from Watson et al., 2014). 
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3.2.2.8 Genetic analysis of family MA20 
For family MA20, the history suggested RP with recessive inheritance due to an 
autozygous mutation (Figure 3.21). The variant list of case 472 (Table 3.21) identified a 
single homozygous missense variant in TRPM1 as well as compound heterozygous 
variants in CEP290 and a variant in CA4, though none of these candidates appeared to 
exactly fit the observed phenotype. As suspected, these variants were either artefacts or 
failed to segregate with disease in this family, suggesting that the pathogenic cause of 
disease has yet to be identified.  
 
 
 
Figure 3.21. Pedigree of family MA20. Individuals from whom DNA was available are 
numbered and the proband is indicated by an arrow. (Adapted from Watson et al., 2014). 
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Chr Position Gene 
Coding 
Effect 
cDNA change20 Protein change 
BLOSUM 
62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity Protein Domain Segregates 
2 110904416 NPHP1 splicing? NM_000272.3:c.1438-4C>T p.? NA NA NA NA Het   
2 96955677 SNRNP200 missense NM_014014.4:c.2800A>G p.Thr934Ala 0 C0 Tolerated good Het   
5 90149261 GPR98 missense NM_032119.3:c.17365A>G p.Lys5789Glu 1 C0 Tolerated good Het   
6 42689868 PRPH2 missense NM_000322.4:c.205G>T p.Val69Leu 1 C0 Tolerated good Het Tetraspanin  
6 135776946 AHI1 missense NM_017651.4:c.1270A>G p.Ile424Val 3 C0 Tolerated good Het   
11 76891457 MYO7A missense NM_000260.3:c.2624C>G p.Ala875Gly 0 C0 Tolerated bad Het   
12 88472996 CEP290 missense NM_025114.3:c.5237G>A p.Arg1746Gln 1 C0 Tolerated good Het  A 
12 88519039 CEP290 missense NM_025114.3:c.1173G>T p.Glu391Asp 2 C0 Tolerated good Het  A 
15 31318408 TRPM1 missense NM_002420.4:c.3497A>T p.His1166Leu -3 C0 Tolerated good Homo  NO 
17 58233966 CA4 missense NM_000717.3:c.158C>T p.Pro53Leu -3 C65 Deleterious bad Het Alpha carbonic anhydrase A 
17 63221207 RGS9 missense NM_003835.3:c.1495T>C p.Ser499Pro -1 C0 Deleterious unknown Het   
X 32459413 DMD missense NM_004006.2:c.3805C>A p.His1269Asn 1 C0 Tolerated good Het Spectrin/alpha-actinin A 
X 38163895 RPGR missense NM_001034853.1:c.927G>T p.Leu309Phe 0 C0 Deleterious good Het 
Regulator of chromosome 
condensation, RCC1 
A 
 
 
Table 3.21. List of candidate variants after alignment, variant calling and filtering for patient 472 (male) for family MA20. Chr = chromosome, NA = 
not annotated, Homo = homozygous, Het = heterozygous and A = artefact. (Adapted from Watson et al., 2014). 
 
 
 
 
 114 
3.3 Discussion  
In the work described in this chapter, the genetic basis of retinal dystrophy was 
investigated in twenty families using targeted capture enrichment and next-generation 
sequencing technology. Likely pathogenic mutations were identified in 12 out of 20 cases 
(60%). A list of these mutations is highlighted in Table 3.22. The mutations consisted of 
previously reported mutations of clinical significance in ABCA4 (c.6088C>T, p.R2030* and 
c.5882G>A, p.G1961E), RDH12 (c.601T>C, p.C201R and c.506G>A, p.R169Q), PROM1 
(c.1117C>T, p.R373C), GUCY2D (c.2512C>T, p.R838C), RPGRIP1 (c.3565C>T, 
p.R1189*), BBS2 (c.1895G>C, p.R632P) and SPATA7 (c.253C>T, p.R85* ); and new 
mutations in CRB1 (c.2832_2842+23del), USH2A (c.12874A>G, p.N4292D), RP2 (c.884-
1G>T) and ABCA4 (c.3328+1G>C). In eight cases the pathogenic mutation could not be 
unambiguously identified. 
 
3.3.1. How useful was the targeted capture reagent? 
The approach used in this study differed from previously described methods 
(Harakalova et al., 2011, which usually pool the samples after the hybridization step to 
multiplex onto one lane of the sequencer. Instead the samples were tagged and pooled in 
batches of four prior to enrichment. This approach refined the use of the targeted capture 
technology, facilitating the enrichment of exons from pooled samples using a single aliquot 
of capture reagent. This technology contributes to the development of a RD diagnostic 
screening method that might benefit RD patients by reducing costs associated with using a 
single aliquot of capture reagent to successfully analyse up to four samples in a single 
experiment. 
 
The strategy used in this chapter succeeded in detecting the causative mutations in 
60% (12/20) of the patients tested. The mutations included single nucleotide (missense, 
nonsense and splice site mutations) and indel (insertion and deletion) changes that existed in 
homozygous or heterozygous (dominant and compound heterozygous) forms. The use of 
targeted next-generation sequencing for retinal disease diagnosis has been previously 
described, using a range of target enrichment methods. Studies detailing a range of 
approaches are listed in Table 3.23. 
 
 
 115 
 
 
 
Table 3.22. List of confirmed likely pathogenic mutations in the 20 patients study. The family ID and diagnosis of the cases studied as well as the 
chromosome and position of the mutation according to the human genome assembly hg19, gene, coding effect, cDNA and protein nomenclature, BLOSUM62, 
AGVGD class, SIFT prediction, MAPP prediction, and zygosity are shown. Rec.= recessive, Dom.= dominant, NA = not annotated, Homo = homozygous, Het 
= heterozygous, FS = frameshift. NS = nonsense, MS = missense and SP = splicing. (Adapted from Watson et al., 2014).  
 
ID Diagnosis 
Inheritance 
Pattern  
Chr  Position Gene 
Coding 
effect 
cDNA  
change  
Protein  
change  
BLOSUM62  
AGVGD 
class  
SIFT 
prediction  
MAPP 
prediction  
Zygosity  
MA1  LCA Rec.  1 197398744  CRB1  FS 
NM_201253.2:c.2832_2842+23de
l  
p.?  NA NA NA NA Homo 
MA2 CRD Rec/Dom. 1 94471056 ABCA4 NS NM_000350.2:c.6088C>T p.Arg2030* NA NA NA NA Homo 
MA3 RP Rec.  1 215848379 USH2A MS NM_206933.2:c.12874A>G p.Asn4292Asp 1 C15 Deleterious bad Homo 
MA4  RP Rec. None confirmed 
MA5 CRD/MD  Dom. None confirmed 
MA6 RP Rec.  14 68193850 RDH12 MS NM_152443.2:c.601T>C p.Cys201Arg -3 C0 Deleterious bad Homo 
MA7  CRD Dom.  4 16014922 PROM1 MS NM_006017.2:c.1117C>T p.Arg373Cys -3 C0 Deleterious bad Het 
MA8  
RP with 
Maculopathy  
Dom./ 
X-linked 
X 46736939 RP2 SP NM_006915.2:c.884-1G>T p.? NA  NA  NA  NA  Homo 
MA9  CRD/MD Dom.  17 7918018 GUCY2D MS NM_000180.3:c.2512C>T p.Arg838Cys -3 C65 Deleterious bad Het 
MA10  CRD Rec.  14 21813304 RPGRIP1 NS NM_020366.3:c.3565C>T p.Arg1189* NA NA NA NA Homo 
MA11  RP Rec.  16 56530894 BBS2 MS NM_031885.3:c.1895G>C p.Arg632Pro -2 C15 Tolerated bad Homo 
MA12  CRD Rec.  None confirmed 
MA13  RP Rec.  None confirmed 
MA14  RP Rec.  None confirmed 
MA15  CRD Rec.  14 88883069 SPATA7 NS NM_018418.4:c.253C>T p.Arg85* NA NA NA NA Homo 
MA16  LCA Rec.  14 68193755 RDH12 MS  NM_152443.2:c.506G>A p.Arg169Gln 1 C35 Deleterious bad Homo 
MA17  RCD Rec.  None confirmed 
MA18 CRD Rec.  1  
94508316 ABCA4 SP  NM_000350.2:c.3328+1G>C p.? NA NA NA NA Het 
94473807 ABCA4 MS NM_000350.2:c.5882G>A p.Gly1961Glu -2 C65 Deleterious bad Het 
MA19  RCD Rec.  None confirmed 
MA20  RP Rec.  None confirmed 
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Authors 
Detecting 
phenotypes 
Library preparation 
NGS  instrument 
Number of 
independent 
samples tested 
Pathogenic 
mutation 
identified (%) Gene number Method 
(Bowne et al., 2011b) adRP 46 PCR amplicons 
454GS FLX Titanium (Roche) & 
GAIIx (Illumina) 
21 5 (24%) 
(Simpson et al., 2011) RP 45 Solid phase customised capture array (NimbleGen) GAIIx (Illumina) 5 3 (60%) 
(Shanks et al., 2013) RP & CRD 73 Solid phase customised capture array (NimbleGen) 454GS FLX Titanium (Roche) 36 9 (25%) 
(Neveling et al., 2012) RP 111 Solid phase customised capture array (NimbleGen) 454GS FLX Titanium (Roche) 100 36 (36%) 
(O'Sullivan et al., 2012) RDs 105 Liquid phase targeted SureSelect capture (Agilent) SOLiD 4 (Life Technologies) 50 21 (42%) 
(Audo et al., 2012a) RDs 254 Liquid phase targeted SureSelect capture (Agilent) GAIIx (Illumina) 13 7 (54%) 
(Coppieters et al., 2012) LCA 16 PCR amplicons GAIIx (Illumina) 17 3 (18%) 
Retinome project 
(Watson et al., 2014) 
RDs 162 Liquid phase targeted SureSelect capture (Agilent) GAIIx (Illumina) 20 12 (60%) 
(Fernandez-San Jose et al., 2015) adRP  73 Liquid phase targeted SureSelect capture (Agilent) Illumina MiSeq  59 27% (16/59) 
(Oishi et al., 2016) COD & CRD 193 Liquid phase targeted SureSelect capture (Agilent) Illumina HiSeq 2500  43  12 (27.9%) 
(Perez-Carro et al., 2016) RP 75 Liquid phase targeted SureSelect capture (Agilent) Illumina MiSeq 47 27(57.4%) 
 
Table 3.23. Comparison of the methodological approaches in key recent publications that have used targeted high throughput NGS for retinal disease 
diagnosis. Retinome project is orange shaded. adRP = autosomal dominant retinitis pigmentosa, RP = retinitis pigmentosa, CRD = cone-rod dystrophy, COD 
= cone dystrophy, LCA = Leber congenital amaurosis and RDs = retinal dystrophies.  
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These previous studies included solid phase capture arrays (Simpson et al., 2011; 
Neveling et al., 2012; Shanks et al., 2013) or liquid phase capture arrays (Audo et al., 
2012a; O'Sullivan et al., 2012; Fernandez-San Jose et al., 2015; Oishi et al., 2016; Perez-
Carro et al., 2016). PCR amplicon-based approaches (Bowne et al., 2011b; Coppieters et 
al., 2012) have also been used. These methods are followed by sequencing on various 
machines including the ABI SOLiD (O'Sullivan et al., 2012), the Illumina Genome 
Analyser (Simpson et al., 2011; (Bowne et al., 2011b; Audo et al., 2012a; Coppieters et 
al., 2012; Fernandez-San Jose et al., 2015; Oishi et al., 2016; Perez-Carro et al., 2016) or 
the Roche 454 (Bowne et al., 2011b; Neveling et al., 2012; Shanks et al., 2013). In these 
studies of RD screening, the success rate in identifying the pathogenic mutation has varied 
from 18% (3 out of 17 cases studied) (Coppieters et al., 2012) to 60% (3 out of 5 cases 
studied) (Simpson et al., 2011) with no correlation between the identification of the 
pathogenic mutation rates and the library preparation methods or machines used for these 
studies.  
 
A 60% success rate (12 out of 20 cases studied) places the Retinome project at the 
higher end of mutation rate detection (Table 3.23). One possible reason for this relatively 
high mutation rate detection may be that the retinome project focused on studying families 
with multiple affected members rather than single cases with no family history. This 
allowed us to assess the pathogenicity of candidate disease-causing variants by following 
the transmission of the mutation with the disease phenotype. It is interesting to note when 
studying isolated cases that several examples of de novo mutations have been 
demonstrated to be the cause of disease (Neveling et al., 2012; Shanks et al., 2013). 
Another possible reason for the increased detection rate in this study is the high number 
of consanguineous cases in the local Yorkshire population, which allows filtering on the 
basis of zygosity.  
 
Although the targeted capture approach is often used, it has a several limitations. 
These include suboptimal capturing efficiency at repetitive regions due to binding 
interference of the target DNA to homologous sequences, and lack of flexibility if new 
regions need to be captured (Chou et al., 2010; Raca et al., 2010). In the current reagent, 
9 exons, including the RPGR-ORF15 that is known to be a hot spot for RD mutations 
(Pusch et al., 2002; Yang et al., 2002), could not be covered because of repetitive nature 
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of the sequence, suggesting that these exons may have to be analysed using alternative 
methods. In terms of data analysis, we observed a number of sequencing artefacts that 
may be due to low coverage as a result of pooling the DNA samples, low sequence quality 
or inaccurate variant calling. In order to reduce the number of false negative results, the 
stringency of variant calling algorithms was relaxed and the use of hard variant calibration 
and filtering was avoided. This conservative approach to capture all possible variants 
inevitably meant that there were also a number of false positives in the annotated variant 
lists. Moreover, with the rapid evolution of next generation sequencing technologies and 
the costs coming down, the customized targeted approach described in this chapter is no 
longer a cost effective method compared to WES.  
 
3.3.2. The genes in which a pathogenic mutation was identified in the 
families following customized targeted capture and NGS 
3.3.2.1. A CRB1 mutation was identified in family MA1 with a diagnosis of 
LCA 
A novel frameshift (deletion) mutation (c.2832_2842+23del) in CRB1 gene was 
identified as the likely causative mutation for LCA in family MA1. CRB1 is one of three 
human homologues of the Drosophila transmembrane protein Crumbs (den Hollander et 
al., 1999). Drosophila Crumbs is required for the maintenance of apico-basal cell polarity 
and the adherens junction in embryonic ectodermal epithelia and has a similar function in 
adult fly retina (Tepass et al., 2001; Izaddoost et al., 2002). CRB1 is named after its 
function in the fly since a homozygous loss-of-function mutation in the gene causes a 
failure in cuticle development resulting in only a few “crumbs” of cuticle of the 
Drosophila embryo (Tepass and Knust, 1990). In humans, CRB1 is located on the long 
arm of chromosome 1 (1q31.1). It encodes a 1406 amino acid transmembrane protein 
with a predicted size of 154 kDa and includes a short intracellular component as well as 
a transmembrane domain and a long extracellular component that contains a signal 
peptide, 19 EGF-like domains and three laminin A G-like domains. The N-linked 
glycosylation motifs in the extracellular domain of CRB1 are responsible for N-
glycosylation (Kantardzhieva et al., 2005; Gosens et al., 2008). 
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CRB1 protein is expressed exclusively in the brain and retina (den Hollander et al., 
2002) and required for appropriate photoreceptor morphogenesis. Mouse mutant models 
of CRB1 show disruptions in the outer limiting membrane and loss of adhesion between 
photoreceptors and Muller cells. This leads to the displacement of photoreceptors and 
progressive retinal degeneration (Aleman et al., 2011). Crb1−/− mice also have an irregular 
number and size of Muller glia cell villi (van de Pavert et al., 2007). The existence of 
genetic modifiers is strongly suspected in CRB1 mutant mice where the photoreceptor 
degeneration varies strongly according to the genetic background (Mehalow et al., 2003). 
This might explain why mutations in this single gene have been associated with a wide-
range of retinal phenotypes that have been described including LCA, EORD, RP and 
autosomal recessive familial foveal retinoschisis (arFFR). No clear genotype-phenotype 
relationship has been established in CRB1 disease (den Hollander et al., 2004; Ehrenberg 
et al., 2013). For example, p.Cys948Tyr and p.Arg764Cys variants have been previously 
associated with LCA, EORD, RP and arFFR in both homozygous and compound 
heterozygous forms in patients of different ethnicities (den Hollander et al., 1999; den 
Hollander et al., 2001; Lotery et al., 2001; Booij et al., 2005; Tosi et al., 2009; 
Bujakowska et al., 2012; Srilekha et al., 2015; Vincent et al., 2016). This suggests that 
genetic and/or environmental factors modify the expression of the CRB1 phenotype. 
However, increased retinal thickness with loss of lamination is a relatively constant 
feature of CRB1-related human diseases (Jacobson et al., 2003; Henderson et al., 2011).  
 
Here a novel frameshift mutation is reported as causing LCA in family MA1. 
Among the LCA genes, CRB1 is one of the most frequently mutated genes, representing 
9-13% of all LCA cases (den Hollander et al., 2008) (Table 1.6). Almost all CRB1 
mutations that cause LCA, including the one reported here, occur in the long extracellular 
component of the protein; 17 mutations occur in the EGF-like domains, 17 in the laminin 
G-like domains, while only 2 are outside of these regions (den Hollander et al., 2004; den 
Hollander et al., 2008; Vincent et al., 2016) (see the public domain, www.uniprot.org), 
while the intracellular domain forms complexes with intracellular proteins that result in 
the Crumbs protein complex (Kantardzhieva et al., 2005; Bulgakova and Knust, 2009). 
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3.3.2.2. ABCA4 mutations were identified in families MA2 and MA18 with a 
diagnosis of CRD 
Screening of families MA2 and MA18 diagnosed with CRD showed that ABCA4 
was the causative gene for these cases. The ABCA4 gene encodes the ATP-binding 
cassette sub-family A member 4, a membrane transporter located in the outer segment 
disc membranes of rods and cones (Illing et al., 1997; Molday et al., 2000). The structure 
of ABCA4 consists of two transmembrane domains (TMDs), two large glycosylated 
extracellular domains (ECD) and two internal nucleotide-binding domains (NBDs) 
(Linton and Higgins, 2007). ABCA4 plays a significant role in visual phototransduction, 
it prevents accumulation of the toxic retinoid derivative N-retinylidene-
phosphatidylethanolamine (N-retinylidene-PE) inside the disks by transporting it across 
the photoreceptor outer segment disk membranes into the cytosol where it can dissociate, 
allowing the released all-trans-retinal to enter the visual cycle (Section 1.4.4) (Beharry et 
al., 2004; Tsybovsky et al., 2010). 
 
Mutations in the gene encoding ABCA4 represent the most common cause of CRD, 
accounting for 30% of all reported cases (Maugeri et al., 2000; Burke and Tsang, 2011). 
More than 800 mutations in the ABCA4 gene have been implicated in three autosomal 
recessive retinal phenotypes, CRD, STGD and RP. It is also associated with AMD 
(Allikmets et al., 1997a; Cremers et al., 1998; Martinez-Mir et al., 1998; Fishman et al., 
2003; Molday, 2015). There is no clear genotype phenotype correlation in ABCA4 
mutations. However the clinical manifestations for ABCA4 mutation usually arRP or 
arCRD with severe mutations, STGD with two mild or moderate mutations and AMD 
with one milder heterozygous mutation (Rozet et al., 1998; Cideciyan et al., 2004; Lorenz 
and Preising, 2005; Valverde et al., 2007; Burke and Tsang, 2011; Riveiro-Alvarez et al., 
2013). Here, a homozygous nonsense mutation (p.R2030*) in one family, and compound 
heterozygous mutations consist of a novel splicing mutation (c.3328+1G>C) and a 
missense mutation (p.G1961E) were identified as the likely cause of CRD in families 
MA2 and MA18 respectively. The grading system of ABCA4 retinopathy seems 
consistent with the results reported here. p.R2030* is located in the second nucleotide-
binding domain of the ABCA4 protein and is predicted to either lead to inactive protein 
or instability of the messenger RNA due to nonsense-mediated mRNA decay (Singh et 
al., 2006); while the G1961E allele is associated with macular atrophy and a trend to 
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delayed onset of symptoms, relative to other manifestations of ABCA4 mutations (Cella 
et al., 2009).  
 
3.3.2.3. An USH2A mutation was identified in family MA3 with a diagnosis of 
RP 
A novel missense mutation in USH2A was identified as causing an RP phenotype 
in family MA3. Located on chromosome 1q41, USH2A has two alternatively spliced 
isoforms. The short USH2A isoform a consists of 21 exons and the long USH2A isoform 
b consists of 51 additional exons at the 3′ end of USH2A (Eudy et al., 1998). The protein 
usherin, encoded by USH2A isoform b, is a transmembrane protein of 5,202 amino acids 
(van Wijk et al., 2004). Usherin is expressed in the developing cochlear hair cells and the 
photoreceptor connecting cilium between the inner and outer segments where it is 
required for the maintenance of retinal photoreceptors (Liu et al., 2007). 
 
Mutations in the USH2A gene were frequently reported in patients with Usher 
syndrome type IIA that is one of the subtypes of Usher syndrome, an autosomal recessive 
condition in which patients have both RP and sensorineural hearing loss (Section 1.6.3.5). 
More than 300 mutations including more than 70 different null alleles and several 
different missense mutations have been identified in the two isoforms of the USH2A gene 
in patients with USH2 (http://www.umd.be/ USH2A/gene. shtml) (Baux et al., 2007; 
Dreyer et al., 2008). The USH2A gene appears to be the major cause of USH2, accounting 
for approximately 50% to 75% of USH2 cases. Furthermore, 12% to 20% of non-
syndromic RP patients carry mutations in USH2A, making it also the most frequently 
mutated genes in recessive RP (McGee et al., 2010). The genotype–phenotype 
correlations have not been very distinct in patients with USH2A mutations. However, 
certain mutations in USH2A, such as p.Glu767Serfs*21, have been associated mainly 
with the syndromic phenotype, while p.Cys759Phe has been linked with non-syndromic 
RP (Le Quesne Stabej et al., 2012; Blanco-Kelly et al., 2015; Lenassi et al., 2015).  
 
The reason why some mutations in USH2A lead to Usher syndrome type IIA and 
others to nonsyndromic RP remains unknown. Among all the mutations that have been 
identified, only one common mutation (p. Glu767Serfs*21) has been reported frequently 
in several populations and has been found to have been derived from a common ancestor 
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(Dreyer et al., 2001), while the majority are unique pathogenic mutations observed only 
in one family (McGee et al., 2010). In addition, most patients have compound 
heterozygous mutations and in some cases, the affected siblings have the same phenotype 
with differences in the severity of the disease (Lenassi et al., 2015). This suggests that 
each phenotype may be caused by a distinct set of genotypes. 
 
3.3.2.4. RDH12 mutations were identified in families MA6 and MA16 with a 
diagnosis of RP and LCA respectively 
RDH12, located on chromosome 14q23, has 7 exons and encodes an NADPH-
dependent retinal reductase, belonging to a sub-family of retinol dehydrogenases that 
metabolize both all-trans-retinal and 11-cis retinal to their corresponding retinols 
(Haeseleer et al., 2002). They are also involved in the metabolism of other non-retinoid 
alcohols/aldehydes (Belyaeva et al., 2005). RDH12 localizes to the inner segment of rod 
and cone photoreceptors (Maeda et al., 2006) , where it plays this critical role in the visual 
cycle (Haeseleer et al., 2002; Kurth et al., 2007) (Section 1.4.4). Mutations in this gene 
increase susceptibility to light-induced photoreceptor apoptosis, leading to severe forms 
of visual impairment such as LCA13 and EORD (Janecke et al., 2004; Perrault et al., 
2004; Maeda et al., 2006; Chacon-Camacho et al., 2013; Kuniyoshi et al., 2014). Patients 
with RDH12 mutations showed severe loss of VA at an early age and severe reductions 
in ffERG amplitudes, while RDH12-/- mice showed decreasing RDH activity, slowing in 
the kinetics of all-trans-retinal reduction, delaying dark adaptation and loss of the 
photoreceptor outer segment after intense light (Maeda et al., 2006; Sun et al., 2007).  
 
Five recessive mutations in RDH12 were first reported in patients with EORD 
(Janecke et al., 2004), closely followed by identification of eleven distinct RDH12 
recessive mutations in patients with LCA (Perrault et al., 2004). To date, over than 60 
different RDH12 mutations have been identified accounting for approximately 3–7% of 
autosomal recessive RD cases (Thompson et al., 2005; Fingert et al., 2008; Valverde et 
al., 2009; Mackay et al., 2011a; Yucel-Yilmaz et al., 2014). These have been reported 
predominantly in LCA patients (Janecke et al., 2004; Perrault et al., 2004; Schuster et al., 
2007; Valverde et al., 2009; Avila-Fernandez et al., 2010; Walia et al., 2010; Chacon-
Camacho et al., 2013; Beryozkin et al., 2014; Yucel-Yilmaz et al., 2014) but also in 
EORD (Janecke et al., 2004; Valverde et al., 2009; Walia et al., 2010; Mackay et al., 
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2011a; Beryozkin et al., 2014; Katagiri et al., 2014) in families with autosomal recessive 
inheritance pattern and in a family with autosomal dominant RP (Fingert et al., 2008) 
with no evidence for genotype/phenotype correlation in this gene. In our study, we found 
two missense mutations that had been described previously; one in the exon five of 
RDH12 (p.C201R) (Sun et al., 2007) causing RP in family MA6 and the other in the same 
exon (p.R169Q) (Mackay et al., 2011a) causing LCA in family MA16. 
 
3.3.2.5. A PROM1 mutation was identified in family MA7 with a diagnosis of 
CRD 
In family MA7 with affected members that have CRD a previously reported 
missense mutation in PROM1 (p.R373C) (Yang et al., 2008; Michaelides et al., 2010) 
was identified to be the pathogenic cause of disease. The prominin 1 (PROM1) gene 
encodes a 5–transmembrane domain protein containing 2 large, highly glycosylated 
extracellular loops and a cytoplasmic tail (Corbeil et al., 2001). PROM1 localizes at the 
base of the photoreceptor outer segment and interacts with protocadherin-21 (PCDH21) 
and with actin filaments, both of which play critical roles in photoreceptor disc membrane 
morphogenesis (Yang et al., 2008). In addition to family MA7 reported here, five other 
families with a heterozygous p.R373C mutation in the PROM1 gene have been identified 
in previous studies (Kniazeva et al., 1999; Michaelides et al., 2003; Yang et al., 2008; 
Michaelides et al., 2010). In all of these families, the p.R373C mutation produces an 
autosomal dominant, fully penetrant retinopathy characterized by the consistent finding 
of bull's-eye maculopathy. There have also been cases of variable rod or rod-cone 
dysfunction associated with this mutation, displaying marked intra- and interfamilial 
variability, where the phenotypes ranged from isolated maculopathy without generalized 
photoreceptor dysfunction to a very severe rod-cone dysfunction and MD. 
 
3.3.2.6. A RP2 mutation was identified in family MA8 with a diagnosis of RP 
A novel splicing variant in RP2 causes RP with macular involvement in family 
MA8. The RP2 gene encodes a polypeptide of 350 amino acids with a tubulin binding 
cofactor C (TBCC) homology domain and a C-terminal nucleoside diphosphate kinase 
(NDK) homology domain (Schwahn et al., 1998; Chapple et al., 2000). RP2 has a 
potentially distinct functional relevance in maintaining Golgi cohesion, targets proteins 
to the plasma membrane and acts as a GTPase activating protein (GAP) for ARL3, to 
 
 
124 
 
control protein trafficking to the primary cilia (Evans et al., 2006; Evans et al., 2010; Patil 
et al., 2011; Schwarz et al., 2012).  
 
Mutations in RP2 cause XLRP with an early age of onset and rapid disease 
progression (Section 1.6.3.3). Mutations in the RPGR gene are the most common cause 
of XLRP, accounting for over 70% of all cases  (Vervoort et al., 2000; Breuer et al., 2002; 
Branham et al., 2012), while mutations in the RP2 gene account for approximately 15-
20% of XLRP cases (Hardcastle et al., 1999; Breuer et al., 2002; Branham et al., 2012). 
Patients with RP2 mutations developed night blindness as an early symptom of the 
disease, followed by peripheral retinal degeneration and, eventually, loss of central 
vision. Moreover, females can be affected as severely as their male counterparts 
(Jayasundera et al., 2010; Churchill et al., 2013; Misky et al., 2016). Unlike RPGR, 
disease-causing mutations in RP2 are found to be spread more uniformly throughout the 
gene, than those that are caused by mutations in RPGR-ORF15. The majority of 
pathogenic RP2 mutations are null mutations, and it is likely that the novel splice mutation 
found in this study is also a null mutation. Most of the missense mutations found in RP2 
are in the TBCC homology domain and a pathogenic missense mutation in NDK domain 
has been also reported (Hardcastle et al., 1999; Sharon et al., 2003; Pelletier et al., 2007; 
Churchill et al., 2013). Mutations in RP2 gene have been associated with only ocular 
phenotypes, however RP2 is ubiquitously expressed in human tissues. This suggests that 
RP2 has either a unique isoform-specific function in the retina or a redundant role in other 
tissues (Evans et al., 2006). 
 
3.3.2.7. A GUCY2D mutation was identified in family MA9 with a diagnosis 
of MD 
A previously reported GUCY2D mutation (p.R838C) (Van Ghelue et al., 2000; 
Wilkie et al., 2000) has been identified as causing dominant MD in family MA9. The 
GUCY2D gene (Section 1.7.4) comprises 18 coding exons, that encode a 1103 amino acid 
(120kD) membrane guanylate cyclase RetGC-1 (retinal guanylyl cyclase-1). This enzyme 
and its associated activator proteins (GCAPs) are involved in the cGMP resynthesis that 
is required for the recovery of the dark state after phototransduction (Section 1.4) (Kelsell 
et al., 1998; Hunt et al., 2010). GUCY2D is expressed specifically in the retina where it 
localizes to the nuclei and inner segments of rod and cone photoreceptors, but its 
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expression is much higher in cones than in rods (Dizhoor et al., 1994; Liu et al., 1994). 
RetGC-1 knockout (GC1ko) mice develop a cone dystrophy (Yang et al., 1999; Boye et 
al., 2010). 
 
To date, more than 130 mutations of the GUCY2D gene have been identified as 
being responsible for retinal degenerations (Kelsell et al., 1998; Gregory-Evans et al., 
2000; Weigell-Weber et al., 2000; Downes et al., 2001b; Payne et al., 2001; Cremers et 
al., 2002; Udar et al., 2003; Ito et al., 2004a; Ito et al., 2004b; Yoshida et al., 2006; Smith 
et al., 2007; den Hollander et al., 2008; Kitiratschky et al., 2008; Auz-Alexandre et al., 
2009; Ugur Iseri et al., 2010; Garcia-Hoyos et al., 2011; Xiao et al., 2011; Xu et al., 2013; 
Zhao et al., 2013b; Jiang et al., 2015; Lazar et al., 2015; Oishi et al., 2016). Homozygous 
or compound heterozygous mutations of the GUCY2D gene are one of the most frequent 
causes of recessive LCA, accounting for 12 to 21% of this disorder, depending on the 
population studied (Cremers et al., 2002; den Hollander et al., 2008; Auz-Alexandre et 
al., 2009). Some recessive GUCY2D missense mutations in the catalytic domain such as 
p.Pro858Ser and p.Leu954Pro, surprisingly showed in vitro a dominant-negative effect 
in heterozygous carriers, indicating by a severe reduction in guanylyl cyclase activities 
(Tucker et al., 2004). Heterozygous GUCY2D mutations are one of the major causes of 
dominant COD/CRD/MD, and over 35% of patients with these types of dystrophies have 
mutations in this gene (Payne et al., 2001; Kitiratschky et al., 2008).  
 
LCA-associated GUCY2D mutations are scattered across the GUCY2D gene, while 
almost all the mutations detected in COD/CRD/MD are located in exon 13 (Kelsell et al., 
1998; Gregory-Evans et al., 2000; Van Ghelue et al., 2000; Weigell-Weber et al., 2000; 
Downes et al., 2001b; Payne et al., 2001; Udar et al., 2003; Ito et al., 2004b; Yoshida et 
al., 2006; Kitiratschky et al., 2008; Hunt et al., 2010; Garcia-Hoyos et al., 2011; Xiao et 
al., 2011; Xu et al., 2013; Zhao et al., 2013b; Jiang et al., 2015; Lazar et al., 2015). The 
only dominant CRD causing mutations that are not located in exon 13 are a complex 
mutation p.I915T/p.G917R in exon 14 (Ito et al., 2004a) and a homozygous mutation 
p.I949T in exon 15 (Ugur Iseri et al., 2010). Moreover, the majority of the mutations in 
exon 13 are clustered at codon 838 in which five distinct variants (p.R838→C/G/H/P/S) 
have been identified (Kelsell et al., 1998; Gregory-Evans et al., 2000; Van Ghelue et al., 
2000; Weigell-Weber et al., 2000; Wilkie et al., 2000; Downes et al., 2001b; Payne et al., 
2001; Udar et al., 2003; Ito et al., 2004b; Yoshida et al., 2006; Smith et al., 2007; 
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Kitiratschky et al., 2008; Hunt et al., 2010; Garcia-Hoyos et al., 2011; Xiao et al., 2011; 
Xu et al., 2013; Jiang et al., 2015; Lazar et al., 2015). Haplotype analysis has shown codon 
838 to be a mutation hot spot (Payne et al., 2001; Kitiratschky et al., 2008) and the 
mutation that has been identified for MA9 (p.R838C) in this study is also located in this 
hot spot. 
 
3.3.2.8. A RPGRIP1 mutation was identified in family MA10 with a diagnosis 
of CRD 
In family MA10, the affected members with CRD harbored a previously reported 
nonsense mutation in RPGRIP1 (p.R1189*) (Abu-Safieh et al., 2013). Patients with 
RPGRIP1 mutations develops a degeneration of both rod and cone photoreceptors with a 
severe loss of central VA and nystagmus early in life (Dryja et al., 2001). The RP GTPase 
regulator interacting protein 1, encoded by RPGRIP1, has different splice variants with 
the largest encoding a protein of 1259 amino acids with a predicted molecular weight of 
144 kDa (Lu and Ferreira, 2005). RPGRIP1 contains two-coiled coil domains that are 
homologous to those found in proteins involved in vesicular trafficking (Hong et al., 
2001). The central region of RPGRIP1 contains two C2 domains. Most LCA-associated 
missense mutations in RPGRIP1 are located in the segment that encodes these two Ca2+ 
binding C2 domains (Roepman et al., 2005). RPGRIP1 binds directly to the RPGR with 
its C-terminal RPGR interacting domain (RID) (Boylan and Wright, 2000). RPGR is 
mutated in the majority of patients with XLRP and disease-associated missense mutations 
in the RCC1-like domain of RPGR disrupt the interaction between RPGR and RPGRIP1, 
suggesting that this defect underlies the pathogenesis of RD (Roepman et al., 2000). 
 
Previous studies (Roepman et al., 2000; Hong et al., 2001; Mavlyutov et al., 2002; 
Lu and Ferreira, 2005; Shu et al., 2005) have shown a prominent localization of both 
RPGR and RPGRIP1 proteins in the ciliary structure that connects the inner and outer 
segments of rod and cone photoreceptors. Studies of the retina of RPGRIP1−/−and 
RPGR−/− mice showed that RPGRIP1 prominently localized to the connecting cilium 
(CC) without RPGR, but that the opposite was not the case, since  RPGR is absent in the 
CC of photoreceptors lacking RPGRIP1, indicating that RPGR is dependent on RPGRIP1 
to be anchored to the connecting cilium (Zhao et al., 2003). This expression pattern of 
RPGRIP1 explains why mutations in the ubiquitously expressed RPGR only cause a 
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photoreceptor-specific phenotype (Hong et al., 2001). Missense mutations in the RID of 
RPGRIP1 could lead to a gain- or loss-of-binding to RPGR (Lu et al., 2005). Recessive 
truncating mutations in RPGRIP1, such as the nonsense mutation that has been found in 
this study in family MA10, are the most common mutations form that cause LCA6 and 
account for 4% to 6% of the total LCA patient population  (Li, 2015). 
 
3.3.2.9. A BBS2 mutation was identified in family MA11 with a diagnosis of 
RP 
A homozygous missense mutation in the BBS2 gene was identified in family MA11, 
linking mutations in the BBS2 gene with partially penetrant RP. Recessive mutations in 
BBS2 have previously been associated with BBS (Section 1.6.3.6) (Forsythe and Beales, 
1993; Fattahi et al., 2014; Bee et al., 2015). BBS2 is one of the twenty BBS genes that 
have been identified and the majority of them are essential for the function of the 
BBSome, the stable core of a protein complex involved in transporting membrane 
proteins into and from cilia (Nachury et al., 2007; Aldahmesh et al., 2014; Scheidecker et 
al., 2014). Mutations in the BBS genes can account for more than 80% of BBS patients 
while 20% of them still lack a molecular diagnosis (Redin et al., 2012). 
 
Mutations in BBS2 were identified in 2001 as a cause of BBS (Nishimura et al., 
2001). Since then, more than 25 mutations have been identified as causing BBS. 
Interestingly, specific BBS2 mutations were reported to be involved in triallelic 
inheritance with the presence of three mutant alleles in both BBS2 and BBS6 in affected 
individuals in four BBS families (Katsanis et al., 2001). In the same study, two individuals 
who carried two BBS2 mutations but not a BBS6 mutation were phenotypically normal, 
suggesting that BBS2 may act as a modifier in contributing to complex disease. It is 
interesting to note that one of the patients (AR171) reported in the previous study 
(Katsanis et al., 2001) was a compound heterozygote in BBS2 for p.D104A and the 
mutation that we found here, p.R632P (mistakenly reported as p.R634P by Katsanis et 
al., 2001). This individual had also exhibited some of the clinical features of BBS 
including obesity and polydactyly. The p.R632P mutation reported here produced 
polydactyly in only one patient while the second has only RP, a result that further 
demonstrates the complexity of the BBS2-related phenotypes and the probable 
involvement of modifier genes. It is known that mutations in five BBS genes can cause 
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non-syndromic or partially penetrant retinal degeneration: BBS1 mutations cause a wide 
spectrum of phenotypes ranging from non-syndromic RP to BBS (Estrada-Cuzcano et al., 
2012a), a BBS3 missense mutation was reported to cause non-syndromic RP in a single 
family (Aldahmesh et al., 2009a), a splice-site BBS8 mutation was reported to cause non-
syndromic RP in a single family (Riazuddin et al., 2010), a nonsense BBS12 mutation 
was reported to cause late-onset retinal dysfunction with postaxial polydactyly in a single 
family (Pawlik et al., 2010) and CEP290 mutations can also cause non-syndromic LCA 
(den Hollander et al., 2006; Vallespin et al., 2007b). The results reported here highlighted 
BBS2 as a sixth BBS gene that can cause partially penetrant retinal degeneration when 
mutated. 
 
3.3.2.10. A SPATA7 mutation was identified in family MA15 with a diagnosis 
of CRD 
In family MA15, affected members with CRD had a previously described nonsense 
mutation in SPATA7 (p.R85*) (Mackay et al., 2011b). The spermatogenesis-associated 
protein 7 (SPATA7) is located on chromosome 14 at the LCA3 locus (Wang et al., 2009b) 
and encodes to a protein expressed in the retina, brain and many other tissues, and 
especially in the testes where it was first identified (Zhang et al., 2003). Despite the 
apparent importance of SPATA7 in human eye disease, it has only one conserved protein 
domain for a predicted coiled-coil domain at amino acids 49-77 (SMART: http://smart. 
emblheidelberg.de; ID=Q6FI63_HUMAN).  
 
SPATA7 directly interacts with the coiled-coil domain of RPGRIP1 at the 
connecting cilium of photoreceptor cells where both ciliary proteins are co-localized. In 
the homozygous knockout mutant mice (Spata7−/−) the level of RPRGIP1 in the retina is 
greatly reduced at the connecting cilium and mislocalized to the inner segment followed 
by mislocalization of the RHO and apoptotic photoreceptor cell death (Eblimit et al., 
2015) . This functional interaction between SPATA7 and RPGRIP1 plays a key role in 
RPGRIP1-mediated protein trafficking across the connecting cilium between the inner 
and outer segment of photoreceptor cells. The apoptotic degeneration of these cells 
triggered by protein mislocalization is the most likely mechanism of disease pathogenesis 
associated with SPATA7 mutations (Eblimit et al., 2015). 
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Recessive mutations in the SPATA7 gene are associated with many types of 
inherited RDs including LCA3, CRD and juvenile RP, accounting for about 1.7 to 4.6% 
of LCA patients in British and Chinese populations respectively (Perrault et al., 2010; Li 
et al., 2011; Mackay et al., 2011b; Kannabiran et al., 2012; Matsui et al., 2016). The 
mutation identified here in SPATA7 has been reported previously in six subjects from 
three consanguineous families of Pakistani and Bangladeshi origin diagnosed with LCA 
or severe autosomal recessive RD (Mackay et al., 2011b). All the patients who have this 
mutation including the patients of MA15 family have the onset of symptoms before six 
years of age, suggesting that, this nonsense mutation may be associated with the early 
onset of the disease.  
 
3.3.3. What of the negative cases after customized targeted capture and 
NGS 
The work described in this chapter leaves a residual cohort of patients and families 
with RD that could not be resolved using the methods described. The mutations causing 
RD in these patients may be in the RD genes known in 2010 when the retinome reagent 
was made, but within regions that were not targeted, such as the regulatory or deep 
intronic regions or one of the 9 exons of repetitive sequence not covered by the retinome 
reagent. Also, the mutation may be a cryptic splice site created by one of the synonymous 
variants that were removed during filtering. Alternatively, the mutation may be in one of 
the 89 additional genes that have been added to RetNet since the capturing reagent was 
manufactured, or it may be in a new gene that has never been implicated in RD. 
Nevertheless, this cohort serves as a powerful resource for further gene identification 
studies. Following WES of genomic DNA samples from these patients, several examples 
of the latter two possibilities are described in the next chapter. 
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Chapter 4. Using whole exome sequencing to find the 
pathogenic mutations in pre-screened inherited retinal 
dystrophy families 
4.1 Introduction 
The introduction of NGS has enabled large scale sequencing experiments to be 
undertaken in individual institutes. Although it took an international consortium 13 years 
to generate the first draft sequence of the human genome, it is now possible to generate 
the same amount of data in a matter of days at a fraction of the cost. This development in 
sequencing technology has revolutionized gene identification studies as it is now possible 
to identify mutations by sequencing the exome or genome of affected patients. Although 
commercial sequencing providers now provide WGS services, it remains a considerable 
bioinformatic challenge to annotate all the non-coding data that is generated, and in 
particular to filter variants of potential significance from the huge amount of sequence 
variation carried by each individual. Thus, the slightly cheaper option of sequencing only 
the encoding parts of the genome, WES, is a widely used research tool in gene 
identification projects. The technology used for this is the same as that used in the 
Retinome project (Chapter 3) but the capture array reagent targets all the exons in the 
genome, as well as other regions of interest such as microRNAs, rather than just a subset 
of genes known to be involved in inherited RDs. This chapter describes how this 
technology was used successfully to identify the pathogenic mutations causing inherited 
RDs. 
  
The work in this chapter focuses on analysing those families in which the causative 
pathogenic mutation(s) was not identified by the targeted NGS strategy used in the 
Retinome project (Chapter 3). Unfortunately, there was insufficient DNA for any of the 
patients from family MA20 to allow further testing. Furthermore, the pedigree structure 
of family MA12 (Figure 3.16, Chapter 3) looks like X-linked inheritance and possibly a 
mutation in ORF15 could account for the disease in this family. The exon ORF15 of 
RPGR is a mutational hot spot for XLRP and one form of cone dystrophies (Vervoort et 
al., 2000; Breuer et al., 2002; Pusch et al., 2002; Sharon et al., 2003; Branham et al., 
2012). However, ORF15 is difficult to sequence using traditional Sanger methods due to 
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a large segment of highly repetitive purine rich sequences in this exon. NGS technologies 
are also currently unable to generate reliable sequence for this exon, which is why ORF15 
was not targeted in the Retinome project (Appendix 4). Due to these technical difficulties, 
it was decided to leave family MA12 to one side. Families MA12 and MA20 were 
therefore excluded from this study.  
 
One or more affected members from each of the five remaining unsolved families 
(MA5, MA13, MA14, MA17 and MA19) were screened using WES. Prior to screening, 
microsatellite genotyping was performed to verify the pedigree structure of each family 
using the methods described in Section 2.7.1. The WES library preparation was 
performed following the methods described in Section 2.10.1. A representative examples 
of the bioanalyser analysis after samples shearing, and before and after hybridisation steps 
are illustrated in Appendix 7. The WES analyses were carried out according the steps 
described in Section 2.10.2 and the major steps in the pipeline and the WES data filtration 
criteria are illustrated in Figure 4.1. Genomic DNA from one affected member of MA14 
and MA17 was also sent to AROS Applied Biotechnology (Denmark) for hybridization 
to Affymetrix 6.0 SNP chips. The genotype data obtained from this was analysed as 
described in Section 2.7.2. 
 
 
 
 
 
 
132 
 
 
 
Figure 4.1. Schematic representation of the WES and variant detection data pipeline used 
in chapter 4. The flowchart illustrates the major steps in the pipeline including (A) WES library 
preparation (modified from http://www.genomics.agilent.com/article.jsp?pageId=3083) and (B) 
the informatics for variant detection, filtering and selection. 
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4.2 Results 
4.2.1 WES analysis of family MA5 identifies compound heterozygous 
mutations in MFSD8 causing non-syndromic retinal disease 
4.2.1.1 Clinical features of the affected members in family MA5 
Family MA5 is a non-consanguineous Caucasian family with three affected siblings 
(two males and one female) who have been diagnosed with MD (Figure 4.2). A summary 
of the clinical features reported is shown in Table 4.1. All three patients had experienced 
a progressive decline in visual acuity (VA) by the third or fourth decade of life, followed 
by discomfort in bright light and delayed adaptation to dark. Night vision was reported to 
be normal. Electrophysiological testing identified localised macular dysfunction with a 
normal ffERG (n=2). None of the individuals reported or displayed signs of neurological 
symptoms. Fundus examination revealed central outer retinal atrophy, confirmed by 
OCT, with a normal periphery in all cases (Figure 4.3). FAF was reduced in the central 
macula surrounded by a rim of increased autofluorescence. Examination findings for all 
siblings were consistent with a clinical diagnosis of presumed autosomal recessive MD. 
 
 
 
Figure 4.2. Pedigree of family MA5. The pedigree shows three generations of the family, with 
three affected children in the lower generation born to unrelated, unaffected parents of Caucasian 
origin. Individuals from whom DNA was available are numbered. * = family members for whom 
DNA was analysed by WES, M1= c.1394G>A, p.R465Q and M2= c.1006G>C, p.E336Q.
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Patient 2278 2749 2277 
Ethnicity Caucasian 
Age of onset 30 28 Early 30s 
Symptoms at onset Gradual binocular reduction in visual acuity 
Visual Acuity 
BCVA (6/18 BE); final BCVA (6/24 BE); 
MSE (-1D BE) 
BCVA (RE 6/9, LE 6/18); final BCVA 
(RE 6/36, LE 6/60) with pin hole; MSE (-
1D BE) 
Final BCVA (6/60 BE); MSE 
(RE -3D, LE -3.5D) 
Neurological symptoms None 
Electrophysiology 
(Slit lamp biomicroscopy) 
Central macular dysfunction only Central macular dysfunction only ND 
Working diagnosis Recessive macular dystrophy 
Fundus photograph 
BE: ill-demarcated area of central macular 
atrophy (1-1.5 DD) with paracentral area 
of hyperpigmentation. 
ND 
BE: Well demarcated circular 
area with a golden sheen 
measuring 1.5-2 DD 
OCT ND BE: Outer retinal atrophy at macula 
Fundus autofluorescence 
(FAF) 
ND 
Smaller circular (RE) and larger oval (LE) 
shaped areas of decreased FAF surrounded 
by halos of increased FAF towards the 
periphery. 
BE: Circular area of reduced 
FAF centrally surrounded by a 
ring of increased FAF on edges 
 
Table 4.1. Summary of clinical data from the three patients 2278, 2749 and 2277 from family MA5. BCVA = best corrected visual acuity, MSE = 
mean spherical equivalent, RE = right eye, LE = left eye, BE = both eyes, DD = disc diameters, OCT = optical coherence tomography, FAF = fundus 
autofluorescence, ERG = electroretinogram and ND= not done.  
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Figure 4.3. Retinal imaging of patients 2278 (A), 2749 (B) & 2277 (C) from family MA5. For 
2278 (A), colour photographs of the fundus for right eye (RE, a1) and for left eye (LE, a2) show 
ill-demarcated areas of central macular atrophy with a paracentral area of hyperpigmentation. For 
2749 (B), fundus autofluorescence (FAF) images show smaller circular (RE, b1) and larger oval-
shaped (LE, b2) areas of decreased FAF surrounded by halos of increased FAF towards the 
periphery. For 2277 (C), colour photographs of fundus (RE, c1 and LE, c2) showed well-
demarcated circular area with a golden sheen, while AF images (RE, c3 and LE, c4) showed a 
circular area of reduced FAF centrally surrounded by a ring of increased FAF on edges. Optical 
coherence tomography (OCT) for 2749 (RE, b3 and LE, b4) and 2277 (RE, c5 and LE, c6) showed 
outer retinal atrophy at the macula. Images courtesy of Mr Martin McKibbin (St James Hospital, 
Leeds).  
 
b4 
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4.2.1.2 Genetic analysis of family MA5 
Genomic DNA from two affected family members (subjects 2278 and 2749, Figure 
4.2) was analysed by WES. The library preparation was performed using the 
SureSelectXT Human All Exon reagent version 5 as described in Section 2.10.1. The 
WES analysis of both individuals was carried out independently according to methods 
described in 2.10.2. The quality of the output data was determined using FastQC tools on 
the Galaxy platform. A representative example of the quality control report for sample 
2278 is shown in Figure 4.4. After quality control monitoring, the sequencing data was 
aligned against the reference genome (hg19/GRCh37) using the Bowtie 2 program. The 
data was then processed in SAM/BAM format using SAMtools and GATK, and a mean 
depth of 56.43 and 59.68 reads per base was observed for subjects 2278 and 2749 
respectively. 
 
After annotation by ANNOVAR, 75,216 and 26,575 variants were detected for 
patients 2278 and 2749 respectively, including both heterozygous and homozygous 
changes. Filtration of variant lists was done according to the strategy described in Figure 
4.1. For subject 2278, a total of 20,259 variants were detected in the exonic/splice (±2bp) 
regions, but only 9,508 were non-synonymous or indel variants and only 827 of these 
were found to have a MAF ≤1  % in dbSNP142, EVS, 1000 Genomes and ExAC databases. 
The same filtering criteria were applied to the list of variants for subject 2749, producing 
a total of 677552 variants in the exonic/splice (±2bp) regions, including 9,751 non-
synonymous and indel variants of which 926 were found to have a MAF ≤1%. The CADD 
pathogenicity score was determined for each variant listed, and 121 and 201 candidate 
variants with a CADD score >10 were identified respectively in patients 2278 and 2749. 
None of these variants occurred in genes that had previously been listed in the RetNet 
database (accessed February 2015). Assuming a recessive mode of inheritance from the 
pedigree structure, there were 15 homozygous variants and 4 genes with compound 
heterozygous variants that were shared between both these individuals. It was noted that 
one of these genes was MFSD8 (encoding the Major Facilitator Superfamily Domain-
containing protein 8) that was previously reported to have caused non-syndromic 
recessive MD in two families (Roosing et al., 2015). MFSD8 therefore became the top 
candidate in this family. 
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Figure 4.4. FastQC quality analysis report for sample 2278 from family MA5. A shows an 
overview of the range of quality values across all bases at each position in the FastQC file. A box 
whisker-type plot is drawn for each position. Red lines show the median value, yellow boxes 
represent the inter-quartile range (25-75%), upper and lower whiskers indicate 10% and 90% 
points, and the blue line represents the mean quality. The y-axis on the graph shows the quality 
scores. The higher the score, the better the base call. The coloured zones on the graph divide the 
y-axis into very good quality calls (green), reasonable quality calls (orange) and poor quality calls 
(red). B shows the average quality per read. C shows the sequence content of each base position 
in a file for which each of the four normal DNA bases have been called. D shows the GC content 
across the whole length of each sequence in a file and compares it to a modelled normal 
distribution of GC content. Sample 2278 represented here had very good quality calls (green zone) 
with zero flagged as poor quality from a total of 143,313,139 sequences , 39 average quality per 
read, little to no difference between the different bases of a sequence run and a normal GC 
distribution curve over all sequences. 
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The compound heterozygous variants in MFSD8 identified in MA5 were 
c.1006G>C, p.E336Q in exon 11 and c.1394G>A, p.R465Q in exon 13. To determine if 
the variants were likely to be pathogenic they were assessed using five different 
pathogenic prediction tools (Section 2.14.2). Four out of five tools predicted that the 
missense variants were probably damaging (Table 4.2). Next, public variant databases 
were checked to determine the frequencies of both alleles (Section 2.14.4). The variant 
c.1006G>C was found at a frequency of 0.04% (2/5008) in dbSNP142 (rs150418024), a 
frequency of 0.19% (25/12981) in EVS, a frequency of 0.04% (2/5000) in 1000 Genomes 
and at a frequency of 0.25% (287/115508) in WES data from 60,706 unrelated individuals 
in the ExAC database, while no c.1394G>A alleles were found in any of these databases. 
Both alleles are therefore rare, compatible with a role in recessive disease. 
 
Variant PolyPhen2 MutationTaster SIFT Blosum62* CADD** 
p.E336Q 
Probably damaging 
(score 1.000) 
Disease causing 
(prediction probability 0.9999) 
Damaging 
(score 0.00) 
Score +2 
Scaled C-
score = 35 
p.R465Q 
Probably damaging 
(score 0.892) 
Disease causing 
(prediction probability 0.9921) 
Damaging 
(score 0.03) 
Score +1 
Scaled C-
score = 33 
 
Table 4.2. Pathogenic prediction scores for MFSD8 identified in family MA5. The scores for 
five different prediction software tools are shown for the two MFSD8 missense variants. 
*Blosum62 scores range from +3 to -3 and negative scores are more likely to be damaging 
substitutions. **CADD scores are reported as scaled C-scores and values ≥ 20 represent the 1% 
most deleterious changes predicted in the human genome. 
 
To confirm the mutations and to segregate them in the family, primer pairs were 
designed to PCR across the candidate variants (Sections 2.4.1). PCR (Section 2.4.3), 
agarose gel electrophoresis (Section 2.5) and Sanger sequencing (Section 2.8) showed 
that the MFSD8 variants segregated with the disease phenotype in a recessive manner in 
the three family members tested (Figures 4.2 and 4.5A). The evolutionary conservation 
of the mutated amino acids was assessed using ClustalW alignment (Section 2.14.5) and 
the normal amino acid residues were fully conserved from human to mosquitoes (Figure 
4.5B). These results indicate that these MFSD8 mutations are the cause of the MD 
phenotype in family MA5. 
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Figure 4.5. Mutations in MFSD8 identified in family MA5. A. Electropherograms of MFSD8 
(NM_152778) sequence around the compound heterozygous mutations of M1 (c.1006G>C, 
p.E336Q) and M2 (c.1394G>A, p.R465Q) in patient 2278 from family MA5 and a wild type 
control. B. ClustalW alignment of the normal amino acid sequence of MFSD8 showing 
evolutionary conservation of the glutamic acid and arginine residues at positions 336 and 465 
respectively. 
  
4.2.1.3 Immunofluorescent localization of MFSD8 in the retina 
In light of the recent findings that mutations in MFSD8 can cause non-syndromic 
retinal disease, the localization of MFSD8 in the retina was investigated using IF staining 
and confocal microscopy on mouse retinal sagittal sections. Mouse eyes from adult age 
P30 wild-type mice were harvested, cryosections were prepared and IF staining 
performed as previously described (Section 2.17). The primary antibody of a goat 
polyclonal anti-MFSD8 was used at a final dilution of 1:100 followed by the secondary 
antibody, Alexa Fluor 568-conjugated donkey anti-goat immunoglobulin at a final 
dilution of 1:500. The nuclei were counterstained with DAPI at a final dilution of 1:1000. 
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In addition, an independent section was stained with secondary antibody only. Confocal 
images were analysed using EZ-C1 3.50 (Nikon) software (Section 2.18). The results 
show that MFSD8 is predominantly localized to the outer plexiform layer (OPL) in the 
mouse retina (Figure 4.6). The secondary antibody control showed that the labelling 
observed was not due to non-specific binding of the secondary antibody. 
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Figure 4.6. Immuno-localisation of MFSD8 to the mouse retina. Immunofluorescence and confocal microscopy images of mouse retinal sections showing 
that MFSD8 is predominantly localized to the outer plexiform layer (OPL) in the retina. Photomicrographs of P30 s mouse retinal sections stained for MFSD8 
(red) antibody are shown in separate channels and merged images (A, B & C) compared to negative control (secondary antibody (Ab) only) (D). RPE = retinal 
pigment epithelium, PL = photoreceptor layer, ONL = outer nuclear layer, INL = inner nuclear layer, IPL = inner plexiform layer and GCL = ganglion cell 
layer. Scale bar = 50µM. 
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4.2.2 WES analysis of family MA13 identifies a novel homozygous 
C8orf37 mutation causing RP 
 
4.2.2.1 Clinical features of the affected members of family MA13 
Family MA13 is a consanguineous UK family of Pakistani origin with two affected 
(one male and one female) and three unaffected (one male and two females) siblings. 
These subjects were recruited through the eye clinic at St. James’s University Hospital, 
Leeds, UK. The pedigree structure is depicted in Figure 4.7. The patients, aged 12 to 27 
years old at the time of the initial examination, were diagnosed with RP after ophthalmic 
assessment by Mr McKibbin. Apart from problems with their vision they had no other 
obvious abnormalities. Peripheral blood was collected from the affected patients, one of 
their parents, and unaffected siblings and genomic DNA was extracted from peripheral 
blood leukocytes (Section 2.2). 
  
 
Figure 4.7. Pedigree of family MA13. The pedigree shows a four-generation consanguineous 
family with two affected members born to unaffected parents of Pakistani origin. Individuals from 
whom DNA was available are numbered, * = Family member from whom DNA was exome 
sequenced, + = wild type allele and M = c.555G>A, p.W185*.  
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4.2.2.2 Genetic analysis of family MA13 
In family MA13, genomic DNA from the proband 863 was analyzed using WES 
(Section 2.10), the library preparation was performed using using the SureSelectXT 
Human All Exon reagent version 4. The output files were processed to generate 47,391 
variants, all has a minimum read depth of 10. According to strategy described in Figure 
4.1, these variants were filtered to exclude those not within exons or the conserved two 
base pair flanking splice-site junctions, and those that have a MAF≤ 1% in the public 
DNA databases (dbSNP 142, EVS and 1000 Genomes). After synonymous variants were 
excluded, 73 homozygous variants remained in the filtered list. One of these variants was 
a null allele in exon 6 of C8orf37 (c.555G>A, p.W185*), a gene previously implicated in 
RD (Estrada-Cuzcano et al., 2012b). This mutation was therefore highly likely to be the 
cause of the RP phenotype in this family. The mutation was confirmed using Sanger 
sequencing (Figure 4.8) and shown to segregate in a recessive manner with the disease in 
the family (Figure 4.7). Public variant databases were checked for the allele (Section 
2.14.4) and it was not reported in EVS, dbSNP137 and 1000 genomes, while it was 
reported once in ExAC (1/121316) which included 16488 unrelated subjects of South 
Asian origin. 
  
                 
 
Figure 4.8. Mutation in C8orf37 identified in family MA13. Electropherograms of C8orf37 
(NM_177965) sequence around the homozygous c.555G>A, p.W185* mutation in patient 863 
from family MA13 and a wild type control. 
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In order to identify the size of the homozygous region in which the C8orf37 gene 
mapped, the WES data of subject 863 was analysed as described in Section 2.12 to locate 
the homozygous regions at the genome level using AutoIdeogram (Figure 4.9). The 
homozygous intervals with a minimum threshold of 1 Mbp are shown in Table 4.3. The 
results showed that C8orf37 (chr8:96,257,141-96,281,462, hg19) maps within the second 
largest homozygous region (~27.2 Mbp) of the patient. 
 
 
 
Figure 4.9. Homozygous regions in the WES data from subject 863 of family MA13. Detected 
homozygous regions are shown in blue. Y-axis shows the chromosome numbers 1-22 and the x-
axis shows the genomic size in mega base pairs (Mbp). * = C8orf37 gene location. 
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Chromosome Start End Length (bp) 
13 41495924 73650117 32154193 
8 69104521 96300181 27195660 
5 32058115 57750267 25692152 
15 35149008 60678328 25529320 
3 73437112 98536571 25099459 
10 68040325 90771829 22731504 
6 133827354 153332926 19505572 
22 30927975 50018069 19090094 
21 27326859 41165566 13838707 
2 71297982 84771480 13473498 
2 43015719 56411817 13396098 
6 155750035 165693624 9943589 
3 386247 8667896 8281649 
20 56186884 62905090 6718206 
5 174937193 180687428 5750235 
5 163260 5200281 5037021 
10 282897 5260812 4977915 
12 128900005 133778796 4878791 
8 21984650 24811064 2826414 
2 208986385 211481257 2494872 
8 123964431 126445544 2481113 
1 247150740 249110906 1960166 
7 128371206 130021488 1650282 
12 20801855 22354921 1553066 
11 63313644 64598944 1285300 
 
Table 4.3. Homozygous intervals in the WES data from subject 863 of family MA13. The 
homozygous intervals (UCSC version hg19) are arranged according to the length in base pairs 
(bp). The C8orf37 gene is located at chr8:96,257,141-96,281,462, hg19 which maps within the 
second largest homozygous region in the patient (shaded orange). 
 
 
4.2.3 WES analysis of family MA14 identifies a homozygous mutation in 
LARGE as the potential cause of non-syndromic retinal dystrophy. 
4.2.3.1 Clinical features of the affected members in family MA14 
Family MA14 is a large consanguineous UK family of Pakistani origin with seven 
family members recruited for this study by Mr Martin McKibbin (Figure 4.10). The 
affected individuals were diagnosed with RP and apart from problems with their vision 
they had no other obvious abnormalities based on family history and assessment in clinic. 
Retinal imaging of patient 1527 showed peripheral retinal atrophy with perifoveal loss of 
the photoreceptors and RPE (Figure 4.11). 
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Figure 4.10. Pedigree of family MA14. The pedigree shows a six-generation consanguineous 
family with multiple affected members by arRP. Individuals from whom DNA was available are 
numbered. * = family members from whom DNA was exome sequenced, * = family member 
whose DNA was SNP chipped, + = wild type allele and M = c.2089G>T, p.V697L. 
 
 
Figure 4.11. Retinal imaging of patient 1527 from family MA14. A. Fundus autofluorescence 
(FAF) image of the left eye (LE) shows intensive peripheral retinal atrophy with decreasing FAF 
in the peripheral retina. B. Optical coherence tomography (OCT) of LE shows that most of the 
outer retina has been lost, with perifoveal loss of the photoreceptors and RPE. Images courtesy of 
Mr Martin McKibbin (St James Hospital, Leeds).  
 
Figure1. Family MA5 structure. * Family members 
for whom DNA was exome sequenced. 
 
 
147 
 
4.2.3.2 Genetic analysis of family MA14 
WES was performed on the proband, individual 1527, in family MA14. The 
genomic DNA was sequenced using the SureSelectXT Human All Exon reagent version 
4 following the standard protocol (Figure 4.1, Section 2.10). Novoalign V2 program was 
used for the data alignment against the reference genome (hg19/GRCh37). Individual 
1527 contained a total of 6,118 variants with a MAF ≤ 1% in dbSNP 142, EVS, 1000 
Genomes and the ExAC databases and MAF ≤ 5% in a cohort of 3222 exomes of British 
Pakistani adults. 227 were exonic or within the two base pair conserved splice 
donor/acceptor sites, and were non-synonymous or indels with a minimum depth of 
coverage 10. Based on consanguinity in the family and hence assuming a recessive mode 
of inheritance and autozygosity, only 43 variants were homozygous. When this variant 
list was compared to the RD genes in the RetNet database (accessed February 2015), none 
were contained within known RD genes. The genomic DNA of patient 1518 in family 
MA14 was analysed by SNP genotyping using the Affymetrix 6.0 chips (Section 2.7.2). 
The locations of the homozygous regions are displayed by a MultiIdeogram (Figure 4.12) 
and the intervals described in Table 4.4. 
 
Figure 4.12. Autozygosity mapping in family MA14. All detected autozygous regions from 
SNP data of patient 1518 and WES data of patient 1527 were visualized from outside to the centre 
respectively. The homozygous regions observed in each individual are shown in blue. The shared 
autozugous regions are shown in red. 
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Chromosome Start End Length (bp) 
6 37287936 124427719 87139783 
10 30264550 71338247 41073697 
5 157777400 180692833 22915433 
22 16055171 37117055 21061884 
4 164560459 179961720 15401261 
10 99868961 114742835 14873874 
9 118957282 132150041 13192759 
11 198510 12566917 12368407 
12 91429973 103248017 11818044 
15 79462776 89415247 9952471 
4 53169664 62771716 9602052 
16 78700674 85820521 7119847 
14 59554796 66553683 6998887 
8 16663961 23179226 6515265 
8 63106536 69524413 6417877 
7 50335232 56559512 6224280 
19 51374047 57258916 5884869 
2 137148547 142978639 5830092 
6 203249 5391286 5188037 
15 54570348 59694505 5124157 
1 244273096 249198692 4925596 
1 90559712 95202007 4642295 
3 193277513 197856433 4578920 
13 26611827 31158331 4546504 
11 15887004 19921293 4034289 
17 2899292 6872983 3973691 
12 116263512 119857079 3593567 
7 110429011 113995296 3566285 
20 59347665 62912463 3564798 
13 44538352 48049494 3511142 
18 57451692 60840128 3388436 
22 45457915 48824664 3366749 
18 11543 316863 3157094 
2 4162616 6958384 2795768 
2 15703 2424495 2408792 
 
 
Table 4.4. Autozygosity mapping in family MA14. The homozygous intervals (UCSC version 
hg19) detected from SNP data of patient 1518. Shared autozygous regions detected from 
combining SNP data of patient 1518 with WES data of patient 1527 are shaded orange. 
 
Of the 43 rare homozygous variants that were identified in subject 1527, only 15 
were located in regions of homozygosity listed in Table 4.4 generated from sibling 1518 
(Table 4.5). When these were limited to the homozygous regions identified from the 
WES-SNP data of individual 1527, only nine variants remained making these the most 
promising candidates for potentially causing RP in this family (Table 4.5). The WES of 
individual 1527 was manually inspected using IGV (Section 2.10.1) around the remaining 
6 variants to confirm the presence of heterozygous alleles. This confirmed the exclusion 
of 6 alleles. Moreover, CNV detection using Fishing CNV and ExomeDepth analysis 
according to methods described in Section 2.13 using WES data from individual 1527 did 
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not reveal any significance homozygous CNV over the homozygous regions identified 
from the SNP data of patient 1518. 
 
However, given the porous nature of the WES SNP data, primer pairs (Appendix 
6) were designed to PCR across all the fifteen variants to confirm and segregate them in 
the available family members using Sanger sequencing (Section 2.8). The only variant 
which segregated in a recessive manner with the disease phenotype was the missense 
mutation in exon 15 of the LARGE gene (NM_133642: c.2089G>T, p.V697L) (Figures 
4.13A and 4.10). LARGE gene (chr22: 33,669,062-34,316,416, hg19) was located in one 
of the shared autozygous regions patients 1518 and 1527 that was 21.06 Mbp in size 
(Table 4.4). Identified missense variant in LARGE was not reported in dbSNP, EVS, 
ExAC or 1000 Genomes databases. The normal amino acid residue was fully conserved 
from human to roundworm (Figure 4.13B), whilst the substitution was predicted to be 
pathogenic by several prediction programs (Figure 4.13C).  
 
Chr Position (hg19) Gene Mutation AAChange.refGene 
1 94057835 BCAR3 ns SNV NM_001261410:exon2:c.G200A:p.R67H 
3 195501121 MUC4 fs Del NM_138297:exon2:c.138delG:p.R46fs 
5 179331789 TBC1D9B ns SNV NM_015043:exon2:c.G142A:p.V48M, 
6 38906708 DNAH8 ns SNV NM_001206927:exon79:c.A11951T:p.K3984M 
6 47251773 TNFRSF21 sg SNV NM_014452:exon3:c.C1144T:p.Q382X 
6 56422262 DST ns SNV NM_015548:exon40:c.A6626G:p.E2209G 
6 76023033 FILIP1 ns SNV NM_015687:exon5:c.C2515T:p.R839W 
6 110636619 METTL24 sg SNV NM_001123364:exon3:c.G483A:p.W161X 
8 17814914 PCM1 ns SNV NM_006197:exon12:c.C1788G:p.N596K 
8 21978365 HR ns SNV NM_005144:exon11:c.G2474A:p.R825H 
10 103871253 LDB1 ns SNV NM_001113407:exon2:c.G66T:p.E22D 
19 52448349 ZNF613 ns SNV NM_001031721:exon6:c.T1213C:p.C405R 
19 54758804 LILRB5 ns SNV NM_001081443:exon5:c.T749G:p.I250R 
19 55527078 GP6 ns SNV NM_001256017:exon6:c.A694C:p.S232R 
22 33670595 LARGE ns SNV NM_133642:exon15:c.G2089T:p.V697L 
 
 
Table 4.5. List of 15 candidate genes for MA14. 15 candidate variants generated after filtering 
of the WES data of patient 1527 against the homozygous regions identified by SNP genotyping 
of patient 1518. Only 9 variants (bold) from the list were limited to the homozygous regions 
identified from the WES-SNP data of individual 1527. Chr = chromosome number, nsSNV = 
non-synonymous single nucleotide variant, sg SNV = stop gain single nucleotide variant and fs 
Del = frameshift deletion.  
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Figure 4.13. Analysis of the missense variant c.2089G>T, p.V697L in LARGE that identified 
in family MA14. A. Sanger sequence chromatograms from an affected family member (1527) 
and a normal unaffected control subject. B. ClustalW alignment of the normal amino acid 
sequence of LARGE showing evolutionary conservation of the valine residue at position 697. C. 
Summary of bioinformatic analyses to predict pathogenicity of the variant in LARGE. 
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4.2.3.3 LOD score for family MA14. 
Linkage analysis was performed between the mutation (c.G2089T) and the disease 
in family MA14 members using Superlink (Section 2.14.6). A maximum two point LOD 
score of 5.16 was obtained by using the mutation as a genetic marker with a MAF of 
0.01%, and the disease was assumed to segregate in the family in a recessive fashion with 
full penetrance.  
 
4.2.3.4 Immunofluorescent localization of LARGE in the retina 
In order to define the precise localization of LARGE within the retina, IF staining 
and confocal microscopy were used on mouse retinal sagittal sections. Sections of 4% 
paraformaldehyde-fixed wild-type mouse eyes from adult age P30 mice were prepared 
(Section 2.17.3) followed by IF staining (Section 2.17.7). Sections were labelled with a 
goat polyclonal anti-LARGE (at a final dilution of 1:50) and a rabbit polyclonal anti-
Rhodopsin (at a final dilution of 1:300) followed by the secondary antibodies Alexa Fluor 
568-conjugated donkey anti-goat immunoglobulin (red) (at a final dilution of 1:500) and 
Alexa Fluor 488-conjugated chicken anti-rabbit immunoglobulin (green) (at a final 
dilution of 1:500) respectively. The nuclei were counterstained with DAPI (at a final 
dilution of 1:1000). An independent section stained with both secondary antibodies only 
and another with peptide competition against the LARGE primary antibody according to 
BPCA described in Section 2.17.8 to serve as negative controls in the experiment. 
Confocal images were analyzed using EZ-C1 3.50 (Nikon) software (Section 2.18). The 
results showed that LARGE is predominantly localized to the photoreceptor inner 
segment (PIS), outer nuclear layer (ONL) and outer plexiform layer (OPL) in the retina, 
while, as expected, Rhodopsin localised to the outer segment of the photoreceptor layer 
(POS) (Figure 4.14). Negative controls sections confirmed the specificity of the primary 
antibody for staining LARGE protein. 
 
4.2.3.5 Screening for additional cases of LARGE related retinopathy 
In an attempt to identify further families with LARGE-associated retinopathy, the 
fourteen coding LARGE exons and their flanking splice sites were PCR amplified and 
Sanger sequenced in a panel of 60 patients diagnosed with RDs. In addition, the last four 
coding exons of LARGE and their flanking splice sites were screened in a panel of 254 
patients diagnosed with RDs. Part of the panel was prepared by WGA method described 
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in Section 2.9. The primer pairs are shown in Appendix 6. The screening did not reveal 
other cases with mutations in LARGE. 
 
 
 
Figure 4.14. Immuno-localisation of LARGE to the mouse retina. Immunofluorescence and 
confocal microscopy images of mouse retinal sections showing that LARGE is predominantly 
localized to photoreceptor inner segment (PIS), outer nuclear layer (ONL) and outer plexiform 
layer (OPL) in the retina. Photomicrographs of P30 sagittal mouse retinal sections stained for 
LARGE (red) and rhodopsin (RHO) (green) antibodies are shown in separate channels and 
merged images (C, D, E, & F) and higher magnification (G) compared to negative controls with 
secondary antibodies only (A) and peptide competition against the LARGE primary antibody (B). 
RPE = retinal pigment epithelium, POS = photoreceptor outer segment, INL = inner nuclear layer, 
IPL = inner plexiform layer and GCL = ganglion cell layer. Scale bars = 50µM (A, B, C, D,E &F) 
and 10µM (G).  
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4.2.4 WES analysis of family MA17 identifies a homozygous mutation in 
FDFT1 as the potential cause of RCD. 
 
4.2.4.1 Clinical features of the affected members in family MA17 
 
Family MA17 is a five-generation UK family of Pakistani origin with two affected 
patients, male and female siblings, from whom DNA was available. They were both 
recruited by Mr McKibbin through the eye clinic at St. James’s University Hospital, 
Leeds, UK. This family (Figure 3.19) was previously analysed in the Retinome project, 
however after revisiting the patient's family it was established that the original pedigree 
structure was incorrect. The updated pedigree structure is depicted in Figure 4.15. The 
family structure is consistent with recessive inheritance and there is evidence of 
consanguinity in the pedigree, but the parents of the sampled patients were not knowingly 
related. The patients were diagnosed as having rod cone dystrophy after ophthalmic 
assessment. Apart from problems with their vision they had no other obvious 
abnormalities. Retinal imaging of patient 3347 showed peripheral retinal atrophy with 
relatively preserved macula is preserved that has a peripheral ring of depigmentation 
(Figure 4.16). 
 
Figure 4.15. Pedigree of family MA17. The pedigree shows a five-generation family with three 
affected members born to unaffected parents of Pakastani origin. Individuals from whom DNA 
was available are numbered. * = family member from whom DNA was exome sequenced, * = 
family member from whom DNA was SNP chipped and M = c.930C>G, p.F310L.  
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Figure 4.16. Retinal imaging of patient 3347 from family MA17. A. Colour fundus photograph 
shows temporal pallor and severely attenuated retinal vessels in the peripheral retina along with 
peripheral retinal atrophy. The macula is preserved but has a peripheral ring of depigmentation. 
B. Fundus autofluorescence (FAF) image showing absence of FAF in the midperiphery with a 
central ring of reduced FAF centrally, surrounded by a ring of increased FAF on edges. Images 
courtesy of Mr Martin McKibbin (St James Hospital, Leeds).  
 
4.2.4.2 Genetic analysis of family MA17 
WES was used to identify the causative mutation for rod cone dystrophy in family 
MA17. A library was prepared from the genomic DNA of patient 3347 using the 
SureSelectXT Human All Exon reagent version 5 as described previously with Novoalign 
V2 aligner program (Section 2.10, Figure 4.1). WES analysis of patient 3347 revealed 
50,771 variants after quality filtering with a minimum depth of coverage 10. Of these, 
21,193 were exonic or presumed splice altering (within 2 bp of exon-intron junctions). 
16,185 remained after removing the synonymous variants, and of these 426 had an allele 
frequency of ≤1% in the dbSNP 142, EVS, 1000 Genomes, ExAC and ≤5% in a cohort 
of 3222 exomes of British Pakistani adults. The absence of a family history of eye disease 
and the non-consanguinity of the parents suggested autosomal recessive inheritance and 
either homozygous or compound heterozygous disease alleles. Filtering for variants that 
fitted this hypothesis identified 66 homozygous and 2 compound heterozygous variants, 
none of which occurred in genes already implicated in retinal disease according to the 
RetNet database (accessed April 2015). The genomic DNA of patient 3348 was analysed 
by SNP genotyping using the Affymetrix 6.0 chips (Section 2.7.2). The resulting data 
were analysed and the homozygous regions are displayed in Figure 4.17 whilst the 
intervals are listed in Table 4.6.  
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Figure 4.17. Autozygosity mapping in family MA17. All detected autozygous regions from 
SNP data of patient 3348 and WES data of patient 3347 were visualized from outside to the centre 
respectively. The homozygous regions observed in each individual are shown in blue. The shared 
autozugous region is shown in red. 
 
Chromosome Start End Length (bp) 
8 1363663 12995633 11631970 
20 24336365 31573320 7236955 
 
Table 4.6. Autozygosity mapping in family MA17. The homozygous intervals (UCSC version 
hg19) detected from SNP data of patient 3348. Shared autozygous region detected from 
combining SNP data of patient 3348 with WES data of patient 3347 is shaded orange. 
 
WES in combination with homozygosity mapping utilizing SNP chip genotyping 
reduced the candidate list to five potentially causative homozygous variants in MYT1 
YWHAB, CST1, DLC1 and FDFT1. Sanger sequencing using primer pairs designed across 
the candidate mutations identified that the missense mutation, NM_004462: c.930C>G, 
p.F310L, in exon 7 of the FDFT1 gene was the only variant of the five candidates that 
both patients 3347 and 3348 have in a homozygous form (Figure 4.18A). This variant is 
absent in dbSNP 142, EVS, 1000 Genomes and the in-house database of 3222 exomes of 
British Pakistani adults, while it occurs only in a heterozygous form at a frequency of 
0.07078 % (87/122918) in the ExAC browser. The amino acid residue was fully 
conserved from human to lamprey (Figure 4.18B) and the substitution is predicted to be 
damaging using a range of in-silico pathogenicity prediction tests (Figure 4.18C). 
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Figure 4.18. Analysis of the missense mutation, c.930C>G, p.F310L, in FDFT1 that 
identified in family MA17. A. Sanger sequence chromatograms of an affected individual from 
family MA17 and a normal control subject. B. ClustalW alignment of the normal amino acid 
sequence of FDFT1 showing evolutionary conservation of the phenylalanine residue at position 
310. C. Summary of the bioinformatic analyses to predict the pathogenic nature of the FDFT1 
variant.  
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To further support the hypothesis that the variant in FDFT1 is the most plausible 
candidate cause of disease symptoms in the affected members of family MA17, three 
confirmatory steps were applied. First, the WES data from patient 3347 was converted to 
homozygosity data according to the methods described in Section 2.12. The locations of 
the autozygous regions common to both individuals are displayed (Figure 4.17, Table 
4.6). These results show that only one homozygous region was shared between these two 
patients 3347 and 3348, FDFT1 was located in this shared regions on chromosome 8 that 
was 11.36 Mbp in size. Second, segregation analysis for the two compound heterozygous 
candidates in SLC45A1 and KLF5 excluded both variants. Furthermore, CNV detection 
using Fishing CNV and ExomeDepth analysis according to methods described in Section 
2.13 using WES data from individual 3347 did not reveal any significance homozygous 
CNV over the homozygous regions identified from the SNP data of patient 3348.  
 
4.2.4.3 Screening for additional cases of FDFT1-related retinopathy 
The coding FDFT1 exons and their flanking splice sites were PCR amplified and 
Sanger sequenced in a panel of 303 patients diagnosed with RDs. The primer pairs are 
shown in Appendix 6 and a representative agarose gel electrophoresis image for the PCR 
for the sixth coding exon of FDFT1 on the panel of sixty patients is depicted in Figure 
4.19. The screen results reveal a heterozygous missense mutation in exon 8: c.1173G>T, 
p.M391I in a female case (4673) with a diagnosis of RP but no family history of eye 
disease (Figure 4.20A). The amino acid residue was conserved from human to western 
clawed frog and the substitution is predicted to be damaging using a range of in-silico 
pathogenicity prediction tests (Figure 4.20B). 
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Figure 4.19. Example of agarose gel electrophoresis used in FDFT1 screening. The gel shows 
the PCR products of the sixth coding exon of FDFT1 amplified from genomic DNA of 60 RD 
patients. Lanes 1-60 = patient samples; lanes C+ = positive control, lane C- = negative control; 
lanes M = EasyLadder I, a DNA molecular weight marker (100bp-2000bp).The PCR product size 
for this reaction was 488 bp.   
 
 
 
Figure 4.20. Analysis of the heterozygous variant c.1173G>T, p.M391I in FDFT1 that 
identified in case 4673 with a diagnosis of RP. A. Sanger sequence chromatograms from case 
4673 and a normal unaffected control subject. B. Summary of bioinformatic analyses to predict 
pathogenicity of the variant. 
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4.2.5 WES analysis of family MA19 identifies a previously described 
homozygous missense mutation in TTLL5 causing RCD 
4.2.5.1 Clinical features of the affected members in family MA19 
Family MA19 is a four-generation Pakistani family with multiple affected 
members. Genomic DNA was available from three affected (two males and one female) 
and three unaffected (one male and two females) family members who were recruited for 
this study. Pedigree structure is depicted in Figure 4.21.  
 
 
 
Figure 4.21. Pedigree of family MA19. The pedigree shows a four-generation family with 
multiple affected members who are Pakistani in origin. Individuals from whom DNA was 
available are numbered, * = family member from whom DNA was exome sequenced, + = wild 
type allele and M = c.1627G>A, p.E543K.   
 
The patients were aged between 18 and 53 years old at the time of the initial 
examination. Patient 1885, a 53 year old, who had a phthisical right eye, said he had good 
vision in his left eye till his 30s but his visual acuity at the time of examination was 
perception of light only. There was high myopia (-8DS) and evidence of rod-cone 
dystrophy with central atrophy and peripheral pigmentary changes. Patient 1888, a 38 
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year-old male, said that his visual acuity was good until he was 30. He was also short 
sighted (-5DS) and had similar features to patient 1885 but with a posterior subcapsular 
cataract. Patient 1886, an 18 year–old female, had high myopia (-12DS) but the retina had 
a fairly normal appearance. Her visual acuity could not be improved beyond 6/60, 
although she denied suffering from night or day blindness. DNA was not taken from two 
other individuals. The first of these is the affected sister of patients 1885 and 1888. She 
had high myopia (-8DS) but no other clinical details recorded. The second was the son of 
patient 1889, aged 10, who was highly myopic but with good visual acuity (6/4 in each 
eye) and a normal retina. The diagnosis given to the family by the recruiting 
Ophthalmologist, Mr McKibbin, was that this is a type of RCD with high myopia as an 
early feature.  
 
4.2.5.2 Genetic analysis of family MA19 
In order to identify the mutation causing rod-cone dystrophy in family MA19, WES 
was performed on genomic DNA from proband 1886. A library was prepared from the 
genomic DNA using the SureSelectXT Human All Exon reagent version 4 (Section 
2.10.1). The output FastQC file was aligned against the reference genome (hg19/ 
GRCh37) using the Bowtie 2 program, then processed in SAM/BAM format using the 
SAMtools and GATK suite of programmes (Section 2.10.2). The combined vcf file of 
SNPs and indels was annotated using ANNOVAR and all variants with MAF ≥1% in 
dbSNP 142, EVS, 1000 Genomes, ExAC database were excluded. Of the remaining 4658 
variants, 786 were exonic or within the 2bp splice consensus sequences, were non-
synonymous missense variants or indels and had a minimum depth of coverage 10. Based 
on known familial consanguinity, a recessive mode of inheritance was considered most 
likely and homozygous variants were prioritised. The final list of 128 variants was 
compared to the retinal dystrophy genes in the RetNet database and one missense variant 
in the BBS10 gene (NM_024685:c.A1631G:p.N544S) was detected but did not segregate 
with the disease phenotype in the other family members from whom DNA was available. 
The aligned file in SAM format of subject 1886 was used to identify the homozygous 
regions using AgileGenotyper (Section 2.12); the locations of the homozygous regions 
are displayed by AutoIdeogram in Figure 4.22 and the intervals were exported into Table 
4.7.  
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Figure 4.22. Homozygosity mapping in family MA19. Homozygous regions detected from the 
WES data of patient 1886 are represented by an AutoIdeogram. The y-axis shows the 
chromosome numbers 1-22 and x-axis shows the genomic size in mega base pairs (Mbp). * = 
TTLL5 gene location. 
 
 
Chromosome Start End Length (bp) 
3 64640206 131415340 66775134 
1 57340727 99418911 42078184 
12 69141678 104698582 35556904 
15 67358478 98995081 31636603 
14 69376623 92530551 23153928 
10 92672564 114884950 22212386 
11 89223616 107224225 18000609 
4 25678199 42025284 16347085 
20 76962 13747441 13670479 
19 36351768 47774772 11423004 
22 27021457 37271882 10250425 
18 57134152 67345034 10210882 
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18 67718688 77927028 10208340 
5 171760544 179780340 8019796 
3 46899516 53926017 7026501 
14 92549586 99182559 6632973 
6 157713777 163987389 6273612 
8 139736933 145578296 5841363 
19 30500118 36322601 5822483 
19 47778221 52887904 5109683 
3 182511351 186954285 4442934 
11 65480768 68834968 3354200 
9 127101924 130164818 3062894 
1 2005740 4834606 2828866 
9 137593099 140374861 2781762 
9 77676285 79922845 2246560 
3 55886573 57743246 1856673 
2 240981262 242814463 1833201 
2 10563233 11853988 1290755 
17 17682484 18541915 859431 
8 145579953 146229161 649208 
17 61559923 62152611 592688 
 
Table 4.7. Homozygosity mapping in family MA19. The homozygous intervals detected from 
the WES data of patient 1886 in family MA19. The regions are arranged according to their length 
in base pairs (bp). The TTLL5 gene maps to chr14:76,127,551-76,421,425, hg19, which is located 
within the fifth largest homozygous region in patient 1886 (shaded orange).  
 
34 variants out of the 128 were located within the homozygous regions. It was noted 
that there was a homozygous missense change in TTLL5, c.1627G>A, p.E543K, present 
in the final list. This gene had only recently been reported as a cause of RD, and indeed 
this specific mutation had been reported as disease causing (Sergouniotis et al., 2014). 
Primers designed to amplify across the variant, confirmed this variant was present and 
clarified the co-segregation with the disease phenotype in the family (Figure 4.21and 
4.23A). The amino acid of the normal glutamic acid residue at position 543 is 
evolutionary conserved from human to lizard (Figure 4.23B). 
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Figure 4.23. Sanger sequence chromatograms of the missense mutation, c.1627G>A, 
p.E543K, in the TTLL5 gene and evolutionary conservation of the normal amino acid 
residue. A. The sequence chromatograms shown are from the DNA of  a carrier, an affected 
member of family MA17 and a normal unaffected subject as control. B. ClustalW alignment of 
amino acid sequence around the TTLL5 mutation showing evolutionary conservation of the 
normal glutamic acid residue at position 543. 
 
4.3 Discussion 
In this chapter, five families with an autosomal recessive pattern of inheritance are 
described. Four of these families were large consanguineous pedigrees of Pakistani origin 
whereas one was a non-consanguineous Caucasian family. Each of these families had 
been pre-screened using the “retinome” reagent but were found to be negative for changes 
in the targeted genes (ie all genes on RetNet in 2010). WES technologies were therefore 
applied on one or more patient samples from each family in order to try to identify the 
most likely, causative variant(s) associated with the disease phenotype in each case. This 
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approach was used independently or combined with homozygosity mapping and leading 
to the identification of mutations in three known causes of RD (C8orf37, MFSD8 and 
TTLL5) and convincing mutations in potentially two new RD genes (LARGE and 
FDFT1). 
 
4.3.1 Confirmation that mutations in MFSD8 cause non-syndromic 
recessive retinal disease. 
In family MA5, compound heterozygous missense variants c.1006G>C, p.E336Q 
and c.1394G>A, p.R465Q in the major facilitator superfamily domain-containing protein 
8 (MFSD8, OMIM 611124) gene were identified as the most likely causative mutations 
for MD in three affected siblings, born to unrelated Caucasian parents. Biallelic mutations 
in MFSD8 were initially described as causing a variant of late-infantile neuronal ceroid 
lipofuscinosis (vLINCL, CLN7, OMIM 610951) (Siintola et al., 2007; Aiello et al., 2009; 
Kousi et al., 2009). The neuronal ceroid lipofuscinoses (NCLs) are collectively the most 
common childhood neurodegenerative disorders (Haltia, 2003). They are characterised 
by lysosomal accumulation of autofluorescent lipopigments, neuronal inflammation and 
subsequent brain atrophy (Haltia, 2003; Mole et al., 2005). Symptoms of vLINCL usually 
start between the ages of 3-6 years, with seizures and developmental regression, followed 
by speech failure, ataxia, visual loss, myoclonus and ultimately premature death (Kousi 
et al., 2009). As a group, NCLs result from dysfunction of lysosome-related proteins or 
enzymes (Kida et al., 2001; Haltia, 2006). MFSD8 is thought to function as a lysosomal 
transporter protein (Siintola et al., 2007). More recently, recessive mutations in MFSD8 
have also been shown to cause non-syndromic MD in two families (Roosing et al., 2015). 
Prior to this finding, MFSD8 mutations had not been associated with non-syndromic 
retinal dysfunction. The work in this chapter confirms the finding of Roosing and are the 
second report of MFSD8 mutations cause non-syndromic RD. 
 
The majority of the reported mutations in MFSD8 are “private” mutations specific 
to each case or family, and are often null variants. In most cases of syndromic MFSD8-
related disease the clinical phenotype is relatively uniform, in keeping with a loss of gene 
function. The ophthalmic features present in conjunction with syndromic disease are 
consistent with a severe, early onset generalised retinal dystrophy (Siintola et al., 2007; 
Aiello et al., 2009; Aldahmesh et al., 2009b; Kousi et al., 2009). It is worth highlighting 
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that one of the MFSD8 missense mutations, p.E336Q, exists in a heterozygous state in all 
three families with non-syndromic MD including family MA5. Based on the 
pathogenicity prediction scores and location of all the MFSD8 missense mutations 
identified so far, there is no obvious correlation between the mutations and whether the 
patient develops vLINCL or non-syndromic RD (Figure 4.24). p.E336Q allele may act as 
a modifier of disease symptoms resulting in the less severe phenotype when paired with 
a null variant (Roosing et al., 2015) or when paired with a missense mutation such as 
p.R465Q reported herein. p.E336Q is close to the edge of the transporting domain and 
the cytoplasmic surface of the protein (Figure 4.24), and may reduce the transporter 
function of MFSD8 on the cytoplasmic surface of the lysosome. 
 
Immunolocalization MFSD8 to OPL of the retina, in a region containing a dense 
network of ribbon synapses between photoreceptors and the dendrites of horizontal and 
bipolar cells (tom Dieck and Brandstatter, 2006) together with the presence of a post 
phototransduction ERG (b-wave) abnormality in patients with MFSD8 mutations 
(Roosing et al., 2015) strongly suggests association between MFSD8 function and the 
signal transmission process at the ribbon synapse. Moreover, synaptic alterations have 
previously been suggested as initiating events causing NCL in a mouse model of 
lysosomal disease due to a defect in cathepsin D function (CLN10) (Partanen et al., 2008) 
and in the CLN5-knockout sheep (Amorim et al., 2015). Furthermore, it was reported that 
reduction in the levels of proteins that are essential for the proper structure and function 
of the ribbon synapse e.g. pikachurin causes RD with a clinical hallmark of an abnormal 
b-wave on the ERG and Pikachurin null-mutant mice showed improper apposition of the 
bipolar cell dendrites to the photoreceptor ribbon synapses, resulting in alterations in 
synaptic signal transmission and visual function (Sato et al., 2008; Nagaya et al., 2015; 
Sugita et al., 2015). 
 
The localization of MFSD8 to OPL and the supposed synaptic alterations by 
MFSD8 mutations may also explain why the condition is MD with more cone 
involvement. Extra-macular photoreceptors are the next most vulnerable, with cortical 
neurons  being  the  most  resistant of the affected cell types. There are  anatomical  and 
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Figure 4.24. Topology prediction diagram of MFSD8 showing the location of pathogenic missense mutations identified to date (July 2016). The twelve 
transmembrane domain protein (TM), spanning the lysosomal membrane, was visualized using methods described in Section 2.14.5 using the protein sequence 
with accession code NP_689991.1. The major facilitator superfamily transporter domain motif is highlighted. Pathogenic missense mutations that give rise to 
vLINCL are depicted in red. Mutations highlighted in blue were reported as either causing vLINCL or combining with the predicted milder mutation p.E336Q 
(highlighted in green) to cause non-syndromic MD. Number in brackets corresponds to CADD scaled C-scores for the mutation and values ≥ 20 and ≥ 10 
respectively represent the 1% and 10% most deleterious changes predicted in the human genome. 
 
 
167 
 
physiological differences between photoreceptor and conventional synapses that could 
account for this differential vulnerability. Photoreceptor terminals release 
neurotransmitter continuously, with light turning off vesicle release, whereas cortical 
neurons are usually switched off and are only triggered by action potentials and 
photoreceptor terminals contain many more synaptic vesicles of which ~85% are freely 
mobile, actively participating in glutamate release, compared to ~20% in conventional 
synapses (Pyle et al., 2000; Richards et al., 2003; Rea et al., 2004; Choi et al., 2005). 
Furthermore, photoreceptor termini possess a synaptic ribbon for vesicle docking, 
necessary for maintaining the higher rates of neurotransmitter release over a sustained 
period of time (Sterling and Matthews, 2005). It is also relevant that peripheral cones 
contain twice as many ribbons as central cones (Chun et al., 1996), suggesting that this, 
or a similar synaptic modification, may underlie the different photoreceptor sensitivities. 
Indeed, as observed in some other cells, the lysosomes may even have a role as ‘non-
professional’ synaptic vesicles, directly releasing neurotransmitter themselves (Andrews, 
2000; Luzio et al., 2007). The consequences of lysosomal dysfunction at the synapse 
could therefore be either disordered neurotransmitter release, or inadequate reuptake, and 
this may result in local excitotoxicity. Whatever this mechanism may be, it appears that 
the photoreceptors in particular are exquisitely sensitive to this. 
 
To conclude, this study describes patients with isolated retinal disease due to 
bilallelic mutations in MFSD8, mutations in which are usually associated with NCL. The 
data suggest that the genotype influences the phenotype, with a mild reduction in MFSD8 
function results in an isolated later onset maculopathy whilst a severe reduction caused 
by functionally null alleles results in central nervous system pathology. This study 
provides an insight into the underlying pathology of disease and contributed to a paper 
that is currently under review at the journal Investigative Ophthalmology and Visual 
Science (IOVS). 
 
4.3.2 A novel C8orf37 homozygous mutation causes RP in a 
consanguineous family of Pakistani origin 
In family MA13, a novel homozygous C8orf37 (OMIM 614477) mutation, 
c.555G>A, p.W185* was identified in the affected patients who had a diagnosis of non-
syndromic RP. C8orf37 spans 23,203 nucleotides of genomic DNA and consists of six 
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exons that encode a 207 amino acid protein (chromosome 8 open reading frame 37) of 
unknown function with a predicted molecular mass of approximately 23kDa. It has no 
significant overall sequence homology with any other human proteins. C8orf37 is 
ubiquitously expressed and immunolocalization studies on human and mouse retinal 
cross-sections have shown that C8orf37 co-localizes with polyglutamylated tubulin, 
acetylated α-tubulin and γ-tubulin, the basal body markers at the base of the connecting 
cilium, between the outer and inner segments in the photoreceptor layer (Estrada-Cuzcano 
et al., 2012b). The basal body acts as the organizing centre for the cilium and permits 
trafficking of proteins and lipids by the intraflagellar transport system from the inner to 
the outer segment, a process necessary for the formation of the outer segment discs (Qin 
et al., 2004; Wright et al., 2010). 
 
C8orf37 mutations were first identified as a cause of RD in 2012 when Estrada-
Cuzcano and colleagues reported three mutations in four families with either CRD or RP 
with early macular involvement (Estrada-Cuzcano et al., 2012b). Since this study more 
mutations have been reported in C8orf37 but they are rare and account for only ≤1% of 
all unrelated RD cases that have been identified (Fahim et al., 2013; Nash et al., 2015). 
Studies on the clinical features seen in patients with mutations in this gene described eight 
patients with a diagnosis of CRD and seven with RP with early macular involvement 
(Estrada-Cuzcano et al., 2012b; van Huet et al., 2013; Jinda et al., 2014; Lazar et al., 
2015; Katagiri et al., 2016). RP (Section 1.6) and CRD (Section 1.7.3) differ in terms of 
the predominant photoreceptor cell type involved, but there can be some overlap between 
these diagnoses depending on the age of the patients and the testing carried out. The 
prevalence of CRD is 1 in 40,000 individuals and for RP, 1 in 4,000 individuals (Haim, 
2002; Hamel, 2007). Distinguishing between RP, in which patients experience night 
blindness followed by progressive visual field constriction, and CRD, where the 
symptoms are photophobia, loss of visual acuity, and central vision, depends on 
recognizing the early symptoms and examination of electroretinography data (van Huet 
et al., 2013). However, in severe end-stage disease there may be considerable phenotypic 
overlap on presentation, making it difficult to diagnose these progressive conditions. 
Sometimes when features of both conditions are present at the early stages it may be 
difficult to assign a disease category (Berger et al., 2010; den Hollander et al., 2010). 
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Of the 81 genes that have mutations leading to RP and the 33 genes that have defects 
leading to COD/CRD (RetNet, May 2016), mutations in only eight genes, including 
C8orf37, account for patients with either diagnosis. These genes affect a wide variety of 
molecular pathways and processes and include dominant mutations in CRX (OMIM 
120970) (Sohocki et al., 1998), SEMA4A (OMIM 607292) (Abid et al., 2006) and PRPH2 
(OMIM 179605) (Kajiwara et al., 1991; Nakazawa et al., 1994); recessive mutations in 
ABCA4 (OMIM 601691) (Allikmets et al., 1997b; Martinez-Mir et al., 1998; Maugeri et 
al., 2000) and CERKL (OMIM 608381) (Tuson et al., 2004; Aleman et al., 2009); X-
linked mutations in RPGR (OMIM 312610) (Meindl et al., 1996; Yang et al., 2002), and 
mutations in PROM1 (OMIM 604365) that show a genotype-phenotype correlation. A 
dominant missense mutation, p.Arg373Cys (dbSNP: rs137853006) causes CRD (Yang et 
al., 2008) whereas recessive mutations lead to RP (Maw et al., 2000; Yang et al., 2008). 
 
Recently, C8orf37 mutations have been linked twice with BBS (Heon et al., 2016; 
Khan et al., 2016a). Khan et al. (2016) identified a previously reported homozygous 
mutation, c.529C>T, p.R177W, in a 6 year old child with BBS from Saudi Arabia. The 
child has obesity, hypodontia, irregular dental spacing, postaxial polydactyly, high 
myopia and CRD. Furthermore, Heon et al. (2016) identified a novel loss-of-function 
homozygous C8orf37 mutation (c.304A>T, p.K102*) in a 17-year-old Caucasian female, 
born to consanguineous parents. She had a slowly progressive CRD, high myopia and 
BBS features that included obesity (with a BMI of 29.1), three-limb post-axial 
polydactyly, a mild learning difficulty, horseshoe kidney, abnormally positioned uterus 
and elevated liver enzymes. This association was confirmed by C8orf37 knockdown in 
Danio rerio (zebrafish) that resulted in impaired visual function and BBS-related 
phenotypes such as such as defects in a ciliated Kuppfer’s vesicle (KV), delays in 
melanosome transport and impairment in visual behaviour (Heon et al., 2016). Patients 
in family MA13 need to a specifically check for ciliopathy features as it is easy to miss 
some of the features of ciliopathies as being overweight is common and the clinician can’t 
see kidney defects and don’t look unless there is a problem.  
 
A summary of all the C8orf37 mutations found in patients with RD to date, together 
with the available clinical information in each case was compiled to deduce any 
phenotype/genotype correlation (Estrada-Cuzcano et al., 2012b; van Huet et al., 2013; 
Jinda et al., 2014; Lazar et al., 2015; Ravesh et al., 2015; Heon et al., 2016; Katagiri et 
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al., 2016; Khan et al., 2016a; Rahner et al., 2016) (Figure 4.25). The clinical features of 
night blindness, visual field constriction and progressive loss of vision appeared to be 
consistent in all patients with C8orf37 mutations, whether the patients had a missense 
mutation or a null allele, suggesting that there does not appear to be an obvious correlation 
between genotype and phenotype. However, all affected patients who harbouring splice 
site mutations affecting intron 1 of C8orf37 have postaxial polydactyly as additional 
feature (Estrada-Cuzcano et al., 2012b; van Huet et al., 2013; Rahner et al., 2016). BBS-
related phenotypes as an additional feature with CRD, together with the known cellular 
localisation, all serve to suggest that this condition is a ciliopathy (Estrada-Cuzcano et al., 
2012b; Heon et al., 2016; Rahner et al., 2016). 
 
 
Figure 4.25. Diagram showing C8orf37 mutations identified to date (July 2016) together 
with diagnosis of the patient(s) in whom they were found. The six coding exons of C8orf37 
are shown. The mutations are annotated relative to the transcript with accession number 
NM_177965 and protein sequence with accession NP_808880.1  
 
To summarize, a novel C8orf37 mutation has been identified in a consanguineous 
family who originated in Pakistan. These findings contribute further data on the 
phenotype and the spectrum of mutations in this form of RP. This work contributed to a 
paper that was published in the journal Molecular Vision (Ravesh et al., 2015). 
 
4.3.3 Exome sequencing identified LARGE as a new candidate gene for 
non-syndromic retinal dystrophy 
In family MA14, a homozygous missense mutation in LARGE was identified as the 
most likely candidate variant for causing RP in the affected members of family MA14. 
 
 
171 
 
The LARGE gene is located at the long arm of chromosome 22 (22q12.3) and spans more 
than 647 kilobases (kbp) (chr22: 33,669,062-34,316,416, hg19) of genomic DNA. 
LARGE is the fifth largest gene in the human genome (hence its name ‘LARGE’). It 
contains 15 exons that encode a 756 amino acid protein containing an amino-terminal 
transmembrane domain, a coiled-coil domain and two catalytic domains of N-
acetylgalactos-aminyl-transferases (Brockington et al., 2005). 
 
The LARGE protein is involved in protein glycosylation, a post-translational 
modification when sugar molecules are added to certain proteins. The amino-terminal 
transmembrane domain of LARGE interacts with the mucin-like domain of alpha-
dystroglycan (α-dystroglycan), defining an intracellular enzyme-substrate recognition 
motif necessary for the post-translational modification of α-dystroglycan which is 
required for the functional glycosylation of α-dystroglycan (Kanagawa et al., 2004). This 
modification acts through two glycosyltransferase activities of the LARGE protein 
(xylosyltransferase and glucuronyl transferase) that allow xylose and glucuronic acid 
containing glycan structures to be added to α-dystroglycan. Addition of a glycan allows 
glycosylated α-dystroglycan to bind laminin-G-domain-containing extracellular matrix 
ligands, which are required for the normal function of skeletal muscle basement 
membranes and neuromuscular junctions (Inamori et al., 2012). Lack of the 
transmembrane domain causes mislocalization of LARGE at the Golgi apparatus, while 
lack of catalytic domains causes inhibition of the glycosyltransferase activities of LARGE 
and prevents α-dystroglycan hyperglycosylation (Brockington et al., 2005). The LARGE 
protein acts on α-dystroglycan which is localized to the outer plexiform layer (OPL) 
(Montanaro et al., 1995). This is consistent with the IF staining results that showed 
localization of LARGE to OPL, PIS and ONL in the mouse retina (Section 4.2.3.4). 
 
Mutations in the LARGE gene have previously been shown to cause 
dystroglycanopathy in a myodystrophy mouse model carrying a null mutation (100-kb 
genomic deletion) in LARGE (Grewal et al., 2001). The LARGEmyd was then used as a 
model for congenital muscular dystrophy (CMD). The phenotypic studies of this model 
showed a sharp decrease in glycosylated α-dystroglycan in muscular dystrophy. They also 
revealed a defect in retinal transmission, with abnormalities of b-wave characteristics for 
ON bipolar cells and the Muller cells, abnormal neuronal migration, and defective laminar 
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architecture of the cerebrum and the cerebellum cortices (Holzfeind et al., 2002; Michele 
et al., 2002). 
 
The first human biallelic mutation in LARGE was identified in 2003 (Longman et 
al., 2003) in a 17-year-old girl with congenital muscular dystrophy, mental retardation, 
structural brain abnormalities and a moderate reduction in the level of glycosylated α-
dystroglycan in muscle sections. This phenotype was named congenital muscular 
dystrophy 1D (MDC1D) and represented one of a heterogeneous group of human muscle-
eye-brain disorders that are characterized by severe CMD, eye abnormalities and central 
nervous system neuronal migration defects. These also include Fukuyama-type CMD and 
Walker–Warburg syndrome (WWS). These diseases result from mutations in one of six 
genes which encode glycosylation enzymes (POMT1, POMT2, POMGnT1, fukutin, 
FKRP and LARGE) (Muntoni et al., 2007). 
 
 
To date, only 15 patients in 12 families have been reported to have mutations in 
LARGE (Table 4.8) (Longman et al., 2003; Godfrey et al., 2007; van Reeuwijk et al., 
2007; Clement et al., 2008; Mercuri et al., 2009; Clarke et al., 2011; Vuillaumier-Barrot 
et al., 2011; Meilleur et al., 2014). Analysis of the mutation spectrum identified in LARGE 
shows association between the pathogenicity of the disease-causing mutation and the 
severity of the phenotype ranging from milder MDC1D to a severe form of CMD (WWS). 
Patients who had a compound heterozygous combination of a frameshift indel or 
nonsense variant with a missense mutation showed a milder phenotype MDC1D or 
Fukuyama-type CMD, with sufficient motor ability to walk or climb stairs and a moderate 
reduction of glycosylated α-dystroglycan. A complete loss of LARGE function due to the 
presence of two nonsense or frameshift indel mutations leads to a severe phenotype of 
WWS with more severe motor inability and sharply decreased glycosylated α-
dystroglycan. This result was consistent with the findings of Goddeeris et al. (2013) who 
reported a direct association between LARGE-glycan extension and its binding capacity 
for extracellular matrix ligands and knocking out of LARGE produced a dystroglycan 
with minimal LARGE-glycan repeats that led to immature neuromuscular junctions and a 
less compact basement membrane. 
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Family ID 
Number of 
patients 
Mutation Zygosity Phenotype Eye Involvement Reference 
1 1 
c.1999insT (p.693X);  
c.1525G>A (p.Glu509Lys) 
C-Hetero MDC1D Nystagmus Longman et al. (2003) 
2 1 c.1548C>G (p.Trp516X) Hetero WWS Retinal detachment Godfrey et al. (2007) 
3 2 
63-kb del (introns 8-10) resulting in 
premature stop codon 
Homo WWS 
Bilateral leukocornia, retinal dysplasia, posterior 
synechia  
van Reeuwijk et al. (2007) 
4 1 
c.253_259dup (p.Gln87fs); c.992C>T 
(p.Ser331Phe) 
C-Hetero MEB-like Myopia (Clement et al., 2008) 
5 1 c.1483T>C (Trp495Arg) Homo WWS NR Mercuri et al. (2009) 
6 2 
Insertion between exons 10 and 11 
deletion (3-4 kb) in intron 10 
Homo MEB-like Mild myopia, strabismus Clarke et al. (2011) 
7 2 
c.871+27358_1132- 21850del42152insT;  
252-kb dup of exons 2-4  
C-Hetero WWS Bulging eyes, horizontal narrow palpebral slit  
Vuillaumier-Barrot et al. (2011)  
8 1 
c.106+6361_408- 
6628del122058insGTGTG; 
c.615+24218_788- 
42869del105083insAATG 
C-Hetero WWS No retinal dysplasia or other eye involvement 
9 1 
74-kb deletion flanking exons 4-6, 
c.1525G>A (p.Glu509Lys) 
C-Hetero 
Fukuyama 
CMD 
Amblyopia, microtropia 
Meilleur et al. (2014) 
 
10 1 c.1328_1329delGCinsAT (p.Cys443Tyr)  Homo WWS 
Thin optic nerves, severe atrophy of ganglion 
cells and very thin nerve fibre layer  
11 1 
330.6-kb deletion of exons 3-7; 74.3-kb 
deletion of exon 7  
C-Hetero WWS 
Complete retinal detachment on the right and 
poor retinal development on the left 
12 1 108-kb homozygous deletion of exons 4-7  Homo WWS Bilateral retinal detachment and blindness 
 
 
Table 4.8. Summary of all case reports of LARGE mutations identified to date (July 2016). Family ID, number of patients studied, mutation, zygosity, 
phenotype and extent of eye involvement. C-Hetero = compound heterozygous, Homo = homozygous, Hetero = heterozygous, MDC1D = Congenital Muscular 
Dystrophy type 1D, MEB = muscle-eye-brain disease, WWS = Walker–Warburg syndrome, Fukuyama CMD = Fukuyama-type Congenital Muscular Dystrophy 
and NR = not recorded. 
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In summary, in this study a novel homozygous missense mutation was identified 
that segregates with non-syndromic RP in a large consanguineous family, giving a very 
significant LOD score. This finding strongly suggests that the phenotype found in this 
family represents the less severe end of the phenotype spectrum of mutations in the 
LARGE gene, causing non-syndromic RP. This mutation is localized in the second 
catalytic domain of the protein and is expected to have minimum effects on the LARGE-
glycan extension. However modelling of the effects of this mutation, screening patients’ 
blood for glycosylation defects, searching for more mutations among RD patients are all 
potential ways to strengthen this finding. 
 
4.3.4 Exome sequencing identified FDFT1 as a potential new candidate 
for retinal dystrophy 
In family MA17, a novel homozygous missense mutation in FDFT1 (NM_004462: 
c.930C>G, p.F310L) was identified as a potential case of the RCD phenotype in the 
family. Farnesyl diphosphate farnesyl transferase1 (FDFT1, OMIM 184420), or squalene 
synthase, is a membrane-associated enzyme located at the branch point in the mevalonate 
pathway. FDFT1 catalyses the conversion of two molecules of farnesyl diphosphate to 
squalene in the first step in the cholesterol biosynthetic pathway (McKenzie et al., 1992; 
Stamellos et al., 1993). FDFT1 is ubiquitously expressed in human tissues (Tansey and 
Shechter, 2001). Targeted disruption of FDFT1 in mice causes embryonic lethality in the 
homozygotes, while the heterozygous mice have phenotypically normal plasma levels of 
total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density 
lipoprotein cholesterol (HDL-C) (Tozawa et al., 1999).  
 
Previous studies have shown association of non-synonymous SNPs such as p.K45R 
of FDFT1 with plasma cholesterol levels (Do et al., 2008), while targeted-overexpression 
of FDFT1 in the mouse liver caused increased plasma TC, LDL-C, and HDL-C levels 
(Okazaki et al., 2006) confirming a strong effect of FDFT1 in regulating plasma 
cholesterol levels (Do et al., 2008). Cholesterol is an essential lipid constituent of cell 
membranes, and cholesterol biosynthesis is required to make vitamin D. There are two 
known pathways of cholesterol input into the retina, in situ cholesterol biosynthesis that 
accounts for the majority (72%) of retinal cholesterol input in the mouse, and tissue 
uptake of cholesterol from the systemic circulation (Lin et al., 2016). Some cholesterol-
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related genes (ABCA1, APOE, CETP and LIPC) are risk factors for AMD (Peter et al., 
2011; Yu et al., 2011; Paun et al., 2015), but the link between cholesterol homeostasis in 
the retina and retinal degeneration are poorly understood (Fliesler and Bretillon, 2010; 
Pikuleva and Curcio, 2014).  
 
 In the work described here, a variant in FDFT1 was shown to be the most likely 
cause of non-syndromic retinal disease. However in the absence of the finding of further 
mutations, this link remains unproven. Work to further substantiate the link between in 
situ cholesterol biosynthesis and inherited retinal degeneration could include modelling 
of the effect of the F310L variant and blood testing in patients to look for an imbalance 
of the cholesterol metabolism. Also the second case with FDFT1 heterozygous mutation 
need first a full clinical examination to check whether her phenotype similar to that in the 
family MA17. Then it might be worth doing WGS on this case to check for the other 
missing heterozygous variant that may be large indel or deep intronic change. 
 
4.3.5 A TTLL5 homozygous mutation causes rod-cone dystrophy in a 
consanguineous family of Pakistani origin  
 
The TTLL5 (tubulin tyrosine ligase-like family member 5, OMIM 612268) gene, 
also called STAMP (SRC1 and TIF2-associated modulatory protein), encodes a 
glucocorticoid receptor that is one of 13 members of the tubulin tyrosine ligase-like 
superfamily (TTLLs) (He and Simons, 2007; Bosch Grau et al., 2013). TTLL5 has been 
mapped to chromosome 14q24.3 and has 32 exons that encode a 1,281 amino acid protein 
with an approximately 400 amino acid carboxy-terminal residue, making it one of the 
longest carboxy-terminal extensions in the TTLL family of proteins (van Dijk et al., 
2007). This protein is expressed in many tissues, with the highest expression profile in 
heart and testes (http://www.proteinatlas.org/ENSG00000119685-TTLL5/tissue) and 
lower expression in eye and the brain. Protein topology predicts a highly homologous 
core amino-terminus tubulin tyrosine ligase domain, three carboxy-terminal receptor 
interaction domains and one carboxy-terminal coactivator interaction domain (Janke et 
al., 2005; Lee et al., 2013). 
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Multiple activities have been associated with TTLL5. The carboxy-terminal 
extension is a transcription cofactor and has polyglutamylation activities (He and Simons, 
2007; van Dijk et al., 2008). Polyglutamylation is a post-translation modification 
associated with sequential attachment of glutamic acids to an internal glutamate residue 
of the target proteins (Edde et al., 1990; Janke et al., 2008). TTLL5 interacts with two 
glucocorticoid receptor coactivators, namely, transcriptional intermediary factor 2 (TIF2) 
and steroid receptor coactivator 1 (SRC-1) to mediate gene induction and repression. It 
also has a function as an alpha tubulin (α-tubulin) polyglutamylase and is required for 
centriole and spindle–associated protein (CSAP) localization to both spindle and cilia 
microtubules (van Dijk et al., 2008). Disruption of TTLL5 leads to male infertility in mice. 
Mutant STAMPtm/tm  mice that lack the carboxy-terminal extension but retain the TTLL 
domain, showed a sharp reduction in the level of polyglutamylation of α-tubulin in sperm, 
correlating with reduced levels of a truncated protein retaining the structural features to 
permit polyglutamylation (Lee et al., 2013). Reduced α-tubulin polyglutamylation 
resulted in abnormal axonemal structures with loss of tubulin doublets in sperm tails and 
defective sperm motility. This reduced fertility in male mice, while female mice were 
apparently normal (Lee et al., 2013). Lastly, TTLL5 was localized to the base of the 
connecting cilium between the basal body and the adjacent daughter centriole in the 
photoreceptor cells of the mouse and human retina (Sergouniotis et al., 2014), so it is 
thought to be responsible for the tubulin polyglutamination in the microtubule triplets of 
the centrioles, increasing the centriole stability. 
 
Recently, biallelic TTLL5 mutations have been shown to cause RD (Sergouniotis et 
al., 2014). These authors identified five patients with TTLL5 mutations from four 
unrelated families, each showing either early or late onset cone dystrophy. The five 
mutations that had been identified consisted of frameshift mutations, p.L134Rfs*45 and 
p.E529Vfs*2, nonsense mutations, p.E543* and p.W1118*, and a missense mutation, 
p.E543K. The missense mutation identified in family MA19 (p.E543K) was a reported in 
this study in a 53-year-old man with adult-onset cone dystrophy. Interestingly, male 
patients of the family MA19 (1885 and 1888) are both fertile (five offspring each). This 
is consistent with the fact that the E543K missense mutation is outside the carboxy-
terminal tail of TTLL5 that is thought to play an essential role in normal male fertility 
(Lee et al., 2013). Also, all 5 RD patients described in the published report were diagnosed 
with cone or cone-rod dystrophy, whilst patients of family MA19 showed a rod first form 
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of the RD, suggesting that disruption of TTLL5 polyglutamylation activities can lead to 
primary loss of either cone or rod photoreceptors in the human retina. This work 
contributed to a paper that the published at Human Molecular Genetics journal (Bedoni 
et al., 2016).
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Chapter 5. An atypical late-onset retinal dystrophy with 
early macular involvement is caused by biallelic 
mutations in the autophagy regulator DRAM2. 
 
5.1 Introduction 
In clinics at the Eye Department of St. James’s University Hospital, Leeds, 
consultant ophthalmologist Mr Martin McKibbin saw a family, designated ES1, of 
Pakistani origin, with multiple affected members diagnosed as having an atypical RD. 
The family tree is illustrated in Figure 5.1.  
 
 
 
 
Figure 5.1. Pedigree of family ES1. Affected individuals are shaded black. The genotypes for 
all tested family members are shown below each individual; + = wild type allele and M = 
c.140delG, p.G47Vfs*3. * = Family member for whom DNA was exome sequenced and * = 
Family member for whom DNA was SNP chipped. (Adapted from El-Asrag et al. (2015) with 
the permission of Elsevier Copyright Clearance Centre, License number: 3919040428835). 
 
The phenotype observed in this family was unusual, with an adult-onset retinal 
dystrophy with early macular involvement. Mr McKibbin has extensive experience of a 
wide range of retinal dystrophies, and was of the view that this represented a condition 
likely to be distinct from any other he had observed. Affected individuals presented with 
symptoms in the second or third decade, describing increasing difficulty with close visual 
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tasks. Neither light sensitivity nor night blindness were significant early symptoms, 
though there was progressive loss of visual acuity in all symptomatic individuals. 
However light sensitivity and difficulty seeing in dim illumination were inconsistent 
features of advanced disease. A summary of the clinical features are shown in Table 5.1. 
 
Patient 
(sex) 
Presenting 
symptom 
Age of 
Onset  
LogMAR 
VA  
RE/LE 
Fundus examination 
Fundus  
AF 
OCT  
III:1 (M)  Central visual loss  16 2.3/2.3 Central macular atrophy with pigment 
clumping and surrounding granular 
appearance; midperipheral bone 
spicule pigmentation; attenuated 
vessels (48, 56, 46) 
ND ND III:4 (M)  Central visual loss  23 2.0/2.0 
III:13 (M) Central visual loss  25  2.0/2.0 
III:5 (F)  Central visual loss  28 1.0/2.0 
Central macular atrophy with 
surrounding granular appearance; 
pigment clumping in left macula only; 
minimal peripheral changes (51) 
ND  ND  
III:6 (M)  Central visual loss  25 1.3/1.3 
Granular macular atrophy with 
associated yellow dots (37, 24, 29) 
ND 
ORL loss (37, 
24, 29) 
IV:8 (F)  Central visual loss  21  0.8/0.8 
IV:11 (F)  Central visual loss 27  1.0/1.0 
IV:6 (F)  Central visual loss  26  0.8/0.8 
Granular macular atrophy with 
associated yellow dots and pigment 
clumping; irregular reflex extending 
beyond the macula (32) 
ND ORL loss (32) 
IV:7 (M)  Central visual loss 22 0.2/0.2 Irregular foveal reflex (23) ND ORL loss (23) 
IV:9 (F)  Central visual loss  22 1.0/1.0 
Granular macular atrophy with yellow 
dots at its temporal edge (25) 
Hyper 
AF ring 
around 
central 
area of 
hypo AF 
(25) 
Reduced foveal 
thickness (21); 
ORL loss (25)  
IV:10 (M)  Asymptomatic  19  0.0/0.0 Within normal limits (19) ND 
Reduced foveal 
thickness, 
disruption of the 
ellipsoid zone 
(19) 
 
Table 5.1. Summary of clinical data from eleven patients from family ES1. VA = visual 
acuity, RE = right eye, LE = left eye, OCT = optical coherence tomography, AF = 
autofluorescence, ORL = outer retinal layer and ND = not done. Number in brackets corresponds 
to the age (years) at which the patient was tested. 
 
As the disease progressed, subjects III:4, III:13, IV:9 and IV:6 developed 
photophobia, while subject III:13 complained of night vision problems. Fundus 
examination revealed maculopathy in all symptomatic individuals tested, with peripheral 
retinal degeneration being a frequent finding in older subjects. Notably, OCT imaging in 
a pre-symptomatic individual (subject IV.9) suggested early central photoreceptor cell 
loss (Figure 5.2) in the second decade of life.  
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Figure 5.2. Retinal imaging of individuals (IV.9 and III.1) from family ES1. Colour fundus 
photograph (A), fundus AF (C), infra-red reflectance (E) and OCT (F) images from the right eye 
of case IV.9 at 25 years. Corresponding images from an unaffected individual are provided for 
comparison (B, D, G and H). Macular atrophy with white dots at its temporal edge are observed 
on fundus photography. On AF imaging, there is a central area of reduced AF surrounded by a 
hyper AF ring. On OCT imaging, there is significant thinning in the foveal region consistent with 
photoreceptor loss. A composite color photograph from the left eye of case III.1, at the age of 48, 
is also shown (I). This reveals macular atrophy, mid-peripheral bone-spicule pigmentation and 
attenuated retinal vessels. On the infra-red reflectance images, the horizontal green lines indicate 
the position and direction of the corresponding OCT scan. AF = autofluorescence and OCT = 
optical coherence tomography. (Reused from El-Asrag et al. (2015) with the permission of 
Elsevier Copyright Clearance Centre, License number: 3919040428835). 
 
Peripheral blood was collected from the affected individuals, parents and their 
unaffected relatives where they consented and were available. Genomic DNA was 
extracted from blood leukocytes as described in Section 2.2. DNA from seven affected 
family members (III.1, III.4, III.5, III.13, IV.6, IV.8 and IV.11; Figure 5.1) was sent away 
to the company MRC GeneService (London, UK) for SNP genotyping using the 
Affymetrix 250K SNP array. This chapter describes the identification of the genetic basis 
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of RD in the affected members of family ES1 and contributed to publications by El-Asrag 
et al. (2015) and Sergouniotis et al. (2015). 
 
5.2 Results 
5.2.1 Analysis of SNP genotyping data by homozygosity mapping 
The multiple consanguineous marriages in the family suggested that an autosomal 
recessive inheritance pattern for retinal dystrophy was the most likely mode of inheritance 
in this family. Analysis was therefore carried out on the assumption that the condition 
was caused by a recessive mutation inherited from a common ancestor, and that this allele 
and the chromosomal region around it would be homozygous in each affected individual. 
Homozygosity mapping of SNP array genotyping data was therefore considered a useful 
method to locate and identify the disease gene. The SNP genotyping data from seven 
affected individuals (III.1, III.4, III.5, III.13, IV.6, IV.8 and IV.11; Figure 5.1) were 
annotated individually by using Affymetrix Genotyping Console Software and then 
analysed using AutoSNPa software to identify regions of homozygosity that overlapped 
in multiple affected individuals and would represent an autozygous region (Section 2.12). 
The output data files were then imported to AgileMultiIdeogram to display the regions of 
homozygosity shared between all the affected individuals at the genome level (Figure 
5.3). 
 
Two homozygous regions were shared among all seven affected individuals: a 
10.1Mb interval on chromosome 1 between rs6677953 and rs814987 and a 2.9Mb region 
on chromosome 7 between rs17140297 and rs12706292. The two homozygous regions 
that were shared among all seven affected individuals of family ES1 contained 167 
RefSeq genes. The larger region on chromosome 1 (Chr1:106188422-116250460, hg38) 
contained 160 RefSeq genes, while the smaller region on chromosome 7 
(Chr7:117088307-119982844, hg38) contained only 7 genes (Figure 5.4). None of the 
genes within these homozygous intervals had been reported previously to be associated 
with retinal dystrophy (RetNet, accessed February 2015).  
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Figure 5.3. Homozygosity mapping in family ES1. The figure displays the locations of the 
homozygous regions identified by SNP genotyping data of multiple individuals against a circular 
ideogram of chromosomes 1–22. Data for individuals III.1, III.4, III.5, III.13, IV.6, IV.8 and IV.11 
are displayed in that order as white circular bands toward the center of the ideogram. The 
homozygous regions in each family member are shown in green. The common autozygous regions 
identified in all affected family members are highlighted in red. (Adapted from El-Asrag et al. 
(2015) with the permission of Elsevier Copyright Clearance Centre, License number: 
3919040428835). 
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Figure 5.4. RefSeq genes in homozygous regions identified in family ES1. Ensembl genome 
browser output displaying the list of genes in the two homozygous regions shared among all seven 
affected individuals III.1, III.4, III.5, III.13, IV.6, IV.8 and IV.11 of family ES1. 160 genes were 
found in the region on chromosome 1 (Chr1:106188422-116250460, hg38) (A), while only 7 
genes were found in the region on chromosome 7 (Chr7:117088307-119982844, hg38) (B).  
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5.2.2 Analysis of WES of patient IV.6 from family ES1 
WES was utilized to identify the molecular pathology in the family. DNA from one 
affected family member (subject IV.6, family ES1; Figure 5.1) was extracted (Section 
2.2) and the concentration of purified DNA was estimated (Section 2.3). 3µg of genomic 
DNA was prepared for whole exome sequencing using the SureSelectXT Human All 
Exon V4 target enrichment reagent, and paired-end sequencing was completed on a 
HiSeq2500 system (Section 2.10.1). The quality of the raw sequence data files was 
checked using FastQC tools and sequencing reads with quality scores less than 20 were 
removed. The FastQ files were then aligned to the human reference genome sequence 
(hg19/GRCh37) using Bowtie2 and a total of 34,490,556 reads were obtained. The 
sequence file was then processed in SAM/BAM format according to methods described 
in Section 2.10.2. Quality score recalibration was achieved and 13.81% of the sample 
reads were removed as PCR duplicates. The annotated VCF file was then filtered by 
removing all variants that lay outside the exons and flanking two base-pair splice donor 
and acceptor sites, synonymous variants, variants with a read depth of less than 5 and 
variants with a MAF ≥1% in dbSNP142, the EVS, the 1000 Genomes or ExAC databases. 
Filtering on the basis that the condition was likely to have a recessive mode of 
transmission from a common ancestor and so the pathogenic variant was likely to be 
homozygous identified a list of 33 homozygous variants (Table 5.2). 
   
Chr Gene Effect cDNA change Protein change 
1 HMGB4 Missense NM_145205:exon2:c.C345A p.N115K 
1 GJB5 Missense NM_005268:exon2:c.C166T p.R56C 
1 DRAM2 Frameshift deletion NM_178454:exon4:c.140delG p.G47fs 
1 LY9 Missense NM_001261456:exon5:c.A1238G p.N413S 
2 NEB Missense NM_004543:exon131:c.T17909C p.I5970T 
2 LY75 Missense NM_001198759:exon12:c.C1960T p.L654F 
3 LOC401052 Missense NM_001008737:exon4:c.A287C p.H96P 
5 SPEF2 Missense NM_024867:exon5:c.A601G p.R201G 
5 BRD8 Missense NM_139199:exon9:c.C671T p.S224F 
6 CD109 Missense NM_001159588:exon4:c.A385G p.I129V 
6 ZNF292 Missense NM_015021:exon8:c.A8132G p.D2711G 
7 FZD1 Missense NM_003505:exon1:c.G1578T p.K526N 
10 GPRIN2 Missense NM_014696:exon3:c.A724G p.R242G 
10 ADAMTS14 Missense NM_080722:exon16:c.C2363T p.A788V 
10 RRP12 Missense NM_001145114:exon24:c.G2847C p.K949N 
10 GBF1 Missense NM_001199378:exon3:c.C112A p.P38T 
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11 OR51V1 Missense NM_001004760:exon1:c.G286C p.G96R 
11 OR52H1 Missense NM_001005289:exon1:c.G3T p.M1I 
12 PLEKHG6 Nonsense NM_001144857:exon9:c.C1023G p.Y341X 
12 TAPBPL Missense NM_018009:exon1:c.G49A p.G17R 
12 NUAK1 Missense NM_014840:exon1:c.A32G p.D11G 
16 SOCS1 Missense NM_003745:exon2:c.C116G p.P39R 
17 CD300C Missense NM_006678:exon2:c.G103C p.V35L 
19 PLIN4 Missense NM_001080400:exon3:c.A2200G p.I734V 
19 OR10H3 Missense NM_013938:exon1:c.G293T p.C98F 
19 OR10H4 Missense NM_001004465:exon1:c.G293T p.C98F 
19 ZNF773 Missense NM_198542:exon4:c.C290A p.A97E 
21 USP16 Missense NM_001001992:exon14:c.A1829G p.E610G 
X SHROOM2 Missense NM_001649:exon4:c.C2725G p.Q909E 
X APEX2 Missense NM_001271748:exon5:c.G509A p.R170H 
X CYLC1 Missense NM_001271680:exon1:c.G14C p.R5T 
X TCEAL5 Missense NM_001012979:exon3:c.C246A p.D82E 
X MAGEA10 Missense NM_021048:exon4:c.A1014C p.E338D 
 
Table 5.2. List of variants identified after filtering WES data from patient IV.6 of family 
ES1. (Adapted from El-Asrag et al. (2015) with the permission of Elsevier Copyright Clearance 
Centre, License number: 3919040428835). 
 
5.2.3 Using the SNP genotype data to further filter the WES analysed 
data. 
WES identified 33 homozygous sequence variants after filtration. SNP genotyping 
data identified 2 homozygous regions in common with the 7 affected members that were 
analysed. By combining these datasets, it was identified that only one of the homozygous 
variants identified by WES mapped within the shared homozygous regions. This was a 
single-base deletion in DRAM2 (DNA-damage regulated autophagy modulator protein 2, 
OMIM 613360), NM_178454.4: c.140delG, p.G47Vfs*3. This variant created a 
frameshift mutation and was predicted to lead to premature protein truncation. This 
change was not present in dbSNP142, the EVS or 1000 Genomes databases. It was found 
once in a heterozygous state in WES data from 61,486 unrelated individuals present in 
the ExAC dataset. Notably, no homozygous presumed loss-of-function variants in 
DRAM2 were present in the ExAC dataset. Sanger DNA sequencing of DRAM2 exon 4 
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(Section 2.8, primer pairs in Appendix 6) confirmed the presence of the mutation in the 
index case (Figure 5.5) and showed that the mutation segregated with the disease in the 
family (Figure 5.1). Sanger sequencing in a control DNA panel of ethnically-matched 
individuals excluded this frameshift mutation from 159 controls. 
 
5.2.4 Calculation of a LOD score for family ES1. 
With the c.140delG variant as a genetic marker, and assuming a minor allele 
frequency of 0.01% and full penetrance in the family according to a recessive manner, a 
LOD score was calculated using the Superlink program, via. the Superlink-online 
website. By analysing nine genotyped family members, a maximum two-point LOD score 
of 2.4 was achieved. 
 
5.2.5 Screening for DRAM2 mutations to identify more independent 
cases with the same disease 
In an attempt to identify further cases with DRAM2-associated retinopathy, panels 
of genomic DNA from RD patients were screened by PCR (primer pairs in Appendix 6) 
and Sanger sequencing of the seven coding exons of DRAM2 and their flanking splice 
sites junctions. The panels consisted of 74 individuals diagnosed with RP, 154 with CRD 
or MD and 94 with infantile-onset retinal dystrophy (LCA). The screen identified one 
additional case in the CRD/MD panel that could be accounted by mutations in DRAM2. 
An isolated female case (subject 1325; Figure 5.6A) of European ancestry was identified 
who was a compound heterozygote for a nonsense mutation in exon 6 of DRAM2, 
c.494G>A, p.W165*, and a missense variant in exon 3 of DRAM2, c.131G>A, p.S44N 
(Figure 5.5).  
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Figure 5.5. Schematic representation of the DRAM2 genomic structure and major transcript (NM_178454.4), showing the location and sequence traces 
of the three disease-causing variants identified in this study. (Adapted from El-Asrag et al. (2015) with the permission of Elsevier Copyright Clearance 
Centre, License number: 3919040428835). 
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The missense change was predicted to be pathogenic by a number of bioinformatic 
prediction tools (Table 5.6B) and was not present in dbSNP142, EVS or ExAC databases. 
Note that the variant affects a serine residue that is conserved from human to zebrafish, 
suggesting that the normal residue may be important for protein structure or function 
(Figure 5.6C). The other mutation, a c.494G>A change, is an annotated variant in 
dbSNP142 (rs201422368), with a MAF of 0.008% (1/13,003) in EVS and 0.003% 
(3/118,572) in ExAC. It is however only reported in the heterozygous state in these 
databases. 
 
Figure 5.6. Genetic analysis of Case 1325. (A) Case 1325 family structure. The genotype for 
the tested case is shown below the individual, with M1 representing c.131G>A, p.S44N and M2 
representing c.494G>A, p.W165*. (B) Summary of bioinformatic analyses to predict the 
pathogenic nature of the missense variant c.131G>A, p.S44N in DRAM2. (C) ClustalW alignment 
of DRAM2 amino acid sequences around the missense mutation, p.S44N, showing a highly 
conserved serine residue at position 44 in the protein. Accession numbers for DRAM2 protein 
are human NP_848549.3, gorilla XP_004026374.1, rhesus AFI36263.1, mouse NP_080289.1, rat 
NP_001020189.1, rabbit XP_008262917.1, cow NP_001070464.1, horse XP_005610395.1, dog 
XP_005621847.1, ferret XP_004816269.1, shrew XP_004620147.1, opossum XP_007485185.1, 
pigeon XP_005505369.1, chicken XP_003642762.1, painted turtle XP_005309999.1, lizard 
XP_003220625.1 and zebrafish NP_001002135.1. 
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5.2.6 Clinical features of case 1325 
Subject 1325, who is a compound heterozygote for DRAM2 mutations, had been 
examined and recruited by Mr Martin McKibbin at a retinal dystrophy clinic in the Eye 
Department, St. James’s University Hospital. In light of genetics findings, her case notes 
were requested and an updated ophthalmic assessment was performed. She had 
experienced blurred vision at the age of 29 and was soon after found to have maculopathy 
on fundus examination. At the age of 35, she also complained of problems with night 
vision and sensitivity to light. Fundus examination revealed mild peripheral retinal 
degeneration in addition to central macular atrophy, with grey dots in the temporal 
macula and intra-retinal pigment migration. At the age of 46, she had acuity of 1.0 
logMAR in each eye and electrophysiology revealed severely attenuated or absent 
ffERGs and pattern ERGs (Figure 5.7). 
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Figure 5.7. Clinical features of Case 1325. Fundus photographs of the right and left eyes at 35 
years of age (A) show central macular atrophy with grey dots in the temporal macula with intra-
retinal pigment migration. Flash and pattern electroretinography (ERG and PERG) of the case (at 
46 years of age) (B) and a normal control individual (C) were recorded to ISCEV standard 
protocols for the right (RE) and left (LE) eyes. Light-adapted single flash photopic ERG, 30Hz 
flicker (cone-isolating) ERG, dark-adapted scotopic rod ERG and PERG traces were all severely 
attenuated or absent compared to the normal control values suggesting a generalised rod-cone 
dysfunction. The attenuated PERGs indicate that the central macular region is affected by this 
condition. (Reused from El-Asrag et al. (2015) with the permission of Elsevier Copyright 
Clearance Centre, License number: 3919040428835). 
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5.2.7 Mapping the mutations on the DRAM2 protein 
Previous overexpression studies in HEK293 cells have localised DRAM2 to lysosomal 
membranes (O'Prey et al., 2009; Park et al., 2009). However apart from these studies, 
DRAM2 has not been extensively characterised. Bioinformatics analyses were used 
(Section 2.14.5) to visualize the normal DRAM2 protein structure. The analysis revealed 
that the DRAM2 gene encodes a 266 amino acid protein containing six putative 
transmembrane domains (Figure 5.8). The mutations identified in human patients have 
been mapped onto the protein schematic and the missense mutation p.S44N maps within 
a loop between the first and second transmembrane domains suggesting that this loop 
may have an important functional role in DRAM2.  
 
 
 
Figure 5.8. Schematic diagram of the DRAM2 transmembrane protein. The proteoform 
shows six putative transmembrane domains, and the location of the mutations that were identified 
in human RD patients are shown. 
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5.2.8 Gene expression profile of DRAM2 in multiple human tissues 
In order to investigate the expression profile of DRAM2, reverse transcription PCR 
(Section 2.16) and agarose gel electrophoresis (Section 2.5) was performed on total RNA 
that had been extracted from various human tissues (Sections 2.15). In order to amplify 
DRAM2 cDNA, a forward sense primer was designed (Section 2.4) to exon 6, whilst the 
reverse antisense primer bound to exon 7. As a control in the PCR, primer pairs against 
the housekeeping gene P53 were used. Primer pairs used in this study are listed in 
Appendix 6. After RT-PCR and agarose gel electrophoresis, DRAM2 was shown to be 
ubiquitously expressed in all the tissues that were analysed (Figure 5.9).  
 
 
 
 
Figure 5.9. DRAM2 mRNA is ubiquitously expressed in all the 21 tissues analysed. cDNA 
was prepared from human adult and fetal tissue total RNA. The retinal cDNA was purchased 
from Clontech. A 222-bp fragment of DRAM2 spanning intron 6 was amplified from the cDNAs 
(genomic PCR expected size = 778 bp). P53 control primers amplified a cDNA product size 408 
bp or genomic PCR size 1057 bp. (Reused from El-Asrag et al. (2015) with the permission of 
Elsevier Copyright Clearance Centre, License number: 3919040428835). 
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5.2.9 Immuno-localisation of DRAM2 to the mouse eye 
As pathogenic mutations in DRAM2 cause retinal dystrophy in human patients, it 
was important to investigate the precise localization of normal DRAM2 protein in the 
retina. First, paraffin fixed cross eye sections of mouse embryo (Postnatal zero (Po)/E21) 
were prepared and stained according to methods described in Sections 2.17.1 and 2.17.3 
followed by IHC staining (Sections 2.17.4 and 2.17.5) using goat DARM2 polyclonal 
antibody at a final dilution 1:50 for 2 hours at 4 °C followed by polyclonal rabbit anti-
goat immunoglobulins/HRP at a final dilution 1:2000 and counterstained with 
haematoxylin. The results showed nonspecific staining to DRAM2 in the eye layers 
(Appendix 8). 
 
IF staining was the performed on sagittal frozen sections of adult mouse retina that 
were labeled with goat anti-DRAM2 (at a final dilution of 1:100) followed by a secondary 
Alexa Fluor 568-conjugated donkey anti-goat immunoglobulin (red). As a positive 
control, the sections were also stained with rabbit anti-Rhodopsin (at a final dilution of 
1:500) and Alexa Fluor 488-conjugated chicken anti-rabbit immunoglobulin (green) as 
secondary. The nuclei were counterstained with DAPI (Figure 5.10A-C). The 
immunofluorescence was visualised by confocal microscopy (Section 2.18) and showed 
that DRAM2 localised to the inner segment of the photoreceptor layer (PIS) and the 
retinal pigment epithelium (RPE).  The rhodopsin protein localised to the outer segment 
of the photoreceptor layer (POS) as expected. An independent section stained with both 
secondary antibodies only and another with peptide competition against the DRAM2 
primary antibody (Section 2.17.8) served as negative controls in the experiment and 
confirmed the specificity of the primary antibody for staining DRAM2 protein (Figure 
5.10D&E).  
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Figure 5.10. Immuno-localisation of DRAM2 to the mouse retina. Immunofluorescence and confocal microscopy images of mouse retinal sections showing 
DRAM2 predominantly localises to the photoreceptor inner segment (PIS) and the retina pigment epithelium (RPE). Immunofluorescence photomicrographs 
of P30 coronal mouse retinal sections stained with antibodies against DRAM2 (red) and Rhodopsin (green) in separate channels and in merged images (A, B & 
C) compared to negative controls of secondary antibodies only (D) and peptide competition against the DRAM2 primary antibody (E). POS = photoreceptor 
outer segment, ONL = outer nuclear layer, OPL = outer plexiform layer, INL = inner nuclear layer, IPL = inner plexiform layer and GCL = ganglion cell layer. 
Scale bar: 50M. (Reused from El-Asrag et al. (2015) with the permission of Elsevier Copyright Clearance Centre, License number: 3919040428835). 
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5.2.10 Immunoprecipitation analysis of the DRAM2 protein to identify 
protein interactants 
Many biological processes require direct physical interactions between proteins. 
Identifying and characterizing protein-protein interactions could provide important 
insights into molecular function. Using existing databases, that are based on yeast-2-
hybrid, such as IntAct (http://www.ebi.ac.uk/intact/b,) (Orchard et al., 2014) and MINT 
(http://mint.bio. uniroma2.it/) (Licata et al., 2012) revealed that no interactant binding 
partners for DRAM2 have been identified so far. In order to attempt to identify DRAM2 
interactant partners, an immunoprecipitation strategy with mass spectrometry was 
considered.  
 
To minimise the number of false-positives in the assay, endogenous levels of 
DRAM2 were pulled-down using a polyclonal anti-DRAM2. Initially retina was isolated 
from mouse eyes or snap frozen cow eye. 1 ml of retinal cell lysates were prepared 
separately from mouse and cow eyes according to methods described in Sections 2.19.1 
and 2.19.2. The two mouse lysates from the same mice were pooled together. The protein 
concentrations were measured using the Bradford assay (Section 2.19.3). These 
highlighted that the amount of protein extracted from the mouse retina was 0.35 to 0.48 
µg/µl while for the cow retina the amount was 2.94 to 4.82 µg/µl.  
 
Given that a minimum of 1 mg was required to perform the pull down assays, there 
was insufficient material available from the mouse retina and so the extract from the cow 
retina was analysed further. Before performing the pull-down experiment, the epitope 
sequence of rabbit anti-DRAM2 was checked against the cow protein sequence and 
showed 88.24% similarity. Then 20 µg of the lysate was investigated by western blotting 
(Section 2.20) against rabbit anti-DRAM2 (with a final dilution 1/200) and rabbit anti-
Rhodopsin (at a final dilution 1/200) with 16 hours incubation time. The secondary 
antibody was anti-rabbit IgG (HRP) used at a final dilution 1/2000 for 60 minutes. The 
purpose of using rhodopsin alongside DRAM2 was to confirm that the lysate is retinal in 
origin, which is an important step, given the difficulty in separating the retina from other 
eye tissues. The results confirmed the presence of DRAM2 and rhodopsin in the retinal 
lysate at the expected band sizes and that the antibody does detect cow DRAM2 (Figure 
5.11). 
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Figure 5.11. Western blot analysis of cow retinal lysates. Two bands are visible for each 
sample from four retinal lysate samples (S1 to S4) isolated from 2 different cow eyes. These were 
incubated with anti-DRAM2 and anti-rhodopsin. A band at 29 kDa highlights DRAM2 and a 
band at 39 kDa indicates rhodopsin.  
 
For the pull-down experiment, 1 mg of the cow retinal lysate was incubated 
with 2.5µg polyclonal rabbit anti-DRAM2 and 30µl Protein A plus agarose beads 
according to the methods described in Section 2.21. The pulldown results were 
checked by migration through a polyacrylamide gel and silver staining (Section 
2.22). No protein appeared to be detected after the pull down assay. However an 
unexpected band at ~98 KDa was found in all samples after the pull down (Figure 
5.12).  
 
Figure 5.12. A representative image of silver stained polyacrylamide gel. The gel showing 
cow retinal lysates before and after the pull-down experiment with rabbit anti-DRAM2 antibody. 
The experiments were performed in triplicate. The staining highlights consistent protein 
composition amongst the lysates, but no protein was detected after the DRAM2 antibody pull-
down except an unexpected band at ~98 KDa, which was found in all the tested samples (S1, S2 
and S3). 
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This experiment was replicated four times with increasing parameters of 
incubations times (2-48 hours), concentration of antibodies (2.5-5µg) and protein A/G 
plus agarose beads (25-50 µl). The same results were still detected after the pull-down in 
each case. Moreover western blotting analysis of all samples after the pull down using 
rabbit anti-DRAM2 did not highlight any protein bands suggesting that the experiment 
did not work under the experimental conditions that were tested. Given that analysis by 
mass spectrometry is very expensive ($1000 per sample), no further work was carried out 
on this aspect of the project. 
 
An attempt was then planned to obtain DRAM2 interactant data via an alternative 
approach. This involved transfecting a DRAM2 expression construct into a cell 
expressing little or no endogenous DRAM2, followed by a pull-down assay in the lysate 
of the transfected cells. This avoids the difficulties of performing pull-down experiments 
against endogenous proteins in their native state. DRAM2 cDNA was cloned using the 
Gateway system into a tagged expression construct according to methods described in 
Sections 2.23, 2.24 and 2.25, to create a clone denoted pDRAM2-C-TAP GW332 that 
was verified by Sanger sequencing. In addition, DRAM2 expression was investigated by 
RT-PCR in various cell lines, using the previously designed primers (Section 5.2.8) on 
total RNA extracted (Section 2.15) from the cell lines. Human cell lines tested included 
MCF7, RPE, RPE1 SS (Serum starved), U2OS, H2B, HRT18, HCT116, MT29, SW480, 
Sh5Y differentiated, Sh5Y undifferentiated, MCF10A, HDF, and HEK293. DRAM2 was 
expressed in all of these cell lines (Figure 5.14).The next step planned will be transfection 
into one or more of these cell lines followed by pull down experiments with anti-C-TAP 
antibody, western blot analysis and mass spectrometry.  
 
  
 
Figure 5.13. DRAM2 mRNA is ubiquitously expressed in all the 13 cell lines analysed. cDNA 
was prepared from cell lines total RNA. A 222-bp fragment of DRAM2 spanning intron 6 was 
amplified from the cDNAs. 
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5.3 Discussion 
5.3.1 Combining homozygosity mapping with WES to identify disease-
causing genes. 
The study of consanguineous families with multiple affected individuals has proved 
a successful approach in determining the causes of autosomal recessive retinal disease. 
The children of consanguineous individuals will have more homozygous DNA than the 
offspring of an outbred marriage (Section 1.9). This leads to an increased likelihood of 
rare, recessive disease-causing variants being inherited from both parents, known as 
identical by descent (IBD) (Modell and Darr, 2002). Homozygosity mapping locates 
regions of the genome containing large stretches of homozygosity that are shared between 
affected individuals to represent the disease loci. However these regions usually contain 
large numbers of genes. WES is an effective way to identify the RD causing gene and 
mutation in such cases, but this approach alone tends to identify long lists of candidate 
variants which are then challenging to filter and exclude. Combining data from these two 
approaches allows the researcher to narrow down the candidate genes and potentially to 
identify the most likely variant that causes disease in any given family. In this chapter, 
these combined approaches were used to identify DRAM2, a novel RD gene.  
 
5.3.2 Further DRAM2 mutations and any possible genotype–phenotype 
correlation. 
Given that affected members of family ES1 are homozygous for a DRAM2 variant 
that is likely to lead either to nonsense-mediated decay of the encoded mRNA or to a 
truncated protein of only 47 amino acids, the molecular pathology of the disease is likely 
to be loss of DRAM2 function. This speculation is further supported by the independent 
finding of five disease-causing variants that have been identified in four RD cases by the 
UK Inherited Retinal Disease Consortium and the European Retinal Disease Consortium 
(ERDC) (El-Asrag et al., 2015; Sergouniotis et al., 2015). Two of these cases (gc17004 
and gc4728) were identified through a gene-based case-control association analysis that 
was performed on 18 families from the inherited retinal disease clinics at Moorfields Eye 
Hospital (London), utilizing 1,917 unrelated control samples generated by a consortium 
of UK-based researchers (“UCL-exomes”). The first (gc17004) was a 37-year-old female 
of European ancestry who was compound heterozygote for a missense variant (c.79T>C, 
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p.Y27H) and an in-frame deletion (c.217_225del, p.V73_Y75del). The second was a 47-
year-old male of South Asian origin who had a homozygous missense change (c.362A>T, 
p.H121L). The third and fourth cases (BL1 and PCI1) were identified by WES. Both are 
in their early forties, one of Indian and the other of Turkish origins, and both have a 
homozygous variant, c.64_66del, p.A22del and c.169G>C, p.G57R respectively. The 
phenotype of these cases was notably similar to the affected members of family ES1 and 
subject 1325. 
 
Interestingly, most the mutations that have been identified so far (Figure 5.14) are 
truncating mutations or severe missense mutations in the transmembrane domains. 
p.S44N is the only missense mutation that has been identified within a loop between the 
first and second transmembrane domains. This variant is identified in compound 
heterozygous Leeds case 1325, who also carries the nonsense mutation p.W165*. No 
precise genotype–phenotype correlations of DRAM2 mutations can be observed from the 
few cases that have been identified. However, affected members of family ES1, and also 
subject 1325 who harbour at least one presumed loss-of-function variant in DRAM2, 
appear to manifest symptoms of retinal disease earlier than the remaining cases (gc17004, 
gc4728, BL1 and PCI1), who harbour only missense changes or in-frame deletions and 
became symptomatic at a later age (El-Asrag et al., 2015; Sergouniotis et al., 2015). 
 
 
Figure 5.14. Schematic diagram of DRAM2 showing the protein domains and the location 
of the affected amino acids identified in patients with DRAM2 retinopathy. 
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5.3.3 DRAM2 is an autophagy regulator 
During autophagy, a cytosolic form of LC3-I (microtubule-associated protein light 
chain 3) conjugates with phosphatidylethanolamine (PE) to form LC3-II (LC31/PE 
conjugate), which is recruited to autophagosomal membranes. DRAM2 overexpression 
studies in HEK293 have shown that it initiates the conversion of endogenous LC3-I to 
LC3-II, the general autophagosome marker protein in the lysosome. These studies 
showed that overexpression of DRAM2 increased GFP-LC3 punctate that represent the 
extent of autophagy. Also, siRNA knockdown of endogenous DRAM2 results in reduced 
conversion to LC3-II in cells subject to starvation-induced autophagy. This suggests that 
DRAM2 may act as a positive regulator of autophagy (Park et al., 2009; Yoon et al., 
2012). 
 
Autophagy is a natural cell survival mechanism triggered in response to stress 
stimuli such as light-induced damage, nutrient starvation or the accumulation of damaged 
organelles. It is responsible for degrading and recycling cytoplasmic proteins and lipids 
as well as organelles within the cell (Levine and Klionsky, 2004). Depending on the mode 
of cargo delivery to the lysosome, autophagy can be subdivided into three categories, 
macroautophagy, microautophagy and chaperone mediated autophagy (CMA) 
(Mizushima and Komatsu, 2011) (Figure 5.15). 
 
Microautophagy and CMA directly involve the lysosome. During the 
microautophagic process, cytosolic components are transported into the lysosome by 
direct invagination of the lysosomal membrane, followed by budding off of the vesicle 
formed into the lysosomal lumen (Kunz et al., 2004; Sahu et al., 2011). During CMA, the 
substrate proteins are targeted to the lysosomal membrane through recognition of a 
targeting motif (a KFERQ-like motif) by a chaperone complex composed of hsc70 and 
its co-chaperones. This substrate chaperone complex is delivered to the lysosomal 
membrane, where it interacts with lysosomal associated membrane protein type 2A 
(LAMP-2A) and is directly translocated across the membrane into the lysosomal lumen 
(Massey et al., 2006; Xilouri et al., 2016). 
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Figure 5.15. Different types of autophagy. (A) Macroautophagy begins with the formation of a 
phagophore which is also called an isolation membrane (nucleation step), followed by the 
engulfment step, which is either nonspecific, involving bulk of cytoplasm, or selective, involving 
specific cargoes. The autophagosome is then formed by elongation of the phagophore and fusion 
of its edges to form the autophagosome (elongation and completion steps). The outer membrane 
of the autophagosome then fuses with the lysosome (fusion step) followed by lysis of the 
autophagosome inner membrane and breakdown of the contents (degradation step). Autophagy-
related genes (Atg) and protein complexes that are involved in each step are shown. (B) chaperone 
mediated autophagy (CMA) refers to the recognition of proteins carrying the pentapeptide 
KFERQ-like sequence by the Hsc70 chaperone, followed by association with the integral 
lysosome membrane receptor LAMP-2A, which leads to the translocation of the bound protein 
into the lysosomal lumen. (C) Microautophagy refers to the sequestration of cytosolic targeted 
components directly by lysosomes through invaginations in their limiting membrane. After all 
three types of autophagy, the resultant degradation products can be used for different purposes, 
such as new protein synthesis and energy production. (Adapted from Boya et al. (2013) with the 
permission of Elsevier Copyright Clearance Centre, License number: 3934340352393) 
 
On the other hand, macroautophagy, the most common form of autophagy, begins 
with isolation of the macromolecules and organelles within the cytoplasm into single 
membrane vesicles, which fuse together to produce an autophagosome (AP). This AP 
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subsequently fuses with a lysosome containing acid hydrolases, to form a double-
membrane autolysosome (Yoshimori, 2004; Kroemer and Jaattela, 2005). APs are 
generated on or in close proximity to the endoplasmic reticulum (ER) (Mizushima et al., 
2011). Recent studies suggest that the plasma membrane, ER, Golgi complex and 
mitochondria are all possible membrane sources for APs (Hailey et al., 2010; Hamasaki 
and Yoshimori, 2010; Ravikumar et al., 2010; Tooze and Yoshimori, 2010). 
Macroautophagy is a highly complex process, dividing into several steps, including the 
formation of autophagosome by membrane isolation, nucleation, elongation and 
autophagosome-vacuole fusion, followed by fusion of autophagosomes with lysosomes 
for degradation of the autophagosomal content. Approximately 30 autophagy-related 
genes (ATGs) were first identified in yeast and have orthologs in humans. The proteins 
encoded by these genes are involved in the regulation of every step of this process 
(Hamasaki and Yoshimori, 2010).  
 
The serine/threonine kinase UNC-51-like kinase -1 (ULK1), which plays a similar 
role as the yeast Atg1 protein, forms a ULK1 complex with mATG13 (a mammalian 
ortholog of yeast Atg13) and FIP200 (a mammalian ortholog of yeast Atg17) to promote 
the membrane isolation which represents the first step in autophagosome generation 
(Ganley et al., 2009; Hosokawa et al., 2009). LC3 (a mammalian ortholog of yeast Atg8) 
binds directly to ULK1 and enhances its activity in autophagy (Kraft et al., 2012). 
Beclin1-class III PI3K complex containing: hVps34, Beclin-1 (a mammalian ortholog of 
yeast Atg6), p150 (a mammalian ortholog of yeast Vps15) and Atg14-like protein 
(Atg14L), AMBRA1 (activating molecule in Beclin1-regulated autophagy protein 1) and 
UVRAG (UV radiation resistance associated gene), are all associated with nucleation of 
the phagophore (Itakura et al., 2008; Simonsen and Tooze, 2009; Li et al., 2012). Atg12-
Atg5-Atg16 complex together with Atg8-phosphatidylethanolamine (Atg8-PE) complex 
(LC3-II), participate in the elongation and enclosure step for autophagosome formation 
(Yorimitsu and Klionsky, 2005). Atg12 is conjugated to Atg5 through Atg7 and Atg10 
(Mizushima et al., 1998). Atg8/LC3 is cleaved by Atg4 to form the cytosolic soluble 
LC3-I, then activation by Atg7 and transferring to the E2-like Atg3 where lipidation by 
conjugation to the lipid PE take place and converting to a membrane-associated form 
LC3-II (Kabeya et al., 2000). LC3-II remains on the mature autophagosomes until fusion 
with lysosomes is completed. Thus, it is commonly used as a marker for the mammalian 
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autophagosome together with LAMP1, a lysosome associated membrane protein 1 
(Weidberg et al., 2011).  
 
5.3.4 Possible role of DRAM2 in regulatory signalling pathways that 
lead to autophagy  
The process of autophagy is controlled by activation/inhibition cascades (Figure 
5.16). The mammalian rapamycin (mTOR), a phosphatidylinositol 3-kinase (PI3K) and 
a serine/threonine kinase (Akt) also known as protein kinase B (PKB), are key regulators 
in various cellular functions in autophagy regulation (Schmelzle and Hall, 2000). mTOR 
consists of two protein complexes, mTORC1 and mTORC2, and activation of the mTOR 
by nutrients or growth factors inhibits autophagy. 
 
Growth factors such as insulin and insulin-like growth factor bind to their receptor 
tyrosine kinases, leading to receptor autophosphorylation and activation of PI3K-
Akt/PKB, which then phosphorylates the tuberous sclerosis complex (TSC2) and 
prevents the formation of TSC1/2. TSC1/2 acts as a GTPase-activating protein for Rheb 
(Ras (small GTPase) homolog enriched in brain). Blocking the activity of TSC1/2 leads 
to Rheb-GTP accumulation which activates mTOR (Proud, 2007). Activation of mTOR 
inhibits autophagy by inhibiting the association between Atg1/Ulk1 and Atg13/mATG13 
by mTORC1 (Kamada et al., 2010). Under conditions of starvation or rapamycin 
treatment, inactivation of mTOR1 leads to dephosphorylation and activation of 
Atg1/Ulk1 that induces autophagy (Shang et al., 2011). Phosphatase and tensin homolog 
(PTEN) is an activator of autophagy by inhibition of the Akt/PKB signaling pathway 
(Shaw and Cantley, 2006). 
 
Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is an 
important regulator of autophagy. It induces autophagy by suppression of mTOR, either 
by enhancing the functions of TSC2 that lead to suppression of mTORC1, or by directly 
phosphorylating the mTOR binding partner Raptor (regulatory associated protein of 
mTOR), leading to inactivation of Raptor and mTORC1 (Gwinn et al., 2008; Herrero-
Martin et al., 2009). AMPK also can directly induce autophagy by phosphorylation of the 
Atg1/Ulk1 complex (Mack et al., 2012). B-cell lymphoma 2 (Bcl-2) apoptotic family 
proteins  also  act  as  autophagy  regulators. The  anti-apoptotic   Bcl-2 family  members 
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Figure 5.16. The regulatory signaling pathways in autophagy. (1) Growth factors bind to their 
receptor tyrosine kinase which stimulates PI3K/Akt directly or through Ras. PI3K inhibits the 
TSC1/2 complex, leading to Rheb-GTP accumulation, which in turn activates mTORC1 and 
causes autophagy inhibition by inhibiting ULK1 complex formation. (2) PTEN inhibits PI3K/Akt/ 
mTOR signaling. (3) AMPK can be activated by LKB1, causing activation of TSC1/2, 
inactivation of mTOR and induction of autophagy. AMPK can also cause inactivation of mTOR 
by directly phosphorylating the mTOR binding partner Raptor. AMPK also can directly induce 
autophagy through ULK1 upregulation. (4) The Bcl-2 family anti-apoptotic proteins have 
inhibitory effects on autophagy by interaction with Atg6/Beclin1, while pro-apoptotic proteins 
have stimulatory effects on autophagy by disrupting the association of anti-apoptotic proteins 
with Atg6/Beclin1. (5) The Raf/MEK1/ERK1 signaling cascade causes the activation of 
autophagy. (6) Intracellular IP3 negatively regulates autophagy via an mTOR-independent 
mechanism. (7) Cytoplasmic p53 is responsible for the inhibition of autophagy. By contrast, 
nuclear p53 stimulates autophagy in a transcription-dependent fashion by activating the 
expression of DRAM and sestrin. Red ovals = autophagy inhibitory and Black ovals = autophagy 
stimulatory. (Sources: Ravikumar et al. (2004), He and Klionsky (2009), Mizushima and Komatsu 
(2011), Peracchio et al. (2012) and Cheng et al. (2013)). 
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members (Bcl-2, Bcl-XL, Bcl-wl, and Mcl-1) inhibit autophagy, while pro-apoptotic Bcl-
2 homology 3 (BH3) proteins (BNIP3L, Bad, Noxa, Puma, BimEL22, and Bik) stimulate 
autophagy (Maiuri et al., 2009). These proteins act through interaction with Atg6/Beclin1 
(Pattingre et al., 2005). The Raf/MEK/ERK pathway also promotes autophagy by the 
disassembly mTORC1 (Wang et al., 2009c). Inositol trisphosphate (IP3) can negatively 
regulate autophagy via an mTOR-independent mechanism (Khan and Joseph, 2010). 
 
Many autophagy inducers, such as starvation and rapamycin, stimulate degradation 
of cytoplasmic p53. Inactivation of cytoplasmic p53 can trigger autophagy (Tasdemir et 
al., 2008). On the other hand, nuclear p53 can stimulate autophagy in a transcription-
dependent fashion by activating the expression of DRAM (DNA-damage regulated 
autophagy modulator) (Crighton et al., 2006) and sestrin (Budanov and Karin, 2008). 
DRAM belongs to a family of five proteins thought to act as modulators of autophagy, 
which also includes DRAM2, DRAM4, DRAM5a and DRAM5b. DRAM2 is by far the 
most closely related human protein to DRAM and shares 45% identity and 67% 
conservation at the amino acid level (O'Prey et al., 2009). Both DRAM and DRAM2 are 
transmembrane proteins, localized in lysosomes, and the expression of both is generally 
down-regulated in tumours. However DRAM2 is different from DRAM in that it not 
induced by p53 (Park et al., 2009). Examination of medical histories in the reported 
subjects with DRAM2-associated RD provided no evidence of increased susceptibility to 
cancer. To conclude, the autophagy is the end target of many different complex and 
interconnected pathways. It seems likely that DRAM2, like its paralog DRAM, is likely 
to fit into these pathways but which one, is unknown yet. 
 
5.3.5 Autophagy and the RPE 
Autophagy proteins are particularly highly expressed in the retinal layers that have 
a high metabolic demand, such as the ganglion cell layer (GCL), inner nuclear layer 
(INL), ONL, PIS and RPE (Mitter et al., 2012; Mitter et al., 2014). DRAM2 
immunolocalisation to the inner segment of the photoreceptor layer and the apical surface 
of the RPE is consistent with a role for DRAM2 in photoreceptor autophagy. A high level 
of autophagy is also expected to take place in the RPE. These cells have a key role in 
processing shed photoreceptor outer segment discs and consequently, in removing toxic 
metabolites and recycling phototransduction components. The process of disc shedding 
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and phagocytosis by the RPE causes up to 10% photoreceptor volume loss each day. It is 
achieved by an atypical autophagy pathway involving the proteins Atg5 and LC3, which 
trigger phagosome fusion with the lysosome, resulting in POS degradation. This process 
is entrained to the circadian rhythm (Young and Bok, 1969; Nguyen-Legros and Hicks, 
2000). Indeed there is increasing interest in the role of autophagy in preserving 
photoreceptor function in connection with the circadian cycle (Yao et al., 2014), the aging 
process (Rodriguez-Muela et al., 2013) and retinal disease pathology (Metrailler et al., 
2012). Autophagy is a housekeeping process that plays an important role in survival, 
development and homeostasis of the ocular tissues and autophagy dysregulation is 
involved in a group of eye diseases such as AMD (Wang et al., 2009a), cataract (Morishita 
and Mizushima, 2016), glaucoma (Wang et al., 2015), diabetic retinopathy (DR) (Lu and 
Xu, 2012) and photoreceptor degeneration (Mellen et al., 2008; Mustafi et al., 2011; Chen 
et al., 2013). It is therefore likely that the absence of DRAM2 in the retina reduces the 
efficiency of autophagy in recycling cell components, which in turn reduces 
photoreceptor renewal, leading to the thin photoreceptor layer observed on OCT, which 
is the first presenting feature in pre-symptomatic patients with DRAM2-induced 
retinopathy.  
 
5.3.6 Autophagy and ciliogenesis  
Influencing ciliogenesis is another possible consequence of DRAM2 retinopathy. 
Photoreceptor outer segments are in a constant state of renewal by ciliogenesis in response 
to light-induced damage. Recent studies have suggested that there is interplay between 
ciliogenesis and autophagy. In one study, it was shown that disruption of ciliogenesis 
partially inhibited autophagy, while blocking autophagy enhanced primary cilia growth 
and cilia-associated signalling during normal nutritional conditions. The authors therefore 
proposed that basal autophagy regulated ciliary growth through the degradation of 
proteins required for intraflagellar transport (Pampliega et al., 2013). In another study, 
the protein OFD1 (oral facial digital syndrome 1), which accumulated at centriolar 
satellites located close to the base of the cilium, was rapidly degraded by serum 
starvation-induced autophagy. This led to ciliary growth suggesting that OFD1 normally 
inhibited ciliogenesis (Tang et al., 2013). 
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5.3.7 What are the DRAM2 interacting binding partners in the retina? 
Future work could involve pull down assays and mass spectrometry of the attached 
proteins to find DRAM2 interacting partners and determine the autophagy pathway 
defects that lead to RD. One possible reason for the failure of the endogenous DRAM2 
pulldown experiments presented in this thesis may be that the rabbit anti-DRAM2 may 
have limited affinity for the DRAM2 protein in its native state, and that it can only detect 
the protein after denaturation with SDS in western blotting. Another possibility could be 
that the protein concentration after the pull down assay was too low to detect by silver 
staining or western blotting. Alternatively, given that the DRAM2 is a transmembrane 
protein that it may pose significant challenges in terms of solubilization without 
disrupting the protein-protein interactions. 
 
In the evolution of this work, the next step could be to transfect human embryonic 
kidney (HEK293) or RPE cell lines with the pDRAM2-C-TAP expression construct. 
Then extract a cell lysate from these transfected cells and use the expressed epitope tagged 
protein as a pull down with an anti-C-TAP antibody. The resultant protein mix could then 
be separated on a polyacrylamide gel for silver staining andon a duplicate gel for western 
blot analysis. If DRAM2 protein can be detected, the mix would then be prepared for 
mass spectrometry analysis to try and identify the protein interacting partners of DRAM2. 
 
Another way that to identify DRAM2 interacting partners could be to use a yeast-
two-hybrid (Y2H) approach (Brückner et al., 2009). With this approach, two fusion 
proteins (hybrids) would be constructed, one between the protein of interest and 
containing the DNA-binding domain (DB) of a transcription factor, while the other would 
contain the activation domain (AD) of the transcription factor combined with a library of 
test proteins. Both hybrids would be co-transfected into yeast cells. If the test protein and 
library protein interact, bringing the DB and AD domains into proximity, activation of 
the transcription of the reporter gene (such as HIS3 and LacZ) is initiated, enabling the 
yeast colony to grow. A great advantage of this system is that it is scalable and can be 
used to identify many interacting proteins in a relatively short time. However Y2H has 
two major disadvantages. The first is the potential for misfolding of the proteins of interest 
inside the yeast cells and secondly, the yeast as a heterologous system and some 
interactions depend upon post-translational modifications that may not occur in yeast. 
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Such modifications are frequent and include the formation of disulfide bridges, 
glycosylation and most commonly phosphorylation (Scott and Pawson, 2009).  
 
5.3.8 Can the new knowledge about DRAM2 be used in therapy to 
modulate retinal disease? 
A Dram2 knockout mouse could help determine the mechanism by which 
dysregulated autophagy, due to the absence of Dram2, leads to an RD phenotype. With 
the current methods that are available for monitoring autophagy such as measuring 
autophagy flux using sequestosome-1 (SQSTM1) or LC3-II (Klionsky et al., 2008), this 
would allow confirmation of an autophagy defect in Dram2 knockout mice. This could 
also be used to monitor the effects of potential therapeutic agents on the mouse model of 
DRAM2 retinopathy. Many drugs and compounds that modulate autophagy are currently 
receiving considerable attention as potential therapies for diverse diseases (Rubinsztein 
et al., 2012; Cheng et al., 2013). These include, autophagy inhibitors, such as chloroquine 
(Fedorko, 1967) and hydroxychloroquine (Amaravadi et al., 2011), PIK3C3 inhibitors 
(Miller et al., 2010) and also autophagy inducers such as the mTORC1 inhibitor 
rapamycin (Ravikumar et al., 2004), mTOR kinase inhibitors (Torin) (Thoreen et al., 
2009), carbamazepine (Hidvegi et al., 2010) and tat-beclin 1 (Shoji-Kawata et al., 2013). 
It is interesting that hydroxychloroquine, widely prescribed in the treatment of 
autoimmune diseases such as systemic lupus erythematosus, can be associated with 
retinal toxicity (Cheng et al., 2013; Marmor and Melles, 2015). In particular, central 
retinal thinning and loss of the ellipsoid zone in the perifoveal area on OCT testing are 
features of DRAM2-retinopathy, and are also frequently observed in hydroxychloroquine 
toxicity (Cukras et al., 2015). Intravitreal administration of rapamycin has been attempted 
in patients with AMD and posterior uveitis (Ibrahim et al., 2015; Petrou et al., 2015). The 
role of these drugs in DRAM2-retinopathy can be tested on an animal model if one was 
available. Understanding how DRAM2, autophagy and RD link together and the 
development of therapeutic compounds may be an avenue for future research. 
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Chapter 6. General discussion and concluding remarks 
6.1 Summary of key findings 
The work outlined in this thesis has described the use of NGS technologies to 
identify new mutations and genes involved in inherited retinal dystrophies.  
 
Chapter three describes the Retinome project, in which a customised targeted 
exome capture reagent was used to produce an enriched NGS template targeting all the 
exons and flanking splice site junctions of the 162 genes known to cause RD at the time 
of reagent design (2010).  After capturing the RD gene exons from patients’ genomic 
DNA, the enriched sample was sequenced by massively parallel NGS to produce a list of 
exonic variants that differed from the reference sequence in each patient sample. Each 
variant list was then filtered to exclude common variants or those unlikely to be 
biologically significant, leading to the identification of the pathogenic mutation in many 
cases. Twenty RD families were studied in this project. Each family included multiple 
members affected with the same type of RD, while the twenty families reflected a range 
of different RD diagnoses. The detection rate for identifying the pathogenic mutation was 
60%, meaning that in 12 out of 20 cases the likely causative mutation was identified 
(Watson et al., 2014; Shevach et al., 2015). The mutations identified consisted of 
previously reported mutations of known clinical significance in ABCA4, RDH12, 
PROM1, GUCY2D, RPGRIP1, BBS2 and SPATA7, and new mutations in CRB1, USH2A, 
RP2 and ABCA4. This relatively high detection rate may be because the analysis involved 
working on families with multiple affected members rather than single cases with no 
family history, which permitted follow up work to check for segregation of possible 
pathogenic variants in other family members. 
 
Chapter four of this thesis focused on analysing five families in which the causative 
pathogenic mutations could not be identified using the targeted NGS strategy employed 
in Chapter three. WES technologies were therefore applied to one or more patient’s 
genomic DNA from each family in order to try and identify the most likely causative 
variant(s) associated with the disease phenotype in each case. This approach was used 
independently or combined with homozygosity mapping. The pathogenic mutations or 
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best candidates causing inherited RD were identified in all five families and included 
known mutations in TTLL5 (Bedoni et al., 2016) and MFSD8, a novel mutation in 
C8orf37 (Ravesh et al., 2015), and putative pathogenic mutations in possibly two new 
RD-causing genes, LARGE and FDFT1. These data were supported with IF staining of 
mouse retina sagittal-sections that revealed localization of MFSD8 to the OPL and of 
LARGE to the PIS, ONL and OPL in the retina. Moreover, the calculated two-point LOD 
score of 5.16 for the RP family with the LARGE mutation was highly significant. 
 
Chapter five describes genetic analysis of a large family with an atypical diagnosis 
of late-onset RD with early macular involvement. This family was not included in the 
Retinome analysis but was analysed in parallel. WES was combined with homozygosity 
mapping to identify a biallelic frameshift mutation in DRAM2 as a novel RD gene (El-
Asrag et al., 2015; Sergouniotis et al., 2015). This data was supported by another RD case 
with compound heterozygous changes identified by screening for mutations in 
DRAM2 among 322 unrelated probands with RD. These results are further supported by 
the additional five likely disease-causing variants identified in four RD cases by 
collaborators in the UK Inherited Retinal Disease Consortium and the European Retinal 
Disease Consortium (ERDC). The clinical features and the course of the retinal 
degeneration were highly similar among affected individuals. DRAM2 is a ubiquitously 
expressed protein and IF staining showed its expression to be particularly strong in the 
PIS and at the apical surface of the RPE. Previous studies suggest that DRAM2 acts as a 
positive regulator of autophagy and this study suggests that DRAM2 is essential for the 
normal function of the retina and photoreceptor survival. Further studies are needed to 
provide insights into its precise role in the retina. This may include identifying DRAM2 
binding partners using pull downs and mass spectrometry. 
 
6.2 Future prospects in inherited eye disease diagnostic 
research 
Patients with inherited RD believe that genetic testing is important (Stone, 2007) 
although various factors may motivate personal decisions to seek genetic testing (Willis 
et al., 2013). Individuals may see many different eye specialists before a definitive 
diagnosis can be made but genetic testing can provide an accurate diagnosis quickly. It 
can confirm the way in which the condition is inherited, giving a clearer picture of the 
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risk to patients and helping with family planning decisions. Genetic testing can help with 
disease prevention strategies and provide patients with an accurate guide to likely future 
function. With all this information, an individual can make informed decisions regarding 
education, employment and lifestyle. 
 
During the last four years, since this project was started, efforts have been made to 
apply NGS technology for mutation detection in RD in a diagnostic setting (http://www. 
cmft.nhs.uk/saint-marys/our-services/manchester-centre-for-genomic-medicine) (Audo 
et al., 2012a; Shanks et al., 2013; Ellingford et al., 2016; Weisschuh et al., 2016). Some 
groups, including the Leeds Vision Research Group, have tested custom reagents for 
screening RD genes in order to sequence a predetermined list of known disease genes. 
These targeted capture NGS approaches require careful design, as they are not readily 
available pre-made panels, though this approach is a significant advance in mutation 
detection technologies compared to the previous laborious gene by gene Sanger 
sequencing approach. By pooling samples before targeted capture, the approach using the 
Retinome reagent, saves the researcher a further 75% on costs for the capturing step. 
However, the approach of using pooled samples poses challenges in data analysis due to 
the small sample size and sequencing artefacts that are detected due to low coverage, low 
sequence quality or variant calling. The stringency of variant calling algorithm was 
relaxed in the Retinome data analysis, to reduce the number of false negative results and 
the filtering pipeline used is very conservative, even though this causes some false 
positive variants to be short-listed. Furthermore, only examining known disease genes in 
the capture reagent limits the flexibility of the reagent to test for more disease genes as 
they are discovered. Another limitation may be that the capture reagent is relatively 
inefficient at detecting copy number variants.  
 
As the costs of WES have decreased, customised targeted sequencing approaches 
have been replaced with a more broad-based NGS strategy that offers more flexibility to 
examine newly identified disease genes, to find variants in genes not previously 
associated with disease and to have greater capacity to identify copy number and 
structural variations (Plagnol et al., 2012; Zhao et al., 2013a; Zhang et al., 2015b). 
Moreover, competition between commercial companies investing in various types of 
NGS platforms have encouraged regular product improvements and lowering of costs, 
making this a more viable diagnostic strategy. Looking forward as costs become even 
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cheaper, WGS may be the future of DNA sequencing. WGS covers the whole genome at 
more consistent coverage than WES, can provide more accurate detection of structural 
variants (Belkadi et al., 2015) and does not rely on the accuracy of the genome annotation. 
Also with the new WGS library preparation kits such as TruSeq® DNA Library Prep kit 
(Illumina), areas that are traditionally difficult to sequence as high GC-rich regions, 
promoters, and repetitive elements are superiorly covered. Moreover the ability to prepare 
a PCR-free library eliminates the biases, gaps and errors associated with previous 
methods (Meynert et al., 2014).Illumina's HiSeq X Ten system are the first sequencing 
platforms to break the $1000 barrier for 30× coverage of WGS with ≥ 75% of bases above 
quality 30 and less than three days per run (Watson, 2014; Warr et al., 2015). However, 
cost is not the only consideration and at the moment this technology still has some 
limitations including data challenges in bioinformatic analysis and secure data storage, 
interpretation of results and ethical dilemmas (Chrystoja and Diamandis, 2014). 
 
Some of these dilemmas also exist in the application of current NGS approaches to 
the diagnostic setting. For example, it is sometimes difficult to interpret the variant lists 
given that in some cases it may not be possible to identify an obvious pathogenic mutation 
based on existing knowledge of the disease phenotype. In such circumstances, even 
though a clear pathogenic cause cannot be established, variants of unknown significance 
are likely to be present and can still be reported back to the clinician who is looking after 
the patients, though their interpretation ought to be treated with caution. Another issue is 
that of incidental findings and how these are reported back to the patient. Secondary 
findings could be a mutation in a gene related to cancer susceptibility or heart disease 
such as BRCA1, BRCA2 or ACTA2 (Regalado et al., 2015; Metcalfe et al., 2016). Though 
these were not the target of the original test, patients ought to be offered the choice as to 
whether they want to know the result of secondary findings as they could have a major 
impact on them. There are also legal issues around the confidential nature of genetic 
findings and whether disclosure may lead to discrimination at the social level in terms of 
job-hunting or applications for health insurance. Best practice for these difficult dilemmas 
is being debated by the patients, scientists and health care professionals. 
 
In terms of where a person is treated, there are considerable differences between 
patients with an inherited disease depending on whether they are living in the UK or 
abroad. Whilst families of Pakistani origin living in the UK have access to appropriate 
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infrastructure for counselling and support such as ophthalmologists, clinical geneticists 
and social services through the National Health Service, there are no specialized genetic 
counselling services in the healthcare system in Pakistan, and often it is left to the 
practicing physician to perform the genetic counselling duties (Hussain and Bittles, 1998; 
Ashfaq et al., 2013). Approximately 60% of marriages in Pakistan are consanguineous 
and 80% of these are between first cousins (Hussain and Bittles, 1998; Qidwai et al., 
2003), making this one of the highest consanguinity rates in the world. This is likely to 
contribute to the high burden of recessively inherited genetic disease in this population 
(Bittles and Black, 2010). While this results in large families that permit gene/mutation 
identification studies, as shown in this thesis, it also highlights how important it is that 
the health care system is improved in poorer countries. 
 
In the research presented in this thesis, two generations of DNA sequencing were 
used. Sanger sequencing represents the first generation, with targeted NGS and WES 
representing the second. Inevitably, this raises the question of what comes next in DNA 
sequencing. Whilst it is relatively simple to identify the divide between first and second 
generation DNA sequencing technologies, there is no general agreement concerning 
whether we have already entered the third generation of developments. However, claims 
have been made that single molecule sequencing (SMS) and the possibility of real-time 
sequencing may be the defining characteristics of the third generation (Macaulay and 
Voet, 2014; Grün and van Oudenaarden, 2015; Lee et al., 2016).Currently, the single 
molecule real time (SMRT) platform (Pacific Biosciences) is the most commonly used 
third-generation technology (van Dijk et al., 2014; Heather and Chain, 2016). This system 
employs so-called zero-mode waveguides (ZMWs) which are microfabricated 
nanostructures used to create an illuminated observation volume small enough to allow 
the monitoring of a single nucleotide being incorporated by DNA polymerase. Individual 
DNA polymerase molecules are deposited inside the illuminated region within the 
ZMWs, then the relevant DNA library and fluorescently labelled dNTPs are washed over, 
a different fluorescent dye being used for each of the four DNA bases. The DNA sequence 
is determined via a charged couple device (CCD) sensor on the basis of fluorescence 
nucleotide detection. Following incorporation of the nucleotide by the DNA polymerase, 
this dye is cleaved away, ending the detectable fluorescence signal for that position. The 
SMRT process not only facilitates very rapid single-molecule sequencing but is also 
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capable of producing extremely long reads of over 10 kb in length and scoring of the 
microsatellite length (Liljegren et al., 2016).  
 
It is anticipated that nanopore sequencing (Oxford Nanopore Technologies) will 
also prove to be another key technology in third-generation DNA sequencing, eventually 
providing high accuracy long read, non-amplified sequence data at a faster speed and 
lower cost than was previously thought possible (Magierowski et al., 2016). In simple 
terms, this method involves passing an ionic current through nanopores embedded in a 
synthetic membrane. Double-stranded DNA is denatured enzymatically then single-
stranded DNA is passed through the nanopore while the different bases prevent ionic flow 
in a distinctive manner. The DNA sequence can then be identified on the basis of the data 
provided by the change in current (Loose et al., 2016). The fact that this new generation 
of nanopore sequencers such as MinION is available as a small USB device that can be 
used in the field, outside the laboratory setting, will radically change not only the type of 
data that can be produced, but where and when it can be produced, and by whom (Check 
Hayden, 2015).Third-generation sequencing platforms will offer many theoretical 
benefits relating to reduced cost, increased speed and removal of PCR-bias; however, this 
technology is still maturing and it is likely to be a few years yet before such platforms 
seriously rival the second-generation instruments and enter mainstream diagnostic use. 
 
As we move into the third generation of DNA sequencing, our understanding of 
genetics and the genome has been greatly enhanced by this rapid revolution in sequencing 
technology in recent years. As a consequence, novel RD genes continue to be discovered, 
improving diagnostic service provision and giving further insights into retinal function. 
The question now is can these genetic findings in RD research help contribute to 
developing therapies for these patients? 
 
6.3 Future directions in eye disease therapeutics 
Diagnosing RD patients using molecular analysis not only stratifies the patients into 
disease categories but may also influence their future prospects as new treatments and 
therapies are developed. Gene replacement therapy is one of a number of the developing 
therapies that depend on the delivery of a normal copy of the mutated gene to restore 
function. The last decade has witnessed significant success in the application of gene 
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replacement therapies to RD using animal models (Acland et al., 2001; Black et al., 2014; 
Pellissier et al., 2015). For these and other therapies to undergo clinical trials, it is 
essential to identify groups of genotyped patients with mutations in each gene and at 
various stages of the disease process. This is one of the major drivers for the development 
of diagnostic testing. 
 
The first successful clinical example was for RPE65, the visual cycle protein in 
which gene mutations cause congenital blindness in 6-16% of all LCA patients. Animal 
model studies in the Rpe65 knockout (KO) mouse and RPE65-deficient Briard dogs 
(Acland et al., 2001; Bemelmans et al., 2006; Pang et al., 2006; Le Meur et al., 2007; 
Bemelmans et al., 2008) were successful and used to develop the treatment in human 
patients (Cideciyan et al., 2013; Ku and Pennesi, 2015; Bennett et al., 2016; Grob et al., 
2016). These human trials have successfully delivered the target gene(s) to the retina via 
adeno-associated virus (AAV) vectors. 
 
Other examples of RD gene therapy trials that have shown promising results using 
a similar approach include the following. AAV-mediated BBS4 delivery to the BBS 
mouse model (Bbs4-KO) was shown to prevent photoreceptor death by rescuing 
rhodopsin mislocalization, whilst preserving the normal-appearing architecture of rod 
outer segments (Simons et al., 2011). The accumulation of lipofuscin pigment A2E in the 
retina of Abca4-KO mice as a model of STGD was sharply reduced by delivering the 
intact human ABCA4 gene by AAV (Kong et al., 2008). Treatment for ACHM was also 
successful in CNGA3-KO and CNGB3-KO mice (Carvalho et al., 2011; Pang et al., 2012). 
Gene therapy has also proved successful in rescuing defects in Peripherin2-KO 
(Schlichtenbrede et al., 2003), Aipl1-KO (Sun et al., 2010), Mertk-KO (LaVail et al., 
2016) and Crb1-KO (Pellissier et al., 2015) mice. These and other mouse models have 
been used for testing the efficacy of gene therapy for RD-specific genes before clinical 
gene therapy trials that have already begun in patients with retinal diseases (Bainbridge 
et al., 2015; Edwards et al., 2016) (www.clinical trials.gov, NCT00481546, 
NCT01367444, NCT01505062 and NCT01482195). 
 
Genome editing technologies represent a promising new approach for the treatment 
of RD in human patients, offering the hope that one day it might be possible to correct 
the defect in a patient’s cells, either in culture for re-implantation or in-vivo. The clustered 
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regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is the most 
advanced of these technologies, whereby targeting a precise genomic position is possible 
with the use of synthetic guide RNAs (Mali et al., 2013). The system edits the genome by 
inducing double-stranded breaks (DSBs) using a nuclease which can then be repaired by 
one of two different pathways that operate in nearly all cell types and organisms: non 
homologous end joining (NHEJ) and homology directed repair (HDR). NHEJ can lead to 
the efficient introduction of insertion/deletion mutations (indels) of various lengths from 
a single-stranded or double-stranded DNA donor template. This therefore provides a 
means of generating knockouts by disrupting the translational reading frame of a coding 
sequence. While the HDR pathway allows precise editing resulting in the newly modified 
target still being in its same position so still under the influence of its endogenous control 
elements such as promoters, enhances and repressors. This is particularly important as it 
prevents incorrect or inappropriate levels of expression of the newly modified gene, while 
allowing introduction of exact changes. Furthermore, a modified version of the CRISPR-
Cas9 system has been developed to induce only a single-strand break, or nick (Shen et 
al., 2014a), as opposed to DSBs where significant misalignment and mispairing has been 
reported. The single-strand break approach allows for the endogenous base excision 
repair pathway to facilitate repair and results in more specific and efficient modification, 
thereby reducing the off target effects (Ran et al., 2013; Hsu et al., 2014). The HDR 
pathway therefore opens up the possibility of engineering exact disease models in animal 
models, or possibly of exact correction to wild-type in cells from patients with specific 
mutations. Progress in developing CRISPR/Cas9 into a set of tools for cell and molecular 
biology research has been remarkable and the application of the CRISPR/Cas9 system in 
conjunction with stem cell technologies is likely to pave the way for new treatments of 
genetic diseases. 
 
Another therapeutic approach depends on the use of antisense oligonucleotides 
(AONs) that can be delivered either as naked oligonucleotides or expressed by viral 
vectors (Evers et al., 2015). This development is not applicable to all mutations, but 
AONs are ideally suited for targeting splicing mutations that cause activation of cryptic 
splice sites. This approach can potentially block these abnormal splicing events, and 
hence restore normal splicing. Among RD genes, the best known example of such a 
mutation is the intronic c.2991+1655A>G variant in CEP290 which accounts for up to 
20% of all LCA cases (Section 1.8.3) (den Hollander et al., 2006; Coppieters et al., 
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2010a). AON-based therapy for CEP290-associated LCA has shown promising results, 
as it redirected normal splicing of CEP290 in patient derived lymphoblast cells, creating 
an increase in correctly spliced CEP290 mRNA and a decrease in levels of aberrantly 
spliced CEP290 in a dose-dependent manner (Collin et al., 2012).Other examples where 
AON-based therapy can be applied are deep intronic mutations in OFD1 
(IVS9+705A>G) that causes XLRP (RP23) (Webb et al., 2012) or in ABCA4 
(c.4539+2001G>A) that causes STGD (Bauwens et al., 2015). 
 
In terms of viral vectors for therapeutic delivery, AAV appears to be safe and can 
be used to deliver genes to both photoreceptors and RPE. However, AAV has a limitation 
in that it cannot accommodate genes over 5 kb in length. Therefore, other methods of 
delivery are being explored. For example, non-viral nanoparticles (NPs) have been used 
to deliver plasmid vectors containing either RS1 or RPE65 to the retina (Delgado et al., 
2012; Koirala et al., 2013). Although AAV-based therapies typically have a better 
transfection efficiency than NP-based systems (Han et al., 2012a), NP technology has a 
number of advantages. NPs can accommodate large vectors with sizes up to 20 kbp, are 
easy to synthesize, have low production cost compared to AAV systems and possess a 
safety profile with low immunogenicity and off-target risk of insertion mutagenesis into 
the genome (Rajala et al., 2014). NPs that have been formulated for gene therapy can be 
divided into three categories (Adijanto and Naash, 2015): metal NPs (gold NPS), lipid 
NPs (liposomes and solid lipid NPs) and polymer NPs which are composed of different 
monomers either proteins such as gelatin and albumin, carbohydrates such as dextran and 
chitosan, or small chemical compounds such as poly-lactic acid (PLA) and poly-lactic-
co-glycolic acid (PLGA). 
 
Of all the NPs that have been tested, a modified polymer-based NP (CK30-PEG) (a 
30-mer cationic polylysine conjugated with 10 kDa polyethylene glycol) has proved to 
be the most successful for gene therapeutic delivery (Boylan et al., 2012; Kim et al., 2014; 
Adijanto and Naash, 2015). Generally, the effectiveness of a NP-based gene delivery 
system is dependent on key factors such as cellular uptake, escaping from endosomal 
vesicles into the cytosol, and delivery of the plasmid DNA into the nucleus. In term of 
cellular uptake, rod-shaped CK30-PEG NPs can effectively transfect both photoreceptor 
cells and the RPE, while in terms of escaping from endosomal vesicles and transfer to the 
nucleus, CK30-PEG NPs are directly transported into the nucleus by a unique nucleolin-
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dependent endocytic process (Chen et al., 2008). Importantly, CK30-PEG NPs were 
found to be non-toxic to the retina even after repeated delivery (Ding et al., 2009; Han et 
al., 2012c). Unsurprisingly, CK30-PEG compacted DNA NPs have been extensively 
tested as a gene therapy for RD, and this was successfully used for the delivery of a gene-
therapy plasmid carrying the human ABCA4 gene into the retina of abca4−/− mice that 
was stably expressed and rescued many features of the Stargardt-associated RD (Han et 
al., 2012b). It was also found to promote phenotypic rescue in the rpe65−/−mouse model 
of LCA (Koirala et al., 2013) and in rhodopsin knockout (RKO) mouse model of RP (Han 
et al., 2015). Recent advances in NPs technology suggested that the time may have come 
to rethink of using only AVV as the standard in gene delivery. 
 
Advances in stem cell technology are the catalysing factor for the cell-based 
therapies that are currently being explored in the context of retinal diseases. Stem cells 
can be induced to differentiate into specific retinal cell types (Idelson et al., 2009; Li et 
al., 2013). Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and 
retinal progenitor cells (RPCs) can be isolated and have been injected into the eye to 
successfully target the RPE, in mouse models of RD, and show regeneration (Tucker et 
al., 2011; Barnea-Cramer et al., 2016; Santos-Ferreira et al., 2016). The iPSC- derived 
from an affected adult’s fibroblasts can differentiate into retinal cells when cultured under 
specific conditions. When reintroduced, such cells will have reduced risk of immune 
system rejection. In a mouse model this allows delivery of retinal cells derived from its 
own stem cells, and in which the defect has been corrected by gene therapy or genome 
editing, back in the mouse, facilitating the repair and restoration of function. Work is also 
now focusing on using IPCS to replace disease-affected retinal cells in humans (Mellough 
et al., 2014; Yvon et al., 2015). ESCs have also shown success in both transplantation and 
restoration of retinal function in mouse models (Mead et al., 2015). These experiments 
have led the way to the launch the first-in-human clinical trial in which RPE-differentiated 
cells derived from human EECs, have been transplanted into the sub-retinal space of 
patients with AMD or STGD. Initial results appear promising with visual acuity 
improvement and confirming that human ESC-derived cells could serve as a potentially 
safe new source for regenerative medicine (Schwartz et al., 2015; Song et al., 2015). 
 
It is reasonable to ask, why was the RPE rather than the photoreceptor cell layer 
chosen as the initial target for the cell based therapy trials? This is due in part to the 
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involvement of the former in diseases such as AMD and RP (Ramsden et al., 2013). 
Importantly, it is much easier to derive from iPSCs cells that display the morphological 
characteristics of RPE cells, and cell replacement in this case would not require the 
formation of neuronal connectivity. Also the fact that RPE can be grown, whereas 
photoreceptors are end differentiated so cannot be amplified in culture. Moving forward 
in cell-based therapy for photoreceptors is dependent on future studies explaining the 
development, maintenance and function of photoreceptor synapses. Additional 
investigations are also required to elucidate complex interactions among retinal neurons 
and supportive retinal Müller glia (Vecino et al., 2016). 
 
Retinal implants (prosthetics), sometimes referred to as ‘bionic eyes’ is also an area 
that is currently being developed. This approach can work in patients who have lost all 
photoreceptors, a group for whom other therapies are likely to prove ineffective as they 
can generally only preserve any remaining limited vision the patient may have (Rizzo et 
al., 2014).The retinal implant uses microchip electrodes surgically implanted into the 
retina and connected to micro-photodiode arrays, utilising the remaining intact neural 
network in order to transmit signals to the visual centres of the brain (Chuang et al., 2014). 
This technology has been successfully applied to RP patients with varying stages of 
disease progression and has resulted in some restoration of visual perception and 
improvements in light detection (da Cruz et al., 2016; Matet et al., 2016). 
 
6.4 Filling the gap between genetics and therapy 
Identification of genes and mutations associated with RD, both before and after the 
development of NGS technology, have considerably improved our knowledge of protein 
and cellular functions in the retina over the last decade. At the same time, treatment for 
genetic diseases is constantly moving forward at a steady pace. However, there is still a 
gap between these parallel trends and this begs the question: how this gap between 
genetics and therapy can be filled? Some researchers believe that the gap is between the 
mutation and the disease. What are the molecular mechanisms and how exactly do 
changes in ABCA4 or rhodopsin or DRAM2 kill cells? Whilst others have the view that 
time will fill this gap. Soon all the genes causing Mendelian disease will be identified, 
and new therapeutic methods will come through increased understanding of the genetics. 
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In reality it will be a combination of both approaches, though a well-structured 
personalized medicine programme would contribute to bridging this gap. 
 
Personalized medicine is a phrase describing the use of specific information about 
a person, including their genetic make-up, to determine which treatment will work best 
for that person. The introduction of personal genomics into clinical practice has been slow 
and many factors have created this gap between genetic knowledge and clinical 
application (Anaya et al., 2016). Funding to support genetic testing is a key factor since 
this is usually expensive and implementation of new testing programs are often limited. 
Despite the decreasing cost of NGS, it is still not possible to apply this to every patient in 
the NHS since the cost of interpreting the sequencing data, then the counselling, and all 
further tests on the patient’s relatives need to be considered. In practise, this can prove 
very expensive, at least in the first instance as the infrastructure is set up. Though once 
established and widely available, it might lead to indirect savings, and possibly save lives. 
 
The heterogeneity and complexity of genomic risk information, points to the need 
for strategies to select and deliver the information most appropriate for particular clinical 
needs (Burke and Korngiebel, 2015). To fill this gap, efforts are needed to improve the 
body of evidence addressing clinical outcomes for genomics, to apply these scientific 
advances in personal genomics, and to develop realistic goals for genomic risk 
assessment. Smart cards such as electronic health records (EHR) and Genome (G) cards 
represent a new approach for personalized medicine, helping every individual to have a 
unique health identity (Jauhari and Rizvi, 2015). The DNA analysis for each individual 
is uploaded, whilst patients themselves can add lifestyle information, such as eating 
habits, exercise and metabolic activities, quantity and quality of sleep, and meditation. 
Environmental data such as pollution and air condition can also be uploaded onto the 
card. When needed, this data will be accessible to the healthcare researcher to analysis 
and compare with the results of other similar cases, as well as being available to 
healthcare professional in order to provide valuable prescriptions to the patient and 
decipher the key to good health. 
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6.5 Concluding remarks 
NGS technology, especially WGS, needs further development in terms of 
bioinformatic analysis and results interpretation, and careful consideration also needs to 
be given to the ethical dilemmas it may pose. The CRISPR-Cas9 system needs to be 
developed to ensure strategies that avoid off-target effects, and combined with iPSC 
technology that might be used to efficiently engineer the genome to correct the pathogenic 
mutations. Moving forward in the various RD therapeutic approaches will mainly depend 
on future studies of the photoreceptor synapses. However it is possible that in the not too 
distant future, RD patients will all have treatment initiated with the collection of blood 
and skin samples to identify the pathogenic mutation and to generate a fibroblast cell line 
from which iPSCs can be derived. Once the mutation is identified by DNA sequencing, 
the most effective therapy and treatment options can be determined and applied by 
adopting a personalized medicine strategy. The chosen therapeutic approach may first be 
tested in the iPSC-derived relevant cell-line if necessary to examine its efficiency, then 
genome editing will be used to correct the DNA mutation, followed by transplanting these 
into the affected retina. This strategy is one of the most promising avenues of future 
research to be explored. The unanswered question is how soon will it be possible to 
achieve these goals? 
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Appendix 
Appendix 1- List of UNIX commands used in targeted NGS and WES analysis  
1.1 Alignment (Novoalign/Bowtie2) 
$ novoalign -c 12 -d <path> b37/human_g1k_v37.nix -f sample_R1_001.fastq.gz sample_R2_001.fastq .gz 
-o SAM $'@RG\tID:sample_novoID\tSM:sample\tPL: ILLUMINA\tLB: sample_ exome' -k –K 
mismatches_sample_novoID.txt 2> novostats_sample_novoID.txt > sample_novoID.sam 
$ <path> /bowtie2- version no /bowtie2 -x <path> /ucsc.hg19.idx -p 6 -q -1 <path> Sample_R1.fastq -2 
<path> Sample_R2.fastq -S <path> Sample.sam --sam-rg ID: IN--sam-rg SM:IN --sam-rg PL:Illumina --
sam-rg PU:HiSeq  
 
1.2 Remove reads which don’t map uniquely 
$ sed '/XS:/d' <path> Sample.sam >  <path> Sample_uniqueAlignment.sam  
  
1.3 Sorting and idexing alignment sam file (Samtools or Picard) 
$ <path> /samtools-version no/samtools view -bt <path> /DataFiles/ucsc.hg19.fasta.fai <path> Sample_ 
uniqueAlignment.sam > Sample_uniqueAlignment.bam 
$ <path> /samtools-version no/samtools sort <path> Sample_uniqueAlignment.bam <path> Sample_ 
uniqueAlignment_sort 
$ <path> /samtools-version no/samtools index <path> Sample_uniqueAlignment_sort.bam  
$ java –Xmx8g -jar <path> /picard/picard-tools- version no/SortSam.jar I= Sample_uniqueAlignment .sam 
O= Sample_uniqueAlignment_sort.bam SO=coordinate CREATE_INDEX=TRUE 
 
1.4 Remove duplicates (Picard) 
$ java –Xmx8g -jar <path> /picard/picard-tools- version no/MarkDuplicates.jar I= <path> Sample_unique 
Alignment_sort.bam O= <path>  Sample_uniqueAlignment_sort.rmdups.bam M=Sample. rmdups. metrics 
CREATE_INDEX=TRUE 
Alternative 
$ java -Xmx8g -jar <path> /picard/picard-tools- version no/MarkDuplicates.jar INPUT= <path> Sample_ 
uniqueAlignment_sort.bam REMOVE_DUPLICATES=true VALIDATION_STRINGENCY =LENIENT 
AS=true METRICS_FILE= Sample_uniqueAlignment_sort_metrics_file.dups OUTPUT= <path> Sample 
_uniqueAlignment_sort.rmdups.bam  
 
1.5 Create indel realigner targets (GATK) 
$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T Realigner 
TargetCreator -R <path> /human_g1k_ v37.fasta –known <path> /b37/1000G_phase1. indels.b37.vcf -
known <path> /Mills_and_1000G_gold_standard.indels.b37.sites.vcf -I <path> Sample_uniqueAlignment 
_sort.rmdups.bam -o <path> Sample_uniqueAlignment_sort.rmdups. indelrealign.intervals 
Alternative 
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$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
RealignerTargetCreator -R <path> /ucsc.hg19.fasta -I <path> Sample_uniqueAlignment_sort. rmdups.bam 
-known <path> /1000G_biallelic.indels.hg19.vcf -log <path> Sample_uniqueAlignment _sort.rmdups. 
indelrealign.intervals.log -o <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals 
 
1.6 Perform indel realignment 
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T IndelRealigner –
R <path> / human_g1k_v37.fasta –known <path> /1000G_phase1.indels.b37.vcf –known <path> 
/Mills_and_1000G_ gold_standard.indels.b37.sites.vcf –I <path>  Sample_uniqueAlignment_sort. 
Rmdups.bam -targetIntervals <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals –o 
<path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam 
Alternative 
$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T IndelRealigner -R 
<path> /ucsc.hg19.fasta -I <path> Sample_uniqueAlignment_sort. rmdups.bam -targetIntervals path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals -log <path> Sample_uniqueAlignment _sort 
.rmdups. indelrealign.intervals.log –o <path> Sample_uniqueAlignment_sort.rmdups.indelrealign .bam 
 
1.7. Recalibrate base quality scores (GATK) 
1.7.1 Get the recalibration model 
 $ java  -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T BaseRecalibrator 
–I <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam -R <path> /human_g1k_v37.fasta –o 
<path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.grp –knownSites <path> /dbSnp version 
no.b37.vcf.gz –knownSites <path> /1000G_phase1.indels.b37.vcf –knownSites <path> /Mills_and_1000G 
_gold_standard.indels.b37.sites.vcf -nct [no.threads (8)] 
 
1.7.2 Check the recalibration model  
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T BaseRecalibrator 
–I <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam -R <path> /human_g1k_v37.fasta –
BQSR <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.grp -o <path> Sample_unique 
Alignment_sort.rmdups.indelrealign.postrecal.grp -knownSites <path> /dbSnp version no.b37.vcf.gz –
knownSites <path> /1000G_phase1.indels.b37.vcf –knownSites <path> /Mills_and_1000G_gold_ 
standard.indels .b37.sites.vcf –nct 8 
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T  Analyze 
Covariates–R <path> /human_g1k_v37. fasta -before  <path> Sample_uniqueAlignment_sort. rmdups. 
indelrealign.recal.grp –after <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.postrecal.grp–
plots <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.postrecal.plots.pdf 
 
1.7.3 Apply the recalibration 
$ java –Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T PrintReads –R 
<path> /human_g1k_v37.fasta -o <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.bam –
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I <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam –BQSR <path> Sample_unique 
Alignment_sort.rmdups.indelrealign.recal.grp –nct 8 
 
1.8 Variant Calling (SNVs and indels) (UnifiedGenotyper/HaplotypeCaller) 
$ java -Xmx4g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T HaplotypeCaller 
–R <path> /human_g1k_v37.fasta -D <path> /dbSnp version no.b37.vcf.gz -stand_call_conf 30 -stand_ 
emit_conf 10 –I <path> Sample_uniqueAlignment_ sort.rmdups.indelrealign.recal –o <path>  Sample_ 
uniqueAlignment_sort.rmdups.indelrealign.recal.raw.vcf 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no/GenomeAnalysisTK.jar –T UnifiedGenotyper 
-R <path> /ucsc.hg19.fasta –I <path>  Sample_uniqueAlignment_ sort.rmdups. indelrealign.recal –D 
<path> /dbsnp_version no.hg19.vcf -L <path> /hg19_exome.interval_list -nt 8 -stand_call_conf 50.0 -
stand_emit_conf 10.0 -dcov 200 -l INFO -A AlleleBalance -A FisherStrand –log <path> 
Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.SNP.log –o <path> Sample_unique Alignment_ 
sort.rmdups.indelrealign.recal.variants.SNP.vcf    
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no/GenomeAnalysisTK.jar –T UnifiedGenotyper 
-R <path> /ucsc.hg19.fasta –I <path>  Sample_uniqueAlignment_ sort.rmdups. indelrealign.recal –D 
<path> /dbsnp_version no.hg19.vcf -L <path> /hg19_exome.interval_list -nt 8 -stand_call_conf 50.0 -
stand_emit_conf 10.0 -dcov 200 -l INFO -A AlleleBalance -A FisherStrand –log <path> 
Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.Indel.log –o <path> Sample_unique 
Alignment_ sort.rmdups.indelrealign.recal.variants.Indel.vcf -glm INDEL 
 
1.9 Variant recalibration/ Hard filtering (GATK) 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
VariantRecalibrator -R <path> /ucsc.hg19.fasta -input Sample_uniqueAlignment_sort.rmdups. 
indelrealign. SNP.vcf resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 <path> 
hapmap_3.3.hg19.vcf -resource:omni,VCF,known=false,training=true,truth=false,prior=12.0 <path> 
/1000G_omni2.5.hg19.vcf -resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 <path> 
DataFiles/dbsnp_version no.hg19.vcf -an QD -an HaplotypeScore -an MQRankSum -an ReadPosRankSum 
-an FS -an MQ --maxGaussians 6 -nt 8 -log <path> Sample_uniqueAlignment_sort. 
rmdups.indelrealign.recal.log -recalFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign. 
recal.recal -tranchesFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.tranches -
rscriptFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.plot.R 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
ApplyRecalibration -R <path> /ucsc.hg19.fasta -input Sample_uniqueAlignment_sort.rmdups. 
indelrealign.SNP -recalFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign. recal.recal -
tranchesFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.tranches -ts_filter_level 
99.0 -log Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.log -o Sample_uniqueAlignment_ 
sort.rmdups.indelrealign.recal.vcf    
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T Variant Filtration 
-R <path> /human_g1k_v37.fasta -V <path> Sample_uniqueAlignment_sort.rmdups .indelrealign 
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.recal.variants.SNP.vcf --filterExpression “QD < 2.0 || FS > 60.0 || MQ < 40.0 || HaplotypeScore > 13.0 || 
MappingQualityRankSum < -12.5 || ReadPosRankSum < -8.0” --filterName “snp_hard_filter” -o <path> 
Sample_uniqueAlignment_sort.rmdups .indelrealign .recal.variants.filtered. SNP.vcf  
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T VariantFiltration 
-R <path> /human_g1k_v37.fasta -V <path> Sample_uniqueAlignment_sort.rmdups .indelrealign 
.recal.variants.Indel.vcf --filterExpression “QD < 2.0 || FS > 200.0 || ReadPosRankSum < -20.0” --
filterName “indel_hard_filter” -o <path> Sample_uniqueAlignment_sort.rmdups .indelrealign 
.recal.variants.filtered.Indel.vcf 
 
1.10 Combine variant lists (SNP and Indel) (GATK) 
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar –T Combine 
Variants -R <path> /ucsc.hg19.fasta (<path> /human_g1k_v37.fasta) --variant <path> Sample_unique 
Alignment_ sort.rmdups.indelrealign.recal.variants.SNP.vcf --variant <path> Sample_ unique Alignment_ 
sort.rmdups.indelrealign.recal.variants.Indel.vcf -o <path> Sample_unique Alignment_ 
sort.rmdups.indelrealign.recal.variants. combined.vcf. 
 
1.11 Variant filtering  
1.11.1 dbSNP 
$ perl <path> /vcfhacks/annotateSnps.pl -d <path> /dbSnp version no.b37.vcf.gz <path>/ clinvar_ 
20150330.vcf.gz -b 129 -f 1 -pathogenic –i <path> Sample_unique Alignment_ sort.rmdups.indelrealign 
.recal.variants. combined.vcf -o <path> Sample_unique Alignment_ sort.rmdups.indelrealign.recal. 
variants. Combined_1pc.vcf 
 
1.11.2 EVS 
$ perl <path> /vcfhacks/filterOnEvsMaf.pl -d <path> /evs/ -f 1 --progress –I <path> Sample_unique 
Alignment_ sort.rmdups.indelrealign.recal.variants.combined.vcf_notindbSNP version no or 1pc –o 
<path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined_1pc_evs.vcf 
 
1.11.3 ExAC  
$ perl <path> /vcfhacks/filterVcfOnVcf.pl -f <path> /ExAC.Version no /sites.vep.vcf.gz -w -y 0.01 -i 
<path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined.vcf_1pc_evs –o 
<path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined_1pc_evs_ExAC.vcf 
 
1.11.4 Control samples (3222 exomes of British Pakistani adults) 
$ perl <path> /vcfhacks/filterVcfOnSample.pl -i <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign.recal.variants.combined.vcf_1pc_evs_ExAC -r <path> /bib/BUILD-2014-19-05/8.BB.anno 
.vcf. gz -o <path> Sample_uniqueAlignment_sort.rmdups. indelrealign.recal.variants.combined_1pc_ 
evs_ExAC_CF.vcf 
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1.12 Variant annotation (ANNOVAR) 
$ perl <path> annovar/convert2annovar.pl  <path> Sample_uniqueAlignment_sort.rmdups. indelrealign. 
recal.variants.combined.vcf_1pc_evs_ExAC_CF –outfile <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign. recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf  
$ perl <path> annovar/table_annovar.pl <path> Sample_uniqueAlignment_sort.rmdups. indelrealign. 
recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf <path> /annovar/humandb -buildver hg19 -
protocolrefGene,phastConsElements46way,genomicSuperDups,esp6500si_all,1000gVersion no apr_all 
,snpversion no,ljb2_all -operation g,r,r,f,f,f,f  -outfile <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign. recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf  
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Appendix 2- List of UNIX and R commands used in Fishing CNV and Exome 
depth analysis 
2.1 Fishing CNV 
2.1.1 Depth of Coverage (GATK) 
$ java –Xmx8g –jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar –T DepthOf 
Coverage –R <path> /human_g1k_v37.fasta –I <path> Sample_uniqueAlignment_sort.bam –o <path> 
Sample_uniqueAlignment_sort.coveragedepth.txt –L <path> SSV4/5_regions_b37.bed -ct 4 -ct 9 -ct 14 -
ct 19 -ct 24 -ct 29 
 
2.1.2 Convert coverage file to PRKM 
$ java –Xmx8g -jar <path> /FishingCNV_ version no_pipeline.jar -cc -c <path> Sample_unique 
Alignment_sort_summary –b <path> /FishingCNV_ version no_pipeline /S04380110_Regions_b37.bed -
o <path> Sample_uniqueAlignment_sort _summary.rpkm   
 
2.1.3 Pooling Multiple RPKM files 
$ java –Xmx8g -jar <path> /FishingCNV_ version no_pipeline.jar -p –rpkm <path> ControlSamples. 
indelrealign.recal_interval_summary.rpkm -o ControlSamples.indelrealign.recal.pooled.controlrpkm.ctr 
 
2.1.4 Apply Fishing CNV 
$ Rscript <path> /FishingCNV_ version no_pipeline /FishingCNV.R -c <path> ControlSamples. 
indelrealign.recal.pooled.controlrpkm.ctr -v -s <path> Sample_uniqueAlignment_sort _summary.rpkm -o 
Sample_uniqueAlignment_sort _summaryResult –pca 
 
2.2 Exome depth analysis 
$ R 
> library(ExomeDepth) 
> data(exons.hg19) 
> print(head(exons.hg19)) 
> Mohammed_bam_files <- c (“Sample_indelrealign_recal(File1).bam”, “File2.bam”,”File3.bam”, etc.) 
> Mohammed_counts<-getBamCounts(bed.frame=exons.hg19, bam.files=Mohammed_bams, 
include.chr=FALSE, referenceFasta=" <path> /human_g1k_v37.fasta") 
> ExomeCount.dafr <- as(my.counts[, colnames(my.counts)], 'data.frame') 
> print(head(ExomeCount.dafr)) 
> Moh_counts.dafr<-as(Mohammed_counts[, colnames(Mohammed_counts)], 'data.frame') 
> print(head(Moh_counts.dafr)) 
> Sample.test <- Moh.counts$ Sample_indelrealign_recal(File1).bam 
> Moh.ref.samples <-c(File2.bam',File3.bam', etc. ) 
> Moh.reference.set<-as.matrix(Moh_Count.dafr[,Moh.ref.samples]) 
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> Moh.choice<-select.reference.set 
(test.counts=Sample.test,reference.counts=Moh.reference.set,bin.length=(Moh_Count.dafr$end 
Moh_Count.dafr$start)/1000,n.bins.reduced=10000) 
> print(Sample_choice[[1]]) 
> Moh.matrix <-as.matrix( Moh_Count.dafr[, Moh.choice$reference.choice, drop = FALSE]) 
> Moh.reference.selected<-apply(X=Moh.matrix,MAR=1,FUN=sum) 
> Sample.all.exons <-new('ExomeDepth',test=Sample.test, reference=Moh.reference.selected,formula 
='cbind(test, reference)~1') 
> Sample.all.exons<-CallCNVs(x=sample_all.exons,transition.probability=10^-4, chromosome =Moh_ 
Count.dafr$space,start=Moh_Count.dafr$start,end=Moh_Count.dafr$end,name=moh_Count.dafr$names) 
> head(Sample.all.exons@CNV.calls) 
> data(Conrad.hg19) 
> head(Conrad.hg19.common.CNVs) 
> Sample.all.exons<-AnnotateExtra(x=Sample.all.exons, reference.annotation=Conrad.hg19.common. 
CNVs, min.overlap=0.5, column.name='Conrad.hg19') 
> print(head(Sample.all.exons@CNV.calls)) 
> exons.hg19.GRanges <- GenomicRanges::GRanges(seqnames=exons.hg19$chromosome,IRanges::I 
Ranges(start=exons.hg19$start,end=exons.hg19$end),names=exons.hg19$name) 
> Sample.all.exons <- AnnotateExtra(x=Sample.all.exons, reference.annotation=exons.hg19.GRanges, 
min.overlap =0.0001, column.name='exons.hg19') 
> Sample.all.exons@CNV.calls[3:6,] 
> output.file <- 'Sample_calls_File1CNVs.csv' 
> write.csv(file=output.file,x=Sample.all.exons@CNV.calls,row.names=FALSE) 
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Appendix 3- Genes targeted in the Retinome project 
ABCA4 CERKL GNAT2 NPHP1 PROM1 RPGRIP1L 
ABCC6 CFB GPR98 NPHP3 PRPF3 RS1 
ADAM9 CFH GRK1 NPHP4 PRPF6 SAG 
AHI1 CHM GRM6 NR2E3 PRPF8 SDCCAG8 
AIPL1 CLN3 GUCA1A NRL PRPF31 SEMA4A 
ALMS1 CLRN1 GUCA1B NYX PRPH2 SNRNP200 
ARL6 CNGA1 GUCY2D OAT PXMP3 SPATA7 
ARMS2 CNGA3 HMCN1 OFD1 RAX2 TEAD1 
ATXN7 CNGB1 HTRA1 OPA1 RB1 TIMM8A 
BBS1 CNGB3 IDH3B OPA3 RBP3 TIMP3 
BBS2 CNNM4 IMPDH1 OPN1LW RBP4 TLR3 
BBS4 COL2A1 INPP5E OPN1MW RD3 TLR4 
BBS5 COL9A1 INVS OPN1SW RDH12 TMEM126A 
BBS7 COL11A1 IQCB1 OTX2 RDH5 TOPORS 
BBS9 CRB1 JAG1 PANK2 RGR TREX1 
BBS10 CRX KCNJ13 PAX2 RGS9 TRIM32 
BBS12 CYP4V2 KCNV2 PCDH15 RGS9BP TRPM1 
BEST1 DFNB31 KLHL7 PDE6A RHO TSPAN12 
C2 DMD LCA5 PDE6B RIMS1 TTC8 
C3 EFEMP1 LRAT PDE6C RLBP1 TTPA 
CA4 ELOVL4 LRP5 PDZD7 ROM1 TULP1 
CABP4 ERCC6 MERTK PEX1 RP1 UNC119 
CACNA1F EYS MFRP PEX7 RP2 USH1C 
CACNA2D4 FBLN5 MKKS PGK1 RP9 USH1G 
CC2D2A FSCN2 MTTP PHYH RPE65 USH2A 
CDH23 FZD4 MYO7A PITPNM3 RPGR VCAN 
CEP290 GNAT1 NDP PRCD RPGRIP1 WFS1 
 
Table S1. List of 162 genes used to generate the targeted reagent of the Retinome project. 
 
 
 
304 
 
Appendix 4- Exons not covered by the targeted reagent of the Retinome project 
LOCATION (hg19) EXON 
Chr1:196670427-196670481 CFH terminal exon of NM_001014975.2 / ENST00000359637 
Chr4:16004948-16004992 PROM1 4bp terminal exon in one UCSC transcript only (non CCDS, refseq or Ensembl) 
Chr4:47972892-47973137 CNGA1 first exon of CCDS47050.1 
Chr6:66042196-66042330 EYS terminal exon of CCDS47446.1 
Chr10:102777320-102777392 PDZD7 terminal exon of CCDS31269.1 
Chr14:88881544-88881630 SPATA7 3rd exon of uc001xws.2 (non-ccds refseq or Ensembl) 
Chr16:53656110-53656288 RPGRIP1L exon 19 of CCDS32447.1 
ChrX:38144793-38146598 RPGR terminal exon of one UCSC transcript only (ORF15) 
ChrX:85226551-85226610 CHM terminal exon of CCDS48139.1 
 
Table S2. List of nine exons that were not covered by the targeted reagent used in the Retinome project. 
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Appendix 5- Validating the Retinome capture reagent and establishing a 
pipeline for variant detection 
To test the feasibility of identifying the pathogenic mutation in genomic DNA from 
patients with retinal degeneration, using the Retinome reagent a pilot study was performed. Four 
patients in whom the mutation had previously been identified and confirmed by Sanger 
sequencing were selected for analysis using the customised reagent. The preparation of libraries 
for targeted next generation sequencing was carried out by Clare Logan and the analysis of the 
data was conducted by David A. Parry, who had no prior knowledge of the mutations in the 
samples. Briefly, each patient’s sonicated DNA was ligated to a different 6bp sequence tag. The 
tagged aliquots were pooled prior to hybridisation against the target enrichment reagent and the 
sample ran on a single lane of the Illumina GAIIx DNA Sequencer. The sequence data for each 
sample was sorted by the corresponding sequence tag and aligned against the human reference 
sequence for analysis of coverage and read depth (Table S3A). Pooling of four samples gave a 
range of coverage with at least 20 good quality reads following duplicate removal of 95.6 to 
96.9%; 1 to 2% had less than 5X read depth. A list of variants was generated for each sample and 
these were filtered without knowledge of family history according to the criteria highlighted in 
Table S3B, to produce a list of candidate variants for each sample (Table S4) 
 
Prioritisation of the variants was based on whether the genotype was consistent with 
disease symptoms, variant type and pathogenicity scores. For sample A with a diagnosis of RP, 
heterozygous mutations in RP9, RP1 and FSCN2 were deemed consistent with disease symptoms, 
and of these a high pathogenicity profile suggested that the strongest candidate for causation in 
sample A was the RP9 variant. For sample B, though a number of changes were observed, only 
compound heterozygosity for a premature stop codon and a high pathogenicity missense mutation 
in CRB1 fitted with the LCA diagnosis in this patient. For sample C, heterozygous variants in 
RP1 and a homozygous variant in USH2A were considered possible candidates for causing RP in 
this patient. However based on pathogenicity scores and variant type, the strongest candidates for 
disease causation in sample C were the RP1 variants. For sample D, only a heterozygous null 
mutation in PRPF31 was identified as consistent with the diagnosis of RP. The variants that had 
previously been deemed causative in each sample are shown in Table S3C. As these variants had 
indeed been implicated as candidates for pathogenicity following filtering and prioritisation as 
highlighted above, this confirmed that the pipeline used to identify the pathogenic mutations was 
robust.
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A 
Sample Tag Aligned Reads Reads on target % Reads on target 
Mean 
coverage 
% ≥ 5 % ≥ 10 % ≥ 15 % ≥ 20 % ≥ 30 % ≥ 50 
Patient A tag1 CAACCT 6,296,720 1,310,107 20.8% 133 98.5 97.7 96.8 95.7 93.3 86.5 
Patient B tag2 AACCAT 5,788,340 1,359,182 23.5% 137 98.4 97.5 96.6 95.6 93.4 87.9 
Patient C tag3 AAGGAT 8,539,613 2,174,816 25.5% 220 98.7 98.2 97.6 96.9 95.9 93.1 
Patient D tag4 AATTAT 4,314,207 1,609,443 37.3% 164 98.5 97.6 96.7 95.8 93.9 88.8 
Patient tag1 to 4, AVERAGE 98.5 97.8 96.9 96.0 94.1 89.1 
B 
                         Filtering process Patient A Patient B Patient C Patient D 
Total variants identified 614 564 595 580 
Exclude outside exon / splice junction 278 282 269 260 
Exclude synonymous variants 134 142 131 124 
Exclude if MAF > 0.01 7 12 10 3 
C 
Patient Diagnosis 
Inheritance 
Pattern 
Chr Position Gene 
Coding 
Effect 
cDNA change Protein change BLOSUM62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity 
A RP Dom. 7 33136162 RP9 missense NM_203288.1:c.410A>T p.His137Leu -3 C15 Deleterious bad Het 
B LCA Rec. 
1 197390534 CRB1 nonsense NM_201253.2:c.1576C>T p.Arg526* NA NA NA NA Het 
1 197404300 CRB1 missense NM_201253.2:c.3307G>A p.Gly1103Arg -2 C25 Deleterious bad Het 
C RP Dom. 8 55538727 RP1 frameshift 
NM_006269.1:c.2285_2289 
delTAAAT 
p.Leu762Tyrfs*17 NA NA NA NA Het 
D RP Dom. 19 54621976 PRPF31 frameshift NM_015629.3:c.201delT p.Ile67Metfs*14 NA NA NA NA Het 
 
Table S3. Targeted capture and NGS for four-patient verification study of the Retinome project. (A) Coverage and read depth. The tagging, aligned reads, 
reads on target, % reads on target, mean coverage and % coverage with a particular minimum read depth are shown for each patient’s DNA. (B) Filtering the 
variant lists. Exonic constitutes coding variants only. Splicing constitutes +/- 5bp around an exon. Full list of variants is shown in Table S4. (C) The previously 
identified pathogenic mutations in the four-patient study. The chromosome and position of the mutation is depicted according to the human genome assembly, 
hg19. NA = not annotated and Het = heterozygous. 
* 
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Patient A 
Chr Position Gene Coding Effect cDNA change Protein change BLOSUM62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity 
1 216219858 USH2A missense NM_206933.2:c.6240G>T p.Lys2080Asn 0 C0 Tolerated good Het 
4 47954624 CNGA1 missense NM_001142564.1:c.302G>A p.Arg101Gln 1 C0 Tolerated good Het 
7 33136162 RP9 missense NM_203288.1:c.410A>T p.His137Leu -3 C15 Deleterious bad Het 
8 55541086 RP1 missense NM_006269.1:c.4644T>G p.Ser1548Arg -1 C0 Tolerated bad Het 
9 2718127 KCNV2 missense NM_133497.3:c.388A>C p.Thr130Pro -1 C0 Deleterious bad Het 
9 120470884 TLR4 missense NM_138554.3:c.137A>G p.Tyr46Cys -2 C15 Tolerated bad Het 
17 79502218 FSCN2 missense NM_001077182.2:c.967G>A p.Ala323Thr 0 C0 Tolerated good Het 
Patient B 
Chr Position Gene Coding Effect cDNA change Protein change BLOSUM62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity 
6 11374 C2 splicing NM_000063.4:c.617-5C>A p.? NA NA NA NA Het 
1 186045644 HMCN1 missense NM_031935.2:c.8375A>G p.Asn2792Ser 1 C45 Deleterious Bad Het 
1 197390534 CRB1 nonsense NM_201253.2:c.1576C>T p.Arg526* NA NA NA NA Het 
1 197404300 CRB1 missense NM_201253.2:c.3307G>A p.Gly1103Arg -2 C25 Deleterious bad Het 
1 215953246 USH2A missense NM_206933.2:c.10878G>T p.Arg3626Ser -1 C0 Tolerated good Het 
4 619426 PDE6B missense NM_000283.3:c.11G>T p.Ser4Ile -2 C0 Deleterious good Het 
6 135811814 AHI1 missense NM_017651.4:c.82C>T p.Arg28Cys -3 C0 Tolerated unknown Het 
9 117266891 DFNB31 missense NM_015404.3:c.191C>A p.Ala64Asp -2 C0 Deleterious bad Het 
10 102782113 PDZD7 missense NM_001195263.1:c.572T>A p.Val191Glu -2 C65 Deleterious bad Het 
12 88472996 CEP290 missense NM_025114.3:c.5237G>A p.Arg1746Gln 1 C0 Tolerated good Het 
X 31676133 DMD missense NM_004006.2:c.8001T>A p.Asn2667Lys 0 C65 Deleterious bad Homo 
X 38147286 RPGR in-frame 
NM_001034853.1:c.1579_ 
1581delTTG 
p.Gln527del NA NA NA NA Het 
Continue Table S4 
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Patient C 
Chr Position Gene Coding Effect cDNA change Protein change BLOSUM62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity 
1 186158843 HMCN1 missense NM_031935.2:c.16741G>A p.Ala5581Thr 0 C0 Deleterious bad Het 
1 216052344 USH2A missense NM_206933.2:c.8320G>A p.Ala2774Thr 0 C0 Tolerated good Homo 
2 110962496 NPHP1 missense NM_000272.3:c.50A>G p.Asn17Ser 1 C0 Tolerated good Het 
8 55533891 RP1 missense NM_006269.1:c.365G>C p.Arg122Pro -2 C15 Deleterious bad Het 
8 55538727 RP1 frameshift 
NM_006269.1:c.2285_2289 
delTAAAT 
  p.Leu762Tyrfs*17 NA NA NA NA Het 
10 50732202 ERCC6 missense NM_000124.2:c.1274A>C p.Asp425Ala -2 C65 Deleterious bad Het 
10 73270907 CDH23 missense NM_022124.5:c.367G>C p.Gly123Arg -2 C15 Deleterious bad Het 
11 76891457 MYO7A missense NM_000260.3:c.2624C>G p.Ala875Gly 0 C0 Tolerated bad Het 
16 57950041 CNGB1 missense NM_001297.4:c.2209C>T p.Arg737Cys -3 C0 Tolerated good Het 
X 38156584 RPGR missense NM_001034853.1:c.1367A>G p.Gln456Arg 1 C0 Tolerated bad Het 
Patient D 
Chr Position Gene Coding Effect cDNA change Protein change BLOSUM62 
AGVGD 
class 
SIFT 
prediction 
MAPP 
prediction 
Zygosity 
3 121500697 IQCB1 missense NM_001023570.2:c.1303C>T p.Arg435Cys -3 C0 Deleterious bad Het 
7 128415833 OPN1SW missense NM_001708.2:c.12G>A p.Met4Ile 1 C0 Deleterious bad Het 
19 54621976 PRPF31 frameshift NM_015629.3:c.201delT p.Ile67Metfs*14 NA NA NA NA Het 
 
Table S4. List of candidate variants in the four-patient verification study of the Retinome project. The diagnosis of the patients was either RP (for A, C 
and D) or LCA (for B). The chromosome and position of the variants are depicted according to the human genome assembly, hg19. NA = not annotated. Homo 
= homozygous. Het = heterozygous. 
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Appendix 6- List of primers used in the work described in this thesis 
Oligo name Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bp) 
Annealing 
temperature (°C) 
Purpose 
ABCA4-I-MA18 CTCTTCCTCACCCTCCACAG CATTGTGGTTCCTGTACTCAGC 298 57 S-PCR 
ABCA4-II-MA18 CCTTGCTCTCACCCTGTCTC TGTGACTTGCATTATGGCATT 232 57 S-PCR 
ABCA4-MA2 GCTCTATGGTCATCCCTCCA GCACGCTTCAGTTTCTCATCT 299 57 S-PCR 
ABCC6-MA5 GGTGCAGGGAAGAGTTCTCA CAGGGACCCAGAGAGAACAG 412 57 S-PCR 
BBS12-I-MA14 CCGTGCTCACTAACCCAGTT GTGGCATTTTGCAGATGATG 376 60 HS-PCR 
BBS12-II-MA14 CAGAATTTGAAGCCAGCACA CTTGGCAATAGCTGGCATTT 408 60 S-PCR 
BBS2-MA11 TAAGCGAACAGGGGAAAGAA CCCTGCACCTGTACTAACCA 263 56 S-PCR 
BCAR3-MA14 GATTAGTGAAGCAGGCGGTC TGACCTCAGCTCTTCCCAAG 399 57 S-PCR 
C8ORF37-EXON6-MA13 CTGCAGTGAGCCATGATTGT TTTTCCCACAGGGAATGGTA 424 57 S-PCR 
CACNA1F-MA11 TACTCGCTCCACACACTCCA GTGTCGTAAAGGGCAGAAGG 371 55 HS-PCR 
CC2D2A-I-MA19 TTAATTGTGCAGAGCGCATT GCAGGGACATCAGCTTTTTC 310 57 S-PCR 
CC2D2A-II-MA19 CTCAACAGAGGGCCAAGAAG ATGTCGTGCATGTGTGTGTG 331 57 S-PCR 
CDH23-I-MA12 AAATGCTGTCAAGGCTGTCA ACTGTCTGGATGGGGTTGAG 408 57 S-PCR 
CDH23-II-MA12 AGGCCAGGAGTAGAGGGAAG CCACTCTTCTAGGCCACAGC 349 57 S-PCR 
CEP290-I-MA17 TTTGTGAAATATGTTCCATTAAACTCA TGTCTAGCCACCAACAGTGC 408 60 HS-PCR 
CEP290-II-MA17 AAAAGGCATACTTGTACCCACA GAAAATGCATCCATCATTTACAA 447 60 HS-PCR 
COL11A1-MA8 TCCAAAGGAGTGCAGAAGTG CCCCACAAAATTGACTGGTT 255 60 S-PCR 
CRB1-MA1 TGTGGTTTCACCGTCAACAT AGGCAAGAGGCCAGTCAGTA 400 60  HS-PCR 
DMD-MA19 GTGGATCGAATTCTGCCAGT CGCTGTGTAACTACGCCAAA 408 57 S-PCR 
DRAM2-EXON1(NC) TCCGGGGGCTACCTTATG CACCAGGGATCGTAATTTCA 450 57 S-PCR 
DRAM2-EXON2(NC) AGCCTAGTATTCTGCCCATGA CCTAACAGATTGCTGGTGCAT 343 57 S-PCR 
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Oligo name Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bp) 
Annealing 
temperature (°C) 
Purpose 
DRAM2-EXON3 GAAACAGCTTGGGGTGGTAA CACAAAGAAAAAGCCAAATTCA 414 55 S-PCR 
DRAM2-EXON4 GGTGAAGTAGGCAGATATTTGTGA TTCCCATAAGTCCGCATTTC 442 57 S-PCR 
DRAM2-EXON5 TCCAGCCTGTGCAACATAGA GAATGCTTCAGGTTTCCCTTT 429 57 S-PCR 
DRAM2-EXON6 TTGTAGAATTGGCCGAGCTT AAAGGCTTCTTATACTGCACCAA 400 60 HS-PCR 
DRAM2-EXON7 ACCCTCTGAGCAGCACATTT GGTGACAGGAGAATATGGAAGG 442 57 S-PCR 
DRAM2-EXON8 GCCTGGTAAGTCAAGGGTTG TAGCCCCATTTTCAAGGCTA 447 56 S-PCR 
DRAM2-EXON9A TGAGAAGCTTGGTTTTTCCAG TGGCTTCTTTCATGTTTCCTG 450 55 S-PCR 
DRAM2-EXON9B (NC) GACACTGCACCTTGCCCTAT AAAAGTGCTCCTAACAAAACATGA 650 57 S-PCR 
DRAM2-EXON9C (NC) GCACCAATCAGTCTGCACAT ACAGGTGCCTCTCTCCTTCA 422 57 S-PCR 
DRAM2-EXOND (NC) CTGGATTCATGTGGGCTCTT TTGGATTGCCAATTTTGTTC 441 56 S-PCR 
DRAM2-Gateway-attb 
GGGGACAAGTTTGTACAAAAAAGCAGGCT
TCATGTGGTGGTTTCAGCAAGG 
GGG GAC CAC TTT GTA CAA GAA AGC TGG 
GTCAATATCTCTGGAAAGTAGCCGT 
- 51 C-PCR   
DRAM2-RT-PCR EX6-GGAGCTGTGCTTACCTTTGG EX7-GGGGTTCCAATGGAGTTTCT 222 /778 57 RT-PCR 
DST-MA14 TTGACATACAACCATCAGACCT TGCTATGCACGAGAGACAGG 423 57 S-PCR 
EYS-I-MA4 TGATGGGAATTCATAACATTTTT CCATGAAACAGTTCGATGACT 290 57 S-PCR 
EYS-II-MA4 AAGCTGACGGAACTCCTGAA TTGTGGAAGTGACGAAGGAA 260 57 S-PCR 
EYS-TERM-MA4 GGCAAATCTATGTTTTCAATCC TCAGATTGTGGAAGTTCCCTTT 445 60  HS-PCR 
FDFT1-EXON1 CGGGGTCTTCCTAGTGTGAG GGGAAGGCTCGAGGAAAG 504 57 S-PCR 
FDFT1-EXON2 ACTCCCACTCCTGCTCCTC CCGGGCTATGTTCTGGATAA 288 57 S-PCR 
FDFT1-EXON3 GTGGCCAGGCACAAGTTATT TATGGAGGCTACCGGACAAC 341 57 S-PCR 
FDFT1-EXON4 TGTGATCTTTGGTGCCATGT ATGAGGACTGCCAGCTCTGT 254 57 S-PCR 
FDFT1-EXON5 CCATTCTCTTTTGAACCTGCTT TTTTCCACATCCCCTTATGC 425 57 S-PCR 
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Oligo name Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bp) 
Annealing 
temperature (°C) 
Purpose 
FDFT1-EXON6 CGCCCAGCCTGTATCATAGT CCTCAAGGCTGAGCTGAGTT 471 60  HS-PCR 
FDFT1-EXON7 ATTGCCCATTCAACAGAAGG TCCAACCTACAGCCTTGCTC 488 57 S-PCR 
FDFT1-EXON8 GCCAGTGGAGGGTTGTTGTA ATGAGGCACCCTTTCCTTTC 492 60  HS-PCR 
FDFT1-M-MA17 TGCCCATTCAACAGAAGGTT GCTCGGCTCCTGTGAATAGA 421 57 S-PCR 
FILIP1-MA14 AGCTCTTAGGCCCAGTGTGA ATCTCCAAAGTCGCAGTGCT 429 57 S-PCR 
FSCN2-MA14 TTCGGCTTCAAGGTCAATGC CTCCGGAAGATGAGGGTGAG 458 57 S-PCR 
GP6-MA14 TGTGTTCGGAGTAGGCACAG TGCTGCCTCGTTATCTGATG 401 57 S-PCR 
GPR98-I-MA13 CTTGGGCAACAGAGTGTGAC GCTCACTTCTGCACCTCCTC 437 56 S-PCR 
GPR98-II-MA13 CTGCTTCTGGGTTTGTTGTG CCAAGTGTGCCTGCTAAAGA 450 56 S-PCR 
GUCY2D-MA9 AGTGAACAGCCCCATGAGAG TCAAAGTACTCGGGCTCCAC 408 57 S-PCR 
HMCN1-MA9 TCCAAAAGTATGATTTCTCTGGAA ACTTGTTGACGGCAAACTGA 252 55 S-PCR 
HR-MA14 CCTTCTCTCTGCGAACTGCT CAGTGCTCCTGGAAGAGGTG 438 57 S-PCR 
LARGE-EXON10 ATGGCTTCCTACAGGTGTGA ATGGGGGAGGTCCTTGAT 299 55 S-PCR 
LARGE-EXON11 AATAAACTCAGGGGAGGGCA ATGTGCCATCTCTTCCTGCT 394 57 S-PCR 
LARGE-EXON12 CAAGTGTCACTGGAGGCAGA CTGGAAAAGAAACCTGTTGGA 484 57 S-PCR 
LARGE-EXON13 CCTCATGGGGGAAAGACCT TAGCTTTGGCATCTGGGTTT 293 57 S-PCR 
LARGE-EXON14 ACAGTTCAACTCACCCGAGG TCCAAGGATCCCTTAAGCTC 391 60 HS-PCR 
LARGE-EXON15 GTCCTTTGCCATCTGCTTGT CTGTAGTGAGGGCAGCTTGG 481 57 S-PCR 
LARGE-EXON2 CAGTTGAACCCCTTTCAGGA TGACTGCTGCCAACTACCTG 450 57 S-PCR 
LARGE-EXON3 AGGAGCCTCGCCATGTAGTA TACACACCCGGGCTAGAATC 529 57 S-PCR 
LARGE-EXON4 CAGGGCAATTTTTCTTTCTAGTGT AACCCTTCCCCAAGGAAATA 248 57 S-PCR 
LARGE-EXON5 TGAAGAGTGTGTTTTTGCAGC GAGCTGAGATTTCTGGCATTG 300 57 S-PCR 
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Oligo name Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bp) 
Annealing 
temperature (°C) 
Purpose 
LARGE-EXON6 TGGATACTTTTTGTGTGCTAGGC GTCAACCCCTATTCTTGGCA 349 55 S-PCR 
LARGE-EXON7 TGTGATGATTTGCCATTACCC CCTCCTCCTGAGCTTTTGC 299 57 S-PCR 
LARGE-EXON8 ATCATCCCCGAGAGACTGTG ACTGGCAAGAATAAGGCAGC 360 57 S-PCR 
LARGE-EXON9 CAGTGCCTTGAGAGCCAAA TAAATCTCCCAGCCATCCAT 286 57 S-PCR 
LARGE-M-MA14 TCCAAAGCTGTTGTGCTGTC TTCCCCTACAGCATGTCTCC 391 57 S-PCR 
LDB1-MA14 TCCCAAGTAGCTGGAACCAC CTACTCCCTCCCCTTTCCAG 385 57 S-PCR 
LILRB5-MA14 GGTCTCAGCTCAGAGCAAGG TGGACAGCAGGTAGGGGTAG 325 57 S-PCR 
METTL24-MA14 CAAGGATGGGGAAGCAATAA AGTGCCTCTGACCAAGGAGA 425 55 S-PCR 
MFSD8-EX11-MA5 TCAGCCATTTTTCAGAGGAG TTGGAGACTTCCAAAGACCAA 440 56 S-PCR 
MFSD8-EX13-MA5 CAGGGCTTCAGCAGACAGTA TATTCCACACACCAGGCTGA 352 56 S-PCR 
MUC4-MA14 AGCGAGAAGCACCCTAGATG GGCAGAGGCCTGACATTAAG 437 57 S-PCR 
MYO7A-I-MA13 AAAGTCATGCCCAGTTCCAG ACCGGGTGACAGATGAGAAG 303 57 S-PCR 
MYO7A-II-MA13 CAGGCCAGCTCTGACTTAGC CATAAATCTCCCAGCCTCCA 492 57 S-PCR 
NR2E3-MA8 TTGGGCAAAAATGTCCAAGC AGGAAGGGTCAGGACGACAC 256 57 S-PCR 
OFD1-MA17 GAGAGAGAACTTGTTCCTGTTTTT CCAACCTACTAATAGCTGCAGGA 300 57 S-PCR 
P53-RT-PCR GTACTCCCCTGCCCTCAACA CTGGAGTCTTCCAGTGTGAT 408/1057 57 RT-PCR 
PCDH15-I-MA19 GGGCCCAAGAGAAAAGATTC TTCCAAGGAACACTCAGCAG 406 57 S-PCR 
PCDH15-II-MA19 TGATCTGGCTACATTTCAGCTC TGCTGTCATCTGTTAAGCCAAA 373 57 S-PCR 
PCM1-MA14 AGCTTCCACTTGGAATGAAGT GGAAAGAGCACACATGAACG 224 57 S-PCR 
PHYH-MA5 TCAAGTCTGCAACCCTTTCC CGGGTTTTACAGGCAGACAT 322 57 S-PCR 
PROM1-MA6 CAGCCTTAGTCCAGCAGCTT GTCCCATCACAGCAGGATCT 387 55 S-PCR 
PROM1-MA7 CTGAGTTGCAAAATGAGTGACTA CGAATGACACAATTGTAAAGCTC 300 55 S-PCR 
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Oligo name Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bp) 
Annealing 
temperature (°C) 
Purpose 
RDH12-MA6 TGGGCTGTCATTCCACTTTC GGTCTGAGGACCATTTTTGC 300 57 S-PCR 
RP2-MA8 GGAAGAAGCAGCTGAGGTGA ACACACCCCAAAAATTCCAA 368 56 S-PCR 
RPGR-MA8 TGCTTTGTGGTGACCTCATCT TCAAGCAAATGTCAGAAAATAAAGA 284 60  HS-PCR 
RPGR-RET CAGAGGTCCAAAATGCCAGT CACAGCTGCATCAGTTGCTT 251 60 HS-PCR 
RPGRIP1-MA10 TCCAGGCAAGGAGTCTAATCTT TTCAGCATCAGCACAAAACC 290 56 S-PCR 
RPGRIP1L-MA5 CCATTGGCCTTCGTGTTTTA GCCTGGCCCAACTTTATTTT 478 56 S-PCR 
RS1-MA8 GCAAAGCAGATGGGTTTGTT TTCCCAGGTTCAAGCAATTC 421 58 S-PCR 
SNRNP200-MA5 GGAGGTAAAATTAGTAGCTCTTTGC ATTATGCTGTGCCCAACAGG 286 57 S-PCR 
SPATA7-MA15 TTGAAAGATTTGTTTTCCCTTTT CAGGAAAAATTTGCTGACCCTA 265 56 S-PCR 
TBC1D9B-MA14 TAGCGTCACCATCCTGTCTG CTCCCAAAGTGCTGGGATTA 431 57 S-PCR 
TNFRSF21-MA14 CCCTGGATGATTGTGCTTTT CAGGGGAAAAGGAGGAAGAG 406 57 S-PCR 
TTLL5-EXON19-MA19 GGGAAGCTTAGCCTTGGAAT CTGGCAGGATCCAGATAAGG 278 57 S-PCR 
USH2A-MA3 ATTGCAAGCACCTCCAGAAG CCAGAGTTGTGATGCTGGTG 284 58 S-PCR 
USH2A-MA5 CATGCATGGGATTTCAGGTT CCTGGATATCGAGAGCCAACT 352 60  HS-PCR 
VCAN-RET TTACATACAATGCACAAAAAGCA TTCCAGTGATTCCACATTGC 251 57 S-PCR 
WFS1-MA19 CAACATGCTCCCGTTCTTCAT AGGATGGTGCTGAACTCGATG 327 57 S-PCR 
ZNF613-MA14 AAAGGTCCAGGCTCACTGAA TGTGAGCAGGATTTTCCACA 421 57 S-PCR 
 
Table S5. List of primers used in this study. Oligo name, forward and reverse primer sequences, product size, annealing temperature and purpose of using 
are shown. NC = non-coding, PCR = polymerase chain reaction, S-PCR = standard PCR, HS-PCR = Hot-Shot master mix PCR, C-PCR = cloning PCR and 
RT-PCR = reverse transcriptase PCR.
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Appendix 7- Representative bioanalyser analysis for WES library 
preparation 
A. The sheared DNA samples were analysed on the BioanalyzerTM using DNA1000 assay kit 
(Agilent Technologies) to assess the distribution of DNA fragment sizes between 150-200 bp. 
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B. The amplified libraries were analysed on the BioanalyzerTM using DNA1000 assay kit (Agilent 
Technologies) and only samples with an electropherogram reading showing a single peak around 
250 to 275 bp were taken through to the hybridisation steps. 
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C. The captured libraries after hybridisation were analysed on the BioanalyzerTM using DNA high 
sensitivity assay kit (Agilent Technologies) to achieve a normal distribution around a peak 
ranging from approximately 300 to 400 bp before the pooling step of the samples. 
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Appendix 8- Immuno-localisation of DRAM2 to the eye cross sections of the mouse embryo 
IHC staining on paraffin fixed cross eye sections of mouse embryo (P0/E21) stained for DRAM2 (brown) (B, C and E) and counterstained with haematoxylin 
(blue) comparing to control sections (A and D). The results showed nonspecific staining of DRAM2 to the eye layers. RPE = retinal pigment epithelium, NR= 
neural retina, HVP= hyaloid vascular plexus, C= cornea, L= lens and OFL= optic fibre layer. 
 
